<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<base target="_blank">
<link rel=File-List href="demans_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="demans_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>DEMANS SENDROMU, ALZHEIMER HASTALI&#286;I ve ALZHEIMER DI&#350;I
DEMANSLAR</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:HideSpellingErrors/>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-alt:\BC14\D0D5;
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\5B8B\4F53;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;
	mso-font-alt:\65B0\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-alt:"\FF2D\FF33 \30B4\30B7\30C3\30AF";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\B3CB\C6C0;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\9ED1\4F53;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;
	mso-font-alt:\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;
	mso-font-alt:\660E\671D;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\AD74\B9BC;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 3 5 7 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Latha;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1048579 0 0 0 1 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:67110535 0 0 0 159 0;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:131075 0 0 0 1 0;}
@font-face
	{font-family:Shruti;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:262147 0 0 0 1 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2097155 0 0 0 1 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:4194307 0 0 0 1 0;}
@font-face
	{font-family:"Estrangella Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Cambria;
	mso-font-alt:"Palatino Linotype";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482993 6144 0 0 31 0;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147476737 14699 0 0 63 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870009 1073741843 0 0 415 0;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147459005 0 128 0 1 0;}
@font-face
	{font-family:"MV Boli";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 256 0 1 0;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421663 -2147483648 8 0 66047 0;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 5 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Menlo Regular";
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Lucida Grande";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Calibri;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750139 0 0 159 0;}
@font-face
	{font-family:"Nimbus Sans L";
	mso-font-alt:Arial;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"DejaVu Sans";
	mso-font-charset:128;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:255;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"\@Batang";
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"\@Nimbus Sans L";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
h1
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:21.6pt;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-21.6pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	font-family:Arial;
	font-weight:bold;}
h2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.8pt;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-28.8pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:12.0pt;
	font-family:Arial;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:36.0pt;
	text-indent:-36.0pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	font-family:Arial;
	font-weight:bold;}
h6
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:57.6pt;
	text-indent:-57.6pt;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:64.8pt;
	text-indent:-64.8pt;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoList, li.MsoList, div.MsoList
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:Batang;
	mso-hansi-font-family:"Arial Unicode MS";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{margin-top:14.0pt;
	margin-right:0cm;
	margin-bottom:14.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Arial Unicode MS";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.heading, li.heading, div.heading
	{mso-style-name:heading;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Nimbus Sans L";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Arial Unicode MS";
	mso-bidi-font-family:"Times New Roman";}
p.caption, li.caption, div.caption
	{mso-style-name:caption;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-style:italic;}
p.ndex, li.ndex, div.ndex
	{mso-style-name:ndex;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.balloontext, li.balloontext, div.balloontext
	{mso-style-name:balloontext;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.decimalaligned, li.decimalaligned, div.decimalaligned
	{mso-style-name:decimalaligned;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.commenttext, li.commenttext, div.commenttext
	{mso-style-name:commenttext;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.commentsubject, li.commentsubject, div.commentsubject
	{mso-style-name:commentsubject;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
p.listparagraph, li.listparagraph, div.listparagraph
	{mso-style-name:listparagraph;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.authors1, li.authors1, div.authors1
	{mso-style-name:authors1;
	margin-top:3.6pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:33.0pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.source1, li.source1, div.source1
	{mso-style-name:source1;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:33.0pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.list2, li.list2, div.list2
	{mso-style-name:list2;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.bodytext2, li.bodytext2, div.bodytext2
	{mso-style-name:bodytext2;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.text, li.text, div.text
	{mso-style-name:text;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.bodytext3, li.bodytext3, div.bodytext3
	{mso-style-name:bodytext3;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.bodytextndent2, li.bodytextndent2, div.bodytextndent2
	{mso-style-name:bodytextndent2;
	margin:0cm;
	margin-bottom:.0001pt;
	text-indent:35.4pt;
	line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.plaintext, li.plaintext, div.plaintext
	{mso-style-name:plaintext;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.date, li.date, div.date
	{mso-style-name:date;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.fulltext-references, li.fulltext-references, div.fulltext-references
	{mso-style-name:fulltext-references;
	margin-top:14.0pt;
	margin-right:0cm;
	margin-bottom:18.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.affiliation2, li.affiliation2, div.affiliation2
	{mso-style-name:affiliation2;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:6.0pt;
	line-height:14.4pt;
	mso-pagination:widow-orphan;
	font-size:9.5pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.pmid3, li.pmid3, div.pmid3
	{mso-style-name:pmid3;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:12.0pt;
	margin-left:6.0pt;
	line-height:14.4pt;
	mso-pagination:widow-orphan;
	font-size:9.5pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.tablecontents, li.tablecontents, div.tablecontents
	{mso-style-name:tablecontents;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.tableheading, li.tableheading, div.tableheading
	{mso-style-name:tableheading;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
p.framecontents, li.framecontents, div.framecontents
	{mso-style-name:framecontents;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.citation, li.citation, div.citation
	{mso-style-name:citation;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.authlist, li.authlist, div.authlist
	{mso-style-name:auth_list;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.title, li.title, div.title
	{mso-style-name:title;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.rprtbody, li.rprtbody, div.rprtbody
	{mso-style-name:rprtbody;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.aux, li.aux, div.aux
	{mso-style-name:aux;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.ww8num4z0
	{mso-style-name:ww8num4z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num4z1
	{mso-style-name:ww8num4z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num4z2
	{mso-style-name:ww8num4z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num5z0
	{mso-style-name:ww8num5z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num5z1
	{mso-style-name:ww8num5z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num5z2
	{mso-style-name:ww8num5z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num6z0
	{mso-style-name:ww8num6z0;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num6z2
	{mso-style-name:ww8num6z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num6z3
	{mso-style-name:ww8num6z3;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num7z0
	{mso-style-name:ww8num7z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num7z2
	{mso-style-name:ww8num7z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num7z4
	{mso-style-name:ww8num7z4;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num8z0
	{mso-style-name:ww8num8z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num8z1
	{mso-style-name:ww8num8z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num8z2
	{mso-style-name:ww8num8z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num9z0
	{mso-style-name:ww8num9z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num9z1
	{mso-style-name:ww8num9z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num9z2
	{mso-style-name:ww8num9z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num10z0
	{mso-style-name:ww8num10z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num10z1
	{mso-style-name:ww8num10z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num10z2
	{mso-style-name:ww8num10z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num11z0
	{mso-style-name:ww8num11z0;
	font-weight:normal;
	font-style:italic;}
span.ww8num11z7
	{mso-style-name:ww8num11z7;
	color:windowtext;}
span.ww8num12z0
	{mso-style-name:ww8num12z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num12z1
	{mso-style-name:ww8num12z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num12z2
	{mso-style-name:ww8num12z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num13z0
	{mso-style-name:ww8num13z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num13z1
	{mso-style-name:ww8num13z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num13z2
	{mso-style-name:ww8num13z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num14z0
	{mso-style-name:ww8num14z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num14z1
	{mso-style-name:ww8num14z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num14z2
	{mso-style-name:ww8num14z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num15z0
	{mso-style-name:ww8num15z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num15z1
	{mso-style-name:ww8num15z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num15z2
	{mso-style-name:ww8num15z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num16z0
	{mso-style-name:ww8num16z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num16z1
	{mso-style-name:ww8num16z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num16z2
	{mso-style-name:ww8num16z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num17z0
	{mso-style-name:ww8num17z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num17z1
	{mso-style-name:ww8num17z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num17z2
	{mso-style-name:ww8num17z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num18z0
	{mso-style-name:ww8num18z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num18z1
	{mso-style-name:ww8num18z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num18z2
	{mso-style-name:ww8num18z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num19z0
	{mso-style-name:ww8num19z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num19z1
	{mso-style-name:ww8num19z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num19z2
	{mso-style-name:ww8num19z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num20z0
	{mso-style-name:ww8num20z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num20z1
	{mso-style-name:ww8num20z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num20z2
	{mso-style-name:ww8num20z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num21z0
	{mso-style-name:ww8num21z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num21z1
	{mso-style-name:ww8num21z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num21z2
	{mso-style-name:ww8num21z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num22z0
	{mso-style-name:ww8num22z0;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num22z2
	{mso-style-name:ww8num22z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num22z3
	{mso-style-name:ww8num22z3;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.heading1char
	{mso-style-name:heading1char;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.heading2char
	{mso-style-name:heading2char;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.heading3char
	{mso-style-name:heading3char;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.heading6char
	{mso-style-name:heading6char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.heading7char
	{mso-style-name:heading7char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.balloontextchar
	{mso-style-name:balloontextchar;
	font-family:"Lucida Grande";
	mso-ascii-font-family:"Lucida Grande";
	mso-hansi-font-family:"Lucida Grande";}
span.footnotetextchar
	{mso-style-name:footnotetextchar;
	font-family:Tahoma;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
span.footnotecharacters
	{mso-style-name:footnotecharacters;
	vertical-align:super;}
span.subtitlechar
	{mso-style-name:subtitlechar;
	font-family:Batang;
	mso-ascii-font-family:Batang;
	mso-fareast-font-family:Batang;
	font-weight:bold;}
span.headerchar
	{mso-style-name:headerchar;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-hansi-font-family:Cambria;}
span.bodytextchar
	{mso-style-name:bodytextchar;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.bodytextndentchar
	{mso-style-name:bodytextndentchar;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.subtleemphasis
	{mso-style-name:subtleemphasis;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	color:gray;
	font-style:italic;}
span.footerchar
	{mso-style-name:footerchar;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
span.commenttextchar
	{mso-style-name:commenttextchar;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
span.commentsubjectchar
	{mso-style-name:commentsubjectchar;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;
	font-weight:bold;}
span.bodytext2char
	{mso-style-name:bodytext2char;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-hansi-font-family:Cambria;}
span.bodytext3char
	{mso-style-name:bodytext3char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.bodytextndent2char
	{mso-style-name:bodytextndent2char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.plaintextchar
	{mso-style-name:plaintextchar;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.datechar
	{mso-style-name:datechar;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.reference-journal-title2
	{mso-style-name:reference-journal-title2;
	font-style:italic;}
span.reference-volume2
	{mso-style-name:reference-volume2;
	font-weight:bold;}
span.msons
	{mso-style-name:msons;
	text-decoration:underline;
	text-underline:single;}
span.footnotecharacters0
	{mso-style-name:footnotecharacters0;
	vertical-align:super;}
span.msons0
	{mso-style-name:mso\0131ns;
	text-decoration:underline;
	text-underline:single;}
span.msodel0
	{mso-style-name:msodel;
	color:red;
	text-decoration:line-through;}
span.src
	{mso-style-name:src;}
span.jrnl
	{mso-style-name:jrnl;}
p.ListParagraph0, li.ListParagraph0, div.ListParagraph0
	{mso-style-name:"List Paragraph";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
p.ListParagraph0CxSp\0130lk, li.ListParagraph0CxSp\0130lk, div.ListParagraph0CxSp\0130lk
	{mso-style-name:"List ParagraphCxSp\0130lk";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
p.ListParagraph0CxSpOrta, li.ListParagraph0CxSpOrta, div.ListParagraph0CxSpOrta
	{mso-style-name:"List ParagraphCxSpOrta";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
p.ListParagraph0CxSpSon, li.ListParagraph0CxSpSon, div.ListParagraph0CxSpSon
	{mso-style-name:"List ParagraphCxSpSon";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
ins
	{mso-style-type:export-only;
	text-decoration:none;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;}
span.msoDel
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:line-through;
	color:red;}
@page Section1
	{size:954.15pt 595.25pt;
	mso-page-orientation:landscape;
	margin:90.0pt 184.3pt 90.0pt 72.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@page Section2
	{size:594.95pt 841.85pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section2
	{page:Section2;}
 /* List Definitions */
 @list l0
	{mso-list-id:22632108;
	mso-list-template-ids:-1188518058;}
@list l0:level1
	{mso-level-start-at:41;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:54668218;
	mso-list-type:hybrid;
	mso-list-template-ids:1913673250 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l1:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2
	{mso-list-id:71511021;
	mso-list-template-ids:-1648340346;}
@list l2:level1
	{mso-level-start-at:15;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3
	{mso-list-id:95488971;
	mso-list-template-ids:905204900;}
@list l3:level1
	{mso-level-start-at:12;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4
	{mso-list-id:287198514;
	mso-list-template-ids:-1987382328;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l4:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5
	{mso-list-id:418137551;
	mso-list-template-ids:-1568099352;}
@list l5:level1
	{mso-level-start-at:18;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6
	{mso-list-id:429594025;
	mso-list-template-ids:1960314602;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l7
	{mso-list-id:455560122;
	mso-list-template-ids:-1503637094;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l8
	{mso-list-id:455831629;
	mso-list-template-ids:-287022200;}
@list l8:level1
	{mso-level-start-at:23;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9
	{mso-list-id:499275716;
	mso-list-template-ids:-1892014798;}
@list l9:level1
	{mso-level-start-at:27;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10
	{mso-list-id:523636168;
	mso-list-template-ids:-1346844508;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l11
	{mso-list-id:577178543;
	mso-list-template-ids:-806462730;}
@list l11:level1
	{mso-level-start-at:14;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12
	{mso-list-id:598564829;
	mso-list-template-ids:-872669832;}
@list l12:level1
	{mso-level-start-at:33;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13
	{mso-list-id:627932391;
	mso-list-template-ids:-16901844;}
@list l13:level1
	{mso-level-start-at:7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l14
	{mso-list-id:675351984;
	mso-list-template-ids:-1613578048;}
@list l14:level1
	{mso-level-start-at:16;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l15
	{mso-list-id:690375151;
	mso-list-template-ids:545572744;}
@list l15:level1
	{mso-level-start-at:9;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16
	{mso-list-id:723019854;
	mso-list-template-ids:-1624367020;}
@list l16:level1
	{mso-level-start-at:20;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17
	{mso-list-id:726758960;
	mso-list-template-ids:-1663766038;}
@list l17:level1
	{mso-level-start-at:28;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18
	{mso-list-id:726807471;
	mso-list-template-ids:-698612664;}
@list l18:level1
	{mso-level-start-at:29;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l19
	{mso-list-id:739403674;
	mso-list-template-ids:-1876767758;}
@list l19:level1
	{mso-level-start-at:10;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20
	{mso-list-id:864756265;
	mso-list-template-ids:1518120352;}
@list l20:level1
	{mso-level-start-at:5;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21
	{mso-list-id:931553093;
	mso-list-template-ids:1553658298;}
@list l21:level1
	{mso-level-start-at:22;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22
	{mso-list-id:932937119;
	mso-list-template-ids:201618086;}
@list l22:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l22:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23
	{mso-list-id:968240070;
	mso-list-template-ids:-20925398;}
@list l23:level1
	{mso-level-start-at:19;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24
	{mso-list-id:1026784376;
	mso-list-template-ids:-1743231660;}
@list l24:level1
	{mso-level-start-at:37;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l25
	{mso-list-id:1065570284;
	mso-list-template-ids:-1501796202;}
@list l25:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l26
	{mso-list-id:1123231621;
	mso-list-template-ids:-1065314434;}
@list l26:level1
	{mso-level-start-at:26;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27
	{mso-list-id:1197083778;
	mso-list-template-ids:794581648;}
@list l27:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l27:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l28
	{mso-list-id:1210192157;
	mso-list-template-ids:1814063790;}
@list l28:level1
	{mso-level-start-at:2;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l29
	{mso-list-id:1238058996;
	mso-list-template-ids:749791040;}
@list l29:level1
	{mso-level-start-at:13;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30
	{mso-list-id:1250962438;
	mso-list-template-ids:780466432;}
@list l30:level1
	{mso-level-start-at:11;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l31
	{mso-list-id:1270506292;
	mso-list-template-ids:514508248;}
@list l31:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l32
	{mso-list-id:1282296507;
	mso-list-template-ids:2010409602;}
@list l32:level1
	{mso-level-start-at:21;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l33
	{mso-list-id:1299796289;
	mso-list-type:hybrid;
	mso-list-template-ids:-618130462 279076514 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l33:level1
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-weight:bold;}
@list l34
	{mso-list-id:1399596011;
	mso-list-template-ids:1452053616;}
@list l34:level1
	{mso-level-start-at:38;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35
	{mso-list-id:1410809325;
	mso-list-template-ids:-339070558;}
@list l35:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l35:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l36
	{mso-list-id:1423145308;
	mso-list-template-ids:669840636;}
@list l36:level1
	{mso-level-start-at:40;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l37
	{mso-list-id:1446802422;
	mso-list-template-ids:-858496434;}
@list l37:level1
	{mso-level-start-at:30;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l38
	{mso-list-id:1488666849;
	mso-list-template-ids:2089732170;}
@list l38:level1
	{mso-level-start-at:32;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l39
	{mso-list-id:1496415823;
	mso-list-template-ids:-632785860;}
@list l39:level1
	{mso-level-start-at:25;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l40
	{mso-list-id:1598634602;
	mso-list-template-ids:-2021612344;}
@list l41
	{mso-list-id:1679580029;
	mso-list-template-ids:1260661088;}
@list l41:level1
	{mso-level-start-at:31;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l42
	{mso-list-id:1698505120;
	mso-list-template-ids:1258720590;}
@list l42:level1
	{mso-level-start-at:36;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43
	{mso-list-id:1765297627;
	mso-list-template-ids:123217036;}
@list l43:level1
	{mso-level-start-at:4;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44
	{mso-list-id:1778984947;
	mso-list-template-ids:-1335443562;}
@list l44:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l44:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45
	{mso-list-id:1784298159;
	mso-list-template-ids:716858502;}
@list l45:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l46
	{mso-list-id:1904098004;
	mso-list-template-ids:1225659884;}
@list l46:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l46:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47
	{mso-list-id:1974404884;
	mso-list-template-ids:1358719256;}
@list l47:level1
	{mso-level-start-at:8;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l48
	{mso-list-id:2064714324;
	mso-list-template-ids:-1294727452;}
@list l48:level1
	{mso-level-start-at:39;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l49
	{mso-list-id:2066903052;
	mso-list-template-ids:-1886469080;}
@list l49:level1
	{mso-level-start-at:24;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50
	{mso-list-id:2078281634;
	mso-list-template-ids:-91453248;}
@list l50:level1
	{mso-level-start-at:3;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="12290"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body bgcolor=white lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><a name="OLE_LINK1"><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>DEMANS
SENDROMU, ALZHEIMER HASTALI&#286;I ve ALZHEIMER DI&#350;I DEMANSLAR</span></b></a><span
style='mso-bookmark:OLE_LINK1'></span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;. Hakan G�rvit</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son G�ncelle&#351;tirme Tarihi: <b>12.5.2010</b></span><span
lang=FR style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G&#304;R&#304;&#350;</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>T&#305;bbi pratikte demans kavram&#305; belli bir
asgari bulgular toplulu&#287;u olarak bir sendroma kar&#351;&#305;l&#305;k
gelir. �rne&#287;in, nas&#305;l nefropati sendromunun alt&#305;nda
hipertansiyondan diyabete �ok say&#305;da etyolojik neden s&#305;ralanabilirse,
demans sendromu da uzun bir listeye ancak s&#305;&#287;d&#305;r&#305;labilecek
bir dizi etyolojik etmenin sonucu olarak geli&#351;ir.&nbsp; Liste uzun olsa
da, ilerleyen b�l�mlerde ayr&#305;nt&#305;yla g�r�lece&#287;i gibi, t�m
demanslar&#305;n ��te ikisinden fazlas&#305; <i>Alzheimer
hastal&#305;&#287;&#305;</i>na (AH) ba&#287;l&#305;d&#305;r.&nbsp; Bu y�ksek
oran, klinik pratikte belli bir ay&#305;r&#305;c&#305; tan&#305;
kolayl&#305;&#287;&#305; sa&#287;larken (demans sendromunu tan&#305;yan
klinisyen ileri gitmeksizin AH tan&#305;s&#305; koyarsa % 65 do&#287;ru
tan&#305; koymu&#351; olacakt&#305;r), AH�nin do&#287;as&#305;ndan kaynaklanan
nedenlerle de, kendine �zg� g��l�kler ta&#351;&#305;r: diabetes mellitustaki
y�ksek kan &#351;ekeri d�zeyi gibi, AH�nin bir biyolojik i&#351;aretleyicisi
olmad&#305;&#287;&#305; i�in kesin tan&#305; ancak n�ropatolojik y�ntemlerle
m�mk�nd�r.&nbsp; Bu durumda klinisyen g�rd�&#287;� klinik tablo i�in AH
de&#287;il, fakat �<i>Alzheimer Tipi Demans</i>� (bundan b�yle &#304;ngilizce
kar&#351;&#305;l&#305;&#287;&#305; olan <i>Dementia of Alzheimer Type</i>
k&#305;saltmas&#305; DAT olarak kullan&#305;lacak) sendromu, ya da bu tablonun
kesin olmasa da, y�ksek olas&#305;l&#305;kla AH�ye ba&#287;l&#305;
oldu&#287;unu d�&#351;�nd�&#287;�n� g�sterir bi�imde �Muhtemel Alzheimer
Hastal&#305;&#287;&#305;� (bundan b�yle &#304;ngilizce
kar&#351;&#305;l&#305;&#287;&#305; olan <i>Probable Alzheimer�s Disease</i>
k&#305;saltmas&#305; PRAD olarak kullan&#305;lacak) tan&#305;s&#305;
koyabilecektir.&nbsp;A&#351;a&#287;&#305;da Alzheimer Hastal&#305;&#287;&#305;
b�l�m�nde ayr&#305;nt&#305;yla g�zden ge�irilece&#287;i gibi, DAT terimi&nbsp;
DSM-IV, PRAD ise NINCDS-ADRDA tan&#305; kriterleri olarak
kullan&#305;ld&#305;&#287;&#305;nda se�ilen �zg�l tan&#305; etiketleridir.
Aralar&#305;ndaki ufak n�anslarla birlikte DAT ve PRAD b�y�k �l��de �rt�&#351;�rler.
Bu b�l�mde PRAD ve DAT kavramlar&#305; �zg�l tan&#305; kriterlerinin
kar&#351;&#305;l&#305;klar&#305; olarak b&#305;rak&#305;lacak, g�nl�k
kullan&#305;mda AH�yle ilintili demans i�in ise �Alzheimer tipi demans� (ATD)
terimi kullan&#305;lacakt&#305;r. Bu durum ilk bak&#305;&#351;ta demansla kar&#351;&#305;la&#351;an
klinisyenler a�&#305;s&#305;ndan ciddi bir zorluk gibi g�r�nse de, geni&#351;
nekropsi serilerinde, klinik olarak PRAD ya da DAT tan&#305;s&#305; konulan
olgular&#305;n %90�&#305;n&#305;n kesin AH patolojik tan&#305;s&#305;
ald&#305;klar&#305; g�r�lm�&#351;t�r.&nbsp; Bir ba&#351;ka deyi&#351;le, ATD
sendromu %10 gibi k���k bir olas&#305;l&#305;kla ba&#351;ka demans etmenleriyle
de ortaya �&#305;kabilmektedir.&nbsp; G�nl�k pratikte, ilk ad&#305;mda demans
sendromunu zihinsel bozuklukla kendini g�steren di&#287;er sendromlardan
ay&#305;rabilmek, demansa karar verildi&#287;i takdirde ikinci ad&#305;mda
demanslar i�inde AH�nin ayr&#305;cal&#305;kl&#305; yeri nedeniyle, AH�ye �zg�
tipik sendromu, di&#287;er demans nedenlerinin klinik n�anslar&#305;ndan
ay&#305;rdedebilmek esast&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu b�l�mde �nce demans sendromu kavramsal olarak
tan&#305;mlanacak, normal ya&#351;l&#305;l&#305;ktan ve di&#287;er zihinsel
bozukluklardan fark&#305; ortaya konulacak ve sonras&#305;nda demans muayenesi,
demanslar&#305;n ay&#305;r&#305;c&#305; tan&#305;s&#305; �zerinde
durulacakt&#305;r.&nbsp; Ard&#305;ndan �zg�l demans nedenlerine ge�ilecek ve AH
ile AH-d&#305;&#351;&#305; demanslar incelenecektir.&nbsp; AH
k&#305;sm&#305;nda klinik tablo, tan&#305; kriterleri, seyir, epidemiyoloji,
genetik, patoloji-patogenez, ve tedavi, alt k&#305;s&#305;mlarda
ayr&#305;nt&#305;yla ele al&#305;nacakt&#305;r.&nbsp; AH-d&#305;&#351;&#305;
demanslar k&#305;sm&#305;nda AH d&#305;&#351;&#305; n�rodejeneratif demans
hastal&#305;klar&#305; aras&#305;nda olan <i>Lewy cisimcikli demans</i> (LCD), <i>fronto-temporal
Demans</i> (FTD) ve <i>Pick Kompleksi</i> kavram&#305;, <i>prion
hastal&#305;klar&#305;</i> ve �zellikle <i>Creutzfeldt-Jacob
hastal&#305;&#287;&#305;</i> (CJH), hareket bozukluklar&#305;yla birlikte
demans, sekonder demanslar aras&#305;nda �zellikle <i>vask�ler demans</i> (VaD)
incelenecek, di&#287;er nadir demans nedenleri k&#305;saca
�zetlenecektir.&nbsp; T&#305;p �&#287;rencileri i�in b�y�k puntolarla
yaz&#305;lm&#305;&#351; olan k&#305;s&#305;mlar esasken, k���k punto ile
yaz&#305;lm&#305;&#351; k&#305;s&#305;mlar ileri okuma olarak
tasarlanm&#305;&#351;t&#305;r.<b>&nbsp;</b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;mso-ansi-language:TR'>DEMANS SENDROMU</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>BIR KL&#304;N&#304;K KAVRAM OLARAK DEMANS<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Dilimizde pop�ler kullan&#305;m&#305;yla <i>bunama</i>
ad&#305; verilen demans kelimesi, etimolojik olarak Latince zihin anlam&#305;na
gelen mens kelimesinden t�remi&#351;tir ve demens zihnin yitirilmesi
anlam&#305;na gelir.&nbsp; Latince�deki kullan&#305;m bi�imiyle
�yerle&#351;mi&#351;, varolan, edinilmi&#351; olan zihnin sonradan yitirilmesi�
anlam&#305;n&#305; ta&#351;&#305;maktad&#305;r. Bu bi�imiyle edinilecek
olan&#305;n, yani zihnin �hi� edinilememesi� durumundan
farkl&#305;d&#305;r.&nbsp; B�ylelikle, demans&#305; zihinsel gerilikler ya da
Yunancas&#305;yla oligofreni (yetersiz zihin), Latincesiyle amensiyadan (zihin
yoklu&#287;u) etimolojik ve semantik olarak da ay&#305;rabiliriz.&nbsp;
Herhangi bir zaman kesitinde bir demansl&#305; hasta ile bir oligofrenik
hastan&#305;n zihinsel �z�rl�l�k, ya da yeterlilik d�zeyleri i&#351;levsel
olarak benzerlik g�sterebilir, ancak demansl&#305;n&#305;n edinsel nedenlerle
(genetik ya da �evresel, s&#305;kl&#305;kla da ikisinin birlikte etkileriyle)
kendinde mevcut olan kapasiteyi yitirdi&#287;ini, oligofrenin ise
geli&#351;imsel nedenlerle bu kapasiteyi yetersiz edindi&#287;ini
s�yleyebiliriz.&nbsp; �yleyse demans&#305;n tan&#305;m&#305;na, �eri&#351;kin
merkezi sinir sisteminin hasarlanmas&#305; sonucu geli&#351;en zihinsel
yeteneklerde bozulma� &#351;eklinde ba&#351;layabiliriz.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Zihinsel yeteneklerde hangi tarz bozulma demans
kavram&#305;n&#305; kar&#351;&#305;lar?&nbsp; Zihinsel yeteneklerde demansa
�zg� tarzda bozulma i�inde, bozulan zihinsel yeteneklerin (ya da teknik
terminolojiyle kognitif i&#351;levlerin) say&#305;s&#305;, bu bozulman&#305;n
ba&#351;lang&#305;� tarz&#305;, &#351;iddeti, s�resi ve do&#287;al seyri, onu
di&#287;er bozulma tarzlar&#305;ndan ay&#305;rdedici olmaktad&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans olarak nitelendirilebilecek bir zihinsel
bozulma, tan&#305;m&#305; gere&#287;i, �ncelikle birden fazla kognitif
i&#351;levi bozmal&#305;d&#305;r.&nbsp; Bu tan&#305;m uyar&#305;nca,
�rne&#287;in serebro-vask�ler olaylar sonucu geli&#351;en sol ya da sa&#287;
hemisfer hasarlar&#305;na e&#351;lik eden izole kognitif bozukluklar (afazi,
ihmal, amnezi, vb.) demans �er�evesinde de&#287;erlendirilmezler.&nbsp;&nbsp;
Oysa ki, orta ve b�y�k �apl&#305; arterlerin birbirini izleyen
t&#305;kanmalar&#305; sonucunda geli&#351;en serebral infarkt�sler demans d�zeyinde
birden fazla kognitif alan bozuklu&#287;una neden olabilir&nbsp; (bu t�r bir
demans VaD alt&#305;nda <i>Multi-infarkt Demans</i> � MID olarak
s&#305;n&#305;flan&#305;r).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans olarak nitelendirilebilecek bir zihinsel
bozulma, tan&#305;m&#305; gere&#287;i, mesleki performans, sokakta, mali
i&#351;lerde ba&#287;&#305;ms&#305;zl&#305;k, s&#305;radan ayg&#305;tlar&#305;n
kullan&#305;m&#305;, hobiler, ev i&#351;leri, kendine bak&#305;m ile
�zetlenebilecek <i>g�nl�k ya&#351;am aktivitelerinde (GYA�lar) kayda de&#287;er
bir bozulmaya yol a�acak &#351;iddette olmal&#305;d&#305;r</i><u>.</u>&nbsp;
�rne&#287;in, AH�li bir hastan&#305;n GYA�lar&#305;, erken evrede&nbsp;mesleki
performans&#305;ndaki bozulma i&#351; arkada&#351;lar&#305; taraf&#305;ndan
farkedilir, kendine yabanc&#305; mekanlarda yolunu kaybedebilir, evde
yeme&#287;ini s&#305;k s&#305;k yakabilir d�zeyde bozulabilecekken, ileri
evrede bu bozulma giyinme, y&#305;kanma gibi temel aktivitelerde yard&#305;ma
gereksinecek d�zeye ula&#351;abilir.&nbsp; Merkez sinir sisteminin bir�ok
hastal&#305;&#287;&#305;na, bu arada �rne&#287;in Parkinson
hastal&#305;&#287;&#305; ya da multipl skleroza da s&#305;kl&#305;kla kognitif
bozulmalar e&#351;lik eder.&nbsp; Bu hastalar, hastal&#305;klar&#305; �ncesine
g�re daha unutkan, zihinsel tepkileri a�&#305;s&#305;ndan daha yava&#351;, yeni
problemlere daha g�� ��z�m �retir durumda olabilirler.&nbsp; N�ropsikolojik
muayeneleri yap&#305;ld&#305;&#287;&#305;nda, bu yak&#305;nmalar&#305;n&#305;
yans&#305;t&#305;r d�zeyde, bellek, dikkat ve y�r�t�c� i&#351;levler
alanlar&#305;nda bozulmalar saptanabilir.&nbsp; Ancak, yine s&#305;kl&#305;kla
bu hastalar&#305;n GYA�lar&#305;, s�zkonusu kognitif sorunlar&#305; nedeniyle
kayda de&#287;er bi�imde k&#305;s&#305;tlanmam&#305;&#351; (parezi ve
bradikinezi gibi motor sorunlara ba&#287;l&#305; k&#305;s&#305;tlanma ihmal
edilmelidir) ve ba&#287;&#305;ms&#305;zl&#305;klar&#305;n&#305; s�rd�r�yor
olacaklard&#305;r (an&#305;lan iki hastal&#305;kta da bazen kognitif
bozulman&#305;n &#351;iddeti demans d�zeyine ula&#351;abilir).&nbsp;&nbsp; Bu
durumda s�z konusu olan demans de&#287;il, fakat frontal y�r�t�c�
bozukluktur.&nbsp;<i>Ya&#351;l&#305;l&#305;kla ilintili unutkanl&#305;k</i>
(age associated memory impairment � AAMI) ve <i>hafif kognitif bozukluk</i>
(mild cognitive impairment � MCI) kavramlar&#305; demansla ayr&#305;lmas&#305;
gereken di&#287;er durumlard&#305;r ve ayr&#305; alt k&#305;s&#305;mlarda daha
ayr&#305;nt&#305;l&#305; ele al&#305;nacaklard&#305;r.&nbsp; AH�nin patogenezi
k&#305;sm&#305;nda ayr&#305;nt&#305;s&#305;yla g�zden ge�irilece&#287;i gibi,
AH�nin patogenetik ba&#351;lang&#305;c&#305;ndan, kendisini ATD &#351;eklinde
klinik olarak ortaya koyana kadar 20 y&#305;ll&#305;k bir s�re gerekebilece&#287;i
hesaplanmaktad&#305;r.&nbsp; Hastal&#305;k limbik sistemde ba&#351;layacak ve
uzun y&#305;llar buraya s&#305;n&#305;rl&#305; kald&#305;ktan sonra neokortikal
asosiasyon alanlar&#305;na ge�ecek ve giderek bu b�lgedeki hasar&#305;n
&#351;iddetini artt&#305;racakt&#305;r.&nbsp; N�rodejenerasyon
limbik-paralimbik alanlara s&#305;n&#305;rl&#305; kald&#305;&#287;&#305; s�rece
bu alanlarda temsil edilen epizodik bellek sistemi giderek
i&#351;levsizle&#351;ece&#287;inden bu durum bir ilerleyici, izole
unutkanl&#305;k olarak yans&#305;yacakt&#305;r. Ancak, n�rodejenerasyon
neokortikal heteromodal kortekslere s&#305;�rad&#305;&#287;&#305;nda, bu
alanlarda temsil edilen dil ve g�rsel-mekansal i&#351;levler de bozulmaya
ba&#351;layaca&#287;&#305;ndan demans&#305;n asgari ko&#351;ulu olan �birden
fazla kognitif bozukluk� kriteri doldurulmu&#351; olacakt&#305;r.
&#304;&#351;te AAMI�ler ve MCI�lar&#305;n bir b�l�m�, muhtemelen limbik ve
paralimbik d�nemlere kar&#351;&#305;l&#305;k gelecek &#351;ekilde, AH�nin
demans �ncesi pre-klinik ve prodromal evrelerini olu&#351;turmakta, ATD ise bu
s�reklilikte demans evresine kar&#351;&#305;l&#305;k gelmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans olarak nitelendirilebilecek bir zihinsel
bozulma, tan&#305;m&#305; gere&#287;i, do&#287;al seyri a�&#305;s&#305;ndan
kal&#305;c&#305; ve s&#305;kl&#305;kla da ilerleyici olmal&#305;d&#305;r.&nbsp;
�yk�n�n ba&#351;lang&#305;� ve seyir �zellikleri g�z �n�ne
al&#305;nmaks&#305;z&#305;n, salt zihinsel durum a�&#305;s&#305;ndan
yap&#305;lacak bir kar&#351;&#305;la&#351;t&#305;rmada, �rne&#287;in akut
konf�zyonel durum (psikiyatrik terminolojide s&#305;kl&#305;kla delirium) ile
demans y�zeysel bir benzerlik ta&#351;&#305;yabilir; hatta demans&#305;n ileri
evreleri dikkatin ileri derecede bozuldu&#287;u bir kronik konf�zyonel durum
�zelli&#287;i g�sterebilir.&nbsp; Oysa ki, <i>akut konf�zyonel durum</i>un
(AKD) akut ba&#351;lang&#305;� ve g�nler, bazen de haftalar s�r�p, yine bazen
kendili&#287;inden t�m�yle d�zelme tarz&#305;ndaki seyri onu demans&#305;n
tarz&#305;ndan kolayl&#305;kla ay&#305;r&#305;r.&nbsp; Demanslar, �zellikle de
AH, s&#305;kl&#305;kla sinsi ba&#351;lang&#305;�l&#305; ve y&#305;llar i�inde
yava&#351; ve s�rekli ilerleyici seyirlidir.&nbsp; Akut olarak demans
&#351;iddetinde bir zihinsel bozuklu&#287;a neden olabilecek etmenler de
vard&#305;r: yeterince &#351;iddetli bir kafa travmas&#305;, kognitif
i&#351;levler a�&#305;s&#305;ndan stratejik bir konumdaki inme, global serebral
iskemi ya da anoksi, klinik profil a�&#305;s&#305;ndan demans �zellikleri
g�steren bir zihinsel bozuklu&#287;a neden olabilirler.&nbsp; Bu durumlarda,
akut ba&#351;lang&#305;� sonras&#305; zihinsel bozuklu&#287;un &#351;iddeti en
fazla olarak en erken evrede g�r�lecek, hasta izleyen aylarda, serebral
plastisitenin devreye girmesiyle, 1. y&#305;l sonuna kadar s�rebilecek&nbsp;
bir d�zelme e&#287;ilimi g�sterecek, sonras&#305;nda ise d�zelme tam
olmam&#305;&#351;sa arta kalan klinik tablo sekel olarak kal&#305;c&#305;
olacakt&#305;r.&nbsp; Bu sekel halen demans &#351;iddetinde olabilir, ancak
AH�den farkl&#305; olarak, klinik ve n�ropsikolojik olarak y&#305;ldan
y&#305;la farkl&#305;l&#305;k g�stermeyen bir statik demans �zelli&#287;i
g�sterecektir.&nbsp; N�roloji literat�r� ve pratik kullan&#305;mda bu t�r
statik tablolara demans yerine <i>ensefalopati </i>(iskemik/anoksik) ya da kafa
travmas&#305;na ba&#287;l&#305; olanlarda �<i>travmatik beyin hasar&#305;</i>�
&#351;eklinde adland&#305;rma e&#287;ilimi vard&#305;r.&nbsp; Bunlara,
zaman&#305;nda m�dahale edilmemi&#351; ya da yetersiz tedavi edilmi&#351;,
ba&#351;ta Herpes simpleks ensefaliti ve tbc meningoensefaliti gibi MSS
infeksiyonlar&#305;n&#305;n bu t�r statik demanslarla sonlanaca&#287;&#305;
eklenebilir. VaD�lar aras&#305;nda MID ya da stratejik infarkt demanslar&#305;,
AH�den farkl&#305; olarak akut ba&#351;larlar.&nbsp; AH�nin s�rekli ilerleyici
seyrine kar&#351;&#305;n VaD�&#305;n mutad seyri basamaks&#305; ilerleme
&#351;eklindedir (iki inme aras&#305;nda de&#287;i&#351;meden kalan bir plato
d�nemi, sonras&#305;nda inmeyi izleyen ani k�t�le&#351;me).&nbsp; AH�nin
y&#305;llar i�inde ilerleme &#351;eklindeki yava&#351; seyrine
kar&#351;&#305;l&#305;k �rne&#287;in CJH 1 y&#305;l i�inde yata&#287;a
ba&#287;&#305;ml&#305; nihai evreye ula&#351;ma ve �l�m &#351;eklinde �ok
h&#305;zl&#305; bir seyir g�sterir. Bir ba&#351;ka deyi&#351;le, sinsi
ba&#351;lang&#305;�, kronik yava&#351; seyirli demanslar&#305;n prototipi, b�yle
bir seyre sahip �ok say&#305;da demans hastal&#305;&#287;&#305; aras&#305;nda
nas&#305;l AH ise, �h&#305;zl&#305; seyirli demanslar�, prototipi CJH olan ve
�ok say&#305;da hastal&#305;ktan olu&#351;an ayr&#305; bir alt ba&#351;l&#305;k
olarak s&#305;n&#305;fland&#305;r&#305;labilir. Bu tarz bir
yakla&#351;&#305;mla, ilk durumda AH�yi alt&#305;n standart olarak alarak
mevcut durumda g�r�len olgunun ne �l��de standart bir AH tablosuyla
�rt�&#351;t�&#287;�, ne �l��de ayr&#305;ld&#305;&#287;&#305; temelinde bir
ay&#305;r&#305;c&#305; tan&#305; ak&#305;l y�r�tmesi yap&#305;lacakken, ikinci
durumda bu kez alt&#305;n standart tipik CJH �zellikleri olacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans tan&#305;s&#305; bilin�
bulan&#305;kl&#305;&#287;&#305; olmayan hastada konulur.&nbsp; AKD�lere yukarda
s�z edilen seyirleri yan&#305;s&#305;ra s&#305;kl&#305;kla bilin�
bulan&#305;kl&#305;&#287;&#305; da e&#351;lik eder.&nbsp; AKD�ler patogenetik
olarak, uyan&#305;kl&#305;k, fark&#305;ndal&#305;k ve global dikkatin n�ral
kar&#351;&#305;l&#305;&#287;&#305; olan retik�ler formasyonun i&#351;levini
bozarak ortaya �&#305;karlar.&nbsp; Dolay&#305;s&#305;yla, klinik tablo bilin�
dalgalanmalar&#305; yan&#305;s&#305;ra, n�ropsikolojik olarak ba&#351;l&#305;ca
global dikkat bozuklu&#287;u ve t�m kognitif i&#351;levlerde buna sekonder
bozulmalard&#305;r.&nbsp; AKD�yi demansa y�zeysel olarak benzer k&#305;lan
�zellik bu global bozulma durumudur.&nbsp; Demans durumlar&#305;n&#305;n
toksik-metabolik ensefalopatilerin AKD�sinden ay&#305;rmak ve muayene
bulgular&#305;n&#305;n dikkat bozuklu&#287;una sekonder ge�ici nitelikte
bulgular de&#287;il, fakat o i&#351;levin n�ral altyap&#305;s&#305;n&#305;n
primer bozuklu&#287;unu yans&#305;tt&#305;&#287;&#305;n&#305; s�yleyebilmek
i�in tan&#305; muayenesinin bilin� dalgalanmas&#305; olmayan bir hastada
yap&#305;lmas&#305; ko&#351;ulu demans tan&#305;m&#305;na giren bir
�l��tt�r.&nbsp; Ancak, klinik pratikte demans ve AKD durumlar&#305;n&#305;n ak
ve kara gibi kutupsall&#305;klar olmad&#305;&#287;&#305; ve seyrek olmayarak i�
i�e ge�ebileceklerini unutmamak gerekir.&nbsp; Bunun ba&#351;l&#305;ca nedeni
demans patogenezinin yaratt&#305;&#287;&#305; n�ronal rezervdeki
a&#351;&#305;r&#305; k&#305;s&#305;tlanma sonucu demans hastas&#305;n&#305;n
toksik-metabolik durumlar ya da sistemik&nbsp;infeksiyonlar s&#305;ras&#305;nda
AKD�ye �ok daha yatk&#305;n olmas&#305;d&#305;r.&nbsp; B�yle bir durumda, AKD
demans seyrinin �zerine binerek tabloyu bir s�re i�in akut olarak
a&#287;&#305;rla&#351;t&#305;racakt&#305;r.&nbsp; Titiz al&#305;nm&#305;&#351;
bir �yk�, sinsi seyirli bir zihinsel y&#305;k&#305;m&#305;n seyrinde aniden
geli&#351;en ve GYA�lar&#305; h&#305;zla bozan bir&nbsp;tabloyu ifade
edecektir.&nbsp; Ayr&#305;ca, LCD�de dikkat dalgalanmalar&#305;n&#305;n,
genellikle bir AKD d�zeyinde olmasa da, daha ba&#351;lang&#305;�tan itibaren klinik
tablonun asli bile&#351;enlerinden biri oldu&#287;u
hat&#305;rlanmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu kez, an&#305;lan �l��tleri de katarak daha tam
bir tan&#305;ma giri&#351;elim:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�Demans, eri&#351;kin MSS�nin hasarlanmas&#305;
sonucu, bilin� bulan&#305;kl&#305;&#287;&#305; olmaks&#305;z&#305;n, birden
fazla kognitif alan&#305;n bozulmas&#305;, bununla ilintili olarak g�nl�k
ya&#351;am aktivitelerinin eski d�zeyinde s�rd�r�lememesine neden olan,
do&#287;al seyri a�&#305;s&#305;ndan kal&#305;c&#305;, s&#305;kl&#305;kla da
ilerleyici bir klinik tablodur�</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANSLARIN SINIFLANDIRILMASI<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demanslar �ncelikle primer&nbsp;ve
sekonder&nbsp;olarak s&#305;n&#305;flan&#305;rlar <b>(Tablo 1</b>).&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH�nin de dahil oldu&#287;u ve en b�y�k b�l�m�
olu&#351;turan primer demanslar, demansa neden olan MSS�nin n�rodejeneratif
hastal&#305;klar&#305;n&#305; i�erir.&nbsp; N�rodejeneratif hastal&#305;k,
zihinsel i&#351;levlerin alt yap&#305;s&#305;n&#305; olu&#351;turan limbik ve
asosiasyon alanlar&#305;nda, s&#305;kl&#305;kla kendine �zg� patolojik izi
b&#305;rakarak (�rne&#287;in, AH�de senil plak ve n�rofibriler yumaklar, LCD�de
Lewy cisimcikleri) buralarda n�ron ve sinaps kayb&#305;yla dejenerasyona yol
a�ar ve i&#351;levini bozar.&nbsp; Bu patogenez belli bir yay&#305;l&#305;m
a&#351;amas&#305;nda klini&#287;e demans olarak yans&#305;r.&nbsp;
N�rodejenerasyon, AH�de oldu&#287;u gibi an&#305;lan alanlara
s&#305;n&#305;rl&#305; kalma e&#287;ilimindeyse, demans izole ya da
a&#287;&#305;rl&#305;kl&#305; klinik tablo olarak kal&#305;r; oysa ki, motor sistem
de dejenerasyona dahil olursa LCD�de oldu&#287;u gibi parkinsonizm, Huntington
hastal&#305;&#287;&#305;nda oldu&#287;u gibi kore, demansla birlikte, bazen
daha da �n�nde&nbsp;klinik tablonun a&#287;&#305;rl&#305;kl&#305; bir
par�as&#305;d&#305;r.&nbsp; Dolay&#305;s&#305;yla, primer demanslar klinik
g�r�n�&#351;lerine g�re, kendi i�lerinde primer izole demanslar ve motor
bozuklukla birlikte olan primer demanslar olarak
s&#305;n&#305;flanabilirler.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�nceki k&#305;s&#305;mdaki nihai tan&#305;m&#305;
hat&#305;rlayal&#305;m: �Demans...birden fazla kognitif
alan&#305;n..bozulmas&#305;na yola�an.... bir klinik tablodur�.&nbsp;Bu
tan&#305;m uyar&#305;nca, bozulan ve salim kalan kognitif alanlar&#305;n tarz&#305;na
g�re de s&#305;n&#305;flamay&#305; ilerletebiliriz.&nbsp; N�rodejenerasyon,
yukarda an&#305;lan alanlarda e&#351;zamanl&#305; ba&#351;lay&#305;p s�regiden
bir seyir izlemez, fakat patogenezin kendine �zg� bir tarz&#305;
vard&#305;r.&nbsp; �rne&#287;in, AH, daha �nce de de&#287;inildi&#287;i gibi
y&#305;llarca limbik alanlara s&#305;n&#305;rl&#305; kald&#305;ktan sonra neokortikal
alanlara ge�er.&nbsp; Ancak, neokortikal asosiasyon alanlar&#305;na ge�i&#351;
de e&#351;zamanl&#305; bir yay&#305;l&#305;m de&#287;ildir, fakat yine �zg�l
bir zamansal seyir g�sterir: posterior heteromodal alanlar prefrontal
korteksten nispeten daha �nce tutulur.&nbsp; Bu zamansal tarz, erken ve orta
evrelerinde AH�nin kendine �zg� n�ropsikolojik profilini belirler: tipik AH
sendromu (ATD) yak&#305;n bellek (limbik), dilsel (sol hemisfer posterior
heteromodal) ve g�rsel-mekansal (sa&#287; hemisfer posterior heteromodal)
i&#351;levlerin bozuldu&#287;u, prefrontal kortekse �zg� y�r�t�c� i&#351;levler
(planlama, soyutlama, zihinsel esneklik, vb.) ve ki&#351;ili&#287;in g�reli
salim kald&#305;&#287;&#305; bir profile sahiptir.&nbsp; Buna
kar&#351;&#305;l&#305;k fronto-temporal demans (�rne&#287;in, Pick hastal&#305;&#287;&#305;)
an&#305;lan seyrin tersine, �ncelikle ve bazen de yaln&#305;zca prefrontal
korteksi tutar, limbik ve posterior neokortikal alanlar salim kal&#305;r.&nbsp;
FTD bu patogenezi yans&#305;t&#305;r bir klinik profile sahiptir: erken d�nemde
y�r�t�c� i&#351;levlerde bozulma, ki&#351;ilik de&#287;i&#351;ikli&#287;i, buna
kar&#351;&#305;l&#305;k yak&#305;n bellek ve mekan oryantasyonu, navigasyonel
i&#351;levlerde (g�rsel-mekansal i&#351;levler) g�reli korunma.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sistemik, n�rolojik ya da psikiyatrik bir
hastal&#305;&#287;&#305;n seyri s&#305;ras&#305;nda, mutad klinik
g�sterilerinin yan&#305; s&#305;ra demansa da neden olmas&#305; durumunda, s�z
konusu demans sekonder demanslar alt&#305;nda s&#305;n&#305;flan&#305;r.
Sekonder demanslar&#305;n en s&#305;k nedeni VaD�dir.&nbsp; Gerek orta ve b�y�k
�apl&#305; serebral arterlerin birbirini izleyen t&#305;kanmalar&#305; (MID),
gerek hipertansif serebral k���k damar hastal&#305;&#287;&#305; (Binswanger hastal&#305;&#287;&#305;)
ve gerekse de stratejik lokalizasyonlu tek infarktlar VaD nedeni
olabilir.&nbsp; Normal n�ronal i&#351;levin gereksindi&#287;i, ekstrasel�ler
ortam&#305;n glukoz i�eri&#287;i, oksijenizasyon d�zeyi, hormonal durum ve
elektrolit dengesini bozabilecek herhangi bir sistemik veya metabolik bozukluk
(diyabet, kalp yetmezli&#287;i, hipotiroidi, kronik obstr�ktif akci&#287;er
hastal&#305;&#287;&#305;, b�brek yetmezli&#287;i, karaci&#287;er
yetmezli&#287;i) ya da normal sinaptik iletimi bozabilecek herhangi bir
terap�tik ama�l&#305; ila�, a&#287;&#305;r metallere maruz kalma gibi durumlarda
toksik-metabolik ensefalopati ortaya �&#305;kar.&nbsp; Toksik-metabolik
ensefalopatiler, b�y�k s&#305;kl&#305;kla AKD olarak g�r�nseler de bazen daha
yava&#351; seyirli bir tabloyla demansa da benzeyebilirler.&nbsp;
&#304;nflamatuar s�re�ler (N�ro-Beh�et sendromu, primer MSS vask�liti,
gran�lomat�z anjiitis, sistemik lupus, paraneoplastik limbik ensefalit),
infeksiyonlar (Tbc meningoensefaliti, Herpes simpleks ensefaliti, HIV, Lyme,
Whipple, n�rosifilis, vb), n�rolojik hastal&#305;klar i�inde multipl skleroz,
primer ya da sekonder beyin t�m�rleri, kronik subdural hematom, normal bas&#305;n�l&#305;
hidrosefali gibi yer kaplay&#305;c&#305; lezyonlar demansa da neden
olabilirler.&nbsp; Psikiyatrik hastal&#305;klar i�inde �zellikle <i>ya&#351;l&#305;l&#305;k
depresyonu</i>, afektif bulgular&#305;n&#305; gizleyen,
a&#287;&#305;rl&#305;kl&#305; bi�imde motivasyonel ve kognitif bulgulardan
olu&#351;an bir demans (baz&#305; yazarlara g�re ps�do-demans) tablosu
&#351;eklinde kendini g�sterebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Primer demanslar&#305;n, bu arada AH�nin klinik
tan&#305;s&#305; i�in sekonder demanslar&#305;n ekarte edilebiliyor olmas&#305;
gerekir.&nbsp; Nitekim, AH i�in yay&#305;nlanm&#305;&#351; olan klinik
tan&#305; kriterleri i�inde, gerek PRAD ve gerekse DAT tan&#305;lar&#305; i�in
bu ko&#351;ulun yerine getiriliyor olmas&#305; esast&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 1. </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Demans
Hastal&#305;klar&#305;n&#305;n S&#305;n&#305;fland&#305;r&#305;lmas&#305;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=329 valign=top style='width:246.4pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Primer
  (Dejeneratif)</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=350 valign=top style='width:262.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sekonder</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width=329 valign=top style='width:246.4pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
  hastal&#305;&#287;&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lewy cisimcikli demans</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fronto-temporal demans</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>FTD-davran&#305;&#351;sal varyant</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;lerleyici tutuk afazi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Semantik demans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>FTD-ALS</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hareket bozuklu&#287;uyla
  birlikte</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:49.65pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Parkinson hastal&#305;&#287;&#305; demans&#305; </span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kortiko-bazal dejenerasyon</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Progresif supran�kleer paralizi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Huntington hastal&#305;&#287;&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multi-sistem atrofiler</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Wilson hastal&#305;&#287;&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�roakantositoz</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion hastal&#305;klar&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Creutzfeldt-Jacob hastal&#305;&#287;&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gerstmann-Str�ussler-Scheinker hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Fatal familyal insomni</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�e&#351;itli pediyatrik
  demanslar</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kufs hastal&#305;&#287;&#305;</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Metakromatik l�kodistrofi</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gaucher hastal&#305;&#287;&#305;</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Niemann-Pick hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er ender demanslar</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Limbik demans</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Poliglukozan cisimcik hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Arjirofilik tah&#305;l hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=350 valign=top style='width:262.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�ler
  demans</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multi-infarkt demans</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Binswanger hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Stratejik infarkt demans&#305;</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CADASIL</span><span lang=DE style='font-family:Tahoma;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal bas&#305;n�l&#305;
  hidrosefali</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toksik-metabolik demanslar</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Wernicke-Korsakoff hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>B12 vitamin eksikli&#287;i</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hipotiroidi</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik karaci&#287;er hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Organik ��z�c�lere maruz kalma</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;la�lar</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyonlar</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Herpes simpleks ensefaliti</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rosifilis</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik menenjitler</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>HIV-demans kompleksi</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Whipple hastal&#305;&#287;&#305;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kafa i�i yer
  kaplay&#305;c&#305; hastal&#305;klar</span><span lang=DA style='font-family:
  Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Neoplastik durumlar</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Subdural hematom</span><span lang=DA style='font-family:
  Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Otoimmun-inflamatuar
  hastal&#305;klar</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multipl skleroz</span><span lang=DA style='font-family:
  Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Beh�et hastal&#305;&#287;&#305;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Paraneoplastik limbik ensefalit</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>VGKC ve NMDAR kanalopatileri</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gran�lomat�z anjitis</span><span lang=FR
  style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Primer sinir sistemi vask�liti</span><span lang=FR
  style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>NAIM sendromu</span><span lang=FR style='font-family:
  Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:9.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Bu tabloda demansa neden olan t�m nedenlerin
s&#305;ralanmas&#305; ama�lanmam&#305;&#351;t&#305;r. B�y�k bir
k&#305;sm&#305;n&#305;n ad&#305; ge�mekle birlikte as&#305;l ama� primer ve
sekonder demans kavramlar&#305;na a�&#305;kl&#305;k getirmektir.
K&#305;saltmalar: VGKC: Voltaj kap&#305;l&#305; potasyum kanal&#305;; NMDAR:
N-metil D-aspartat resept�r�; NAIM: Non-vask�litik otoimmun meningoensefalit.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANSTA �YK� �ZELL&#304;KLER&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bir zihinsel y&#305;k&#305;m tablosu olarak
tan&#305;mlad&#305;&#287;&#305;m&#305;z demans sendromunu olu&#351;turan
hastal&#305;klar, esas olarak primer sensoryel-motor alanlarla ilintili
b�lgeleri de&#287;il, fakat zihinsel i&#351;levlerin alt yap&#305;s&#305; olan
b�lgeleri (limbik ve asosiasyon alanlar&#305;) hasarlar.&nbsp;
Dolay&#305;s&#305;yla, demansa �zg� belirtiler g��s�zl�k, hissizlik, g�rme
alan&#305; kay&#305;plar&#305; gibi klasik n�rolojik muayeneyle
bulgular&#305;n&#305; ortaya koymaya al&#305;&#351;t&#305;&#287;&#305;m&#305;z
belirtiler de&#287;il; unutkanl&#305;k, konu&#351;ma bozuklu&#287;u, y�n bulma
g��l�&#287;�, yarg&#305;lama-problem ��zme g��l�kleri, tan&#305;ma
bozuklu&#287;u, el becerilerinde bozukluk, ki&#351;ilik
de&#287;i&#351;iklikleri, anksiyete, disfori, hezeyan ve hal�sinasyonlar gibi
belirtiler olacakt&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunun semptomatolojisi, �� ana (kardinal)
kategoride s&#305;n&#305;flanabilir:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>1. Kognitif, <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>2. Davran&#305;&#351;sal, <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>3. &#304;&#351;levsel
(GYA�lar).&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans �yk�s�, bu �� kardinal alana �zg�
yak&#305;nmalar&#305;n bir sistematik i�inde sorgulanmas&#305; ile
al&#305;n&#305;r.&nbsp; Bunlar&#305;n yan&#305;s&#305;ra <i>motor, otonom
sistemler ve uyku</i> <i>bozukluklar&#305;</i>na ili&#351;kin yak&#305;nma ve
belirtilerin sorgulanmas&#305; da baz&#305; demans sendromlar&#305;
a�&#305;s&#305;ndan �nem ta&#351;&#305;r ve kardinal alanlar&#305;n
yan&#305;s&#305;ra bu alanlar da ikincil alanlar olarak
d�&#351;�n�lebilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�yk� m�mk�nse hastadan birinci derecede sorumlu
bir hasta yak&#305;n&#305;n&#305;n da varl&#305;&#287;&#305;nda, paralel olarak
al&#305;nmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yak&#305;nmalar&#305;n ba&#351;lang&#305;� (sinsi,
akut veya subakut) ve ilerleme tarz&#305; (statik, kronik s�rekli veya
basamaks&#305;, h&#305;zl&#305;) belirlenip kaydedilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif belirtiler</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda mutlak olmasa da
en s&#305;k rastlan&#305;lan belirti bellek alan&#305;na aittir.&nbsp; Hasta ya
da yak&#305;n&#305; ayn&#305; sorular&#305;n, ayn&#305; konular&#305;n
tekrarlanmas&#305;, �zel e&#351;yan&#305;n kaybedilmesi, randevular&#305;n
unutulmas&#305;, yeme&#287;in ocakta, oca&#287;&#305;n a�&#305;k
unutulmas&#305;ndan yak&#305;nmaktad&#305;r.&nbsp; G�rsel-mekansal
i&#351;levlere ait bozulma kendini �nce yabanc&#305; mekanlarda, giderek bildik
mekanlarda y�n bulma g��l�&#287;� ve bazen kaybolma &#351;eklinde
g�sterir.&nbsp; Dil bozuklu&#287;u erken d�nemde adland&#305;rma g��l�&#287;�,
kelime hazinesinde daralmayla ba&#351;lay&#305;p, giderek AH�de daha mutad
oldu&#287;u gibi anlaman&#305;n da bozuldu&#287;u bir ak&#305;c&#305; afaziye,
ya da ilerleyici tutuk afazide daha mutad oldu&#287;u gibi gramer
yap&#305;s&#305;n&#305;n da bozuldu&#287;u bir tutuk afaziye
d�n�&#351;�r.&nbsp; Semantik demansta ise s&#305;radan nesnelerin
anlamlar&#305;n&#305;n kayboldu&#287;u bir tek kelime anlama bozuklu&#287;u s�z
konusudur. &#304;lerleyici afazisi olan bir hastan&#305;n kelime bulma
g��l�&#287;� olan temel yak&#305;nmas&#305;n&#305;n da s&#305;kl&#305;kla hasta
ve hasta yak&#305;n&#305; taraf&#305;ndan �unutkanl&#305;k� olarak ifade
edilece&#287;i g�z �n�nde bulundurulmal&#305;d&#305;r. �yk� derinle&#351;tirildik�e
bu t�rden bir unutkanl&#305;k yak&#305;nmas&#305;n&#305;n adresinin limbik
yak&#305;n bellek sistemi de&#287;il de sol hemisferik dil sistemi
oldu&#287;unun alt&#305; �izilir. Praktik bozukluklar (apraksiler) nedeniyle,
basit g�ncel ayg&#305;tlar&#305;n (tarak, makas, di&#351; f&#305;r�as&#305;,
sofra ayg&#305;tlar&#305;, vb.)&nbsp; manipulasyonlar&#305; bozulabilir.&nbsp;
Gnostik bozukluklar (agnoziler), nesnelerin ve y�zlerin
tan&#305;nmas&#305;n&#305;, mekanda bir nesnenin, di&#287;er nesnelere g�re
pozisyonunun belirlenmesini bozabilir.&nbsp; Y�r�t�c� i&#351;levler
alan&#305;ndaki bozukluk nedeniyle hasta zihinsel esnekli&#287;ini kaybetme
e&#287;ilimindedir; metaforlar&#305;n soyut anlamlar&#305;n&#305; kavramakta,
davran&#305;&#351;lar&#305;n&#305; planlamakta, bireysel ve toplumsal sorunlar
�zerine ak&#305;l y�r�tmekte, g�nl�k ya&#351;amda
kar&#351;&#305;la&#351;t&#305;&#287;&#305; problemlere uygun ��z�mler �retmekte
zorlan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal belirtiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda, apatiye
varacak &#351;ekilde kendili&#287;indenli&#287;in kayb&#305;, disinhibisyona
varacak &#351;ekilde d�rt� kontrol�nde bozukluklar (hiperseks�alite, hiperfaji)
say&#305;labilir.&nbsp; Apati spektrumundaki hasta giderek daha az spontanite
�rnekleri sergiler.&nbsp; &#304;nisiyatif g�stermez, kendili&#287;inden bir
&#351;ey talep etmez, kendisine y�nelinmedi&#287;inde konu&#351;maz.&nbsp;
�evresinde olup biten hi�bir &#351;ey ilgisini �ekmez gibidir.&nbsp;
Disinhibisyon kendini �ncelikle sosyal uygunsuz davran&#305;&#351; olarak
adland&#305;r&#305;lan sosyal konumla ba&#287;da&#351;mayan rahat
davran&#305;&#351;lar, al&#305;&#351;&#305;lmad&#305;k giri&#351;kenlik,
&#351;akac&#305;l&#305;k, �ocuksulukla g�sterir; hasta yak&#305;nlar&#305; bu
de&#287;i&#351;iklikleri s&#305;kl&#305;kla aile i�in bir utan� vesilesi olarak
aktar&#305;rlar.&nbsp; Hiperseks�alite hastan&#305;n o zamana kadar
edindi&#287;i sosyal normlar d&#305;&#351;&#305;nda cinsel i�erikli imalar ta&#351;&#305;yan
s�z ve davran&#305;&#351;lar sergilemesinden uygunsuz cinsel taleplere kadar
varan &#351;iddetlerde g�r�lebilir.&nbsp; Hiperfaji hastan&#305;n
al&#305;&#351;&#305;lagelen a&#287;&#305;z tad&#305;n&#305;n
de&#287;i&#351;mesi, oburla&#351;mas&#305; ve �zellikle &#351;ekerlemeye
d�&#351;k�nle&#351;mesi &#351;eklinde ba&#351;lar ve �ay po&#351;eti, kendi
fe�esi gibi yenilmeyecek nesnelerin dahi a&#287;za
t&#305;k&#305;&#351;t&#305;r&#305;labildi&#287;i &#351;iddetlere ula&#351;abilir.&nbsp;
Psikotik belirtiler d�&#351;�nce ve alg&#305; bozukluklar&#305; &#351;eklinde
ortaya �&#305;kar. D�&#351;�nce bozukluklar&#305; �zellikle
h&#305;rs&#305;zl&#305;k (�bak&#305;c&#305; param&#305; �al&#305;yor�),
sadakatsizlik (�e&#351;im beni bir ba&#351;kas&#305;yla aldat&#305;yor�) ve
terkedilme (�beni bak&#305;mevine atacaks&#305;n&#305;z�) hezeyanlar&#305;,
misidentifikasyon �buras&#305; benim evim de&#287;il, eve gidelim� ve Capgras
hezeyan&#305; (tan&#305;&#351; olmas&#305; gereken ki&#351;i onun yerine
ge�mi&#351; bir taklidi) &#351;eklinde ortaya �&#305;kar. Alg&#305;
bozukluklar&#305; ise t�m duysal modalitelerde olabilecekleri gibi �zellikle
g�rsel hal�sinasyonlar &#351;eklindedir. Bunlar �evresel uyaranlar&#305;n
yanl&#305;&#351; yorumland&#305;&#287;&#305; ill�zyonlar, mekanda bir
varl&#305;&#287;&#305;n mevcudiyeti hissi gibi forme olmayan hal�sinasyonlar
veya canl&#305; r�yalar gibi �ok hafif alg&#305; bozukluklar&#305;ndan
nesneler, insan ve hayvanlar gibi forme hal�sinasyonlar&#305;n oldu&#287;u daha
a&#287;&#305;r durumlara de&#287;i&#351;ir. Alg&#305; bozukluklar&#305;
a&#287;&#305;rla&#351;t&#305;k�a i�g�r� kaybolur ve geceye
s&#305;n&#305;rl&#305;yken giderek g�nd�zleri de g�r�lmeye
ba&#351;larlar.&nbsp; Duygudurum bozukluklar&#305; aras&#305;nda depresyon
�zellikle s&#305;k olabilir ve afektif-motivasyonel y�nleri
sorgulanmal&#305;d&#305;r.&nbsp; Anksiyete, huzursuzluk, yerinde duramama,
s�rekli yer ve mekan de&#287;i&#351;tirme, �ok �abuk s&#305;k&#305;lma
&#351;eklinde ortaya �&#305;kabilir; �zel bir �e&#351;idi de yakla&#351;an
randevularla artan anksiyetedir.&nbsp; Mani, klasik psikiyatrik tablosundan �ok
uygunsuz ne&#351;e ve/veya �fke, duygudurum dalgalanmalar&#305;, grandiozite,
sald&#305;rganl&#305;k &#351;eklindeki g�sterilerin bir veya
birka�&#305;n&#305;n toplam&#305; &#351;eklinde g�r�lebilir.&nbsp; Fobiler,
hastaya �zg� �e&#351;itlilikler g�sterebilece&#287;i gibi, �zellikle de
e&#351;in g�z �n�nden uzakla&#351;mas&#305; endi&#351;esi ve bu nedenle
e&#351;in pe&#351;inden ayr&#305;lmama veya yaln&#305;z kalma korkusu
&#351;eklindedir.&nbsp; Fiziksel veya verbal &#351;iddeti de i�eren ajitasyon,
ama�s&#305;z-tekrarlay&#305;c&#305; hareketler (ama�s&#305;z
dola&#351;ma-ad&#305;mlama, dolaplar&#305; a�&#305;p-kapama, �ar&#351;af&#305;
katlay&#305;p-a�ma gibi ayn&#305; hareketi tekrarlama, uygunsuz yerlere,
toplama, istif etme) g�zlenebilir davran&#305;&#351;sal sorunlar
aras&#305;ndad&#305;r. G�zlenebilir davran&#305;&#351;sal bozukluklar da
&#351;iddetlendik�e ba&#351;lang&#305;�ta �g�ne&#351; batma fenomeni� ad&#305;
verilen geceye s&#305;n&#305;rl&#305; olmaktan, giderek g�ne yay&#305;lma
e&#287;ilimi g�sterirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel alana ait belirtiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>, i&#351;ini s�rd�rmek,
ev d&#305;&#351;&#305;nda yolculuk, al&#305;&#351;veri&#351;, mali
i&#351;leri&nbsp; (fatura �demeleri, banka i&#351;leri, vb.) �ekip �evirmek,
g�nl�k ayg&#305;tlar&#305; kullanmak, hobilerini s�rd�rmek, ev i&#351;lerini
y�r�tmek, kendine bak&#305;m veya hijyene (giyinmek, y&#305;kanmak, beslenmek,
tuvalet, vb.) muktedir olmak &#351;eklinde �rneklenebilecek �zellikleri
bozabilir (i&#351;levsel alana ait belirtilerin AH�de bozulma hiyerar&#351;isi
i�in ilerdeki �<i>Alzheimer Hastal&#305;&#287;&#305;n&#305;n Klinik Evreleri</i>�
k&#305;sm&#305;na bak&#305;n&#305;z).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Motor bozukluklar</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda ba&#351;ta
y�r�y�&#351; bozuklu&#287;u olmak �zere ekstrapiramidal bulgulara atfedilecek
yak&#305;nmalar&#305;n sorgulanmas&#305; (k���k ad&#305;mlarla y�r�me, donma,
istemeden h&#305;zlanma, d�&#351;me, dengesizlik, hareketlerde yava&#351;lama,
tremor, konu&#351;ma ve yutma bozuklu&#287;u) �nemlidir. Vask�ler demansa
parezi sekellerinin, fronto-temporal demansa amiyotrofinin e&#351;lik
edebilece&#287;i ak&#305;lda tutulmal&#305; ve zaaf, kas erimesi gibi temel
belirtileri sorgulanmal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Otonom bozukluklar</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda ise �riner
inkontinans&#305;n bulunup bulunmamas&#305; �nem ta&#351;&#305;r.&nbsp;
&#304;drara yeti&#351;me g��l�&#287;� (urgency) d�zeyinde hafif bir
inkontinans&#305;n dahi kaydedilmesi gerekir.&nbsp; Ortostatizm
yak&#305;nmalar&#305;, senkopal e&#287;ilim, kronik konstipasyon, impotans
demans sendromlar&#305;n&#305;n ay&#305;rt edilmesinde �nem ta&#351;&#305;yan
di&#287;er otonomik yak&#305;nmalar aras&#305;ndad&#305;r.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Parasomniler</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda �zellikle REM
uykusu s&#305;ras&#305;nda tonik inhibit�r aktivitenin ��z�lmesi sonucu ortaya
�&#305;kan r�yalar&#305;n yatakta s&#305;�rama, d�v�nme, d�&#351;me,
konu&#351;ma, hayk&#305;rma &#351;eklinde d&#305;&#351;avurumu olan REM uykusu
davran&#305;&#351; bozuklu&#287;u (RUDB) belirtileri �nem
ta&#351;&#305;r.&nbsp; Uykuya dalma g��l�&#287;�, kesintili uyuma, sabah �ok
erken uyanma gibi insomnia belirtileri ve insomnian&#305;n veya uyku apnesinin
sonucu olarak veya ba&#287;&#305;ms&#305;z bir fenomen olarak
�a&#351;&#305;r&#305; g�nd�z uyuklamas&#305;�, gerek ay&#305;r&#305;c&#305;
tan&#305;daki �nemleri ve gerekse de t�m demans hastalar&#305;n&#305;n zihinsel
performanslar&#305;na belirgin olumsuz etkileri ve g�reli olarak da kolay
tedavi hedefleri olma �zellikleriyle titizlikle sorgulanmal&#305; ve
kaydedilmelidirler. Demansta �yk� �zellikleri i�in <b>Tablo 2</b>�ye
bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�yk� sonunda klinisyen temel sorunu saptayarak
�ekirdek kognitif bulguyu ba&#351;lang&#305;� ve seyriyle belirlemi&#351;
olmal&#305;, buna kognitif alandan varsa di&#287;er kat&#305;l&#305;mlar&#305;,
�ekirdek ve ikincil kognitif bozukluklar&#305;n GYA�lar&#305; etkileme
d�zeyini, davran&#305;&#351;sal ve di&#287;er (ikincil) alanlar&#305;n
kat&#305;l&#305;m zamanlamalar&#305;n&#305; ve &#351;iddetlerini
canland&#305;rabilmelidir. &#304;yi al&#305;nm&#305;&#351; bir �yk� �zellikle
tipik olgularda ay&#305;r&#305;c&#305; tan&#305;y&#305; daha bu a&#351;amada
b�y�k �l��de ��zece&#287;i ve hastal&#305;k &#351;iddetini a&#351;a&#287;&#305;
yukar&#305; belirleyece&#287;i gibi, mental durum muayenesi i�in
kullan&#305;lacak standart testlerin yan&#305;s&#305;ra �zellikle
odaklan&#305;lmas&#305; gereken kognitif alanlar i�in �zg�l testlerin
esneklikle se�imine de rehberlik edecektir. Dolay&#305;s&#305;yla, sinsi
ba&#351;lay&#305;p, y&#305;llar i�inde ilerlemi&#351;, zaman i�inde kelime
bulma ve d&#305;&#351; mekanda y�n�n� bulma g��l�klerinin eklendi&#287;i, bu
nedenle hastan&#305;n son zamanlarda art&#305;k yaln&#305;z ba&#351;&#305;na
soka&#287;a �&#305;kamad&#305;&#287;&#305;, ancak evinde y&#305;kanma, giyinme
gibi temel GYA�lar&#305;n&#305; halledebildi&#287;i bir �yk�
kar&#351;&#305;s&#305;nda klinisyen orta evrede bir AH�li hasta ile
kar&#351;&#305; kar&#351;&#305;ya oldu&#287;unu rahatl&#305;kla �ng�r�p muayene
sonu�lar&#305;n&#305;n da bu �ng�r�s�n� destekleyece&#287;ini tahmin
edebilirken, temel sorunu bellek de&#287;il de mekanda y�n�n� bulmak, g�z�n�n
�n�ndeki nesneleri bulamamak olan bir hasta kar&#351;&#305;s&#305;nda bu kez
�ok daha ender bir n�rodejeneratif antite olan �posterior kortikal atrofi�nin
ilerleyici simultanagnozisinin ifade edilmekte oldu&#287;unu ay&#305;rdedip
normalde standart muayenesinin i�inde yeralmayabilecek simultanagnozi
testlerini se�meye karar verebilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANSTA �Z VE SOYGE�M&#304;&#350; �ZELL&#304;KLER&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demansl&#305; hastan&#305;n �yk�s�
s&#305;ras&#305;nda �zge�mi&#351;i i�inde belirli genel medikal, n�rolojik,
psikiyatrik ve toksik �zelliklerin soru&#351;turulmas&#305; �nemlidir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genel medikal �zge�mi&#351; i�inde vask�ler risk
fakt�rleri (hipertansiyon, iskemik kalp hastal&#305;&#287;&#305;, diyabet),
endokrin-metabolik bozukluklar (�zellikle hipotirodi, B12 vitamini
yetmezli&#287;i), kronik infeksiyonlar (t�berk�loz, sifilis, AIDS), sistemik
otoimmun-inflamatuar hastal&#305;klar (Sistemik lupus, Sj�gren, romatoid
artrit, Beh�et), sistemik neoplazi, genel anestezi kullan&#305;lm&#305;&#351;
cerrahi giri&#351;imler, �zellikle kardiyak giri&#351;imler
kaydedilmelidir.&nbsp; Bunlardan bir b�l�m� sekonder demanslar&#305;n nedenleri
olabilece&#287;i gibi, B12 eksikli&#287;i, hipotiroidi, vask�ler risk fakt�rleri,
genel anestezi gibi durumlar AH�yi komplike eden ve kontrol edilebilecek
komorbid durumlar da olabilirler.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�rolojik �zge�mi&#351;te geli&#351;imsel
bozukluklar, ge�irilmi&#351; hemorajik-iskemik inme ya da ge�ici iskemik
ataklar, �zellikle &#351;uur kay&#305;pl&#305; kafa travmas&#305;, subdural
hematom, MSS infeksiyonlar&#305; (menenjit, ensefalit), epilepsi, beyin t�m�r�,
hidrosefali gibi durumlar&#305;n varl&#305;&#287;&#305;
sorgulanmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ge�irilmi&#351; depresyon, psikoz, eski
psikiyatrik hospitalizasyonlar sorgulan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Toksik �zge�mi&#351; �zellikleri aras&#305;nda
a&#287;&#305;r metallere maruz kalma kronik toksik ensefalopatilerin nedenleri
aras&#305;ndad&#305;r.&nbsp; Kronik alkolizm ve/veya madde kullan&#305;m&#305;
kaydedilmelidir.&nbsp; Geriyatrik pop�lasyon �zellikle polifarmasinin
yayg&#305;n oldu&#287;u bir gruptur.&nbsp; Benzodiazepinler, trisiklik antidepresanlar
ve di&#287;er anti-kolinerjik ajanlar, alfa-metil-dopa, reserpin gibi
antihipertansif ila�lar kognitif bozuklu&#287;un tek ba&#351;&#305;na nedeni ya
da a&#287;&#305;rla&#351;t&#305;r&#305;c&#305; etkeni olarak bulunabilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Soyge�mi&#351; �zellikleri sorgulan&#305;rken
�zellikle primer dejeneratif demanslar&#305;n b�y�k �l��de genetik ve �evresel
fakt�rlerin karma&#351;&#305;k bir etkile&#351;iminin �r�n� olduklar&#305; g�z
�n�nde bulundurulmal&#305;d&#305;r. N�ro-genetikteki b�y�k ilerlemelere
ra&#287;men AH ve FTD gibi ailede demans varl&#305;&#287;&#305;n&#305;n �nemli
bir risk fakt�r� oldu&#287;u durumlarda hala ke&#351;fedilmeyi bekleyen
Mendelyen ge�i&#351; ve yatk&#305;nl&#305;k genleri bulunmaktad&#305;r.
�rne&#287;in, bu iki durum i�in hala g�sterilmi&#351; bir resesif ge�i&#351;
geni yoktur ve akraba evlili&#287;inin g�reli s&#305;kl&#305;&#287;&#305;yla
�lkemizdeki demans prati&#287;i bu a�&#305;dan gelecekteki b�yle bir bulu&#351;
i�in avantajl&#305; olabilir. Birinci derece akrabalar aras&#305;nda demans,
Parkinson hastal&#305;&#287;&#305;, motor n�ron hastal&#305;&#287;&#305; gibi
n�rolojik, depresyon, psikoz, alkolizm gibi psikiyatrik hastal&#305;klar&#305;n
mevcudiyeti �zellikle sorgulanmal&#305;d&#305;r. Ana-baban&#305;n akraba veya
ayn&#305; k�yden olup olmad&#305;&#287;&#305;,&nbsp;ana-baba ve
karde&#351;lerin sa&#287; olup olmad&#305;klar&#305;, �ld�lerse
ya&#351;lar&#305; ve �l�m nedenleri ayr&#305; ayr&#305; kaydedilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Tablo 2</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>. Demansta 3 kardinal ve 3 ikincil alan&#305;n
sorgulanmas&#305;<o:p></o:p></span></p>

<div style='margin-left:14.2pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-14.2pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=113 valign=top style='width:3.0cm;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:0cm;margin-right:-7.2pt;margin-bottom:
  0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kognitif</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=189 valign=top style='width:5.0cm;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dikkat</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dil</span></b><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�rsel-mekansal i&#351;levler</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�r�t�c� i&#351;levler</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Praksis</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gnosis</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=408 valign=top style='width:305.8pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yak&#305;n:
  yak&#305;n ge�mi&#351;e ait ki&#351;isel ve akt�el olaylar;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Uzak: ilkokul �&#287;retmeni,
  okudu&#287;u okullar, evlilik, emeklilik tarihleri, vb.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dalgalanma, konsantrasyon,
  �elinebilirlik</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kelime bulma, anlama, okuma,
  yazma, hesaplama g��l�kleri</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yabanc&#305;/tan&#305;d&#305;k
  mekanlarda dola&#351;abilme, yaz&#305; karakterinde (ortografik)
  de&#287;i&#351;iklik</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Problem ��zme,
  yarg&#305;lama, soyutlama bozukluklar&#305;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alet kullanma, giyinme,
  oturma-y�r�me g��l�kleri</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nesneleri tan&#305;ma,
  mekanda birbirinden ay&#305;rma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=189 valign=top style='width:5.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;ilik
  de&#287;i&#351;iklikleri</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Duygudurum bozukluklar&#305;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alg&#305; bozukluklar&#305;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D�&#351;�nce
  bozukluklar&#305;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=408 valign=top style='width:305.8pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Apati,
  disinhibisyon, sosyal uygunsuzluk</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Keder, isteksizlik,
  huzursuzluk, yerinde duramama, sinirlilik, uygunsuz ne&#351;e, e&#351;in
  pe&#351;inden ayr&#305;lmama</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�rsel ve di&#287;er
  hal�sinasyonlar</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>H&#305;rs&#305;zl&#305;k,
  sadakatsizlik, Capgras ve di&#287;er t�rden hezeyanlar</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=189 valign=top style='width:5.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sokakta
  GYA�lar</span></b><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evde GYA�lar</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kendine bak&#305;m</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=408 valign=top style='width:305.8pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;
  ya&#351;am&#305;, yolculuk, mali i&#351;ler, al&#305;&#351;veri&#351;, sosyal
  ili&#351;kiler</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hobiler, ev
  ayg&#305;tlar&#305;n&#305; kullanma, yemek pi&#351;irme, di&#287;er ev
  i&#351;leri, k���k tamirat, gazete-TV ilgisi</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yemek yeme, y&#305;kanma,
  giyinme, makyaj, tra&#351; olma, tuvalet mekani&#287;i, sfinkter kontrol�</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Motor</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=597 colspan=2 valign=top style='width:447.55pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�r�y�&#351;
  bozuklu&#287;u, d�&#351;meler, donmalar, dengesizlik, hareket
  yava&#351;l&#305;&#287;&#305;, g��s�zl�k, erime, seyirme</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Otonom</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=597 colspan=2 valign=top style='width:447.55pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nkontinans,
  empotans, ortostatizm, konstipasyon, terleme</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Uyku</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=597 colspan=2 valign=top style='width:447.55pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>REM-davran&#305;&#351;
  bozuklu&#287;u, a&#351;&#305;r&#305; g�nd�z uykusu, uyku apne sendromu</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANS MUAYENES&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif ve/veya davran&#305;&#351;sal
yak&#305;nmalar&#305;n&#305; ileten hastan&#305;n muayenesi demans sendromunun
mevcut olup olmad&#305;&#287;&#305;n&#305;, mevcutsa demans sendromlar&#305;
i�inde tipik bir tabloya uyup uymad&#305;&#287;&#305;n&#305; saptamaya y�nelik
olmal&#305;d&#305;r.&nbsp; Demans muayenesi:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>1. Davran&#305;&#351;sal
g�zlemler, <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>2. Mental durum muayenesi
(MDM), <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>3. Somatik n�rolojik muayene
alt ba&#351;l&#305;klar&#305;yla kaydedilebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal G�zlemler</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastan&#305;n muayene s&#305;ras&#305;ndaki
davran&#305;&#351;lar&#305; gerek MDM�den al&#305;nacak sonu�lar&#305;n
de&#287;erlendirilmesinde �nem ta&#351;&#305;rken, gerekse de baz&#305;
durumlarda tan&#305; koydurucu olabilir.&nbsp; Bu alt ba&#351;l&#305;k
alt&#305;nda apati, sosyal uygunluk gibi �l��lmesi zor ya da m�mk�n olmayan
bulgular �zerine muayene edenin yarg&#305;lar&#305; belirtilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Motivasyon</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>un optimal olmas&#305; MDM
sonu�lar&#305;n&#305;n uygun de&#287;erlendirilebilmesi i�in gerek
&#351;artlar&#305;n ba&#351;&#305;nda gelir.&nbsp; Muayene edenin tecr�be ve
mahareti, muayene tekniklerini iyi uygulayabilmesinin yan&#305;s&#305;ra
hastan&#305;n&nbsp; muayene boyunca motivasyonunu korumas&#305;n&#305;
sa&#287;layabilmesini de gerektirir.&nbsp; Motivasyonsuzluk, gerek
d�rt�sellik/�elinebilirlik, ve gerekse de apati &#351;ekillerinde muayeneye
i&#351;birli&#287;ini bozacak ve a&#287;&#305;rl&#305;&#287;&#305; �l��s�nde
MDM�yi istenildi&#287;i d�zeyde uygulanamaz k&#305;lacakt&#305;r.&nbsp;
Motivasyonsuzluk, apati y�n�nde muayene s&#305;ras&#305;nda hastadan
beklenen&nbsp; normal inisiyatif d�zeyinin g�zlenememesi &#351;eklinde bir
kendili&#287;indenlik azalmas&#305;ndan, oturdu&#287;u yerde �evresine t�mden
ilgisizli&#287;e kadar de&#287;i&#351;ebilir.&nbsp;Di&#287;er yandan
d�rt�sellik ve dikkatin �elinebilirli&#287;i de, MDM�de optimal performans i�in
gereken sebatl&#305;l&#305;&#287;&#305; bozacak perseveratif cevaplar&#305;
artt&#305;racakt&#305;r.&nbsp;AH�de erken evrelerde motivasyonun korunmu&#351;
olmas&#305; ya da muayene performans&#305;n&#305; bozmayacak d�zeyde bir
kendili&#287;inden davran&#305;&#351;ta azalma beklenirken, ileri evrede apati
ya da �elinebilirlik nedeniyle formel muayene m�mk�n olmayabilir. FTD daha
erken evrelerden itibaren apati ve/veya d�rt�sellik ile karakterizedir.&nbsp;
Bu nedenle baz&#305; FTD hastalar&#305; ba&#351;lang&#305;�tan itibaren
muayeneye izin vermeyebilirler.&nbsp; Yine motivasyon bozuklu&#287;unun,
�zellikle geriyatrik pop�lasyonda kendi ba&#351;&#305;na ya da dejeneratif
demanslarla birlikte oldu&#287;unda, depresyonun ba&#351;l&#305;ca belirtisi
oldu&#287;u s�ylenebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayene eden, <i>duygudurum ve afekt</i> �zerine
g�zlemlerini de kaydetmelidir.&nbsp; Kendili&#287;inden g�zlenebilen
parmaklar&#305;yla ya da giysileriyle oynamaktan, koltukta oturamay&#305;p
s�rekli dola&#351;ma ya da oday&#305; terketme iste&#287;ine kadar
de&#287;i&#351;en huzursuz, anksiy�z davran&#305;&#351; bizzat muayenedeki
performans bozuklu&#287;uyla da ortaya �&#305;kabilir.&nbsp; &#304;ritabilite,
kolay sinirlenme, negativizm, disfori e&#287;ilimi, kederli ruh hali, kolay
a&#287;lamayla kendini g�sterecektir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;�g�r� bozuklu&#287;u inkar e&#287;ilimiyle
ba&#351;layabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sosyal uygunluk</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>, muayene edenin hastan&#305;n
genel davran&#305;&#351;&#305;n&#305;n geldi&#287;i sosyal �evrenin
normlar&#305;ndan bekledi&#287;i davran&#305;&#351;a ne derecede uygun
d�&#351;t�&#287;� �zerine yarg&#305;s&#305;d&#305;r.&nbsp;&nbsp;Disinhibisyonun
bir par�as&#305; olan uygunsuz davran&#305;&#351;lar alayc&#305;l&#305;k
e&#287;iliminden sald&#305;rganl&#305;&#287;a kadar de&#287;i&#351;ebilir.&nbsp;
AH�de sosyal uygunluk ileri evrelere kadar korunurken FTD�de en erken d�nemden
itibaren bozulan tan&#305; koydurucu �zelliklerdendir. �Kullanma
davran&#305;&#351;&#305;� yine ba&#351;l&#305;ca FTD�ye �zg� bir disinhibisyon
�zelli&#287;idir. Kullanma davran&#305;&#351;&#305; sergileyen hasta muayene edenin
masas&#305;n&#305; kar&#305;&#351;t&#305;racak, kalemlerini alma,
dosyalar&#305;n&#305; d�zenleme, ka&#287;&#305;tlar&#305;n&#305; okuma gibi
davran&#305;&#351;lar sergileyecektir; masa �st�nde bulunabilecek refleks
�ekici, g�zl�k gibi nesneler yoklan&#305;p kullan&#305;lmaya
�al&#305;&#351;&#305;lacakt&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mental Durum Muayenesi</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mental durum muayenesi (MDM) kendi i�inde �yatak
ba&#351;&#305; testleri� ve �tarama testleri� olarak
s&#305;n&#305;flanabilir.&nbsp; Gerekti&#287;inde davran&#305;&#351;sal
belirtilerin a&#287;&#305;rl&#305;&#287;&#305;n&#305; saptayacak, i&#351;levsel
durumu nicelle&#351;tirecek, demans &#351;iddetini belirleyecek �l�ekler de
kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yatak Ba&#351;&#305; Testleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MDM, yatak ba&#351;&#305;&nbsp; testlerinden
olu&#351;an bir k&#305;sa n�ropsikolojik muayene olarak
d�&#351;�n�lebilir.&nbsp; N�ropsikoloji laboratuar&#305;nda standart normlara
g�re uygulanan ve de&#287;erlendirilen n�ropsikolojik muayenenin tersine, hastan&#305;n
�yk�, sosyok�lt�rel durum ve davran&#305;&#351;sal �zelliklerine g�re muayene
edenin esnek bi�imde de&#287;i&#351;tirebilece&#287;i genellikle basit, nicel
skorlardan �ok nitel performans de&#287;erlendirmelerine dayanan testlerden
olu&#351;ur.&nbsp; Ama�, limbik-paralimbik ve heteromodal alanlarda temsil edilen
kognitif i&#351;levler ve unimodal alanlarda temsil edilen karma&#351;&#305;k
alg&#305;sal ve motor i&#351;levlerin etkilenme d�zeyleri �zerine yorum
yap&#305;labilecek kadar test edebilmektir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu i&#351;levler, 1. Dikkat, 2.Dil, 3.
G�rsel-mekansal i&#351;levler, 4. Bellek,<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>5. Y�r�t�c� i&#351;levler, 6. Gnosis, 7. Praksis
alt ba&#351;l&#305;klar&#305;nda s&#305;ralanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�rolojik muayenede normal ve anormal bulgular
olduk�a kesindir.&nbsp; Bireysel ve k�lt�rel varyasyonlar genellikle ihmal
edilebilir d�zeydedir. Oysa MDM sonu�lar&#305;n&#305; de&#287;erlendirirken
kognitif i&#351;levlerin birbirinden ayr&#305;ld&#305;&#287;&#305;
s&#305;n&#305;rlar&#305;n o kadar a&#351;ikar olmad&#305;&#287;&#305;,
testlerin e&#287;itim d�zeyi ve ya&#351;tan b�y�k �l��de etkilendi&#287;i
hesaba kat&#305;lmal&#305;d&#305;r.&nbsp; A&#287;&#305;r dikkat bozuklu&#287;u
nedeniyle kay&#305;t g��l�&#287;� olan hastan&#305;n yak&#305;n bellek
testlerindeki ger�ek performans&#305;n&#305; de&#287;erlendirmek m�mk�n
olmayabilir. Yine adland&#305;rmay&#305; bozacak bir dil bozuklu&#287;u,
genellikle bir kelime listesi �&#287;renmek tarz&#305;nda olan yak&#305;n
bellek muayenesini verbal olmayan yollara uyarlamay&#305; zorunlu k&#305;lar.&nbsp;
E&#287;itimsiz bir ki&#351;ide saptanan bir performans bozuklu&#287;u o
e&#287;itim d�zeyi i�in normal s&#305;n&#305;rlarda kalabilecekken, y�ksek
e&#287;itimli bir ki&#351;inin bozuklu&#287;unu ortalama testler ortaya
koymayabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayenenin sonunda �n planda ve ikincil d�zeyde
bozulan alanlarla korunan alanlar&#305;n bildirilece&#287;i bir kognitif profil
belirlenir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tarama Testleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tarama testleri, �zellikle AH�de kognitif
y&#305;k&#305;m&#305;n a&#287;&#305;rl&#305;&#287;&#305;n&#305; saptamak,
y&#305;k&#305;m&#305;n zaman i�indeki ilerleme h&#305;z&#305;n&#305; ve ilaca
cevab&#305; izlemekte kullan&#305;lan k&#305;sa global kognitif muayene
ara�lar&#305;d&#305;r.&nbsp; Epidemiyolojik �al&#305;&#351;malar gibi
geni&#351; saha �al&#305;&#351;malar&#305;nda duyarl&#305;l&#305;k ve �zg�ll�k
oranlar&#305; uyar&#305;nca normalleri demansl&#305;lardan ay&#305;rmak i�in
kullan&#305;lsalar da, ofiste tek bir hastan&#305;n muayenesinde, hi� bir zaman
as&#305;l MDM�nin yerine tan&#305; ama�l&#305; olarak kullan&#305;lmamal&#305;,
as&#305;l i&#351;levlerinin uzunlamas&#305;na izlemede tek bir hastadaki
de&#287;i&#351;imi nicel olarak belgelemek olduklar&#305;
unutulmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu t�r bir�ok test geli&#351;tirilmi&#351;se de,
uluslararas&#305; literat�rde en fazla ad&#305; ge�en ve yurdumuzda da �teden
beri yayg&#305;n olarak kullan&#305;lanlar&#305;n ba&#351;&#305;nda Mini Mental
Durum Muayenesi (MMSE), Blessed Oryantasyon Bellek Konsantrasyon Testi (BOMC),
K&#305;sa Mental Durum Testi (STMS) say&#305;labilir. Montreal Kognitif
De&#287;erlendirme Testi (MoCA) ve Addenbrook Kognitif
Muayenesi-Yenilenmi&#351; (ACE-R) yukarda an&#305;lan nispeten eski testlerin
zaaflar&#305;n&#305;n giderilmesine y�nelik olarak tasarlanm&#305;&#351;,
yak&#305;n tarihlerde kullan&#305;lmaya ba&#351;lanan tarama testleridir. Bu
yeni testlerin demans �ncesi kognitif bozuklu&#287;u (yani, MCI) normal
kognisyondan ay&#305;rma yetenekleri oldu&#287;u ileri s�r�lmektedir.
ACE-R�&#305;n 40 y&#305;la yakla&#351;an bir s�redir en yayg&#305;n olarak
kullan&#305;lan test olmas&#305;yla b�t�n zaaflar&#305;na ra&#287;men
terkedilemeyen MMSE maddelerini i�inde bar&#305;nd&#305;rmas&#305; ve bir alt
skor olarak MMSE skorunu da belirlemesinin bir avantaj&#305; oldu&#287;u
s�ylenebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal �l�ekler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal belirtilerin
a&#287;&#305;rl&#305;&#287;&#305;n&#305; saptamak, zaman i�indeki seyirlerini
ve ilaca cevaplar&#305;n&#305; izlemekte davran&#305;&#351;sal �l�ekler de
kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Alzheimer Hastal&#305;&#287;&#305;nda
Davran&#305;&#351;sal Bozukluklar �l�e&#287;i (BEHAVE-AD), AH�de bu amaca
hizmet eden kullan&#305;l&#305;&#351;l&#305; bir testtir.&nbsp; N�ropsikiyatrik
Envanter (NPI) t�m demanslarda kullan&#305;labilecek &#351;ekilde
geli&#351;tirilmi&#351; son &#351;ekliyle 12 davran&#305;&#351;sal ekseni
sorgulayan bir �l�ektir.&nbsp; Frontal Davran&#305;&#351; Envanteri (FBI)
�zellikle FTD'li hastalar&#305;n davran&#305;&#351;sal bozukluklar&#305;n&#305;n
�l��m� i�in geli&#351;tirilmi&#351;tir. Geriyatrik Depresyon �l�e&#287;i
(Geriatric DS),&nbsp;demansl&#305; pop�lasyonda di&#287;er depresyon �l��m
ara�lar&#305;na g�re daha g�venilir bir ara� olabilir. Orijinal &#351;ekli olan
30 madde, 15 maddeye k&#305;salt&#305;larak (GDS-15) yo&#287;un bir pratikte
daha da kullan&#305;&#351;l&#305; k&#305;l&#305;nm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel �l�ekler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif y&#305;k&#305;ma ba&#287;l&#305; olarak
Tablo 2�de g�sterilen GYA�lardaki bozulmay&#305; nicel olarak saptamay&#305;
hedefleyen �l�eklerdir.&nbsp; Bunlar aras&#305;nda, G�nl�k ya&#351;am
Aktiviteleri/Enstr�mental G�nl�k Ya&#351;am Aktiviteleri �l�e&#287;i
(ADL/IADL), Blessed Demans Derecelendirme �l�e&#287;i�CERAD versiyonu
(BDRS-CERAD) ve Alzheimer Hastal&#305;&#287;&#305; &#304;&#351;birli&#287;i
�al&#305;&#351;mas&#305;�G�nl�k Ya&#351;am Aktiviteleri �l�e&#287;i (ADCS-ADL)
say&#305;labilir.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Parasomni �l�ekleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gerekti&#287;inde RUDB ve insomniaya neden olan huzursuz
bacak ve uyku apne gibi durumlar&#305; nicelle&#351;tiren Mayo Uyku
Soru&#351;turusu (MSQ) ve a&#351;&#305;r&#305; g�nd�z uykululu&#287;unu
nicelle&#351;tiren Epworth Uykululuk �l�e&#287;i (ESS) kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�rolojik Muayene</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Di&#287;er n�rolojik hastal&#305;klarda
oldu&#287;u gibi, do&#287;al olarak demans hastal&#305;klar&#305;n&#305;n
muayenesine de tam bir somatik n�rolojik muayenenin e&#351;lik etmesi
beklenir.&nbsp; Bununla birlikte baz&#305; demans sendromlar&#305;yla �zellikle
baz&#305; n�rolojik bulgular birlikte gitti&#287;i i�in s�z konusu bulgular&#305;n
bulunup bulunmamas&#305; �nem ta&#351;&#305;r.&nbsp; Bunlar aras&#305;nda
ekstrapiramidal sistem bulgular&#305;n&#305;n (EPS) �zel bir yeri
vard&#305;r.&nbsp; G�z hareketleri muayenesinde ortaya konabilecek
a&#351;a&#287;&#305; bak&#305;&#351; felci, y�r�y�&#351; bozuklu&#287;u varsa
bunun Parkinsonyen ve/veya ataktik niteli&#287;i, ge�irilmi&#351; inmelere ait
fokal n�rolojik bulgular&#305;n t�m� de demans sendromlar&#305;n&#305;n
ay&#305;rt edilmesinde kullan&#305;lacaklard&#305;r. �zellikle EPS�nin
nicelle&#351;tirilmesi amac&#305;yla Parkinson hastal&#305;&#287;&#305;n&#305;n
(PH) belirti ve bulgular&#305; i�in geli&#351;tirilen UPDRS isimli �l�e&#287;in
K&#305;s&#305;m III alt b�l�m� kullan&#305;labilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANS SENDROMUNUN FENOMENOLOJ&#304;K AYIRICI
TANISI<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunun tan&#305;s&#305;nda, daha �nce
de belirtildi&#287;i gibi, �� kardinal semptomatolojik kategori aras&#305;nda
i&#351;levsel alanda bozulma &#351;artt&#305;r.&nbsp; Demans&#305;n
ay&#305;r&#305;c&#305; tan&#305;s&#305;, i&#351;levsel bozulmaya yol a�an
kognitif alana ait bozulman&#305;n profili, davran&#305;&#351;sal alana ait
bozuklu&#287;un olup olmamas&#305;, mevcut ise tabloya kat&#305;lma
zamanlamas&#305; ve a&#287;&#305;rl&#305;&#287;&#305;, yine motor
bozuklu&#287;un mevcudiyeti ve tabloya kat&#305;lma zamanlamas&#305;,
a&#287;&#305;rl&#305;&#287;&#305; de&#287;erlendirilerek
yap&#305;l&#305;r.&nbsp; �rne&#287;in, ATD �yk�s� a&#287;&#305;rl&#305;kl&#305;
olarak, izole kognitif demans olarak ba&#351;lar; davran&#305;&#351;sal ve
motor bulgular tabloya ileri evrelerde kat&#305;l&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�ropsikolojik Profil</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans&#305;n n�ropsikolojik profili patogenezin
n�ral co&#287;rafyadaki
yatk&#305;nl&#305;&#287;&#305;n&#305;&nbsp;yans&#305;t&#305;r ve
dolay&#305;s&#305;yla hastal&#305;&#287;&#305; y�ksek olas&#305;l&#305;kla
tahmin ettirir.&nbsp; Daha �nce de de&#287;inildi&#287;i gibi, demans daha
yak&#305;n zamana kadar tasarland&#305;&#287;&#305; gibi, MSS�nin yayg&#305;n
hasar&#305;yla geli&#351;en global bir zihinsel y&#305;k&#305;m de&#287;ildir.
Farkl&#305; n�rodejeneratif etyopatogenetik s�re�ler farkl&#305; n�roanatomik
yatk&#305;nl&#305;klar g�sterirler.&nbsp; N�ropsikolojik profilleri de, bu
yatk&#305;nl&#305;&#287;&#305; yans&#305;tacak &#351;ekilde, kognitif ve
davran&#305;&#351;sal alanlar&#305;n bazen izole, ama s&#305;kl&#305;kla da
kendine �zg� bile&#351;imlerinden olu&#351;an bozukluklar&#305;n&#305;n
ifadesidir.&nbsp; N�ropsikolojik profil, bozulan ve g�reli korunan alanlar&#305;
belgeleyerek, n�roanatomiyi dolayl&#305; olarak sergiler.&nbsp; Hasarl&#305;
oldu&#287;u varsay&#305;lan anatomik alan daima tek bir etyopatogeneze
kar&#351;&#305;l&#305;k gelmeyebilir.&nbsp; Farkl&#305; s�re�ler, benzer bir
anatomik yatk&#305;nl&#305;k g�sterebilirler.&nbsp; Ancak, g�n�m�ze kadar
biriken n�ropatolojik veriler, farkl&#305; n�ropsikolojik profillerin,
dolay&#305;s&#305;yla anatomik yatk&#305;nl&#305;klar&#305;n belli
hastal&#305;k s�re�lerine kar&#351;&#305;l&#305;k gelme ya da t�m�yle
d&#305;&#351;lama olas&#305;l&#305;klar&#305;n&#305; g�venilir bi�imde ortaya
koyabilmektedir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Farkl&#305; n�rodejeneratif
s�re�ler,&nbsp;genellikle bir �e&#351;it nihai ortak yola sahiptirler.&nbsp;
Dolay&#305;s&#305;yla, hastal&#305;&#287;&#305;n �ok ilerledi&#287;i,
a&#287;&#305;r ve yayg&#305;n y&#305;k&#305;m&#305;n ger�ekle&#351;ti&#287;i
son evrede n�ropsikolojik olarak farkl&#305; profiller ay&#305;rmak m�mk�n
olmayabilir.&nbsp;N�ropsikolojik profiller, �zellikle erken evrede anlaml&#305;
farkl&#305;l&#305;klar sergileyeceklerdir.&nbsp; Bu profiller
s&#305;kl&#305;kla, en az&#305;ndan ba&#351;lang&#305;�ta simetrik ya da
asimetrik olarak fokal kalacak olan dejenerasyonu yans&#305;t&#305;rlar.&nbsp;
Altta yatan patolojik s�recin niteli&#287;ine g�re, hastal&#305;&#287;&#305;n
nihai evrelerinde dejenerasyon fokal �zelli&#287;ini b&#305;rak&#305;p
yayg&#305;nla&#351;&#305;rken, klinik tablo da global bir y&#305;k&#305;m
�zelli&#287;i edinecektir.&nbsp; Pick hastal&#305;&#287;&#305; (PiH) gibi
baz&#305; s�re�ler ise b�t�n evrelerinde daima fokal kalabilirler.&nbsp;
Mesulam ve Weintraub, �zellikle erken evre profillerini vurgulayarak, demanslar
i�in 4 farkl&#305; n�ropsikolojik profil tan&#305;mlar:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>1.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Progresif amnestik disfonksiyon (PAD)</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>2.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Primer progresif afazi (PPA)&nbsp;</span><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>3.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Progresif g�rsel-mekansal Bozukluk (PGMB)</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>4.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Progresif davran&#305;&#351;sal/y�r�t�c� bozukluk
(PDB/PYB) ya da progresif frontal &#351;ebeke sendromu&nbsp;&nbsp;</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam ve Weintraub�un bu 4 tablosuna progresif
apraksiyi de m�mk�n bir 5. tablo olarak eklemek listeyi daha
kapsay&#305;c&#305; bir hale getirecektir.&nbsp; Yazarlar&#305;n da i&#351;aret
etti&#287;i gibi, bunlar demans&#305;n m�mk�n ba&#351;lang&#305;�
g�sterilerinin t�m� de&#287;ildir ve baz&#305; olgular bu 4 ya da 5 tabloya
g�re s&#305;n&#305;flanamayabilir.&nbsp; Baz&#305; patolojik s�re�lerde biri �n
planda olmak �zere bu tablolar bir arada g�r�nebilir (�rne&#287;in FTD�de 2 ve
4 ya da FTD�nin semantik demans varyant&#305;nda 2, 4 ve 3�den �zellikler,&nbsp;KBD�de
4 ve 5).&nbsp; Yine de, g�nl�k demans prati&#287;inde b�y�k �l��de
kapsay&#305;c&#305; �zelli&#287;iyle bu yakla&#351;&#305;m, hem
ay&#305;r&#305;c&#305; tan&#305;da pratik bir yol olmakta, hem de hasta ve
hasta yak&#305;nlar&#305;na yap&#305;lacak non-farmakolojik e&#287;itici m�dahalelerrde,
bozulan ve korunan niteliklerinin belirlenmesiyle yol g�stermekte
yard&#305;mc&#305; olmaktad&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam, tan&#305;mlad&#305;&#287;&#305;
tablolar&#305;n tan&#305; kriterlerinin ortak �zellikleri olarak k&#305;saca,
tabloya ad&#305;n&#305; veren bozuklu&#287;un en az iki y&#305;l boyunca
ilerleyici (progresif) izole bozukluk olarak kalmas&#305;n&#305; (primer) ve bu
s�re i�inde GYA�lar&#305; bozan yegane neden olmas&#305;n&#305; ileri
s�rer.&nbsp; Bu iki y&#305;ll&#305;k s�re sonras&#305;nda di&#287;er kognitif
alanlardaki bozulmalar da tabloya kat&#305;labilir.&nbsp;A&#351;a&#287;&#305;da
s&#305;ralanan n�ropsikolojik profillerde Mesulam ve Weintraub�un �nerileri
temel al&#305;nmakla birlikte, ad&#305; ge�en �neride �primer� s&#305;fat&#305;
i�in gerekli ko&#351;ul olan �en az 2 y&#305;l izole bozukluk� kriteri
s&#305;k&#305; bir &#351;ekilde korunmam&#305;&#351;, bunun yerine �primer�
s&#305;fat&#305; izole olsun ya da olmas&#305;n, en a&#287;&#305;r olarak bozulan
veya profilin �ekirde&#287;inde bulunan kognitif bozuklu&#287;u nitelemek amac&#305;yla
kullan&#305;lm&#305;&#351;t&#305;r. Dolay&#305;s&#305;yla, burada
s&#305;ralanan profiller ayr&#305; ayr&#305; antiteler olarak de&#287;il fakat
ay&#305;r&#305;c&#305; tan&#305; ama�l&#305;, en g��l� ihtimalle belli
n�rodejeneratif hastal&#305;klara kar&#351;&#305;l&#305;k gelmesi beklenen
klinik sendromlar olarak anla&#351;&#305;lmal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Amnestik Disfonksiyon (PAD)</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ba&#351;ka bir kognitif bozukluk
olmaks&#305;z&#305;n yak&#305;n bellekte saptanan ilerleyici karakterli
bozukluk GYA�lar&#305; da bozmaktad&#305;r.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tipik bir hasta, genellikle 65
ya&#351;&#305;n&#305;n �zerindedir.&nbsp; Unutkanl&#305;ktan yak&#305;nan hasta
ve/veya yak&#305;n&#305; bunu �zel e&#351;yalar&#305;n&#305; kaybetmek,
ayn&#305; sorular&#305; ve konular&#305; tekrarlamak, okuduklar&#305;n&#305;
akl&#305;nda tutamamak, randevular&#305;n&#305;, al&#305;&#351;veri&#351;
listesini, yeni g�rd�&#287;� mekan ve y�zleri unutmak &#351;eklinde
�rneklendirir.&nbsp; Unutkanl&#305;&#287;&#305; genellikle i&#351;
arkada&#351;lar&#305; ve ailesi taraf&#305;ndan da farkedilmektedir.&nbsp;
Bunlar d&#305;&#351;&#305;nda, sokakta ve sosyal ortamlarda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;
k&#305;s&#305;tlanmam&#305;&#351;t&#305;r.&nbsp; D&#305;&#351; mekanda eskisi
gibi kaybolmadan dola&#351;&#305;r, mali i&#351;lerini ve
al&#305;&#351;veri&#351;i ancak listeyle eskisi gibi halleder.&nbsp; Ev
i&#351;lerinde zaman zaman yemek yak&#305;yor olmak d&#305;&#351;&#305;nda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; s�rd�r�r, hobilerini devam
ettirir.&nbsp; N�ropsikolojik olarak kayda de&#287;er bir verbal ve g�rsel
yak&#305;n bellek bozuklu&#287;u saptan&#305;rken, di&#287;er alanlardaki
performans korunmu&#351; ya da normal s&#305;n&#305;ra yak&#305;n
d�zeylerdedir.&nbsp; &#304;kinci bir kognitif alan&#305;n da bozulmas&#305; ve
bunun g�nl�k ya&#351;ama yans&#305;mas&#305;yla birlikte art&#305;k PRAD ya da
DAT kriterleri doldurulur hale gelir.&nbsp; N�ropsikolojik olarak en erken,
yak&#305;n bellek bozuklu&#287;una eklenen demansa ili&#351;kin bulgular s�zel
ak&#305;c&#305;l&#305;kta kategori ak&#305;c&#305;l&#305;&#287;&#305;n&#305;n
(�rne&#287;in 1 dakikada m�mk�n oldu&#287;unca fazla hayvan ismi s�ylemek),
leksikal ak&#305;c&#305;l&#305;&#287;a (�rne&#287;in 1�er dakikada K, A ve S
harfleriyle ba&#351;layan m�mk�n oldu&#287;unca fazla cins isim s�ylemek) g�re
daha erken ve a&#287;&#305;r bozulmas&#305; ve karma&#351;&#305;k
g�rsel-mekansal i&#351;levlerde bozulma olmaktad&#305;r.&nbsp; Zaman i�inde
uzunlamas&#305;na izlenen bir hastada �nceleri bu i&#351;levler korunurken
sonradan bozulduklar&#305;n&#305;n g�sterilmesi, art&#305;k n�rodejenerasyonun
limbik sistemin d&#305;&#351;&#305;na, sol ve sa&#287; temporo-parietal
heteromodal neokortekse ge�ti&#287;i anlam&#305;na gelir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu tablo demanslar&#305;n erken evreleri i�inde en
s&#305;k rastlan&#305;lan tablodur.&nbsp; PAD'&#305;n ilerde daha
ayr&#305;nt&#305;l&#305; tart&#305;&#351;&#305;lacak olan MCI tablosu ile
pratik olarak ayn&#305; anlama geldi&#287;i s�ylenebilir.&nbsp; Nadiren �ok
uzun y&#305;llar boyunca, ya da b�t�n seyri boyunca ayn&#305; kalsa da b�y�k
s&#305;kl&#305;kla AH�nin hen�z PRAD/DAT kriterlerinin
doldurulamad&#305;&#287;&#305; erken veya prodromal evresine
kar&#351;&#305;l&#305;k gelmektedir. G�r�nt�leme �al&#305;&#351;malar&#305;nda,
�zellikle MRG ile vol�metrik olarak hippokampal atrofi saptanabilir.&nbsp;<b>(&#350;ekil
1)</b>&nbsp; Son y&#305;llarda geli&#351;tirilen PET ile amiloid g�r�nt�leme
tekni&#287;i, PAD sergileyen hastalar aras&#305;nda yo&#287;un serebral amiloid
y�k� ta&#351;&#305;yanlar&#305; ay&#305;rt ederek ilerde ATD geli&#351;tirecek,
bir di&#287;er deyi&#351;le pre-demans veya prodromal AH�yi �ng�rebilir. Yine,
BOS�ta total tau ve fosfo-tau proteini d�zeyleri ile amiloid-beta fragman&#305;
d�zeyi benzer bir i&#351;lev g�rebilir. Hippokampus vol�metrisi, PET ile
amiloid g�r�nt�leme ve BOS�ta an&#305;lan protein d�zeyleri ilerde AH�nin
potansiyel biyoi&#351;aretleyicileri b�l�m�nde ayr&#305;nt&#305;yla tart&#305;&#351;&#305;lacakt&#305;r.
N�ropatoloji simetrik olarak limbik sistemde ve a&#287;&#305;rl&#305;kla da,
hippokampal-entorinal yap&#305;lardad&#305;r.&nbsp; An&#305;lan b�lgelere
yatk&#305;nl&#305;&#287;&#305; dolay&#305;s&#305;yla, tahmin edilebilece&#287;i
gibi, beklenen hastal&#305;k y�ksek ihtimalle AH'dir.&nbsp; Non-spesifik
dejenerasyon, PiH, LCD, arjirofilik tah&#305;l hastal&#305;&#287;&#305; veya
sadece yumak demans&#305; di&#287;er nadir asosiasyonlard&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#350;ekil 1.</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Hippokampus G�r�nt�lemesi,</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans1a.JPG">&#350;ekil 1a.</a> 73
ya&#351;&#305;nda normal ya&#351;l&#305; hippokampuslar&#305;;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
sa&#287; hippokampusun normalde biraz daha b�y�k g�r�nd�&#287;�ne dikkat ediniz
(Hippokampus ba&#351;&#305;ndan ge�en T1 a&#287;&#305;rl&#305;kl&#305; koronal
kesit).</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans1b.JPG">&#350;ekil 1b.</a> 75
ya&#351;&#305;nda hafif demansl&#305; kad&#305;n hasta</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>; hippokampus
ba&#351;lar&#305;ndaki hacim kayb&#305;na dikkat ediniz (Hippokampus
ba&#351;&#305;ndan ge�en T2 a&#287;&#305;rl&#305;kl&#305; kesit).</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span style='font-family:Tahoma'><a href="demans1c.JPG"><b><span
lang=TR style='font-size:10.0pt;mso-ansi-language:TR'>&#350;ekil 1c.</span></b></a></span><span
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <b><span
lang=TR>Ayn&#305; olgunun 5 y&#305;l sonraki MRG�si</span></b><span lang=TR>;
demans art&#305;k a&#287;&#305;r evrede ve hippokampal atrofi �ok daha belirgin
hala gelmi&#351; (&#350;ekil 1b ile ayn&#305; �zellikte kesit.</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Afazi (PA)</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici dil bozuklu&#287;unun, izole olarak
veya di&#287;er kognitif ve/veya davran&#305;&#351;sal bozukluklarla birlikte
�ekirdek bozukluk oldu&#287;u tablolard&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tipik bir hasta, genellikle 65
ya&#351;&#305;n&#305;n alt&#305;ndad&#305;r.&nbsp; Konu&#351;ma
bozuklu&#287;undan yak&#305;nan hasta, bunu kelime bulma, nesneleri ve
ki&#351;ileri adland&#305;rma, bazen d�&#351;�ncelerini yaz&#305;l&#305; ve
s�zl� ifade etme, bazen de yaz&#305;l&#305; ve s�zl� ifadeleri anlama, okuma
g��l�&#287;� &#351;eklinde �rneklendirir.&nbsp; �zel bir alt tipi olan <i>semantik
demans</i>ta (SD) tek tek kelimelerin anlamsal i�erikleri
bo&#351;alm&#305;&#351;t&#305;r. Hastalar s&#305;radan nesnelerin isimlerini
ilk kez duyuyorlarm&#305;&#351; gibi davran&#305;rlar. Dil kullanmak
gerekmedi&#287;i durumlarda sokakta ve evde
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; k&#305;s&#305;tlayacak g�nl�k
olaylar&#305; hat&#305;rlama, d&#305;&#351; mekanda yolunu bulma, g�nl�k
olaylar �zerine ak&#305;l y�r�tme, hobilerini s�rd�rme gibi sorunlar&#305; yoktur.
Di&#287;er bir alt tip olan logopenik PA�l&#305; (LPA) hastalar hesaplama
g��l�&#287;�nden yak&#305;n&#305;rlar. SD�li hastalar progresif afazilerinin
yan&#305;s&#305;ra a&#351;ina y�zleri tan&#305;ma g��l�&#287;� ve disinhibisyon
belirtileri sergileyebilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�ropsikolojik profil, tutuk ya da ak&#305;c&#305;
afazi tarz&#305;ndad&#305;r.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yerle&#351;mi&#351; bir tutuk afazi profili,
klasik Broca afazisini and&#305;ran tarzda agramatik spontan konu&#351;ma ve
tekrarlama bozuklu&#287;u ile birlikte anlaman&#305;n g�reli korundu&#287;u bir
tarzd&#305;r. Bununla birlikte, klasik afazik sendromlar&#305;n, tablonun akut
olarak yerle&#351;ti&#287;i ve zaman i�inde d�zelmeye y�z tuttu&#287;u
bi�imlerinin tersine ilerleyici afazilerin sinsi ba&#351;lang&#305;�l&#305;,
tedrici ilerleyici seyirleri g�z �n�ne al&#305;nmal&#305;d&#305;r.
Dolay&#305;s&#305;yla, erken d�nemdeki bir ilerleyici tutuk afazi&#287;in
klasik afazi muayenesiyle ay&#305;rt edilemeyebilece&#287;i, klasik afazik
sendromlar&#305;n olmazsa olmaz ko&#351;ullar&#305;ndan konfrontasyon
adland&#305;rmas&#305;n&#305;n dahi salim kalabilece&#287;i kaydedilmelidir. Bu
erken d�nem hastalar spontan konu&#351;malar&#305;nda kelime bulma g��l�kleri,
fonemik parafaziler, dizartrik, bazen kekelemeli konu&#351;ma tarz&#305;,
prozodilerinde sanki bir yabanc&#305;n&#305;n aksanl&#305;
konu&#351;mas&#305;ym&#305;&#351;cas&#305;na de&#287;i&#351;me ve kelime
ak&#305;c&#305;l&#305;klar&#305;nda, �zellikle de leksikal ak&#305;c&#305;l&#305;klar&#305;nda
bozulma ile ay&#305;rt edileceklerdir. &#304;lerleyici tutuk afazi (progressive
non-fluent aphasia-PNFA) bir FTD alt tipidir. Hastal&#305;k seyri
s&#305;kl&#305;kla y&#305;llarca izole dil bozuklu&#287;u &#351;eklinde
kalabilirken (yani, Mesulam PPA�s&#305;), daha erken d�nemde y�r�t�c� bozukluk
�zelikleri de e&#351;lik edebilir. KBD tarz&#305; bir asimetrik sa&#287;
hemiparkinsonizm ve amiyotrofik lateral skleroz (ALS) muhtemel motor
e&#351;lik�ilerdendir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici ak&#305;c&#305; afazi SD veya LPA
&#351;ekillerinde sunulur. SD�de a&#287;&#305;r konfrontasyon
adland&#305;rmas&#305; bozuklu&#287;u bir nesne agnozisini and&#305;r&#305;r
�zellik ta&#351;&#305;r.&nbsp; Hasta i�in kelimeler anlam&#305;n&#305;
yitirmi&#351;tir.&nbsp; Nesneleri adland&#305;ramayan (anomi) hasta bir
Wernicke afazi&#287;inin aksine bir b�l�m�n�n ne i&#351;e
yarad&#305;&#287;&#305;n&#305; da s�yleyemez (agnozi). Bununla birlikte,
kar&#351;&#305;l&#305;kl&#305; ileti&#351;im genellikle m�mk�nken, karma&#351;&#305;k
gramerin kullan&#305;ld&#305;&#287;&#305; emirlerle de anlaman&#305;n
korundu&#287;u g�r�l�r.&nbsp;SD�li hastan&#305;n semantik bellek testleri
(�rne&#287;in, Piramidler ve Palmiye A&#287;a�lar&#305; Testi) ve me&#351;hur
y�zleri tan&#305;ma testleri de bozulmu&#351;tur. LPA bir ilerleyici anomi
olarak d�&#351;�n�lebilir. Spontan konu&#351;ma kelime bulma g��l�kleriyle
giderek yoksulla&#351;&#305;r. Anlama korunmu&#351;tur. Anomik hasta
ayr&#305;ca nesne agnozisi, semantik bellek ve y�z tan&#305;ma
bozukluklar&#305; gibi SD �zellikleri sergilemez. Akalkuli ba&#351;ta olmak
�zere, sa&#287;-sol disoryantasyonu ve parmak agnozisi gibi Gerstmann sendromu
�zellikleri g�r�lebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gerek PNFA�da ve gerekse de ak&#305;c&#305;
t�rlerde verbal dolay&#305;ml&#305; testler, �zellikle de kelime listesi
�&#287;renme gibi klasik bellek testleri, dil bozuklu&#287;una sekonder olarak
bozuk bulunabilir.&nbsp; Ancak&nbsp;dil dolay&#305;m&#305;na dayanmayan g�rsel
bellek, sa&#287; hemisfer g�rsel-mekansal i&#351;levleri iyi
korunmu&#351;tur.&nbsp;Bununla birlikte, LPA�n&#305;n ileri
a&#351;amalar&#305;nda simultanagnoziye varan a&#287;&#305;r g�rsel-mekansal
bozukluklar g�r�lebilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PNFA�da BT ve MRG ile asimetrik sol peri-sylvien
geni&#351;leme, <b>(&#350;ekil 2)</b> bazen sol fronto-temporal atrofi, SPECT
ve PET ile ad&#305; ge�en b�lgede hippoperf�zyon veya hipometabolizma, EEG ile
sol temporal yava&#351;lama saptanabilir.&nbsp;SD�nin ay&#305;r&#305;c&#305;
�zelli&#287;i MRG�de b�y�k s&#305;kl&#305;kla solda bask&#305;n, �zellikle
koronal T1 kesitlerde rahatl&#305;kla ay&#305;rt edilebilen temporopolar (TP)
atrofidir <b>(&#350;ekil 3</b>). rTV�de atrofi tam tersine sa&#287;da
bask&#305;nd&#305;r <b>(&#350;ekil 4).</b> LPA�n&#305;n n�ropatolojik
kar&#351;&#305;l&#305;&#287;&#305; olan sol anguler girus atrofisi yap&#305;sal
g�r�nt�lemede g�zden ka�abilirse de SPECT veya PET ile fonksiyonel g�r�nt�leme
asimetrik bir sol parietal hipoperf�zyon/metabolizmay&#305; ortaya
koyacakt&#305;r <b>(&#350;ekil 5).</b>&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PNFA s&#305;kl&#305;kla KBD, PSP ve FTD
spektrumuna dahil taupatilerle ili&#351;kiliyken, ALS e&#351;lik etti&#287;i
durumlarda beklenen n�ropatoloji bir tau-/ubikutin+ (T-/Ub+) proteinopati veya
ubikutinize proteinin ad&#305;yla bir TDP-43 proteinopatisidir. SD hemen daima
bir TDP-43 proteinopatidir. LPA�n&#305;n AH�nin atipik sunumlar&#305;ndan biri
oldu&#287;una dair deliller birikmektedir. PNFA, dvFTD, parkinsonizm ve ALS
bile&#351;imlerinin ailevi bi�imlerinin genetik kar&#351;&#305;l&#305;klar&#305;
a&#351;a&#287;&#305;da �progresif davran&#305;&#351;sal bozukluk� i�inde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r. SD�nin ailevi bi�imi
bildirilmemi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Wernicke afazisine benzer anlaman&#305;n da erken
d�nemde bozuldu&#287;u bir ilerleyici tutuk afazi izole bi�imde de&#287;il
fakat s&#305;kl&#305;kla, bellek ve di&#287;er kognitif bozukluk bulgular&#305;
aras&#305;nda dil bozuklu&#287;unun �n planda oldu&#287;u tablolar bir atipik
sunum olarak AH ile ilintili olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;page-break-before:always;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans2.JPG">&#350;ekil 2.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;lerleyici tutuk afazide
asimetrik sol peri-sylvien atrofi</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sol frontal
operkulum ve sol anterior insula atrofisine ba&#287;lanabilecek asimetrik sol
peri-sylvien geni&#351;leme (�st s&#305;ra, sa&#287;), bir �st kesitte de
hafif�e daha geni&#351; sol ventrik�l frontal boynuzuyla birlikte (�st
s&#305;ra, sol) g�r�l�yor. Sol lateral ventrik�l de sa&#287;a k&#305;yasla hafif�e
daha geni&#351; (alt s&#305;ra).</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans3.JPG">&#350;ekil 3.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Semantik demansta asimetrik sol
bask&#305;n temporopolar atrofi</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>T2
a&#287;&#305;rl&#305;kl&#305; koronal kesitlerde sol frontopolar
a&#287;&#305;r, sa&#287;da daha hafif atrofi (�st s&#305;ra), mezial temporal
b�lgeden ge�en kesitlerde 2 yanl&#305; amigdala atrofisi (alt s&#305;ra).</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans4.JPG">&#350;ekil 4.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sa&#287; temporal varyant
semantik demans g�r�nt�lemesi.</span><span lang=FR style='font-family:Tahoma;
mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>T12
a&#287;&#305;rl&#305;kl&#305; aksiyel ve koronal kesitlerde sa&#287;da
bask&#305;n, 2 yanl&#305; temporopolar atrofi</span><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans5.JPG">&#350;ekil 5.</a> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Logopenik
progresif afazide SPECT.</span><span lang=FR style='font-family:Tahoma;
mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tc<sup>99</sup> HMPAO-SPECT ile MRG�sinde ay&#305;rt
edilebilir bir bulgu olmayan logopenik progresif afazili bir olguda asimetrik
a&#287;&#305;r sol parietal hipoperf�zyon.</span><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=FR style='font-family:Tahoma;mso-ansi-language:
FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif G�rsel-Mekansal Bozukluk (PGMB)</span></i><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></i></b><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu profilin ba&#351;l&#305;ca �zellikleri g�rsel
i&#351;leme bozukluklar&#305;d&#305;r.&nbsp; N�rodejenerasyon iki yanl&#305;
oksipitoparietal b�lgededir.&nbsp; &#304;lk belirtiler s&#305;kl&#305;kla,
bildik yerler dahil d&#305;&#351; mekanda yolunu bulamama,
arad&#305;&#287;&#305; bir nesneyi g�z�n�n �n�nde oldu&#287;u halde di&#287;er
nesnelerden ay&#305;r&#305;p bulamama,&nbsp;okurken sat&#305;rlar&#305;n
birbirine kar&#305;&#351;mas&#305;, yaz&#305; karakterinin bozulmas&#305; ve
giyinme g��l�&#287;�d�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayenede Balint sendromunun bile&#351;enleri
(a&#287;&#305;rl&#305;kla simultanagnozi ve daha silik olarak optik ataksi,
ok�ler apraksi) ile giyinme apraksisi saptan&#305;r.&nbsp; N�ropsikolojik
olarak g�rsel-mekansal testlerde a&#287;&#305;r bozukluk g�r�l�r ve spesifik
testlerle bak&#305;ld&#305;&#287;&#305;nda simultanagnozi ortaya konulur.&nbsp;
Bellek&nbsp; korunmu&#351;tur.&nbsp; Y�r�t�c� i&#351;levler ve dilsel
i&#351;levlerde hafif bozukluklar e&#351;lik edebilir.&nbsp; N�rodejenerasyon
inferior parietal lob�lleri de tuttu&#287;unda sol mekan ihmali ve Gerstmann
sendromu �zellikleri de (sa&#287;-sol disoryantasyonu, parmak agnozisi, agrafi,
aleksi, akalkuli) tabloya kat&#305;labilir ve LPA�y&#305; and&#305;ran bir
anomi yerle&#351;ebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G�r�nt�leme �al&#305;&#351;malar&#305;nda bu
profili yans&#305;t&#305;r &#351;ekilde iki yanl&#305; oksipito-parietal atrofi
(�zellikle, MRG koronal T1 kesitlerde ay&#305;rt edilen), hipoperf�zyon ve
hipometabolizma saptan&#305;r <b>(&#350;ekil 6 </b>ve <b>7).</b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yay&#305;nlanm&#305;&#351; az say&#305;daki otopsi
olgular&#305;nda non-spesifik dejenerasyonun yan&#305;s&#305;ra
s&#305;rad&#305;&#351;&#305; olarak parietal neokortekste
yo&#287;unla&#351;m&#305;&#351; n�rofibriller yumaklarla AH
say&#305;labilir.&nbsp;Fokal atrofiler i�inde en az �Pick kompleksi�
patolojileri, tersine en fazla AH ile ilintili oland&#305;r. H&#305;zl&#305;
seyirli oldu&#287;unda tipik bir CJH sunumu olabilir. Ailevi bi�imleri
bilinmemektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans6.JPG">&#350;ekil 6.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Posterior kortikal atrofide
MRG.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Posterior
kortikal atrofili koronal T1 kesitlerde simetrik dorsal parietal atrofi</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans7.JPG">&#350;ekil 7.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Posterior kortikal atrofide
SPECT.</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Posterior kortikal atrofili bir olguda Tc<sup>99</sup>
HMPAO-SPECT incelemesinin koronal kesitleri. �st s&#305;ra frontal kesitlerden
alt s&#305;ra oksipital kesitlere do&#287;ru �nden arkaya do&#287;ru
izlendi&#287;inde, 2. s&#305;ra 1. kesitte sa&#287; frontoparietal olarak
asimetrik ba&#351;layan hipoperf�zyon ayn&#305; s&#305;radaki 4. kesitte
simetrikle&#351;iyor ve 3. s&#305;radaki dorsal parietal ve alt s&#305;ra 1.
kesitteki oksipitoparietal kesitlerde a&#287;&#305;rla&#351;&#305;yor</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Davran&#305;&#351;sal/Y�r�t�c� Bozukluk
(PDB/PYB)</span></i><span lang=DA style='font-family:Tahoma;mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Prefrontal sisteme atfedilen i&#351;levlerin
ilerleyici bozuklu&#287;u bu tablonun temel �zelli&#287;idir.&nbsp; Tipik bir
hasta 65 ya&#351;&#305;n&#305;n alt&#305;ndad&#305;r.&nbsp; Toplumsal konumuyla
ba&#287;da&#351;mayan tarzda davran&#305;&#351;lar, normlara
ald&#305;r&#305;&#351;s&#305;zl&#305;k, �ocuksuluk, uygunsuz cinsel imalar,
beslenme al&#305;&#351;kanl&#305;&#287;&#305;nda de&#287;i&#351;iklik ya da
oburluk, dikkatin kolayca �elinebilir olmas&#305;, i�g�r� kayb&#305;,
inisiyatif kullan&#305;m&#305;n&#305;n azalmas&#305; erken belirtilerdir.&nbsp;
Hasta unutkan gibi g�r�nebilir, fakat&nbsp;&nbsp; muayene sonucu bunun dikkat
bozuklu&#287;una ikincil oldu&#287;u ortaya konacakt&#305;r.&nbsp; Sokakta
kaybolmadan dola&#351;abilir.&nbsp; Baz&#305; durumlarda sokaktaki
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; yitirmi&#351; gibi
g�r�nebilir, fakat uygun bir sorgulamayla bunun mekan oryantasyonuyla ilgili
de&#287;il, fakat sosyal uygunsuz davran&#305;&#351;lar&#305;n sonucu olarak
hasta yak&#305;nlar&#305;n&#305;n d&#305;&#351;ar&#305; �&#305;kmay&#305;
k&#305;s&#305;tlamas&#305; nedeniyle oldu&#287;u g�r�lecektir.&nbsp; Bu tablo,
izole ilerleyici bir tablo gibi seyredebilece&#287;i gibi, bazen PNFA tipi, bir
dil bozuklu&#287;u da eklenebilir. Bu tablo PNFA ve SD ile birlikte FTLD
tan&#305; kriterlerinde bir ���nc� alt tip olarak belirlenmi&#351;tir ve
davran&#305;&#351;sal varyant olarak da adland&#305;r&#305;l&#305;r (dvFTLD).
Sa&#287; temporal varyant olarak adland&#305;r&#305;lan SD (RTV-SD) tipinde
tablo dvFTLD�den ay&#305;rt edilemeyen bir davran&#305;&#351;sal bozuklukla
ba&#351;layabilir fakat hemen daima daha ba&#351;lang&#305;�tan itibaren veya
k&#305;sa zaman i�inde eklenen bir a&#351;ina y�zleri tan&#305;ma g��l�&#287;�
ile daha geri planda SD tipi bir dil bozuklu&#287;u bulunacakt&#305;r. dvFTLD�ye
e&#351;lik edebilecek motor bozukluklar ise asimetrik akinetik-rijid veya
aksiyel post�ral bozukluklarla parkinsonizm veya ALS olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�elinebilirlik (distraktibilite), d�rt�sellik
(impulsivite) ve motivasyon g��l�&#287;� (apati) nedeniyle bu hastalar&#305;n
n�ropsikolojik muayeneleri son derece g�� olabilir.&nbsp; Bu nedenlerle
performans&#305; de&#287;erlendirmek m�mk�n olamayabilece&#287;i gibi, ger�ek
ya&#351;amda �zellikle kar&#351;&#305;la&#351;&#305;lan yeni problemler
kar&#351;&#305;s&#305;nda �ok ciddi sorunlar&#305; olan bir hastan&#305;n �ofis
performans&#305;� dolay&#305;s&#305;yla bunlar n�ropsikolojik testlerle ortaya
konulamayabilir ve testler t�m�yle normal s&#305;n&#305;rlarda olabilir.&nbsp;
Ancak, tipik bir hastada y�r�t�c� i&#351;levlerle ilgili testlerde ak&#305;l
y�r�tme, planlama, soyutlama, zihinsel esneklik ve sebatl&#305;l&#305;kta
bozukluk, uygunsuz cevab&#305; bask&#305;layamama, perseverasyonlar gibi
bulgular&nbsp;saptan&#305;r.&nbsp; G�rsel-mekansal i&#351;levler ve PA
e&#351;lik etmiyorsa dilsel i&#351;levler korunmu&#351;tur.&nbsp; Yak&#305;n
bellek testlerinde kay&#305;t ve serbest hat&#305;rlamada g��l�klere
kar&#351;&#305;n tan&#305;man&#305;n korundu&#287;u g�r�l�r.&nbsp; Bu hastalarda
limbik sistem salim, dolay&#305;s&#305;yla uzun s�reli bellek
kay&#305;tlar&#305; m�mk�n, ancak prefrontal �ar&#351;ivleyici� sistem bozuk
oldu&#287;undan bu kay&#305;tlara kendili&#287;inden etkin bir bi�imde
ula&#351;mak g�� olmaktad&#305;r.&nbsp; Bazen ekstrapiramidal motor bulgular
asimetrik veya aksiyel bask&#305;n, asimetrik apraksi, ALS
varl&#305;&#287;&#305; durumunda 1. ve 2. motor n�ron bulgular&#305; (el
intrensek kaslar&#305;nda atrofi, bulber zaaf, fasik�lasyonlar, piramidal
bulgular) saptanabilir. �ok nadiren inkl�zyon cisimci&#287;i miyoziti ve Paget
hastal&#305;&#287;&#305; (IBM/Paget) bulgular&#305; saptanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MRG�de simetrik veya asimetrik, frontal loblara
s&#305;n&#305;rl&#305; veya birlikte anterior temporal loblar&#305; da i�eren
atrofi saptan&#305;r. RTV-SD�de, klasik SD�nin tam tersine sa&#287;da
bask&#305;n temporopolar atrofi izlenir. Asimetrik parkinsonizm e&#351;lik
etti&#287;inde parkinsonizmin kontrlateralindeki hemisferde bask&#305;n
asimetrik fronto-parietal atrofi daha muhtemeldir. SD ve RTV-SD�de MRG
�zellikle koronal T1 kesitler i�erdi&#287;inde hemen daima tek ba&#351;&#305;na
yeterli olurken, izole PDB ve asimetrik parkinsonizmli PDB bazen MRG ile
ay&#305;rt edilemeyebilir. B�yle durumlarda SPECT veya PET ile izole PDB�de
frontal loblara s&#305;n&#305;rl&#305;, parkinsonizm durumunda asimetrik
fronto-parietal perf�zyon ya da metabolizma azalmas&#305;n&#305; g�stermek
yararl&#305; olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Bu klinik tablonun alt&#305;nda en s&#305;k
rastlan&#305;lan n�ropatoloji e&#351;it oranlarda denebilecek &#351;ekilde
taupati ve TDP-43 proteinopatidir. ALS ve SD e&#351;li&#287;i hemen daima
TDP-43 ile ili&#351;kiliyken PNFA veya parkinsonizm e&#351;li&#287;i hemen
daima taupati ili&#351;kilidir. Saf davran&#305;&#351;sal varyant&#305;n geriye
kalan %10�luk bir hasta grubunda ubikutinize protein yak&#305;n zamanlara kadar
tan&#305;mlanamam&#305;&#351;t&#305; ve atipik ubikuitin pozitif FTLD
(aFTLD-U), aksonal sferoidli n�ronal orta boy (�intermediate�) filaman
hastal&#305;&#287;&#305; (NIFID) ve bazofilik inkl�zyon cisimci&#287;i
hastal&#305;&#287;&#305; (BIBD) olarak ��e ayr&#305;lmaktayd&#305;. Bu
tan&#305;mlanamayan proteinin de yak&#305;n tarihlerde �fused in� sarkoma (FUS)
proteini oldu&#287;u bulundu. Davran&#305;&#351;sal varyant&#305;n &#351;imdiye
kadar AH patolojisiyle ili&#351;kisi bildirilmemi&#351;tir.&nbsp;&nbsp;H&#305;zl&#305;
seyirli bi�imleri, CJH ve FTD-ALS akla getirmelidir.&nbsp; Ailevi taupatiler
17. kromozomda kodlanan tau proteini genindeki (<i>17q21 MAPT</i>) mutasyonlar
sonucuyken, ailevi TDP-43 proteinopatileri (s&#305;kl&#305;kla parkinsonizmli
davran&#305;&#351;sal varyant &#351;eklinde sunulurlar) yine 17. kromozomda
kodlanan progranulin proteini genindeki (<i>17q24 PGRN</i>) mutasyonlarla
ili&#351;kilidir. FTD-ALS, 9. kromozomda p21 lokusundaki hen�z bilinmeyen bir
gendeki ve 3. kromozomda kodlanan kromatin modifiye edici protein genindeki (<i>3p
CHMP2B</i>) mutasyonlarla ili&#351;kilidir. Nihayet, IBM/Paget ve dvFTLD 9.
kromozomda kodlanan valozin i�eren protein genindeki (<i>9p13 VCP</i>)
mutasyonlar sonucu geli&#351;ir. 16. kromozomda kodlanan FUS ve 1. kromozomda
kodlanan TDP-43 gen mutasyonlar&#305;n&#305;n (<i>TARDP</i>)
a&#287;&#305;rl&#305;kla saf ailevi ALS�ye neden olduklar&#305;
g�sterilmi&#351;tir (FALS). Sadece bir <i>TARDP</i> mutasyonlu olgu ALS
olmaks&#305;z&#305;n PDB fenotipine e&#351;lik eden vertikal bak&#305;&#351;
paralizisi ve koreyle sunulmu&#351;tur. <i>FUS </i>mutasyonlu bir olguda ise
FTD-ALS fenotipi bildirilmi&#351;tir</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Apraksi</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>S&#305;kl&#305;kla asimetrik olarak tek bir
ekstremiteye ait ilerleyici beceriksizlik, sakarl&#305;k bu tablonun temel
�zelli&#287;idir.&nbsp; 65 ya&#351;&#305;n alt&#305;nda pre-senil
ba&#351;lang&#305;� daha mutadd&#305;r.&nbsp; Hasta elini eskisi gibi
kullanamad&#305;&#287;&#305;ndan, eline ald&#305;&#287;&#305; nesneleri
d�&#351;�rebildi&#287;inden yak&#305;nmaktad&#305;r.&nbsp;
�atal-ka&#351;&#305;k kullanmak, d�&#287;me iliklemek gibi iki elin
koordinasyonunu gerektiren eylemler g��le&#351;mi&#351;tir.&nbsp; Dominan el
apraktik oldu&#287;unda do&#287;al olarak zorluklar daha da artmaktad&#305;r:
yaz&#305; yazmak, alet kullanmak �ncelikle bozulanlard&#305;r.&nbsp; Aksiyel kaslar
kat&#305;ld&#305;&#287;&#305;nda yatma, oturma, y�r�me ve giyinme gibi
eylemlerin, beden eksenini nesnelere g�re ayarlayamamaktan kaynaklanan
bozukluklar&#305; ortaya �&#305;kar. Yatakta d�nmek
zorla&#351;m&#305;&#351;t&#305;r.&nbsp; Hasta koltu&#287;a i&#287;reti,
d�&#351;ecekmi&#351; gibi oturur. Y�r�y�&#351; s&#305;ras&#305;nda d�z yoldaki
basamak, t�msek gibi d�zensizliklere ad&#305;mlar&#305;n&#305;
ayarlayamaz.&nbsp; D�&#351;ebilir ya da basamaklar&#305; iki&#351;er, ��er
ad&#305;mlayabilir.&nbsp; Kap&#305;lara, engellere �arpabilir. Giyinmek
g��le&#351;mi&#351;tir.&nbsp; Ters d�nm�&#351; bir giysiyi d�zeltemez,
kollar&#305;n&#305; bulmakta, d�&#287;melerini iliklemekte&nbsp; g��l�k
�eker.&nbsp; &#304;lerlemi&#351; olgularda apraktik el yabanc&#305; el
sendromunda oldu&#287;u gibi t�m�yle denetimden �&#305;kabilir.&nbsp;
&#304;leri a&#351;amadaki bir ba&#351;ka g�r�n�mde tutulan elin s�rekli bir
distonik post�rde �kullan&#305;&#351;s&#305;z el� durumuna gelmesidir. Bu tablo
saf&nbsp; ilerleyici bir tarzda seyredebilece&#287;i gibi, daha s&#305;kl&#305;kla
ki&#351;ilik de&#287;i&#351;ikli&#287;i, depresyon ve PNFA tablonun bir
par�as&#305; olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayenede genellikle asimetrik taraf apraksisi ve
g�vde apraksisi tek ba&#351;&#305;na ya da tutuk afazi, y�r�t�c� bozukluk ve
bazen de g�rsel-mekansal bozukluk bulgular&#305;yla birliktedir.&nbsp; Bellek
g�reli olarak korunmu&#351; veya dikkate sekonder olarak
bozulmu&#351;tur.&nbsp; Ekstrapiramidal sistem tutulumunu i&#351;aretleyen
motor bulgular da s&#305;kl&#305;kla apraktik taraftad&#305;r.&nbsp; Bazen iki
nokta ayr&#305;m&#305;nda bozukluk, agrafestezi, astereognozi gibi kortikal
duyu kusurlar&#305; da mevcuttur. Bu tabloya �kotikobazal sendrom (KBS)�
ad&#305; da verilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G�r�nt�leme �al&#305;&#351;malar&#305;nda
fronto-parietal, s&#305;kl&#305;kla asimetrik bir atrofi ve/veya
hipoperf�zyon-hipometabolizma saptan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu klinik tablo, tipik &#351;ekliyle kortiko-basal
dejenerasyonun (KBD) en iyi bilinen klinik sendromudur.&nbsp;
A&#287;&#305;rl&#305;k aksiyel tutulumda oldu&#287;unda bazen progresif
supran�kleer paralizi (PSP) de b�yle bir tablonun nedeni olabilir.&nbsp;
Sporadik olgular b�y�k �l��de KBD tarz&#305; bir taupati olmakla birlikte
ailevi olgular Kr-17 <i>PGRN </i>mutasyonu ile ili&#351;kili TDP-43
proteinopatisi sonucu olabilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Andrew Kertesz davran&#305;&#351;sal,
dilsel ve motor varyantlardan biriyle ba&#351;layan ve s&#305;kl&#305;kla zaman
i�inde �n planda olan �zelli&#287;e di&#287;erlerinin de eklenmesiyle ilerleyen
bu tablolar&#305;n t�m�n� i�ermek �zere �Pick Kompleksi� kavram&#305;n&#305;
�nermi&#351;tir. </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 3: </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�ekirdek N�ropsikolojik
Profillerin Ay&#305;r&#305;c&#305; Tan&#305;s&#305;<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.25pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=140 valign=top style='width:104.65pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�ekirdek Progresif Sendrom</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amnezi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=297 colspan=3 valign=top style='width:222.6pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Afazi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Agnozi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Apraksi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Ana semptom</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Unutkanl&#305;k</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kelime bulma, konu&#351;ma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kelime anlam&#305;n&#305;n kayb&#305;, me&#351;hur y�zlerin
  tan&#305;namamas&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kelime bulma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Apati, disinhibisyon</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Y�n bulma, g�z�n�n �n�ndeki nesneleri ay&#305;rt edememe</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sakarl&#305;k</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Kognitif tarz</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Bozuk tan&#305;ma belle&#287;i, semantik ak&#305;c&#305;l&#305;k</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Agramatizm, anomi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Anomi, g�rsel agnozi, prosopagnozi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Anomi, akalkuli</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Y�r�t�c�</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Simultanagnozi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Apraksi, y�r�t�c�</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>N�rolojik muayene</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal, bazen asimetrik parkinsonizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal, bazen parkinsonizm/ALS</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik parkinsonizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>MRG</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Hippokampal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol peri-sylvien geni&#351;leme</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik anterior temporal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol parietal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Frontal, fronto-temporal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Simetrik dorsal parietal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik fronto-parietal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Anatomik yatk&#305;nl&#305;k </span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Limbik</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Anterior peri-sylvien</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol temporo-polar</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol inferiyor parietal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Prefrontal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Bilateral oksipito-parietal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik fronto-parietal, basal ganglia</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Hastal&#305;k</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Alzheimer </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>FTLD-PNFA</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>FTLD-SD</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Logopenik PA (Atipik AH)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>FTLD-dv (KBD, PSP, ALS)</span><span lang=DE style='font-family:Tahoma;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Posterior kortikal atrofi (Atipik AH, LCD, CJH)</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>KBD</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>N�ropatoloji</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>AP, NFY</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>T+NI, GCI, </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ub+/T- DN</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>NFY (?)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>T+NI, Ub+/T-&nbsp; NCI, NII, DN, Ub+T-TDP- NCI</span><span lang=FR
  style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>AP, NFY, DLDH, PrP+, LC</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>GCI</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:29.85pt'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Proteinopati</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#946;-Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>TDP-43</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#946;-Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tau, TDP-43 veya FUS</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#946;-Tau, &#945;-SN, PrP<sup>Sc</sup></span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;mso-yfti-lastrow:yes'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Genetik</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>PS1, PS2, APP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>MAPT, PGRN, CHMP2B, VCP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>?</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>?</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>MAPT, PGRN, CHMP2B, VCP, </span></i><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>9p, <i>TARDP, FUS</i></span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>?, PRNP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>MAPT, PGRN, CHMP2B, VCP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar: </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#946;:
amiloid beta protein fragman&#305;; AH: Alzheimer hastal&#305;&#287;&#305;;
ALS: amiyotrofik lateral skleroz; AP: amiloid plak; APP: amiloid prek�rs�r
protein geni;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CHMP2B: kromatin modifiye edici protein 2B geni; CJH: Creutzfeldt-Jacob
hastal&#305;&#287;&#305;; dv: davran&#305;&#351;sal varyant; DN: distrofik
n�ritler; FTLD: &nbsp;&nbsp; fronto-temporolobar dejenerasyon;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FUS: �fused in� sarkoma;
GCI: glial sitoplazmik inkl�zyon; KBD: kortiko-basal dejenerasyon; LCD: Lewy
cisimcikli demans; MAPT: mikrot�b�l asosiye tau geni; NCI: n�ronal sitoplazmik
inkl�zyonlar; NII: n�ronal intran�kleer inkl�zyonlar; NFY: n�ro-fibriller
yumak; NI: n�ronal inkl�zyon; PGRN: progranulin geni; PNFA: ilerleyici tutuk
afazi; PRNP: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prion proteini geni;
PrP: prion proteini; PS1: presenilin 1 proteini geni; PS2: presenilin 2
proteini geni; PSP: progresif supran�kleer paralizi; T: tau proteini; TARDP:
TDP-&nbsp;&nbsp; 43 geni; Ub: ubikutin proteini; VCP: valosin i�eren protein
geni<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demansta Davran&#305;&#351;sal �zellikler</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunun kognitif veya motor olmayan ve
semiyolojik olarak genel psikiyatrinin alan&#305;na giren semptomatolojisini
adland&#305;rma konusunda ya&#351;l&#305;l&#305;k ve demans alan&#305;nda
terminolojik bir g��l�k izlenmektedir.&nbsp; Baz&#305; yazarlar �demans&#305;n
non-kognitif belirtileri� tan&#305;m&#305;n&#305; tercih etseler de kognitif
olmayan �zellikler yaln&#305;zca psikopatoloijk de&#287;il ayn&#305; zamanda da
motor, otonom ve uyku bozukluklar&#305;n&#305; da kapsad&#305;&#287;&#305; i�in
bu terim kast&#305;n&#305; a&#351;maktad&#305;r.&nbsp; Daha fazla
rastlan&#305;lan terim �demans&#305;n davran&#305;&#351;sal �zellikleri� &#351;eklindedir.&nbsp;
Bu b�l�mde de s�zkonusu terim tercih edilmi&#351; olmakla birlikte, bu
literat�rle bir uzla&#351;&#305;m ihtiyac&#305; gere&#287;idir.&nbsp;
�Davran&#305;&#351;sal� terimi genel psikolojide insan
davran&#305;&#351;&#305;n&#305;n g�zlenebilir �zelliklerini
kar&#351;&#305;lamak �zere kullan&#305;l&#305;r ve do&#287;al olarak alg&#305;lama
ve d�&#351;�nce s�re�lerine ili&#351;kin i�sel ya&#351;ant&#305;lamalar&#305;
d&#305;&#351;ta b&#305;rak&#305;r.&nbsp; Oysa ki bizim
kullan&#305;m&#305;m&#305;zda �demans&#305;n davran&#305;&#351;sal �zellikleri�
g�zlenebilir davran&#305;&#351;sal bozukluklar&#305;n yan&#305;s&#305;ra
duygudurum, alg&#305; ve d�&#351;�nce bozukluklar&#305;n&#305; da i�erecek
&#351;ekildedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Duygudurum bozukluklar&#305;</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> anksiyete, depresyon,
mani, fobiler gibi maj�r bozukluklar ve bunlara e&#351;lik edebildikleri gibi
yaln&#305;z ba&#351;&#305;na da g�r�lebilen emosyonel labilite, iritabilite,
disfori, �fori, ajitasyon gibi duygudurum halleridir.&nbsp; &#304;lgili b�l�mde
daha ayr&#305;nt&#305;l&#305; s�z edilece&#287;i gibi demans sendromu
tan&#305;s&#305; konulmadan 10 y&#305;l kadar �nceye giden depresyon AH i�in
ba&#351;l&#305; ba&#351;&#305;na bir risk fakt�r�d�r.&nbsp; Depresyon AH�de
s&#305;kl&#305;kla erken evrede g�r�l�r.&nbsp; Depresyon kaybolmakta olan
zihinsel yeteneklere kar&#351;&#305; psi&#351;ik reaksiyon olarak ortaya
�&#305;kabilece&#287;i gibi depresif ve depresif olmayan AH�li olgular&#305;n
otopsilerinin kar&#351;&#305;la&#351;t&#305;r&#305;lmas&#305;n&#305;n
g�sterdi&#287;i �zere n�rotransmitter kay&#305;plar&#305;na ikincil biyolojik
nedenli de olabilir.&nbsp; An&#305;lan �al&#305;&#351;malarda depresif
olgular&#305;n beyinsap&#305;nda noradrenerjik locus ceruleus, serotonerjik
dorsal raphe ve dopaminerjik substantia nigra ve ventral tegmental Tsai
�ekirdeklerinde depresif olmayan olgulara k&#305;yasla n�ron kayb&#305;n&#305;n
anlaml&#305; d�zeyde fazla oldu&#287;u g�r�lm�&#351;t�r.&nbsp; Gen� depresif
hastalardaki keder, �l�m d�&#351;�nceleri, su�luluk ve de&#287;ersizlik
hisleri, karamsarl&#305;k ile karakterize afektif, isteksizlik, hevessizlik,
kendili&#287;indenlikte azalma, sosyal �ekilme ile karakterize motivasyonel
bile&#351;enleri demansl&#305; hastalarda al&#305;&#351;agelen bi�imde
ay&#305;rt etmek her zaman kolay olmayabilir.&nbsp; Bazen motivasyonel
�zellikler affektif olanlar&#305; g�lgeleyip depresyon tan&#305;s&#305;n&#305;
geciktirebilece&#287;i gibi kendine �zg� n�ral alt yap&#305;s&#305; ile
demanslar&#305;n apati spektrumunda apayr&#305; bir davran&#305;&#351;sal
g�sterisi olabilen motivasyonel bozukluklar depresyonla
kar&#305;&#351;t&#305;r&#305;labilir.&nbsp; Saf <i>motivasyonel bozukluklar </i>AH�de
orta-ileri evrelerde g�r�l�rken FTD�nin erken d�neminin ba&#351;l&#305;ca
�zelliklerindendir.&nbsp; &#304;nsomni ve g�nd�z uyuklamalar&#305;
&#351;eklindeki diurnal ritm bozukluklar&#305; AH�de erken evrelerden itibaren
depresyon �er�evesinde veya izole olarak g�r�lebilir ve performans
bozuklu&#287;una ciddi katk&#305;da bulunabilir.&nbsp; Anksiyete
&nbsp;depresyon �er�evesinde izlenebilece&#287;i gibi AH�de orta evreden
itibaren primer olarak da g�r�l�r.&nbsp; Kognitif bozukluk artt&#305;k�a
&#351;iddeti de artar.&nbsp; Genellikle huzursuzlukla birlikte ama�s&#305;z
dolanma, bulunulan mekan&#305; terketme iste&#287;iyle birlikte g�r�l�r.&nbsp;
�fori, iritabilite gibi duygudurum halleri yine orta evreden itibaren
bask&#305;n hale gelir.&nbsp; Bazen uykusuzluk, grandiozite,
sald&#305;rganl&#305;k e&#351;li&#287;i ile a&#351;ikar bir mani halini
alabilir.&nbsp; Ajitasyon terimi iritabilite ve genellikle verbal ve fiziksel
&#351;iddet g�sterilerinin eklenebildi&#287;i
sald&#305;rganl&#305;&#287;&#305;n e&#351;lik etti&#287;i mani benzeri tablolar
i�in kullan&#305;l&#305;r.&nbsp; AH�de fobiler yine orta evrenin �zellikleri
aras&#305;ndad&#305;r.&nbsp; Yaln&#305;z kalma/b&#305;rak&#305;lma, banyo gibi
temalar i�erebilir.&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hezeyanlar AH�de duygudurum bozukluklar&#305;ndan
sonra 2. s&#305;kl&#305;kta g�zlenen <i>d�&#351;�nce bozukluklar&#305;</i>na
ili&#351;kin g�sterilerdir.&nbsp; Hezeyanlar da AH�de orta evrenin
�zelliklerindendir.&nbsp; Buna kar&#351;&#305;l&#305;k LCD�de destekleyici
tan&#305; kriterleri aras&#305;nda yeralmalar&#305;ndan
anla&#351;&#305;laca&#287;&#305; gibi ilk evrede g�r�lmeleri
mutadd&#305;r.&nbsp; Daha �nce de s�zedildi&#287;i gibi
h&#305;rs&#305;zl&#305;k hezeyan&#305; en s&#305;kt&#305;r.&nbsp; Bununla birlikte
e&#351;in sadakatsizli&#287;i, kendisine k�t�l�k yap&#305;laca&#287;&#305;,
misidentifikasyon/Capgras, terkedilme hezeyanlar&#305; da izlenir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hal�sinasyonlar <i>alg&#305; bozukluklar&#305;</i>na
ili&#351;kin g�sterilerdir.&nbsp; AH�de yine orta evreden itibaren
g�r�l�rler.&nbsp; &#350;izofrenide en s&#305;k i&#351;itsel hal�sinasyonlar
kaydedilirken, demans sendromlar&#305;nda g�rsel hal�sinasyonlar daha
s&#305;kt&#305;r, i&#351;itsel modalite onu izler.&nbsp; Olfaktor, gustatuar ve
taktil hal�sinasyonlar da izlenebilir.&nbsp; LCD�de ise g�rsel hal�sinasyonlar
temel tan&#305; kriterleri, di&#287;er modalitelerdeki hal�sinasyonlar ise
destekleyici �zellikler aras&#305;nda yeral&#305;r.&nbsp;
Dolay&#305;s&#305;yla, LCD�de hem erken evrenin �zelliklerindendirler, hem de
AH�ye g�re �ok daha s&#305;k g�r�l�rler.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ki&#351;ilik de&#287;i&#351;ikli&#287;i</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> yukarda s�zedilen
motivasyonel bozukluk spektrumunda apati &#351;eklinde g�r�lebilece&#287;i gibi
hiperseks�alite ve oburluk tarz&#305; d�rt� kontrol bozukluklar&#305;
&#351;eklinde de g�r�lebilir.&nbsp; FTD�de klinik tablonun temel
�zelli&#287;ini olu&#351;turan ki&#351;ilik de&#287;i&#351;ikli&#287;i, bu iki
u�tan biri ya da di&#287;erinin izole olarak ortaya �&#305;kmas&#305;
&#351;eklinde g�r�lebilece&#287;i gibi s&#305;kl&#305;kla birinin bask&#305;n
oldu&#287;u her ikisinden de �zellikler ta&#351;&#305;yan tablolar
&#351;eklinde izlenirler.&nbsp; AH�de d�rt� kontrol bozukluklar&#305; apatiye
k&#305;yasla daha seyrektir.&nbsp; Hiperseks�alitenin de oburlu&#287;a
k&#305;yasla daha seyrek oldu&#287;u s�ylenebilir. LCD/PHD�de d�rt� kontrol
kusurlar&#305; dopaminerjik replasman tedavisinin (DRT) bir komplikasyonu
olarak dopamin disreg�lasyon sendromu (DDS) �er�evesinde g�r�l�r. Patolojik
kumar DDS�in bir par�as&#305; olarak veya izole &#351;ekilde bir d�rt� kontrol
kusuru olarak ortaya �&#305;kabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G�zlenebilir <i>davran&#305;&#351;sal bozukluklar</i>
AH�nin orta-ileri evrelerinin �zellikleridir.&nbsp; Ama�s&#305;z
ad&#305;mlama/dolanma &#351;eklinde hiperaktivite en s&#305;k g�r�lendir.&nbsp;
Ama�s&#305;z tekrarlay&#305;c&#305; hareketler de s&#305;k izlenir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans E&#351;lik�isi Motor ve Di&#287;er Bulgular</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�� temel alan&#305;n yan&#305;s&#305;ra, motor
belirtiler de baz&#305; demanslar&#305;n ana bile&#351;enlerinden
olabilirler.&nbsp; Yukar&#305;da s�zedildi&#287;i gibi, motor bulgularla
birilikte olan demanslar, demans s&#305;n&#305;flamas&#305;n&#305;n temel
kategorilerindendir.&nbsp; Bu t�r demanslar&#305;n klinik tablosunda motor
bulgular, s&#305;kl&#305;kla demansa g�re daha a&#287;&#305;rl&#305;kl&#305; ya
da e&#351;de&#287;er nitelikte olurlar.&nbsp; Motor bulgular
a&#287;&#305;rl&#305;kla ekstrapiramidal sisteme ait hipokinetik bir hareket
bozuklu&#287;u �zelli&#287;i g�sterirler: bradikinezi, rijidite, parkinsonyen
y�r�y�&#351;, post�ral denge bozuklu&#287;u.&nbsp; multi-sistem atrofilerde
(MSA�lar), �zellikle de parkinsonyen formunda (MSA-P), simetrik akinetik-rijid
sendrom, a&#287;&#305;rl&#305;k ve zamanlama olarak demans&#305;n �n�ndedir;
serebellar ve otonom bulgular e&#351;lik edebilir.&nbsp;&nbsp; Kortiko-basal
ganglionik dejenerasyonda (KBD) belirgin bir asimetrik akinezi s�z
konusudur.&nbsp; Akinetik taraf s&#305;kl&#305;kla apraksiden, a&#287;&#305;r
distoni ve �yabanc&#305; el� fenomenine kadar de&#287;i&#351;en �zellikler
g�sterir ve ayn&#305; tarafta kortikal duyu kusuru saptanabilir.&nbsp; KBD
bazen demans, bazen de hareket bozuklu&#287;u &#351;eklinde ba&#351;layabilir.&nbsp;&nbsp;
Motor n�ron hastal&#305;&#287;&#305;na (MNH) bazen FTD &#351;eklinde ve
h&#305;zl&#305; seyirli bir demans da e&#351;lik edebilir (FTD-MNH).&nbsp; Bu
durumda, MNH�ye �zg� intrensek el kaslar&#305;nda atrofi, hafif yutma
g��l�&#287;� &#351;eklinde bulgular demans&#305;n gerisinde gizlenebilir.&nbsp;
NPH�da y�r�me g��l�&#287;� ve sfinkter kusuru demansla
e&#351;zamanl&#305;d&#305;r.&nbsp; Binswanger sendromunda yine NPH�ya �ok
benzer bir triad (demans, y�r�me g��l�&#287;�, sfinkter kusuru) g�r�l�r.&nbsp;
Buradaki y�r�me g��l�&#287;� �alt beden yar&#305;s&#305; parkinsonizmi� ya da
vask�ler parkinsonizm ad&#305; verilen &#351;eklindedir ve derin k���k
infarktlara ba&#287;l&#305;d&#305;r.&nbsp; Gerek parkinsonizm ve gerekse de
sfinkter kusuru AH�ye hastal&#305;&#287;&#305;n ileri evrelerinden itibaren
kat&#305;l&#305;r.&nbsp; Multi-infarkt demansta hemiparezi sekelleri, g�rme
alan&#305; kusurlar&#305; saptanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunda motor bulgular&#305;n
varl&#305;&#287;&#305; b�y�k s&#305;kl&#305;kla subkortikal i&#351;lev
bozuklu&#287;unu i&#351;aret eder. Bu i&#351;lev bozuklu&#287;unun nedeni
subkortikal gri (lak�ner durum) ya da beyaz madde (Binswanger
Hastal&#305;&#287;&#305;, CADASIL) yap&#305;lar&#305;nda �ok say&#305;da
iskemik vask�ler hasar sonucu olabilece&#287;i gibi do&#287;rudan bazal
ganglia-serebellum sistemlerinin n�rodejenerasyonu sonucu da olabilir.&nbsp;
Ger�ekten de, primer&nbsp; (n�rodejeneratif) demanslar motor bulgularla
birlikte oldu&#287;unda bir ka� istisna d&#305;&#351;&#305;nda bu bulgular
hemen daima&nbsp; bir ekstrapiramidal sendrom (EPS) niteli&#287;ini
ta&#351;&#305;r.&nbsp; MSA�n&#305;n serebellar formunda (MSA-C), ba&#351;ta
g�vde ve ekstremite ataksisi ve dizartri olmak �zere serebellar bulgular
a&#287;&#305;rl&#305;kl&#305; bulgulard&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Daha �nce de de&#287;inildi&#287;i gibi, patolojik
de&#287;i&#351;ikli&#287;in kortikal ya da subkortikal
a&#287;&#305;rl&#305;&#287;&#305;na g�re tabloda motor bulgular kognitif
bulgulara g�re, geri ya da �n planda, bazen de e&#351;it d�zeyde olurlar.&nbsp;
Baz&#305; hastal&#305;klar bu a&#287;&#305;rl&#305;k a�&#305;s&#305;ndan
uniform nitelikte olurlarken (�rne&#287;in, AH, PSP, Huntington), di&#287;er
baz&#305; hastal&#305;klar&#305;n kendi i�inde, dejenerasyonun
yatk&#305;nl&#305;&#287;&#305; bazen kortikal, bazen ise subkortikal y�nde
bozulabilir (�rne&#287;in, LCD, KBD).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANS TANISINDA YARDIMCI LABORATUAR
Y�NTEMLER&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tan&#305; ve ay&#305;r&#305;c&#305; tan&#305;da
kognitif, davran&#305;&#351;sal ve i&#351;levsel alanlar&#305; sorgulayan titiz
al&#305;nm&#305;&#351; bir �yk�n�n yan&#305;s&#305;ra mental durum muayenesi ve
�zellikle fokal bulgular, y�r�y�&#351; bozukluklar&#305; ve ekstrapiramidal
bulgulara dikkat edilecek n�rolojik muayeneden olu&#351;an klinik y�ntem esas
olmakla birlikte, asgari d�zeyde laboratuar incelemeleri de
duyarl&#305;l&#305;&#287;&#305; artt&#305;racakt&#305;r.&nbsp; Amerikan
N�roloji Akademisi�nin (AAN) 1995�te yay&#305;nlad&#305;&#287;&#305; Uygulama
Elkitab&#305;�n&#305;n �Demans Tan&#305; ve De&#287;erlendirmesi�<sup> </sup>b�l�m�nde
a&#351;a&#287;&#305;daki biyokimyasal testlerin rutin olarak
yap&#305;lmas&#305; gerekti&#287;i s�ylenir: tam kan say&#305;m&#305;,
elektrolitler, kalsiyum, glukoz, BUN/kreatinin, karaci&#287;er testleri, tiroid
testleri, serum B12 vitamin d�zeyi ve sifilis serolojisi.&nbsp;
Klini&#287;imizdeki rutin uygulamada sifilis serolojisine de ihtiyari olarak
ba&#351;vurulmaktad&#305;r <b>(Tablo 4</b>).&nbsp; Elkitab&#305;�nda di&#287;er
biyokimyasal testler, g�r�nt�leme (BT/MRG), n�ropsikolojik muayene, EEG ve
lomber ponksiyon gibi inceleme y�ntemlerinin, rutin d&#305;&#351;&#305;nda
kalan �zel durumlarda yap&#305;labilece&#287;i belirtilmektedir.&nbsp; BT ya da
MRG�nin, klinik de&#287;erlendirme tecr�beli bir klinisyen elinde
yap&#305;ld&#305;&#287;&#305;nda veya hasta tipik olarak 60
ya&#351;&#305;n&#305;n �zerinde, sinsi ba&#351;lang&#305;�l&#305;, fokal bulgular,
n�betler ya da y�r�y�&#351; bozukluklar&#305;&nbsp;g�stermeyen bir demans
tablosu sergiledi&#287;inde nadiren gerekece&#287;i kaydedilir.&nbsp; Yine de,
�ok erken olgularda al&#305;&#351;k&#305;n bir g�z MRG�nin koronal T1
kesitlerinde g�rd�&#287;� hippokampal atrofiyle klinik olarak arada
kald&#305;&#287;&#305; bir olguda DAT/PRAD karar&#305; verebilir. Yukarda
�ekirdek N�ropsikolojik Sendromlar b�l�m�nde de&#287;inilen ve
a&#351;a&#287;&#305;da Alzheimer D&#305;&#351;&#305; Demanslar b�l�m�nde daha
ayr&#305;nt&#305;l&#305; g�zden ge�irilecek olan �zg�l atrofi tarzlar&#305;n&#305;n
saptanmas&#305; Alzheimer d&#305;&#351;&#305; demanslar&#305;n
tan&#305;s&#305;nda de&#287;erli olabilir. �yk�de bir ya da daha fazla lober
hematomla birlikte MRG�de gradyan eko tekni&#287;iyle saptanan mikro-kanamalar
demans&#305; serebral amiloid anjiyopatiyle (CAA) ili&#351;kilendirebilir.
Yine, h&#305;zl&#305; seyirli bir demansta ba&#351;ta dif�zyon
a&#287;&#305;rl&#305;kl&#305; g�r�nt�lemede (DWI) olmak �zere FLAIR�de de
g�r�lebilen kortikal ve bazal ganglionik-talamik y�ksek sinyal CJH�yi
i&#351;aretleyebilir. Ancak, s&#305;kl&#305;kla rutin bir MRG taramas&#305;na
dahil edilmedikleri i�in atrofi de&#287;erlendirilmek istendi&#287;inde koronal
T1 kesitlerin, CAA veya CJH�dan ku&#351;kulan&#305;ld&#305;&#287;&#305;nda
gradyan eko veya DWI teknikli incelemelerin dahil edilmesi radyoloji
laboratuar&#305;ndan �zel olarak talep edilmelidir. N�ropsikolojik muayene
temel olarak erken demans&#305; de&#287;erlendirmekte, demans ve depresyonu
ay&#305;rmakta, hukuki ehliyetin dok�mantasyonunda yararl&#305;
olacakt&#305;r.&nbsp; EEG�ye, n�betlerin varl&#305;&#287;&#305;nda,
Creutzfeldt-Jacob hastal&#305;&#287;&#305; ku&#351;kusunda
ba&#351;vurulabilir.&nbsp; Lomber ponksiyon, metastatik kanser, MSS infeksiyonu
ku&#351;kusu, reaktif sifilis serolojisi, hidrosefali, gen� demans,
h&#305;zl&#305; seyirli ve atipik demans, immunosupresyon ve MSS vask�liti
ku&#351;kusu durumlar&#305;nda rutin olarak yap&#305;lmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Rutin ve tek olgu incelemesi
d&#305;&#351;&#305;nda kalan, �zellikle AH�de ara&#351;t&#305;rma ama�l&#305;
bir dizi y�ntemden de s�zedilebilir.&nbsp; MRG-vol�metri ile hippokampus, entorhinal
korteks ve superior temporal sulkus vol�metrisi y�ntemi, �zellikle normal
ya&#351;lanma-MCI-AH devaml&#305;l&#305;&#287;&#305;n&#305;n
ayr&#305;m&#305;nda giderek rafine edilmektedir <b>(&#350;ekil 1</b>).&nbsp;
MR-Spektroskopi (MRS) y�ntemi ile bir n�ronal i&#351;aretleyici olan N-asetil
aspartat miktar&#305;nda meziyal temporal b�lgelerden yap&#305;lan
�l��mlerde&nbsp; saptanan azalman&#305;n yine hippokampal vol�m ile korele
etti&#287;i g�sterilmi&#351;tir.&nbsp; MRS ile NAA/Cr d�zeyleri n�ron
kayb&#305;yla karakterize olan AH, FTLD ve VaD gibi demanslarda d�&#351;er.
MI/Cr d�zeyleri ise AH ve FTLD gibi gliozis ile karakterize demanslarda
y�kselir. Nihayet, Cho/Cr d�zeyleri AH ve LCD gibi a&#287;&#305;r kolinerjik
kay&#305;p ile karakterize demanslarda y�kselir. &#304;&#351;aretli glukoz
kullanan klasik FDG-PET ile pariyeto-temporal hipometabolizma, SPECT ile
ayn&#305; b�lgelerde hipoperf�zyon bulgular&#305;n&#305;n AH�de
duyarl&#305;l&#305;&#287;&#305; y�ksek olsa da yeterince �zg�l
de&#287;ildirler.&nbsp; FDG-PET ile posterior singulat
hipometabolizmas&#305;n&#305;n AH�nin en erken bulgular&#305;yla korele
etti&#287;ine ili&#351;kin bildirimler mevcuttur.&nbsp; Yeni geli&#351;mekte
olan PET-amiloid g�r�nt�lemenin potansiyeline daha �nce PAD b�l�m�nde
de&#287;inilmi&#351;ti. BOS�ta baz&#305; A&#946; fragmanlar&#305; d�zeylerinde
azalma, yine total ve fosfo-tau proteini d�zeyinde artma �mit vaadeden
laboratuar y�ntemleri aras&#305;nda ayn&#305; b�l�mde s�z edilmi&#351;ti.&nbsp;
Genetik inceleme ile AH�de bir risk fakt�r� olan APO-E e4 alellerinin
saptanmas&#305; art&#305;k atipik olgularda d�&#351;�n�lebilir.&nbsp;Familyal
gibi duran olgularda genetik analizin yarar&#305; a&#351;ikard&#305;r. Kognitif
elektrofizyoloji �zel olarak tasarlanm&#305;&#351; ve analiz edilmi&#351; olaya
ili&#351;kin potansiyeller (O&#304;P) bi�iminde AH�nin erken d�neminde
ay&#305;rt edici bir y�ntem olarak kullan&#305;m alan&#305; bulabilir.
Ba&#351;lang&#305;�ta ucuz ve basit bir y�ntem olarak umut
vaadeden&nbsp;anti-kolinerjik damla (tropicamide) ile anormal pupiller cevab&#305;n
�zg�ll�&#287;� kabul edilir bulunmam&#305;&#351;t&#305;r.&nbsp;<b>&nbsp;</b>G�n�m�zde
sadece ara&#351;t&#305;rmalara s&#305;n&#305;rl&#305; gibi g�r�nen bu
y�ntemlerden baz&#305;lar&#305; gelecekte AH rutininde kullan&#305;labilecek
potansiyel biyo-i&#351;aretleyiciler aras&#305;ndad&#305;rlar. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="tablo4.JPG">Tablo 4.</a></span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Demans
tan&#305;s&#305;nda rutin laboratuvar</span><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;mso-ansi-language:TR'>ALZHEIMER HASTALI&#286;I</span></b><span
lang=FR style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans antik �a&#287;lardan beri bilinen bir
hastal&#305;kt&#305;r.&nbsp; Ancak, Alzheimer hastal&#305;&#287;&#305;n&#305;n
(AH) ilk olgusu olma onuru bayan Auguste D.�ye aittir. <span style='color:black'>Auguste
D 1850 May&#305;s�&#305;nda do&#287;mu&#351;tu. 1890�lar&#305;n sonlar&#305;na
do&#287;ru bellek ve dil bozukluklar&#305; &#351;eklinde tan&#305;mlanan demans
semptomlar&#305; geli&#351;tirmeye ba&#351;lad&#305;. K&#305;sa zamanda ciddi
psikotik �zellikler ve ajitasyon eklendi ve Kas&#305;m 1901�de, Alois Alzheimer
taraf&#305;ndan muayene edilece&#287;i Frankfurt Ak&#305;l Hastanesi�ne
getirildi, 8 Nisan 1906�da bu hastanede �ld�. Alzheimer 1902�de Kraepelin�in
daveti �zerine �nce Heidelberg�e gitmi&#351;, 1 y&#305;l sonra da yine
Kraepelin ile birlikte M�nih�e ge�mi&#351;ti. Auguste D.�nin �l�m�n� duyan
Alzheimer eski �al&#305;&#351;ma arkada&#351;lar&#305;ndan klinik kay&#305;tlar&#305;n&#305;
ve beyin dokusunu rica etti. 3 Kas&#305;m 1906�da, T�bingen�deki G�neydo&#287;u
Alman Psikiyatri Derne&#287;i�nin 37. Toplant&#305;s&#305;�nda Auguste D.�nin
klinik ve n�ropatolojik bulgular&#305;n&#305; &quot;�ber einen eigenartigen,
schweren Erkrankungsprozess der Hirnrinde&quot; isimli 11. bildiriyle sundu.
Hastan&#305;n ya&#351;&#305;n&#305;n gen� olmas&#305; dolay&#305;s&#305;yla
hastal&#305;k bir pre-senil demans bi�imi olarak de&#287;erlendirilecektir.
Beynin n�ropatolojik incelemesinde serebral korteksin normale g�re
incelmi&#351; oldu&#287;unu g�rd�. Ayr&#305;ca, daha sonra amiloid plaklar
olarak adland&#305;r&#305;lacak miliyer odaklar&#305; ve yine daha sonra
n�rofibriler yumaklar ad&#305;n&#305; alacak intrasel�ler fibril
birikintilerini tan&#305;mlad&#305;. </span>Auguste D. ile ilk kez
tan&#305;mlanm&#305;&#351; olan klinik olarak demans ile n�ropatolojik olarak
NFY ve AP bug�n hala AH�nin ana diyagnostik triad&#305;n&#305;
olu&#351;turmaktad&#305;r.&nbsp;Hocas&#305; ve �al&#305;&#351;ma
arkada&#351;&#305;, &#351;izofreninin de isim babas&#305; Emil Kraepelin <i>Psychiatrie:
Ein Lehrbuch f�r Studierende und Aerzte </i>adl&#305; d�neminin en �nl� ders
kitab&#305;n&#305;n 1913�teki 8. bask&#305;s&#305;nda bu t�r olgulara
Alzheimer�in ad&#305;n&#305; verdi.&nbsp;Tuhaf olan bunca yayg&#305;n bir
hastal&#305;&#287;&#305;n �Havva� olgusu olarak adland&#305;r&#305;labilecek
olan ilk olgunun atipik bir olgu olmas&#305;d&#305;r.&nbsp; Gerek erken
ba&#351;lang&#305;� ve gerekse de, asl&#305;nda erken
ba&#351;lang&#305;�l&#305; AH olgular&#305;nda ayk&#305;r&#305; olmayacak
&#351;ekilde, davran&#305;&#351;sal belirtilerin �n planda oldu&#287;u klinik
tablo ATD�nin tipik tablosu de&#287;ildir.&nbsp; 1970�ler ortalar&#305;na kadar
AH�nin �Pre-senil demanslar� kategorisi alt&#305;nda PiH�le birlikte nadir
hastal&#305;klardan biri olarak s&#305;n&#305;fland&#305;r&#305;lmas&#305;
b�y�k �l��de bu nedenledir.&nbsp; Bir as&#305;rl&#305;k tarihinin son
�eyre&#287;inde asl&#305;nda �ok daha s&#305;k g�r�len ve �kronik organik beyin
sendromu� ya da �serebral skleroz� gibi adlar da verilen �senil
demans&#305;n�&nbsp;AH ile ayn&#305; patolojik de&#287;i&#351;iklikleri
payla&#351;an bir ve ayn&#305; antite oldu&#287;u
kavranm&#305;&#351;t&#305;r.&nbsp; Robert Katzman�&#305;n 1976�da �senil demans
AH�dir demesiyle AH tarihinin moderan �a&#287;&#305;na ge�ilmi&#351; olur.
G�n�m�zde, �zellikle ortalama ya&#351;am beklentisinin giderek
artt&#305;&#287;&#305; geli&#351;mi&#351; �lkelerde, hen�z etyolojisinin
ayd&#305;nlat&#305;lamam&#305;&#351; ve kesin tedavisinin bulunamam&#305;&#351;
olmas&#305; nedenleriyle de, en �nde gelen morbidite ve mortalite nedenlerinden
biri olmaktad&#305;r. Alzheimer anahtar kelimesi ile Pub Med�de bir
ara&#351;t&#305;rma yap&#305;larak son yar&#305;m y�zy&#305;l&#305;n 10�ar
y&#305;ll&#305;k dilimlerindeki yay&#305;n say&#305;s&#305;na
bak&#305;ld&#305;&#287;&#305;nda bulunan nerdeyse logaritmik art&#305;&#351;
�ok �arp&#305;c&#305;d&#305;r: 1960-69: 28, 1970-79: 327, 1980-89: 5464,
1990-99: 17328, 2000-09: 29738.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>KL&#304;N&#304;K TABLO<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tan&#305; Kriterleri</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yukar&#305;da yeri geldi&#287;ince
tart&#305;&#351;&#305;ld&#305;&#287;&#305; gibi ATD, merkezini limbik sistem
dejenerasyonuna ba&#287;l&#305; yak&#305;n bellek bozuklu&#287;unun
olu&#351;turdu&#287;u, sinsi ba&#351;lang&#305;�l&#305;, yava&#351; seyirli bir
tempoyla neokortikal tutulumun da kat&#305;lmas&#305;yla di&#287;er kognitif
i&#351;levlerin de bozuldu&#287;u bir demans sendromudur (GYA�lar&#305; bozan
sinsi ba&#351;lang&#305;�, yava&#351; seyirli en az iki kognitif
bozukluk).&nbsp;Bu tan&#305;mdan anla&#351;&#305;laca&#287;&#305; gibi demans
AH n�rodejenerasyonunun g�reli ge� bir g�sterisidir.&nbsp; AH�nin klinik
tan&#305;s&#305; i�in yay&#305;nlanm&#305;&#351; olan ve bug�n yayg&#305;n
bi�imde kullan&#305;lan NINCDS-ADRDA (National Institute of Neurological and
Communicative&nbsp; Disorders and Stroke-Alzheimer�s Disease and Related Disorders
Association) ve DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,
4th edition) kriterlerinin her ikisi de (<b>Tablo 5 </b>ve<b> Tablo 6)</b> bir
tak&#305;m n�anslar&#305;na kar&#351;&#305;n �zetle yukardaki
ko&#351;ullar&#305;n doldurulmas&#305;n&#305; AH�ye �zg� tipik&nbsp; sendromun
tan&#305;s&#305; i�in zorunlu tutmaktad&#305;rlar.&nbsp; B�yle bir tabloya yola�abilecek
sekonder nedenlerin (sistemik, n�rolojik, psikiyatrik) ekarte edilebiliyor
olmas&#305; da her ikisi i�in zorunlu d&#305;&#351;lama kriteridir.&nbsp; Bu
ko&#351;ullar&#305;n&nbsp; ger�ekle&#351;tirildi&#287;i tipik tabloya DSM-IV
�Alzheimer Tipi Demans� (DAT) ad&#305;n&#305; vermektedir.&nbsp; NINCDS-ADRDA
i�in ise ayn&#305; tablonun ad&#305; �Muhtemel Alzheimer
Hastal&#305;&#287;&#305;� (PRAD) olmaktad&#305;r.&nbsp;&nbsp; Her iki sisteme
g�re de son kliniko-patolojik serilerdeki tan&#305; �zg�ll�&#287;� %90�a
yakla&#351;maktad&#305;r.&nbsp; Bir ba&#351;ka deyi&#351;le PRAD/DAT
tan&#305;s&#305; %10 ihtimalle AH d&#305;&#351;&#305; durumlara
yanl&#305;&#351; olarak konulmakta veya AH d&#305;&#351;&#305; nedenler
PRAD/DAT tablosunu taklit ederek sunulmaktad&#305;rlar.&nbsp; Tipik klinik
tablonun duyarl&#305;l&#305;&#287;&#305; t�m AH olgular&#305;n&#305;n yine %90
kadar&#305;n&#305; kapsamaktad&#305;r.&nbsp; Bir ba&#351;ka deyi&#351;le AH
hastalar&#305;n&#305;n %10�u atipik klinik tablolar g�sterdikleri i�in PRAD/DAT
tan&#305;s&#305; alamamaktad&#305;rlar. NINCDS-ADRDA, ba&#351;lang&#305;� ve
seyirde beklenmedik �zellikler (akut ba&#351;lang&#305;� ve/veya
h&#305;zl&#305; seyir), demansa neden olabilecek fakat klinisyenin demans
nedeni olarak d�&#351;�nmedi&#287;i 2. bir durumun varl&#305;&#287;&#305;
(�rne&#287;in, inme, hipotiroidi, vb.) ve izole tek bir ilerleyici kognitif
bozukluk olarak s&#305;ralad&#305;&#287;&#305; atipik tablolar i�in �M�mk�n
Alzheimer Hastal&#305;&#287;&#305;� (Possible AD-PosAD) ad&#305;n&#305;
kullan&#305;r.&nbsp; PosAD tan&#305;s&#305;yla duyarl&#305;l&#305;k artar, yani
tan&#305; konulmayan olgular&#305;n say&#305;lar&#305; azal&#305;rken �zg�ll�k
azalmakta, yani yanl&#305;&#351; tan&#305;lar&#305;n say&#305;s&#305;
artmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Her iki yakla&#351;&#305;m da AH�nin demans
a&#351;amas&#305;n&#305;n tan&#305;nmas&#305; i�in �zellikle
duyarl&#305;l&#305;k ve bir �l��de de �zg�ll�k a�&#305;s&#305;ndan kabul
edilebilir d�zeyler sa&#287;lasalar da tan&#305;sal kesinlikten uzak olduklar&#305;
da a�&#305;kt&#305;r.&nbsp;Nitekim, her 2 kriter dizisi de AH�nin g�reli ge�
bir a&#351;amas&#305;na kar&#351;&#305;l&#305;k gelen bir klinik tablo, sendrom
tan&#305;mlamaktad&#305;r. NINCDS-ADRDA kriterlerinde a�&#305;k�a ifade
edildi&#287;i gibi kesin tan&#305; n�ropatologa b&#305;rak&#305;lmaktad&#305;r.
Bir ba&#351;ka deyi&#351;le mevcut durumda klinisyenler de&#287;il, sadece
patologlar Alzheimer hastal&#305;&#287;&#305; tan&#305;s&#305; koyabilirler.
Hastal&#305;&#287;&#305;n seyrine m�dahale olanaklar&#305;n&#305;n
s&#305;n&#305;rl&#305; oldu&#287;u yak&#305;n tarihlere kadar bu durumun pek de
sak&#305;nca yaratt&#305;&#287;&#305; s�ylenemezdi. Bununla birlikte,
hastal&#305;&#287;&#305;n n�robiyolojisinin kavranmas&#305;ndaki ba&#351;
d�nd�r�c� geli&#351;meler do&#287;rudan etyopatogenetik mekanizmalar&#305;
hedefleyen nedene y�nelik tedavilerin ara&#351;t&#305;r&#305;labilir
olmas&#305;na olanak sa&#287;lad&#305;. A&#351;a&#287;&#305;da daha
ayr&#305;nt&#305;l&#305; g�zden ge�irilece&#287;i gibi, bu ama�la s&#305;nanan
ve b�y�k maddi kaynaklar ayr&#305;larak klinik �al&#305;&#351;malar&#305;n
olgun a&#351;amalar&#305;na kadar gelebilen �ok say&#305;da molek�l nihai
engelde tak&#305;larak ipi g�&#287;�sleyemedi. Bu �st �ste hayal
k&#305;r&#305;klar&#305;n&#305;n nedenleri aras&#305;nda mutad
�al&#305;&#351;ma tasar&#305;m&#305;ndan kaynaklanan nedenler ve etkisizlik
yan&#305;s&#305;ra kuvvetle muhtemel bir di&#287;eri ise bu klinik
�al&#305;&#351;malar&#305;n an&#305;lan kriterlerle tan&#305; konmu&#351;
demans evresindeki hastalar&#305; toplamas&#305; gibi g�r�n�yor; oysa ki
do&#287;rudan bir etyopatogenetik mekanizma basama&#287;&#305;n&#305;
hedefleyen bir ajan i�in yerle&#351;mi&#351; demans ajan&#305;n ger�ek
potansiyelini sergileyebilmesi i�in �ok ge� kal&#305;nm&#305;&#351; bir
a&#351;ama olabilir. AH�nin demans a&#351;amas&#305;n&#305; kanserin metastatik
a&#351;amas&#305;na benzetip tedavi ba&#351;ar&#305;s&#305; beklentisi
a�&#305;s&#305;ndan bir analoji kurabiliriz. Bu nedenle AH�nin daha demans
�ncesi a&#351;amada tan&#305;ya y�nelik biyo-i&#351;aretleyicilerin de
yard&#305;m&#305;yla g�venilir bir &#351;ekilde ay&#305;rt edilmesi, AH
tan&#305;s&#305;n&#305;n bizzat klinisyen taraf&#305;ndan konulmas&#305;
giderek artan bir �nem arzetmektedir. A&#351;a&#287;&#305;da, AH�de
yard&#305;mc&#305; tan&#305; y�ntemleri ve potansiyel biyo-i&#351;aretleyiciler
g�zden ge�irildikten sonra yak&#305;nlarda bir �neri olarak sunulan b�ylesi bir
yeni tan&#305; kriterleri dizisi tan&#305;t&#305;lacakt&#305;r. Ayr&#305;ca
benzer bir perspektifle her 2 kriter dizisinin g�zden ge�irilmekte oldu&#287;u,
NINCDS-ADRDA�in NIA-AA (Ulusal Ya&#351;l&#305;l&#305;k Enstit�s� � Alzheimer
Derne&#287;i) &#351;ekliyle 2010 sonlar&#305;nda DSM-IV2�n DSM-V olarak 2011
i�inde yenilenmesinin beklendi&#287;i kaydedilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 5.</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> NINCDS-ADRDA Alzheimer
Hastal&#305;&#287;&#305;n&#305;n Klinik Tan&#305; Kriterleri (McKhann et al.
1984)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>I.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MUHTEMEL Alzheimer Hastal&#305;&#287;&#305; klinik tan&#305; kriterleri
&#351;unlar&#305; i�erir:</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Klinik muayene ile saptanan,
Mini-Mental Test, Blessed Demans �l�e&#287;i ya da benzer bir test ile
dok�mante edilen ve n�ropsikolojik testlerle de do&#287;rulanan demans tablosu;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&#304;ki ya da daha fazla
kognitif s�re�te bozulma;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Bilin� bozuklu&#287;u yok;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Ba&#351;lang&#305;� 40-90
ya&#351;lar&#305; aras&#305;nda, b�y�k s&#305;kl&#305;kla da 65
ya&#351;&#305;ndan sonra;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Bellek ya da di&#287;er
bili&#351;sel s�re�lerde ilerleyici bozuklu&#287;a yola�abilecek sistemik ya da
beyne ait ba&#351;ka bir hastal&#305;k yok.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>II.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MUHTEMEL Alzheimer Hastal&#305;&#287;&#305; tan&#305;s&#305; &#351;unlarla
desteklenir:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Dil (afazi), motor yetenekler
(apraksi) ve alg&#305; (agnozi) gibi �zg�l kognitif i&#351;levlerde ilerleyici
bozulma;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;G�nl�k ya&#351;am
aktivitelerinde bozulma ve davran&#305;&#351; bi�iminde de&#287;i&#351;me;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Ailede benzer bozukluk �yk�s�
(�zellikle patolojik olarak kan&#305;tlanm&#305;&#351;sa);</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Laboratuarda:</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Standart tekniklerle normal lomber ponksiyon,</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
EEG�nin normal olmas&#305; yada yava&#351; dalga aktivitesinde art&#305;&#351;
gibi non-spesifik de&#287;i&#351;iklikler,</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BT�de serebral atrofiye ili&#351;kin bulgular ve seri incelemelerde bu
bulgular&#305;n ilerleyi&#351;i.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-47.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>III.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Alzheimer hastal&#305;&#287;&#305; d&#305;&#351;&#305;ndaki nedenler
d&#305;&#351;land&#305;ktan sonra, MUHTEMEL Alzheimer Hastal&#305;&#287;&#305;
tan&#305;s&#305; ile uyumlu olabilecek di&#287;er klinik �zellikler
&#351;unlard&#305;r:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-47.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Hastal&#305;&#287;&#305;n
seyrinde platolar;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Depresyon, uykusuzluk,
inkontinans, hezeyan, ill�zyon ve hal�sinasyonlar, verbal, emosyonel ya da
fiziksel katastrofik patlamalar, cinsel bozukluklar ve kilo kayb&#305; gibi
e&#351;lik�i bulgular;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Baz&#305; hastalarda, �zellikle
hastal&#305;&#287;&#305;n ileri d�nemlerinde, kas tonusunda art&#305;&#351;,
miyoklonus ya da y�r�me g��l�&#287;� gibi di&#287;er n�rolojik bozukluklar;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Hastal&#305;&#287;&#305;n ileri
evresinde n�betler;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Ya&#351; i�in normal BT.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>MUHTEMEL
Alzheimer Hastal&#305;&#287;&#305; tan&#305;s&#305;n&#305;
belirsizle&#351;tiren ya da ihtimal d&#305;&#351;&#305;na �&#305;karan
�zellikler &#351;unlard&#305;r:</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&#304;nme tarz&#305;nda ani
ba&#351;lang&#305;�;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Hemiparezi, duysal kay&#305;p,
g�rme alan&#305; defektleri ve inkoordinasyon gibi fokal n�rolojik
bulgular&#305;n hastal&#305;&#287;&#305;n erken evrelerinde bulunmas&#305;;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>� N�betler ya da y�r�y�&#351;
bozukluklar&#305;n&#305;n, daha ba&#351;lang&#305;�ta ya da
hastal&#305;&#287;&#305;n �ok erken evrelerinde bulunmas&#305;;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>V.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M�MK�N
Alzheimer Hastal&#305;&#287;&#305; tan&#305; kriterleri &#351;unlard&#305;r:</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Demansa neden olabilecek
di&#287;er n�rolojik, psikiyatrik ya da sistemik bozukluklar
olmaks&#305;z&#305;n, ba&#351;lang&#305;�, prezantasyon ya da klinik seyirde
varyasyonlar&#305;n bulunmas&#305; durumunda konulabilir;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>� Demansa neden olabilecek, ancak
demans&#305;n nedeni gibi g�r�nmeyen ikinci bir sistemik ya da beyin
hastal&#305;&#287;&#305;n&#305;n bulunmas&#305; durumunda konulabilir;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Di&#287;er belirlenebilir
nedenlerinin d&#305;&#351;land&#305;&#287;&#305;, tek ve yava&#351; ilerleyici
bir bili&#351;sel bozuklu&#287;un bulunmas&#305; durumunda, ara&#351;t&#305;rma
�al&#305;&#351;mas&#305; ama�l&#305; olarak kullan&#305;labilir.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-47.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>VI.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KES&#304;N
Alzheimer Hastal&#305;&#287;&#305; tan&#305;s&#305; kriterleri
&#351;unlard&#305;r:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>� Muhtemel Alzheimer
Hastal&#305;&#287;&#305; klinik kriterleri;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;Biyopsi ya da otopsiyle elde
edilen histopatolojik kan&#305;tlar.</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:45.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:2.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<b>Tablo 6. </b>DSM-IV Alzheimer Tipi Demans
&#304;�in Tan&#305; Kriterleri (1995)<o:p></o:p></span></p>

<div style='margin-left:24.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-24.0pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Birden fazla kognitif alan&#305; i�eren bozukluk kendini
a&#351;a&#287;&#305;daki iki maddeyi de kapsayacak &#351;eklinde ortaya
�&#305;kar:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bellek bozuklu&#287;u (yeni bir bilgi �&#287;renme ve �&#287;renilmi&#351; eski
&nbsp;&nbsp; bir bilgiyi hat&#305;rlama yetene&#287;inin bozulmas&#305;)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A&#351;a&#287;&#305;da
s&#305;ralanan kognitif bozuklardan en az biri:</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(a)&nbsp;&nbsp;&nbsp;&nbsp; Afazi (dil
bozuklu&#287;u)</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(b)&nbsp;&nbsp;&nbsp;&nbsp; Apraksi
(motor i&#351;levlerin normal olmas&#305;na kar&#351;&#305;n belirli motor
eylemlerin yerine getirilmesi yetene&#287;inde &nbsp; bozulma)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(c)&nbsp;&nbsp;&nbsp;&nbsp; Agnozi
(duysal i&#351;levlerin salim olmas&#305;na kar&#351;&#305;n
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nesneleri
tan&#305;makta g��l�k)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(d)&nbsp;&nbsp;&nbsp;&nbsp;Y�r�t�c�
i&#351;levlerde bozulma (planlama, organize etme, s&#305;ralama, soyutlama)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A1 ve A2 kriterlerinde tan&#305;mlanan bili&#351;sel bozukluklar toplumsal ve
mesleki i&#351;levselli&#287;i ciddi bi�imde bozmakta ve eski i&#351;levsellik
d�zeyine g�re anlaml&#305; bir gerilemeyi temsil etmektedir.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:49.65pt;margin-bottom:.0001pt;text-align:justify;text-indent:-49.65pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Seyir, sinsi ba&#351;lang&#305;� ve yava&#351; ilerleyici kognitif
y&#305;k&#305;m �zelliklerindedir.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A1
ve A2 kriterlerinde tan&#305;mlanan bili&#351;sel bozukluklar
a&#351;a&#287;&#305;da s&#305;ralanan nedenlerden herhangi birine
ba&#287;l&#305; de&#287;ildir:</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bellek ve di&#287;er bili&#351;sel i&#351;levlerde ilerleyici bozulmaya neden
olabilecek &nbsp; merkezi sinir sistemine ait di&#287;er durumlar (�rne&#287;in
serebrovask�ler hastal&#305;k, Parkinson hastal&#305;&#287;&#305;, Huntington
hastal&#305;&#287;&#305;, subdural hematom, normal bas&#305;n�l&#305;
hidrosefali, beyin t�m�r�)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Demansa neden olabilece&#287;i bilinen sistemik durumlar (�rne&#287;in
hipotiroidizm, B12 vitamini ya da folik asid eksikli&#287;i, niasin
eksikli&#287;i, hiperkalsemi, n�rosifilis, HIV infeksiyonu)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;la�lar ve madde kullan&#305;m&#305; ile ilgili durumlar</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>E.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bozukluklar delirium seyri d&#305;&#351;&#305;nda ortaya
�&#305;km&#305;&#351;t&#305;r.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>F.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bozukluk
ba&#351;ka bir Eksen I hastal&#305;&#287;&#305; ile a�&#305;klanabilir
nitelikte de&#287;ildir.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><a name="OLE_LINK2"></a><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
Hastal&#305;&#287;&#305;n&#305;n Pre-Demans Evreleri: Normal
Ya&#351;lanma-Ya&#351;la &#304;lintili Unutkanl&#305;k-Hafif Kognitif
Bozukluk-Demans Devaml&#305;l&#305;&#287;&#305;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici hastal&#305;klar patogenetik s�re�leri
i�inde belli bir e&#351;i&#287;i ge�tikleri a&#351;amada klinik olarak
saptanabilir olurlar.&nbsp; Bu e&#351;ik de hemen daima normal kabul
edilemeyecek bir belirtidir.&nbsp; �rne&#287;in, glioblastoma yeterince b�y�y�p
kafa i�i bas&#305;nc&#305;n&#305; artt&#305;rarak
ba&#351;a&#287;r&#305;s&#305;na neden olana kadar sub-klinik olarak
ilerler.&nbsp; Ba&#351;a&#287;r&#305;s&#305; kadar a&#351;ikar bir anormal
belirti olmayan unutkanl&#305;k durumunda sub-klinik d�nemle klinik d�nem daha
kal&#305;n �izgilerle i�i�e girer.&nbsp; Alzheimer
hastal&#305;&#287;&#305;n&#305;n zamansal evrimi bunun en g�zel
�rneklerindendir.&nbsp;AH demans a&#351;amas&#305;na ula&#351;madan �nce uzun
y&#305;llar (baz&#305; hesaplamalara g�re 15-20 y&#305;l) klini&#287;e
ilerleyici unutkanl&#305;k &#351;eklinde yans&#305;yan bir demans �ncesi veya
�prodromal� evreden ge�ecektir. Bununla birlikte, unutkanl&#305;k ya&#351;l&#305;l&#305;kta
son derece s&#305;kl&#305;kla duyulmaya al&#305;&#351;&#305;lm&#305;&#351;,
gayet normal kabul edilen bir yak&#305;nmad&#305;r.&nbsp; Bellek de dahil olmak
�zere baz&#305; kognitif yeteneklerde ya&#351;lanmayla birlikte beklenen
�normal� azalma n�ropsikolojik standardizasyonda e&#287;itimle birlikte g�z
�n�ne al&#305;nmas&#305; gereken temel �zelliklerindendir.&nbsp; Bir yak&#305;n
bellek testinde yetmi&#351;li ya&#351;lar&#305;n normal de&#287;eri yirmili
ya&#351;lar&#305;n normalinin yar&#305;s&#305; olabilir.&nbsp; Normal
ya&#351;lanma kavram&#305; bellek de dahil kognitif kapasitelerini hi�
yitirmeyen k���k bir az&#305;nl&#305;&#287;&#305; da i�erse de,
a&#287;&#305;rl&#305;kla n�ropsikolojik testlerde ya&#351;a g�re uyarlanm&#305;&#351;
d�zeylerde bir performansa kar&#351;&#305;l&#305;k gelir.&nbsp; MRG/BT�de
kortikal sulkuslar ve ventrik�l sistemi geni&#351;lemeye
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; Bu t�r g�r�nt�lemelerin
raporlar&#305;n&#305;n sonu� b�l�m�nde s&#305;kl&#305;kla �ya&#351;la ilintili
atrofi� yazacakt&#305;r.&nbsp; Kognitif a�&#305;dan normal ki&#351;ilerin<b> </b>otopsileri,
t�m�yle normal olabilece&#287;i gibi 50�li ya&#351;lar&#305;n
ba&#351;lar&#305;ndan itibaren neokortekste gev&#351;ek nitelikli amiloid
plaklar ve bazen bunlara e&#351;lik eden entorhinal kortekste NFY�lerin
g�r�lebilece&#287;ini ortaya koymaktad&#305;r. Sa&#287;duyu bu 2. gruba ait
beyinlerde AH n�rodejenerasyonun ba&#351;lad&#305;&#287;&#305; fakat hen�z
klinik belirti e&#351;i&#287;ini ge�medi&#287;ini d�&#351;�nd�rmelidir.
Ba&#351;ka bir deyi&#351;le, 2. grup de&#287;i&#351;iklikleri g�stermeye
ba&#351;layan beynin sahibi yeterince uzun ya&#351;asayd&#305;,
yak&#305;nmalar&#305;n&#305;n zaman i�inde g�r�n�r olup sonunda AH klinik
kriterlerini dolduraca&#287;&#305; ileri s�r�lebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans8.JPG">&#350;ekil 8.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal ya&#351;lanmadan
a&#287;&#305;r demansa bellek bozuklu&#287;u s�reklili&#287;i</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sosyal ya&#351;amda ba&#351;ka a�&#305;lardan
sa&#287;l&#305;kl&#305; bir ya&#351;l&#305;n&#305;n �zel isimleri unutuyor,
�zel e&#351;yalar&#305;n&#305; kolayl&#305;kla bulam&#305;yor olmas&#305;
anormal kabul edilmez.&nbsp; Ayn&#305; sorular&#305; tekrarlar olmas&#305;
yak&#305;nlar&#305; aras&#305;nda ku&#351;ku uyand&#305;rmaya
ba&#351;lar.&nbsp; &#304;&#351;ini s�rd�remez olmas&#305;, ya da yabanc&#305;
bir mekanda kaybolmas&#305; ise art&#305;k normal olarak kabul edilemez
olur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;�Ya&#351;la &#304;lintili Bellek Bozuklu&#287;u
(AAMI)� kavram&#305; tam da yukar&#305;daki paragrafta anormal bulunmayan
unutkanl&#305;k durumuna kar&#351;&#305;l&#305;k gelmektedir.&nbsp; Daha �nceki
y&#305;llarda �Selim Ya&#351;l&#305;l&#305;k Unutkanl&#305;&#287;&#305;�
kavram&#305;yla kar&#351;&#305;lanmaya �al&#305;&#351;&#305;lan ve isminin de
�a&#287;r&#305;&#351;t&#305;rd&#305;&#287;&#305; gibi demansa ilerlemeyecek iyi
huylu unutkanl&#305;&#287;a kar&#351;&#305;l&#305;k gelecek &#351;ekilde
kullan&#305;lan s�z konusu durum i�in Amerikan Ulusal Zihinsel Sa&#287;l&#305;k
Enstit�s� (NIMH) 1986 y&#305;l&#305;nda ara&#351;t&#305;rma ama�l&#305;
tan&#305; kriterleri yay&#305;nlad&#305; <b>(Tablo 7</b>).&nbsp; AAMI
tan&#305;m&#305;na uygun d�&#351;en yak&#305;nmalar&#305; olan bir
ya&#351;l&#305; g�nl�k ya&#351;am&#305;nda t�m�yle
ba&#287;&#305;ms&#305;zd&#305;r.&nbsp; Bu ki&#351;inin n�ropsikolojik
muayenesinde �zellikle yak&#305;n bellek testlerinde ya&#351;a g�re normal
s&#305;n&#305;rlarda, fakat gen� eri&#351;kinlere g�re ortalama de&#287;erlerin
1 standart sapma (SD) alt&#305;nda yer ald&#305;&#287;&#305;
saptanacakt&#305;r.&nbsp;Hangi ya&#351;l&#305; �selim� ya&#351;l&#305;l&#305;k
de&#287;i&#351;ikliklerini g�stermekte, hangisi ise AH�nin en erken izlerini
ta&#351;&#305;maktad&#305;r sorular&#305;n&#305;n cevab&#305;n&#305;
&#351;imdiki durumda ne salt klinik fenomenoloji ne de mevcut n�ropatolojik
kavray&#305;&#351; ile vermek m�mk�n de&#287;ildir. AAMI tan&#305;s&#305; alan
bir ki&#351;i yak&#305;nmalar&#305; karakter de&#287;i&#351;tirmeden
�ld�&#287;� takdirde beyni t�m�yle normal bulunabilece&#287;i gibi, �<i>N�ropatoloji</i>�
k&#305;sm&#305;nda ayr&#305;nt&#305;s&#305;yla g�r�lece&#287;i gibi, limbik
sisteminde az say&#305;da n�rofibriler yumak&nbsp; ve neokorteksinde
gev&#351;ek karakterli amiloid plaklar ta&#351;&#305;yor olabilir.&nbsp; PET tekniklerinde
yeni geli&#351;melerle sadece amiloid plaklara (PIB-PET) ve hem plaklara hem
yumaklara (FDDNP-PET) ba&#287;lanan ligandlarla bu t�r patolojik
de&#287;i&#351;iklikleri ta&#351;&#305;yan ve ta&#351;&#305;mayan kognitif
olarak normal ya&#351;l&#305; ki&#351;ileri saptamak m�mk�n olmaktad&#305;r.
Uzunlamas&#305;na izlenen kognitif olarak normal veya AAMI tan&#305;s&#305;
alan ya&#351;l&#305;lar&#305;n PIB/FDDNP+ olanlar&#305;, PIB/FDDNP- olanlara
g�re anlaml&#305; olarak daha fazla demans geli&#351;tirdikleri
g�sterildi&#287;i takdirde bu y�ntem prodromal/pre-klinik AH�nin bir
i&#351;aretleyicisi olarak yerle&#351;ebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ya&#351;l&#305;l&#305;kta pre-demans kognitif
bozuklu&#287;u tan&#305;mlama gayretiyle bir dizi daha kavram ve kriterler
dizisi ileri s�r�lm�&#351; olsa da t�m� de demansa ilerleyen bir bellek
bozuklu&#287;u kavray&#305;&#351;&#305;ndan ziyade demans kadar &#351;iddetli
olmayan bir �hafif kognitif bozukluk�u �e&#351;itli isimlerle
tan&#305;mlam&#305;&#351;lard&#305;r. Bunlar aras&#305;nda 1990�lar boyunca
tan&#305;mlanan ICD-10�un �minimal kognitif bozukluk � MCD�, DSM-IV��n �hafif
n�ro-kognitif bozukluk � MNCD�, Uluslararas&#305; Psikogeriyatri Birli&#287;i�nin
�Ya&#351;la &#304;lintili Kognitif Bozukluk � AACD� ve Kanada
Sa&#287;l&#305;kl&#305; Ya&#351;lanma �al&#305;&#351;mas&#305; (CSHA)
�er�evesinde kullan&#305;lan �demans olmayan kognitif bozukluk � CIND�
kavramlar&#305; say&#305;labilir. T�m bu tan&#305;mlamalar, belli
n�anslar&#305;na ra&#287;men, tan&#305;mlad&#305;klar&#305; demans
&#351;iddetinde olmayan kognitif bozukluk durumunu esas olarak statik �zerk
antiteler olarak g�rmektedirler; �yle ki, bunlar aras&#305;ndan bir
k&#305;s&#305;m hasta d�zelip normale d�nebilece&#287;i gibi, bir
k&#305;sm&#305; ise ilerleyip demans geli&#351;tirdi&#287;inde nitelik
de&#287;i&#351;tirip ba&#351;ka bir antiteye d�n�&#351;m�&#351; gibi kabul
edilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<b>Tablo 7. </b>NIMH-AAMI Tan&#305;
Kriterleri</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-3.9pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=576 valign=top style='width:431.65pt;border:solid gray 1.0pt;
  padding:2.0pt 2.0pt 2.0pt 2.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;
  &gt; 50.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�nl�k ya&#351;amda
  belle&#287;e ili&#351;kin yak&#305;nmalar.</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gen� eri&#351;kinlere g�re 1
  standart sapma daha d�&#351;�k nesnel bellek performans&#305;.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demans mevcut de&#287;il.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal ya da normalin �st�
  zeka seviyesi.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
  DE'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='font-family:
Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ger�ekte, AAMI tan&#305;s&#305; alan
ya&#351;l&#305;lar&#305;n AH n�rodejenerasyonuna sahip bir b�l�m� daha da
k�t�le&#351;ecek ve bellek yak&#305;nmalar&#305; yak&#305;nlar&#305;n&#305;n da
dikkatini �ekmeye ba&#351;layacakt&#305;r. Gene de b�yle bir ki&#351;i
an&#305;lan bellek problemlerinin yaratt&#305;&#287;&#305;, ancak listeyle
al&#305;&#351;veri&#351;e �&#305;kar olmak gibi genellikle �stesinden
gelebildi&#287;i g��l�kler d&#305;&#351;&#305;nda, g�nl�k ya&#351;am&#305;nda
halen ba&#287;&#305;ms&#305;zd&#305;r.&nbsp; N�ropsikolojik muayenesinde
a&#287;&#305;rl&#305;kla bazen de tek ba&#351;&#305;na bellek
alan&#305;nda,&nbsp; anlaml&#305; d�zeyde d�&#351;�k performans g�sterir.&nbsp;
Bu tabloya �Hafif Kognitif Bozukluk� (MCI) ad&#305; verilir <b>(Tablo 8</b>).&nbsp;
Orijinal bi�imiyle bu tan&#305;m, prodromal AH olmas&#305; muhtemel, ATD�ye
d�n�&#351;me riski ta&#351;&#305;yan bir alt grubu ara&#351;t&#305;rma ve
m�mk�nse tedavi hedefi yapmak �zere belirlenmi&#351;se de sonradan revize
edilen bi�imiyle amnestik olmayan demanss&#305;z kognitif bozukluklar da dahil
edilerek prodromal AH�ye olan vurgu �abas&#305; kapsay&#305;c&#305;l&#305;k
ad&#305;na zay&#305;flam&#305;&#351; g�r�nmektedir <b>(Tablo 9</b>).&nbsp;
&#304;lgili tablodan da g�r�lece&#287;i gibi, s&#305;n&#305;flama t�m�yle
bellek bozuklu&#287;unun bulunup bulunmamas&#305;na ve mevcut kognitif bozuklu&#287;un
tek veya �o&#287;ul olma durumuna g�redir. Bu farkl&#305; tablolar&#305;n
ilerledikleri takdirde en mutad olarak belli demans hastal&#305;klar&#305;na
d�n�&#351;ecekleri beklenir. &#304;lk bak&#305;&#351;ta bu s&#305;n&#305;flama
yukarda tan&#305;mlanan ��ekirdek sendromlar� yakla&#351;&#305;m&#305;n&#305;n
bir benzeri gibi d�&#351;�n�lebilirse de burdaki �mevcut MCI tablosu-ilerdeki
demans sendromu� ili&#351;kisi �ok daha indirgemeci bir ak&#305;l y�r�tmedir.
��ekirdek sendromlar&#305;n anatomik adreslerinden bu anatomik adrese
yatk&#305;nl&#305;k sergileyen en muhtemel proteinopati� tarz&#305; bir
ak&#305;l y�r�tme esnekli&#287;i sergileyemez. �rne&#287;in, progresif
simultanagnozi-simetrik dorsal parietal alanlar-amiloidopati silsilesi
progresif simultanagnozinin bu s&#305;n&#305;flamadaki
kar&#351;&#305;l&#305;&#287;&#305; olan izole non-amnestik MCI ile, bu MCI alt
s&#305;n&#305;f&#305;n&#305;n AH�ye d�n�&#351;mesi beklenmedi&#287;inden
sa&#287;lanamaz. Dahas&#305;, �ekirdek sendrom yakla&#351;&#305;m&#305;yla,
ilerde demansa d�n�&#351;�p d�n�&#351;meyece&#287;ine
bak&#305;lmaks&#305;z&#305;n anatomik yatk&#305;nl&#305;k ve muhtemel
proteinopatiden yola �&#305;karak hastal&#305;k tan&#305;s&#305;na varmak
m�mk�nken, MCI tan&#305;m&#305; ile ancak demans a&#351;amas&#305;nda bir
hastal&#305;ktan s�zedilebilecek durumla normallik aras&#305;nda
kalm&#305;&#351; bir ge�i&#351; a&#351;amas&#305; tasarlanm&#305;&#351;
olmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Uzunlamas&#305;na izlenen b�y�k serilerde MCI�&#305;n demansa d�n�&#351;me
h&#305;z&#305; y&#305;ll&#305;k %8-14�ken 5 y&#305;ll&#305;k izlemlerde %50
kadard&#305;r.&nbsp; Oysa ki, normal pop�lasyonda demans insidans&#305;
%1-2�dir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>G�r�nt�leme �al&#305;&#351;malar&#305;nda mezyal temporal patoloji bu
hastalar&#305; normallerden ay&#305;rmaktad&#305;r.&nbsp; MRG-vol�metride
baz&#305; �al&#305;&#351;malarda hippokampus, di&#287;er baz&#305;lar&#305;nda
ise entorhinal korteks atrofisi MCI�l&#305; serilerde ya&#351;la
e&#351;lenmi&#351; normal kontrollere g�re anlaml&#305; d�zeyde
g�r�lmektedir.&nbsp; FDG-PET�le yap&#305;lan �al&#305;&#351;malarda
ba&#351;lang&#305;� noktas&#305;nda ba&#351;l&#305;ca posterior singulat
hipometabolizmaya sahip olman&#305;n izlemde d�n�&#351;menin anlaml&#305; bir
�ng�r�c�s� oldu&#287;u ortaya konmu&#351;tur.&nbsp; PIB-PET ile yap&#305;lan
�al&#305;&#351;malarda ATD�lilerin hemen t�m� PIB tutulumu g�sterirken
MCI�lar&#305;n yar&#305;s&#305;ndan fazlas&#305;nda ve enteresan olan&#305;
normal ya&#351;l&#305;lar&#305;n da k���k bir b�l�m�nde g�r�lmektedir.
Dahas&#305; gerek MCI�l&#305;lar ve gerekse de normallerde PIB tutulumu
g�steren grupta PIB y�k� ile bellek skorlar&#305; korele etmektedir. Bu bulgu
MCI ve normal olarak s&#305;n&#305;flanm&#305;&#351; olan PIB tutulumuna sahip
bu bireylerin ger�ekte s&#305;ras&#305;yla prodromal ve pre-klinik AH
ta&#351;&#305;d&#305;klar&#305; &#351;eklinde yorumlanabilir. Ay&#305;rt edici
ba&#351;ka bir bulgu ise n�ritik plaklara ba&#287;lanan PIB ligand&#305; ile ancak
demans a&#351;amas&#305;nda mezyal temporal tutulum g�r�l�rken MCI ve
normallerde g�r�lmemesidir. Buna kar&#351;&#305;l&#305;k NFY�lere de
ba&#287;lanan FDDNP-PET ile normal ya&#351;l&#305;larda ve MCI�l&#305;larda
bellek skorlar&#305;yla korele eden bulgular saptanmaktad&#305;r. FDDNP-PET ile
bu bulgu da PIB-PET ile yukar&#305;daki yoruma benzer bir &#351;ekilde
yorumlanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>MCI otopsilerinde normalden hafif PRAD patolojilerine kadar
de&#287;i&#351;en bir spektrum izlenmekle birlikte, NFY�nin halen
limbik-paralimbik alanlara s&#305;n&#305;rl&#305; ancak say&#305;sal olarak
normallere g�re anlaml&#305; d�zeyde artm&#305;&#351; olmas&#305; en
tutarl&#305; bulgu gibi g�r�nmektedir.&nbsp; N�ritik plaklar hen�z limbik
sistemde g�r�lmemektedir. APOE-&#949;4 alel s&#305;kl&#305;&#287;&#305; ve
BOS�ta total tau ve fosfo-tau proteini d�zeylerinde art&#305;&#351; ile
&#946;-amiloid<sub>42</sub> d�zeylerinde d�&#351;�&#351;�n, entorhinal ve/veya
hippokampal atrofi yan&#305;s&#305;ra demansa d�n�&#351;ecekleri
d�n�&#351;meyenlerden ay&#305;ran �ng�r�c�ler oldu&#287;u ileri
s�r�lmektedir.&nbsp; MCI�&#305;n bir klinik antite olarak yani prodromal AH
olarak daha iyi s&#305;n&#305;rlar&#305;n&#305;n �izilmesi, bu evrede etkili
olacak&nbsp; tedavilerle demansa d�n�&#351;menin geciktirilmesi ya da �n�ne
ge�ilmesi, g�n�m�zde AH�nin y�k�n�n azalt&#305;lmas&#305;nda temel bir hedef
gibi g�r�nmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 8.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Petersen-Mayo MCI
Kriterleri</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-3.9pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=449 valign=top style='width:336.95pt;border:solid gray 1.0pt;
  padding:2.0pt 2.0pt 2.0pt 2.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp; Hasta
  yak&#305;n&#305; taraf&#305;ndan da do&#287;rulanan bellek
  yak&#305;nmas&#305;.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp; Genel kognitif
  i&#351;levlerde bozulma yok.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp; G�nl�k ya&#351;am
  aktivitelerinde bozulma yok.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp; Ya&#351; ve
  e&#287;itim normlar&#305;na g�re saptanan bellek bozuklu&#287;u.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5.&nbsp; Demans mevcut
  de&#287;il.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yukar&#305;daki paragrafta tan&#305;mlanan,
art&#305;k sa&#287;duyunun da normal kabul edemedi&#287;i, g�nl�k ya&#351;amda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; s�rd�remeyecek d�zeyde
bozulma durumunda art&#305;k demanstan s�zedilebilir.&nbsp; Bu duruma
kar&#351;&#305;l&#305;k gelen otopsilerde NFY�ler art&#305;k neokortekse
yay&#305;lm&#305;&#351;, gev&#351;ek bi�imden n�ritik bi�ime
de&#287;i&#351;mi&#351; AP�ler limbik sistemde g�r�l�r olmu&#351; durumdad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="tablo9.JPG">Tablo 9.</a> Revize MCI
Kriterleri ve Muhtemel Demans &#304;zd�&#351;�mleri</span></b><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;Alzheimer Tipi Demans&#305;n Evreleri</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici bir hastal&#305;ktan
s�zetti&#287;imize g�re klinik tabloyu statik bir profille tarif
edemeyiz.&nbsp; Yine sa&#287;duyu ile amat�r bir yakla&#351;&#305;m dahi
ilerleyen bir tablonun hafif, orta ve a&#287;&#305;r olarak
s&#305;n&#305;fland&#305;r&#305;lmas&#305; gerekti&#287;ini �ng�rebilir.&nbsp;
Formel evreleme �l�eklerinin de taklit etti&#287;i y�ntem bundan farkl&#305;
de&#287;ildir.&nbsp; Zihinsel y&#305;k&#305;m&#305;n demans d�zeyine
ula&#351;mas&#305; g�nl�k aktivitelerde bozulma ile belirlendi&#287;ine g�re,
evrelemeyi de GYA�lara g�re kabaca yapabiliriz: AAMI�y&#305; s�bjektif bellek
yak&#305;nmalar&#305;,&nbsp;MCI�y&#305; GYA�lar&#305;n korundu&#287;u ama
yak&#305;n ki&#351;ilerin fark&#305;nda oldu&#287;u bir bellek bozulmas&#305;
olarak tarif etmi&#351;tik; bu durumda devaml&#305;l&#305;k �l��t�n� g�z�n�nde
tutarak hafif demans&#305; i&#351;te ve ev d&#305;&#351;&#305;nda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n bozulmaya
ba&#351;lad&#305;&#287;&#305;, orta demans&#305;, bunlar t�m�yle
ba&#287;&#305;ml&#305;la&#351;&#305;rken ev ya&#351;am&#305; ve kendine
bak&#305;mda sorunlar&#305;n ba&#351;lad&#305;&#287;&#305;, a&#287;&#305;r
demans&#305; ise s�rekli bak&#305;m gereken, hastan&#305;n t�m�yle
ba&#287;&#305;ml&#305; oldu&#287;u bir durum olarak tarif edebiliriz.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bug�n yayg&#305;n olarak kullan&#305;lan iki
evreleme sisteminden biri olan �Global Bozulma �l�e&#287;i� (Global
Deterioration Scale-GDS)�nin de geli&#351;tiricisi olan Reisberg, AH�deki
ilerleyici y&#305;k&#305;m s�recini, bebeklik-erken ve ge� �ocukluk ve ergenlik
&#351;eklindeki insan&#305;n ilerleyici
bireyselle&#351;me-ba&#287;&#305;ms&#305;zla&#351;ma geli&#351;imsel s�recinin
tam tersine �evrilmesi oldu&#287;unu ileri s�rer ve bu ilerleyici
y&#305;k&#305;m&#305; retrogenez olarak adland&#305;r&#305;r. Buna g�re
AAMI-MCI�l&#305; ya&#351;l&#305; b�y�k �l��de ba&#287;&#305;ms&#305;z olsa da
baz&#305; kararlar&#305; i�in eri&#351;kin g�zetimine gerek duyan ergene, hafif
demansl&#305;, evinde ve ev d&#305;&#351;&#305;nda tan&#305;d&#305;k mekanlarda
belli bir ba&#287;&#305;ms&#305;zl&#305;&#287;&#305; kazanm&#305;&#351;, ancak
sosyal ili&#351;kiler, muhakeme gerektiren karma&#351;&#305;k i&#351;levlerde
halen denetim gereksinen 7-12 ya&#351;lar&#305;ndaki okul �ocu&#287;unu
and&#305;r&#305;r.&nbsp; Orta demansl&#305; ise kabaca, ev ya&#351;am&#305; ve
giyinme, y&#305;kanma, yemek yeme gibi temel GYA�larda hen�z g�zetim gereken
2-6 ya&#351;lar&#305; aras&#305;ndaki okul �ncesi �ocu&#287;u gibidir.&nbsp;
A&#287;&#305;r demansl&#305;, ya&#351;am&#305;n&#305; s�rd�rmek i�in 24 saat
ana-babaya (bak&#305;c&#305;ya) t�m�yle ba&#287;&#305;ml&#305; 0-2 ya&#351;
bebe&#287;ine benzer.&nbsp; A&#287;&#305;r evrenin kendisi de, yani giderek t�m
motor ve verbal yeteneklerin kaybedildi&#287;i yata&#287;a tam
ba&#287;&#305;ml&#305; nihai d�neme do&#287;ru y&#305;k&#305;m, oturma, y�r�me,
konu&#351;ma, sfinkter kontrol�n�n geli&#351;ti&#287;i bebekli&#287;in dinamik
geli&#351;iminin tam tersi olarak kavran&#305;p alt evrelere
ayr&#305;labilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>GDS s�zedildi&#287;i gibi AH�yi evrelemeye yarayan
�l�eklerden birisidir.&nbsp; AH d&#305;&#351;&#305; demanslarda AH�ye
�zg�ll�&#287;� dolay&#305;s&#305;yla kullan&#305;lamaz.&nbsp; GDS evreleri 1
ila 7 aras&#305;nda de&#287;i&#351;ir.&nbsp; Kabaca, GDS1 hi� yak&#305;nmas&#305;
ve bulgusu olmayan normal ya&#351;l&#305;ya kar&#351;&#305;l&#305;k
gelirken&nbsp; GDS2�ye AAMI, GDS3�e ise MCI evreleri denilebilir.&nbsp; GDS
4-5-6-7 ise hafif, orta, a&#287;&#305;r ve �ok a&#287;&#305;r olmak �zere
AH�nin klinik evreleridir.&nbsp; Demans&#305;n Klinik Evrelendirilmesi
(Clinical Dementia Rating Scale-CDR) ise yayg&#305;n olarak kullan&#305;lan 2.
�l�ektir.&nbsp; CDR�da bellek yine merkezi �nemde olmakla birlikte, �ok eksenli
tasar&#305;m&#305;yla di&#287;er demanslar&#305;n evrelenmesinde de
kullan&#305;labilir.&nbsp; CDR evreleri 0-0,5-1-2-3 olarak
s&#305;ralan&#305;rlar.&nbsp; CDR 0, AAMI�&#305; da i�erecek &#351;ekilde
normal ya&#351;l&#305;l&#305;&#287;a kar&#351;&#305;l&#305;k gelir.&nbsp; CDR
0,5 MCI�ya kar&#351;&#305;l&#305;k gelir ve �ku&#351;kulu demans� evresi
ad&#305;n&#305; al&#305;r.&nbsp; CDR 1, 2 ve 3 s&#305;ras&#305;yla hafif, orta
ve a&#287;&#305;r evrelerdir <b>(Tablo 10, 11</b>).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hafif evredeki demansl&#305; hasta halen
�al&#305;&#351;maktaysa art&#305;k i&#351;inde verimlili&#287;ini
yitirmi&#351;tir.&nbsp; Yarat&#305;c&#305;l&#305;k gerektirmeyen tekd�ze
i&#351;ler ba&#351;lang&#305;�ta s�rd�r�lebilse de, i&#351;
arkada&#351;lar&#305; performans d�&#351;�kl�&#287;�n�n
fark&#305;ndad&#305;rlar ve k&#305;sa s�re i�inde emeklilik
ka�&#305;n&#305;lmaz olur.&nbsp; Yak&#305;n ge�mi&#351;e ait olaylar&#305;n
hat&#305;rlanmas&#305;ndaki g��l�k, ayn&#305; sorular&#305;n
tekrarlanmas&#305;, kelime bulma g��l�kleri yak&#305;nlar&#305;n dikkatini
�eken ba&#351;l&#305;ca �zelliklerdir.&nbsp; Halen bildik mekanlarda
dola&#351;abilse ve yolculuk yapabilse de, yabanc&#305; mekanlarda
kaybolabilir.&nbsp; Araba kullan&#305;rken sinyalizasyona dikkatsizlik,
tepkilerde yava&#351;lama, y�nleri kar&#305;&#351;t&#305;rma gibi g��l�kler
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; Banka i&#351;leri, fatura �demeleri gibi
mali i&#351;lerde hatalar olmaktad&#305;r.&nbsp; Banka kart&#305;, cep telefonu
gibi yenilikleri �&#287;renip kullanmay&#305; ba&#351;aramaz.&nbsp; Hobiler
(diki&#351;-nak&#305;&#351;, bah�ecilik, sanatsal u&#287;ra&#351;&#305;lar,
yetenek oyunlar&#305;, vb.) s�rd�r�lemez olmu&#351;tur.&nbsp; Yemek lezzetinde
bozulmalar gibi mutfak i&#351;lerinde g��l�kler
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; �ama&#351;&#305;r, bula&#351;&#305;k
gibi ev i&#351;lerini s�rd�rebilse de, bunlarda eski �zenini bir �l��de
yitirmi&#351;tir.&nbsp; Okumak ve gazete-TV arac&#305;l&#305;&#287;&#305;yla
akt�aliteye ilgi azalm&#305;&#351;t&#305;r.&nbsp; Giyinmek, y&#305;kanmak,
sofra al&#305;&#351;kanl&#305;klar&#305; ve temel hijyende hen�z bir sorun
yoktur.&nbsp; &#304;ritabilite, duygulan&#305;mda k�ntle&#351;me ve inkar
e&#287;ilimi ile kendili&#287;indenli&#287;in azalmas&#305;
d&#305;&#351;&#305;nda davran&#305;&#351;sal belirtiler yoktur ve sosyal
uygunluk iyi korunmu&#351;tur.&nbsp; Uyku kalitesi bozulmaya ba&#351;lar.&nbsp;
Cinsel ilgi ve i&#351;tah bozulur.&nbsp; Eksikliklerin farkedilmesinin de
katk&#305;s&#305;yla baz&#305; olgularda depresyon belirtileri �n planda
olabilir.&nbsp; Ancak depresyon s&#305;kl&#305;kla keder ifadesi gibi afektif
belirtilerden �ok, isteksizlik gibi motivasyonel belirtilerle kendini
g�sterir.&nbsp; Muayenede yak&#305;n bellek �n planda olmak �zere,
g�rsel-mekansal bozukluk, uzak bellekte bozulmalar, adland&#305;rma g��l�kleri,
dikkat ve soyutlama-planlamada bozulmalar saptan&#305;r.&nbsp; Praksis
muayenesinde �beden-par�as&#305;-nesne-gibi� cevaplar al&#305;n&#305;r.&nbsp;
Hen�z gnostik bir kusur saptanmaz.&nbsp; Somatik n�rolojik muayene
normaldir.&nbsp;&nbsp; MMSE skoru kabaca 20-26 aras&#305;nda olabilir.&nbsp;
S&#305;kl&#305;kla GDS 4, CDR 1 olarak evrelenirler.&nbsp; Bu hastalar&#305;n
otopsilerinde heteromodal kortekste NFY�ler, limbik sistemde n�ritik SP�ler
saptan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Orta demans evresine
ula&#351;&#305;ld&#305;&#287;&#305;nda, hasta ev d&#305;&#351;&#305;ndaki
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; art&#305;k t�m�yle
yitirmi&#351;tir.&nbsp; G�zetimle soka&#287;a �&#305;kabilse de, yaln&#305;z
kald&#305;&#287;&#305; takdirde yolunu bulamaz.&nbsp;
Ba&#351;kalar&#305;n&#305;n evinde odalar&#305; kar&#305;&#351;t&#305;rabilir.&nbsp;
Yeni �&#287;renme art&#305;k hemen hi� m�mk�n olamamaktad&#305;r.&nbsp; Anlama,
okuma ve yazma giderek bozulur; evrenin sonlar&#305;na do&#287;ru imzas&#305;
tan&#305;nmaz olabilir. &nbsp;Birinci derece yak&#305;nlar&#305;
hakk&#305;ndaki bilgiyi genellikle korusa da, torunlar&#305;n&#305;n
say&#305;s&#305;, isimleri, okullar&#305; gibi bilgileri
kar&#305;&#351;t&#305;rmaktad&#305;r.&nbsp; Evdeki i&#351;levselli&#287;i son
derece y�zeyselle&#351;mi&#351;tir.&nbsp;&nbsp; Ancak sofray&#305; toplamaya
veya sebze do&#287;ramaya yard&#305;m d�zeyinde olabilir.&nbsp; Giyinme
s&#305;ras&#305;nda mevsime ya da g�n�n saatine uygun giysiyi se�mede zorlanma,
giysilerin s&#305;ras&#305;n&#305; kar&#305;&#351;t&#305;rma (g�mle&#287;in
�zerine i� �ama&#351;&#305;r&#305; gibi), d�&#287;meleri yanl&#305;&#351;
ilikleme gibi g��l�kler ba&#351;lar.&nbsp; Sofrada �ncelikle
b&#305;�a&#287;&#305; kullanamaz oldu&#287;unda yemeklerinin �nceden kesilmesi
gerekir.&nbsp; Giderek d�k�p sa�arak yemek belirginle&#351;ir.&nbsp;
�atal-b&#305;�a&#287;&#305; kar&#305;&#351;t&#305;rmak, s&#305;v&#305;lar&#305;
�atalla almaya �al&#305;&#351;mak gibi hatalar g�r�lebilir.&nbsp;
Y&#305;kanmakta �ncelikle s&#305;ca&#287;&#305; so&#287;u&#287;u ayarlamakla
ba&#351;layan yard&#305;m gereksinimi ortaya �&#305;kar.&nbsp;&nbsp;&nbsp;
Hen�z sfinkter kontrol� seyrek gece ka�&#305;rmalar&#305;
d&#305;&#351;&#305;nda sorunsuzdur.&nbsp; Tuvalet mekani&#287;i, elini y�z�n�
y&#305;kamak gibi i&#351;levleri kendi ba&#351;&#305;na yapabilir.&nbsp;
Davran&#305;&#351;sal belirtiler art&#305;k vurgulanmaya
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; H&#305;rs&#305;zl&#305;k, terkedilme ve
sadakatsizlik hezeyanlar&#305; olabilir.&nbsp; Yaln&#305;z kalmaktan �rker ve
yak&#305;n&#305;n&#305; (e&#351;i, �ocu&#287;u) s�rekli g�z�n�n �n�nde
ister.&nbsp; Hekim vizitleri gibi yakla&#351;an randevular a&#351;ikar bir
beklenti anksiyetesine yola�abilir.&nbsp; Uyku-uyan&#305;kl&#305;k ritiminde
bozulma art&#305;k belirginle&#351;mi&#351;tir.&nbsp; Gece s&#305;k uyanmalar
ve g�nd�z s&#305;k uyuklamalarla ge�er.&nbsp; Muayenede hafif evre
bulgular&#305; biraz daha a&#287;&#305;rla&#351;m&#305;&#351;t&#305;r.&nbsp;
Dilsel i&#351;levlere ait bulgular&#305;n a&#287;&#305;rla&#351;mas&#305; dile
dayanan testlerin yap&#305;lamaz olmas&#305;na neden olabilir.&nbsp; Praksis
bozuklu&#287;u taraf apraksisi d�zeyine ula&#351;abilir.&nbsp; Gnostik
bozukluklar, �zellikle sofrada g�z �n�ndeki nesneyi di&#287;erleri
aras&#305;ndan ay&#305;r&#305;p bulamamak (simultanagnozi) &#351;eklinde
olabilir.&nbsp; Temel n�rolojik muayenede hafif parkinsonyen
de&#287;i&#351;iklikler saptanabilir.&nbsp; MMSE skoru 10-19 aras&#305;nda
de&#287;i&#351;ir.&nbsp; GDS 5, CDR 2 olarak evrelenirler. Bu hastalar&#305;n
otopsilerinde NFY�ler unimodal asosiasyon kortekslerine de
yay&#305;lm&#305;&#351; olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>A&#287;&#305;r demans evresinde bellekte
art&#305;k sadece par�ac&#305;klar s�z konusudur.&nbsp; Yak&#305;n&#305;n&#305;
(e&#351;i, �ocu&#287;u) ana-babas&#305;yla kar&#305;&#351;t&#305;rabilir,
aynadaki kendi y�z�n� tan&#305;yamayabilir.&nbsp; Giyinmek, y&#305;kanmak,
yemek gibi temel GYA�larda art&#305;k tam bir g�zetim gerekmektedir.&nbsp;
Evrenin sonlar&#305;nda yutma g��l�&#287;� de ortaya �&#305;kar.&nbsp; Kelime
hazinesi son derece fakirle&#351;mi&#351;tir.&nbsp; Evrenin sonlar&#305;nda t�m
verbal yetenekler yitirilir.&nbsp; Ambulasyon giderek zorla&#351;&#305;r ve
sonlara do&#287;ru giderek oturmak dahi m�mk�n olmaz hale gelir.&nbsp;
Televizyondaki ki&#351;ileri ev i�indeymi&#351; gibi san&#305;p konu&#351;mak,
aynadaki kendi hayaliyle yabanc&#305;ym&#305;&#351; gibi konu&#351;mak
g�zlenebilir.&nbsp; Ambulasyonun korundu&#287;u s&#305;rada ama�s&#305;z
dola&#351;ma, istif�ilik, ama�s&#305;z tekrarlay&#305;c&#305; hareketler
izlenebilir.&nbsp; Tuvalet mekani&#287;inde bozulmalar (idrar ya da gaita
sonras&#305; uygun bi�imde temizlenme, sifonu �ekme sorunlar&#305;), idrar
ka�&#305;rma giderek belirginle&#351;ir.&nbsp; Epileptik n�betler ortaya
�&#305;kabilir.&nbsp; A&#287;&#305;r evredeki hastalar&#305;n formel muayenesi
son derece g��t�r ve m�mk�n olamayabilir.&nbsp; Yap&#305;labildi&#287;inde
global bir y&#305;k&#305;m saptan&#305;r.&nbsp; Temel n�rolojik muayenede&nbsp;
tonus de&#287;i&#351;iklikleri, y�r�y�&#351; bozukluklar&#305; &#351;eklinde
parkinsonyen bulgular biraz daha ortaya �&#305;km&#305;&#351;t&#305;r.&nbsp;
MMSE 0-9 aras&#305;ndad&#305;r.&nbsp; GDS 6-7, CDR 3 olarak evrelenirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#350;ekil 9</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�da AH�nin klinik ve bir dizi
laboratuar �l��t�n�n pre-klinik evreden ba&#351;layarak a&#287;&#305;r demans
evresine kadar g�sterdi&#287;i de&#287;i&#351;kenlik g�sterilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans9b.JPG">&#350;ekil 9.</a> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n evreleri boyunca klinik ve laboratuar
g�stergelerinin de&#287;i&#351;imi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BOS A&#946; d�zeyi daha preklinik evrede PIB-PET ile
amiloid y�k�n�n saptanabilmesinden �nce d�&#351;meye ba&#351;lar; klinik
evrelerden itibaren PIB-PET ile amiloid y�k� fazlaca de&#287;i&#351;mez.
AAMI�dan itibaren kognisyon bozulmaya, BOS tau d�zeyleri artmaya ba&#351;lar.
MCI evresinde FDG-PET ile b�lgesel metabolizma azalmas&#305; izlenir olur ve
sonras&#305;nda demans evreleri boyunca yayg&#305;nla&#351;arak &#351;iddetlenir.
Hippokampus hacmi AAMI�dan itibaren k���lmeye ba&#351;lar. &#304;&#351;levsel
bozukluk (GYA�lar) tan&#305; gere&#287;i demans a&#351;amas&#305;ndan itibaren
ba&#351;lar ve ilerleyici olarak k�t�le&#351;ir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;
font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar: </span></b><span
lang=TR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AAMI: ya&#351;la ilintili bellek bozuklu&#287;u; BOS:
beyin-omurilik s&#305;v&#305;s&#305;; FDG-PET: i&#351;aretli glukoz pozitron
emisyon tomografisi; GYA�lar: g�nl�k ya&#351;am aktiviteleri; MCI: hafif
kognitif bozukluk; PIB: Pittsburgh bile&#351;eni<o:p></o:p></span></p>

</div>

<span lang=TR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:
Tahoma;mso-fareast-font-family:"Times New Roman";mso-ansi-language:TR;
mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=all
style='page-break-before:always;mso-break-type:section-break'>
</span>

<div class=Section2>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 10.</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Demans&#305;n Klinik
Evrelendirilmesi �l�e&#287;i -CDR (Morris 1997)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=114 valign=top style='width:85.5pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CDR</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.
  Bellek&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.
  Oryantasyon</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.
  Yarg&#305;lama �</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Problem ��zme</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek
  kayb&#305; yok ya da hafif ve belirsiz unutkanl&#305;k</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>T�m�yle
  oryante</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�nl�k problemler ve
  �al&#305;&#351;ma hayat&#305; ve&nbsp;mali i&#351;lerle ilgili problemleri
  iyi ��zer;&nbsp;yarg&#305;lama iyidir</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0,5</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hafif
  fakat a&#351;ikar unutkanl&#305;k;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>olaylar&#305;n k&#305;smen
  hat&#305;rlanabilmesi; &quot;selim&quot;
  unutkanl&#305;k&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Zaman
  ili&#351;kilerinde hafif g��l�k d&#305;&#351;&#305;nda t�m�yle oryante</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Problem ��zme, benzerlik ve
  farkl&#305;l&#305;klar&#305; kavramakta hafif bozukluk</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orta
  d�zeyde unutkanl&#305;k, yak&#305;n</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>d�nem olaylar&#305; i�in daha
  belirgin; &nbsp;unutkanl&#305;k g�nl�k aktiviteleri&nbsp;etkiliyor</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Zamanda
  orta d�zeyde g��l�k;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>muayene s&#305;ras&#305;nda mekana
  oryante, d&#305;&#351;ar&#305;da co&#287;rafi disoryantasyonu olabilir</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orta
  d�zeyde bozukluk; toplumsal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>yarg&#305;lama genellikle
  korunmu&#351;tur</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#287;&#305;r d�zeyde
  unutkanl&#305;k; yaln&#305;zca �ok iyi �&#287;renilmi&#351; materyel
  tutulabilir; yeni materyel h&#305;zla yitirilir</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Zaman
  ili&#351;kilerinde a&#287;&#305;r d�zeyde</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>g��l�k; genellikle zamana,
  s&#305;kl&#305;kla da mekana disoryante</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#287;&#305;r
  d�zeyde bozukluk; genellikle</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>toplumsal yarg&#305;lama da
  bozuktur</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#287;&#305;r
  d�zeyde unutkanl&#305;k; yaln&#305;zca par�ac&#305;klar kal&#305;r</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yaln&#305;zca
  ki&#351;ilere oryante</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yarg&#305;lama
  ve problem ��zme t�m�yle bozuk</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CDR</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.
  Ev d&#305;&#351;&#305;nda i&#351;levsellik</span></b><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5.
  Ev ya&#351;am&#305; � Hobiler</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.
  Ki&#351;isel bak&#305;m</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;te,
  al&#305;&#351;veri&#351;te, g�n�ll� gruplar ve toplumsal gruplar i�inde her
  zamanki d�zeyde ba&#287;&#305;ms&#305;z i&#351;levsellik</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  ya&#351;am&#305;, hobiler ve entelekt�el</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ilgiler iyi korunmu&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kendine
  bak&#305;ma t�m�yle muktedir</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0,5</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>An&#305;lan
  aktivitelerde hafif bozulma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  ya&#351;am&#305;, hobiler ve entelekt�el</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ilgilerde hafif bozulma</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>An&#305;lan
  aktivitelerden baz&#305;lar&#305;n&#305; halen s�rd�rse de,
  ba&#287;&#305;ms&#305;z i&#351;lev g�rememe; y�zeysel bir bak&#305;&#351;la
  hala normal g�r�nebilir</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evdeki
  i&#351;levlerde hafif fakat a&#351;ikar</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>bozulma; g�� ev i&#351;leri,
  karma&#351;&#305;k</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>hobiler ve ilgiler
  terkedilmi&#351; durumda</span><span lang=DA style='font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gayrete
  getirilmesi gerekiyor</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  d&#305;&#351;&#305;nda ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; t�m�yle
  &nbsp;yitirmi&#351; / Ev d&#305;&#351;&#305;nda aktivitelere g�t�r�lebilecek
  kadar iyi g�r�n�r</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yaln&#305;zca
  basit i&#351;ler yap&#305;labiliyor; ilgiler son derece
  s&#305;n&#305;rl&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Giyinme,
  hijyen ve di&#287;er ki&#351;isel bak&#305;m i�in yard&#305;m gerekiyor</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  d&#305;&#351;&#305;nda ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; t�m�yle
  yitirmi&#351; / Ev d&#305;&#351;&#305;nda aktivitelere g�t�r�lemeyecek kadar
  hasta g�r�n�r</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evde
  kayda de&#287;er bir i&#351;levselli&#287;i yok</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;isel
  bak&#305;m i�in �nemli �l��de yard&#305;m gerekir; genellikle
  inkontinand&#305;r</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Evrelendirme: Bellek ekseninin d&#305;&#351;&#305;ndaki eksenlerden
en az ��� bellek ekseninden farkl&#305; de&#287;ilse, evre bellek ekseniyle
ayn&#305;d&#305;r.&nbsp; Farkl&#305; oldu&#287;u durumda ise, evre bellek
ekseninin �st�nde ya da alt&#305;nda kalan bu 3 eksenin derecesidir.&nbsp; Bu
kural&#305;n tek istisnas&#305; bellek ekseni d&#305;&#351;&#305;nda kalan 5
eksenden ���n�n belle&#287;in bir taraf&#305;nda geri kalan&nbsp;ikisinin
di&#287;er taraf&#305;nda olmas&#305;d&#305;r ki bu durumda da evre bellek
ekseniyle ayn&#305;d&#305;r.&nbsp; Bellek ekseni 0,5 ise evre 0 olamaz;
di&#287;er eksenlerin derecesine ba&#287;l&#305; olarak 0,5 ya da 1
olmal&#305;d&#305;r.&nbsp; Bellek 0, fakat en az iki eksen 1 ya da daha fazla
ise, evre 0,5 olmal&#305;d&#305;r.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
<br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<b>Tablo 11.</b> Global Bozulma
�l�e&#287;i �GDS (Reisberg et al. 1998)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=52 valign=top style='width:39.15pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek
  kusuruna ili&#351;kin yak&#305;nma yok.</span><span lang=FI style='font-family:
  Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klinik g�r�&#351;me ile
  bellek kusuru saptanm&#305;yor.</span><span lang=FI style='font-family:Tahoma;
  mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek
  kusuruna ait, �zellikle a&#351;a&#287;&#305;da s&#305;ralanan alanlarda
  yak&#305;nmalar var:</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  e&#351;yalar&#305;n&#305; koydu&#287;u yerleri unutuyor;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; �nceden iyi
  bildi&#287;i isimleri unutuyor.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Klinik g�r�&#351;mede bellek kusuruna ait nesnel bir kan&#305;t yok.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &#304;&#351; ve toplumsal ortamlarda nesnel bir bozukluk yok.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Semptomatolojiye y�nelik uygun d�zeyde endi&#351;e
  ta&#351;&#305;yor.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>En
  erken g�sterilebilir bozukluk bulgular&#305;.</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  A&#351;a&#287;&#305;daki alanlarda birden fazla bulgu:</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iyi
  bilmedi&#287;i �evrelere gitti&#287;inde kaybolabiliyor.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; i&#351;
  arkada&#351;lar&#305;, hastan&#305;n bozulmaya y�ztutan �al&#305;&#351;ma
  performans&#305;n&#305;n fark&#305;ndalar.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kelime
  ve isim bulma g��l�kleri yak&#305;nlar&#305; taraf&#305;ndan fark ediliyor.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bir kitap
  yada yaz&#305;y&#305; okudu&#287;unda eskisi gibi hat&#305;r&#305;nda
  kalm&#305;yor.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yeni
  tan&#305;&#351;t&#305;&#287;&#305; insanlar&#305;n isimlerini
  hat&#305;rlamakta g��l�&#287;� var.</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  de&#287;erli bir nesne kaybedilmi&#351; yada konulmamas&#305; gereken bir
  yere konmu&#351;.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; konsantrasyon
  eksikli&#287;i klinik testler s&#305;ras&#305;nda a&#351;ikar.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify;text-indent:-1.0cm;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bellek bozuklu&#287;una ili&#351;kin, ancak yo&#287;un bir g�r�&#351;meden
  sonra ortaya konulabilen nesnel bulgular.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  U&#287;ra&#351;&#305; gerektiren i&#351; ko&#351;ullar&#305; yada toplumsal
  ortamlarda d�&#351;�k performans.</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Hastada inkar mekanizmas&#305; belirgin hale gelir olmu&#351;.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Belirtilere
  &#305;l&#305;ml&#305;&nbsp; yada orta d�zeyde bir anksiyete e&#351;lik
  edebilir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dikkatli
  bir klinik g�r�&#351;me sonras&#305;nda ortaya konulan a&#351;ikar bozukluk
  bulgular&#305;.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bozukluk a&#351;a&#287;&#305;daki alanlarda ortaya konuyor:</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; g�nl�k ve
  yak&#305;n ge�mi&#351;e ait olaylara ili&#351;kin bilgide azalma.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ki&#351;isel
  ge�mi&#351;e ait baz&#305; bellek problemleri.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  �&#305;karma dizileriyle ortaya konulan konsantrasyon bozuklu&#287;u.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yolculuk
  yapma, para i&#351;leriyle u&#287;ra&#351;ma gibi yeteneklerde azalma.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  A&#351;a&#287;&#305;daki alanlar genellikle sorunsuz:</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yer ve zaman
  oryantasyonu</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bildik
  ki&#351;i ve y�zlerin tan&#305;nmas&#305;.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bilinen
  yerlere yolculuk yapabilme.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Karma&#351;&#305;k i&#351;levlerin yerine getirilemez olmas&#305;.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bask&#305;n savunma mekanizmas&#305; olarak inkar kullan&#305;l&#305;yor.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duygulan&#305;mda k�ntle&#351;me ve
  s&#305;k&#305;nt&#305; yaratan durumlardan ka�&#305;nma.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;amlar&#305;n&#305;
  s�rd�rebilmeleri i�in yard&#305;m gerekmektedir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Hasta g�ncel ya&#351;am&#305;na ili&#351;kin temel �zelliklerden birini
  hat&#305;rlayam&#305;yor. �rne&#287;in:</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  y&#305;llard&#305;r kullanmakta oldu&#287;u adres yada telefon
  numaras&#305;n&#305;.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yak&#305;n
  aile �yelerinin isimlerini (torunlar gibi).</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mezun
  oldu&#287;u lise yada y�ksek okulun ad&#305;n&#305;.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Zaman (g�n, haftan&#305;n g�n�, mevsim, v.b) yada mekan oryantasyonunda
  bozulmalar.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  E&#287;itimli bir ki&#351;i, 40'tan geriye 4er, yada 20'den geriye 2'&#351;er
  saymakta g��l�k �ekebilir.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bu evredeki ki&#351;iler kendilerine ve di&#287;erlerine ait temel ger�eklere
  ili&#351;kin bilgiyi korurlar.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Kendi isimlerini daima, e&#351; ve �ocuklar&#305;n&#305;nkileri genellikle
  bilirler.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:53.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-53.0pt;
  text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Temizlenmek
  ve yemek yemekte yard&#305;m gerekmez, ancak uygun giysiyi se�mekte
  g��l�kleri&nbsp;&nbsp; olabilir.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>6</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bazen,
  ya&#351;amlar&#305;n&#305; s�rd�rmek i�in t�m�yle ba&#287;&#305;ml&#305;
  olduklar&#305; e&#351;lerinin ismini&nbsp; unutabilirler.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Ya&#351;amlar&#305;ndaki yak&#305;n ge�mi&#351;e ili&#351;kin olay ve
  deneyimlerin t�m�nden b�y�k �l��de habersizdirler.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  �evreye ili&#351;kin baz&#305; bilgiler korunabilir; y&#305;l, mevsim, v.b.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  10'dan geriye, bazen de ileriye do&#287;ru 1'er saymakta g��l�kleri olabilir.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  G�nl�k ya&#351;am aktivitelerinde yard&#305;m gerekir:</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; idrar
  inkontinans&#305; olabilir.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yolculuk i�in
  yard&#305;m gerekir, fakat bazen bildik yerlere gidebilirler.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Diurnal ritm s&#305;kl&#305;kla bozulmu&#351;tur.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Hemen daima kendi isimlerini hat&#305;rlarlar.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Genellikle, �evrelerindeki tan&#305;d&#305;k ki&#351;ileri yabanc&#305;lardan
  ay&#305;rabilirler.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Ki&#351;ilik ve emosyon de&#287;i&#351;iklikleri g�r�l�r.&nbsp; Bunlar
  olduk�a de&#287;i&#351;kendir ve &#351;unlar&#305; i�erir:</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp; hezeyan davran&#305;&#351;&#305;, �rn.,
  e&#351;lerini taklit olmakla su�layabilirler; �evredeki
  hayali&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ki&#351;ilerle, yada
  aynadaki kendi imgeleriyle konu&#351;abilirler.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp; (b)&nbsp;&nbsp; obsesif
  belirtiler olabilir, �rn., hasta s�rekli olarak&nbsp; basit bir temizlik hareketini
  tekrarlayabilir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;anksiyete belirtileri, ajitasyon
  ve daha �nce mevcut olmayan tarzda bir sald&#305;rganl&#305;k&nbsp;
  g�r�lebilir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
  (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kognitif abuli, �rn., amaca y�nelik bir
  davran&#305;&#351;&#305;n uygulanmas&#305; i�in gerekli d�&#351;�ncenin
  yeterli s�re ta&#351;&#305;namamas&#305; nedeniyle irade g�c�n�n kayb&#305;.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu
  evre s�recinde t�m verbal yetenekler kaybedilir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu evrenin erken d�neminde
  baz&#305; kelime ve c�mleler s�ylenebilse de konu&#351;ma son derece
  s&#305;n&#305;rlanm&#305;&#351;t&#305;r.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evrenin ilerlemesiyle,
  homurdanmak d&#305;&#351;&#305;nda, konu&#351;ma t�m�yle yitirilir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;drar inkontinans&#305;;
  temizlik ve yemek yemek i�in yard&#305;m gerekir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Temel psikomotor yetenekler
  (�rn. y�r�mek) evrenin ilerlemesiyle kaybedilir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Beyin bedene ne yapmas&#305;
  gerekti&#287;ini s�yleme yetene&#287;ini art&#305;k yitirmi&#351; gibidir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genel ve kortikal n�rolojik
  bulgu ve belirtiler bu evrede genellikle mevcuttur.</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>EP&#304;DEM&#304;YOLOJ&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Prevalans ve &#304;nsidans</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>D�nyada &#351;imdiye kadar yap&#305;lan prevalans
(belli bir zaman kesitinde bulunan t�m olgular&#305;n n�fusa oran&#305;)
�al&#305;&#351;malar&#305;n&#305;n metaanalizi 65-70 ya&#351;lar&#305;
aras&#305;nda %4-5 kadar olan AH�nin her 5 y&#305;lda bir katlanarak art&#305;p
90�l&#305; ya&#351;larda %50�ye kadar ula&#351;t&#305;&#287;&#305;n&#305;
ortaya koymaktad&#305;r.&nbsp;T�rkiye�den ilk �al&#305;&#351;ma
diyebilece&#287;imiz Istanbul, Kad&#305;k�y�de ger�ekle&#351;tirilen TAPS
isimli prevalans �al&#305;&#351;mas&#305;n&#305;n sonu�lar&#305; <b>Tablo 12</b>�de
g�sterilmi&#351;tir. 90�l&#305; ya&#351;lardan sonraki prevalans konusunda
hen�z bir uzla&#351;&#305;m olmamakla birlikte art&#305;&#351;&#305;n devam
etmeyip bu oran&#305;n plato �izdi&#287;i (�AH ya&#351;la ilintilidir�)
g�r�&#351;� ile s�rekli y�kseldi&#287;i (�AH ya&#351;lanmayla ilintilidir)
g�r�&#351;� aras&#305;ndaki tart&#305;&#351;ma tam olarak
��z�mlenmemi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ya&#351;a-�zg�l insidans, ya da belli bir zaman
aral&#305;&#287;&#305;nda ortaya �&#305;kan yeni olgular&#305;n
say&#305;s&#305; da ya&#351; aral&#305;klar&#305; artt&#305;k�a h&#305;zla
artar.&nbsp; Jorm ve Jolley�in 1998 tarihli bir meta-analizlerinde 65-69 ile
ba&#351;lay&#305;p 85-89 ile sonlanan 5�er y&#305;ll&#305;k 5 ya&#351;
katman&#305;nda insidans %1.6, %3.5, %7.8, %14.8 ve %26.0 &#351;eklinde yine
katlanarak artmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 12.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> TAPS
�al&#305;&#351;mas&#305;�nda ya&#351;a ve cinsiyete g�re
katmanland&#305;r&#305;lm&#305;&#351; prevelans oranlar&#305;<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext 1.0pt;
 mso-padding-alt:0cm 0cm 0cm 0cm;mso-border-insideh:1.0pt solid windowtext;
 mso-border-insidev:1.0pt solid windowtext'>
 <tr style='mso-yfti-irow:0'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PRAD</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toplam
  AH</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toplam
  demans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;
  gruplar&#305; bir arada</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>T�m�</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%11</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%16</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%20</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:25.5pt'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:25.5pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Erkek</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%9</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%13</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%17</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kad&#305;n</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%13</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%17</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%22</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Cinsiyet
  gruplar&#305; bir arada</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-74</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%9</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%14</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%18</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>75-79</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%14</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%19</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%22</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>80+</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%13</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%17</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%23</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Erkek</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-74
  </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%8</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%12</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%16</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>75-79</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%9</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%12</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%15</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>80+</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%11</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%16</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%20</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kad&#305;n</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-74</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%10</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%15</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%19</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>75-79</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%18</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%23</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%26</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;mso-yfti-lastrow:yes'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>80+</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%15</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%20</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%25</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PRAD: muhtemel Alzheimer
hastal&#305;&#287;&#305;; toplam AH: PRAD art&#305; m�mk�n AH; toplam demans:
toplam AH art&#305; non-AH demanslar. (Kaynak 15�den
uyarlanm&#305;&#351;t&#305;r.)<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Risk Fakt�rleri (Tablo 13)</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G�n�m�zde ya&#351;am beklentisindeki dramatik
art&#305;&#351; global bir fenomendir.&nbsp; Bat&#305;l&#305; �lkeler
ba&#351;ta olmak �zere, t�m d�nyada ya&#351;l&#305; n�fusun genel n�fusa
oran&#305;n&#305;n giderek artmas&#305; bir toplumsal sorun olarak AH�nin
�nemini de artt&#305;rmaktad&#305;r.&nbsp;Hastal&#305;&#287;&#305;n toplumsal
maliyetinin demans &#351;iddetiyle do&#287;ru orant&#305;l&#305; oldu&#287;unu
g�steren �al&#305;&#351;malar mevcuttur.&nbsp;TAPS�ta da ya&#351; bir risk
fakt�r� olarak ortaya konmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bir risk fakt�r� olarak cinsiyet
tart&#305;&#351;mal&#305;d&#305;r. Bir �ok �al&#305;&#351;ma AH
prevalans&#305;n&#305;n kad&#305;nlarda erkeklere g�re daha fazla oldu&#287;unu
g�stermektedir.&nbsp; Ancak bu prevalans farkl&#305;l&#305;&#287;&#305;
genellikle kad&#305;nlarda ya&#351;am beklentisinin daha uzun olmas&#305;yla
a�&#305;klanmaktad&#305;r.&nbsp; Bununla birlikte �strojen beyinde bir
n�rotrofik fakt�r olarak i&#351;lev g�rmekte, erkeklerde �m�r boyu mevcut olan
testosteron beyinde �strojene �evrilip i&#351;levini s�rd�r�rken, kad&#305;nlar
menopoz sonras&#305; �strojensiz kalmaktad&#305;rlar. Bu durum
ya&#351;am&#305;n ikinci yar&#305;s&#305;nda bir n�rotrofik fakt�rden yoksun
kalan kad&#305;nlar&#305;n neden demans i�in daha fazla risk
ta&#351;&#305;d&#305;klar&#305;n&#305;n a�&#305;klamalar&#305;ndan biri
olabilir. Nitekim, epidemiyolojik �al&#305;&#351;malarda post-menopozal d�nemde
�strojen replasman&#305; kullanan kad&#305;nlarda kullanmayanlara g�re demans
prevalans&#305;n&#305;n daha d�&#351;�k olmas&#305; bu varsay&#305;m&#305;
destekler niteliktedir. Cinsiyetin ger�ek anlamda bir risk olup
olmad&#305;&#287;&#305;na daha iyi bir cevap verebilecek olan insidans
�al&#305;&#351;malar&#305;n&#305;n sonu�lar&#305; ise �eli&#351;kilidir.&nbsp;
Bir �al&#305;&#351;ma 85 ya&#351;&#305;n&#305;n �zerindeki erkeklerde AH
insidans&#305;n&#305; y&#305;lda %2.7, buna kar&#351;&#305;l&#305;k
kad&#305;nlarda %8.9 oldu&#287;unu bulmu&#351;tur.&nbsp; Ba&#351;ka bir
�al&#305;&#351;mada ise bir AH�linin 1. derece kad&#305;n
akrabalar&#305;n&#305;n 1. derece erkek akrabalar&#305;na g�re ya&#351;am boyu
hastal&#305;k riskinin daha fazla oldu&#287;u g�sterilmi&#351;tir. Ancak �ok
say&#305;da ba&#351;ka �al&#305;&#351;mac&#305; grubu bu farkl&#305;l&#305;&#287;&#305;
do&#287;rulamayarak herhangi bir farkl&#305;l&#305;k
bulmam&#305;&#351;lard&#305;r.&nbsp; TAPS �al&#305;&#351;mas&#305;nda da
kad&#305;nlarda prevalans daha y�ksek olsa da cinsiyetin bir risk fakt�r�
olmad&#305;&#287;&#305; g�r�lm�&#351;t�r. Bununla birlikte,&nbsp; d�rt
ayr&#305; prospektif Avrupa �al&#305;&#351;mas&#305;n&#305;n
havuzlanm&#305;&#351; verilerini analiz eden EURODEM Insidens
Ara&#351;t&#305;rma Grubu kad&#305;n cinsiyetin 85 ya&#351; ile birlikte bir
risk fakt�r� olarak belirdi&#287;ini, 90 ya&#351; �zerinde bu riskin daha da
artt&#305;&#287;&#305;n&#305; bildirmi&#351;lerdir. TAPS �al&#305;&#351;mas&#305;nda
85 ve 90 ya&#351; �zeri tabakalardaki birey say&#305;s&#305;n&#305;n azl&#305;&#287;&#305;
bizim �al&#305;&#351;mam&#305;zdaki negatif sonucun a�&#305;klamas&#305;
olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yorumu yine tart&#305;&#351;mal&#305; olsa da
d�&#351;�k e&#287;itimin ba&#351;l&#305; ba&#351;&#305;na bir risk fakt�r�
oldu&#287;u art&#305;k yerle&#351;mi&#351; bir bilgidir.&nbsp;E&#287;itim
deneyimindeki art&#305;&#351;&#305;n bireyin kognitif rezervinin
geni&#351;lemesine yola�arak&nbsp;hastal&#305;&#287;&#305;n ortaya
�&#305;k&#305;&#351; e&#351;i&#287;ini y�kseltmesi �ekici bir a�&#305;klama
gibi durmaktad&#305;r.&nbsp;TAPS �al&#305;&#351;mas&#305;nda da d�&#351;�k
e&#287;itim demans i�in bir risk fakt�r� olarak belirlenmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TAPS �al&#305;&#351;mas&#305;nda elektro-manyetik
alan (EMF) maruziyeti de AH i�in bir risk fakt�r� olarak ortaya konmu&#351;tur.
Elektrik�iler, tamirciler, santral operat�rleri, teknisyenleri,
kaynak�&#305;lar, marangozlar, terziler gibi elektrikli aletlerle
�al&#305;&#351;anlar a&#351;&#305;r&#305; d�&#351;�k frekansl&#305; (ELF) EMF
maruziyeti i�in risk alt&#305;nda meslek gruplar&#305;d&#305;r. Bizim
�al&#305;&#351;mam&#305;z&#305; da i�eren ELF-EMF maruziyeti ve AH
ili&#351;kisi ile ilgili 12 �al&#305;&#351;man&#305;n meta-analizi olan bir
�al&#305;&#351;mada bu ili&#351;kinin ba&#287;&#305;ms&#305;z bir risk
oldu&#287;u kabullenilmekle birlikte mevcut �al&#305;&#351;malarda maruziyet
dozu ile risk art&#305;&#351;&#305; ve maruziyet ile cinsiyetlerin ili&#351;kisinin
belirlenememi&#351; olmas&#305; dolay&#305;s&#305;yla daha fazla
�al&#305;&#351;man&#305;n gerekti&#287;inin alt&#305; �izilmi&#351;tir. Maruz
kal&#305;nan di&#287;er toksik ve zararl&#305; durumlar aras&#305;nda organik
��z�c�ler, al�minyum ve genel anestezi �n plana �&#305;kar gibi
g�r�nmektedir.&nbsp; Ancak bunlar&#305;n yerle&#351;mi&#351;
tutarl&#305;l&#305;kta bulgular oldu&#287;u s�ylenemez. Sigara i�enlerde,
kolinerjik nikotinik resept�rlerin �st-reg�lasyonu ve bunun sonucu olarak
A&#946; d�zeylerinin d�&#351;mesi ile a�&#305;klanan bi�imde AH�nin daha az
g�r�ld�&#287;� bulgusu, ba&#351;lang&#305;�ta sigara i�enlerin ileri
ya&#351;lara gelmeden di&#287;er hastal&#305;klar nedeniyle �lmeleri ve
vask�ler demansa daha yatk&#305;n olmalar&#305; &#351;eklinde metodolojik
olarak ele&#351;tirilmi&#351;ken, son zamanlardaki Rotterdam ve New York
�al&#305;&#351;malar&#305;nda tam tersine AH riskini bir ka� kez
artt&#305;rd&#305;&#287;&#305; y�n�nde bulgular elde edilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ayr&#305; bir alt ba&#351;l&#305;kta
tart&#305;&#351;&#305;lacak olan otozomal dominant ge�i&#351;li familyal AH
olgular&#305; yan&#305;s&#305;ra, ailede demans �yk�s� AH i�in kendi
ba&#351;&#305;na bir risk fakt�r�d�r.&nbsp;AH�li hastalar&#305;n karde&#351;lerinde
ya&#351;am boyu hastal&#305;k riski beklentisi ikiye katlanarak %23�ten %48�e
�&#305;kar.&nbsp; Monozigotik ikizlerde dizigot ikizlere oranla AH
birlikteli&#287;i anlaml&#305; oranda fazlad&#305;r.&nbsp;APOE-&#949;4 aleli
ile AH ili&#351;kisi &quot;genetik&quot; altba&#351;l&#305;&#287;&#305;
alt&#305;nda tart&#305;&#351;&#305;lacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yine genetik ba&#351;l&#305;&#287;&#305;
alt&#305;nda s�zedilecek olan Down sendromu ve AH ili&#351;kisi
yan&#305;s&#305;ra, Down sendromu aile �yk�s� AH riskini 2 ila 3 misli
artt&#305;rmaktad&#305;r.&nbsp; Ayr&#305;ca enteresan bir bulgu, Down sendromlu
�ocuk do&#287;uran annelerin AH riskinin, di&#287;er tiplerde mental retarde
�ocuklar do&#287;uran annelere g�re 5 misli artmas&#305;d&#305;r.&nbsp; Bu
farkl&#305;l&#305;k anne ya&#351;&#305;n&#305;n do&#287;umda 35�in alt&#305;nda
oldu&#287;u durumlarda ortaya �&#305;kmaktad&#305;r.&nbsp; Down
babalar&#305;nda AH i�in ayr&#305;ca bir risk s�z konusu de&#287;ildir.&nbsp;
Bu bulgu, AH geli&#351;tirmek ve 35 ya&#351;&#305;n&#305;n alt&#305;nda Down
sendromlu �ocuk do&#287;urmak aras&#305;nda payla&#351;&#305;lan bir genetik
yatk&#305;nl&#305;k olas&#305;l&#305;&#287;&#305; y�n�nde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kafa travmas&#305; �yk�s� ile AH aras&#305;nda
ili&#351;ki bildiren �nemli �al&#305;&#351;malar olmakla birlikte
(�rne&#287;in, EURODEM) bunu reddenler de vard&#305;r (�rne&#287;in, Rotterdam
�al&#305;&#351;mas&#305; ve Kanada Sa&#287;l&#305;k ve Ya&#351;lanma
�al&#305;&#351;mas&#305;). Bilin� kayb&#305;na neden olmu&#351; &#351;iddetteki
kafa travmalar&#305;n&#305;n bir risk fakt�r� olarak de&#287;erlendirilmesi
mevcut �al&#305;&#351;malardaki �eli&#351;ik sonu�lar&#305; a&#351;abilir.
APOE-&#949;4 y�k� ile kafa travmas&#305;n&#305;n AH�nin ba&#351;lang&#305;�
ya&#351;&#305; �zerine birlikte etkisi oldu&#287;unu ileri s�ren
�al&#305;&#351;malar&nbsp; mevcuttur.&nbsp; Bir �al&#305;&#351;mada ise tek
ba&#351;&#305;na etkisiz g�r�n�rken, normalde iki misli artm&#305;&#351; olan
APOE-&#949;4 heterozigotlar&#305;n&#305;n riskini 10 misline
artt&#305;rd&#305;&#287;&#305; ortaya konmu&#351;tur.&nbsp; Kafa travmas&#305;n&#305;n
etkisinin &#946;-amiloid metabolizmas&#305; �zerinden olmas&#305; muhtemel
g�r�nmektedir. Dementia pugilistica geli&#351;tiren boks�rlerin otopsilerinde
saptanan gev&#351;ek neokortikal amiloid plaklar bu varsay&#305;m&#305;
destekler niteliktedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�z ge�mi&#351;te 10 y&#305;la kadar geriye giden
tedavi gerektirmi&#351; bir depresyon �yk�s� AH riskini 3 kat
artt&#305;r&#305;r.&nbsp; Depresyonun hastal&#305;&#287;&#305;n erken bir
g�sterisi oldu&#287;unu iddia eden �al&#305;&#351;malar vard&#305;r.&nbsp;Jorm
taraf&#305;ndan yap&#305;lan 2001 tarihli meta-analizde
ya&#351;l&#305;l&#305;kta depresyon �zge�mi&#351;inin demans geli&#351;tirme
riskini ikiye katlad&#305;&#287;&#305; bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K&#305;s&#305;tl&#305; sosyal ili&#351;kiler
Kungsholmen, &#304;sve� ve Kuzey Manhattan, ABD gibi �nemli toplum temelli
kesitsel ve uzunlamas&#305;na g�zlem �al&#305;&#351;malar&#305;nda
ba&#287;&#305;ms&#305;z bir risk fakt�r� olarak ortaya konmu&#351;tur. Sosyal
ili&#351;kiler akraba ve arkada&#351; ili&#351;kilerinin zenginli&#287;i,
sinema, lokanta, kl�p, dernek faaliyetleri ama�l&#305; soka&#287;a
�&#305;kmalar olarak �zetlenebilir. Honolulu-Asya Ya&#351;lanma
�al&#305;&#351;mas&#305;�nda bu risk orta ya&#351;lar&#305;ndan itibaren sosyal
aktiviteleri d�&#351;en bireylerle s&#305;n&#305;rl&#305; bulunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Vask�ler olaylar aras&#305;nda miyokard iskemisi,
hipertansiyon, diyabet ve inme �yk�s� ile metabolik sendrom mevcudiyetinin AH
riskini anlaml&#305; bi�imde artt&#305;rd&#305;&#287;&#305; bir �ok
�al&#305;&#351;mada g�sterilmi&#351;tir.&nbsp; Bu bulgular o denli g��l�d�r ki,
daha yak&#305;n zamanlara kadar 2. s&#305;kl&#305;kta demans nedeni olarak
g�sterilen vask�ler demans&#305;n AH�den ba&#287;&#305;ms&#305;z bir antite
olarak varl&#305;&#287;&#305; bile son y&#305;llarda tart&#305;&#351;ma konusu
olmu&#351;tur. Ayn&#305; zamanda bir inme risk fakt�r� olan y�ksek plazma
homosistein d�zeyinin AH i�in de ba&#287;&#305;ms&#305;z bir risk fakt�r�
oldu&#287;u bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K���k kafa �evresi ile AH aras&#305;nda baz&#305;
�al&#305;&#351;malarda g�sterilen ili&#351;ki, e&#287;itim ile olan
ili&#351;kide oldu&#287;u gibi kognitif rezerv teorisiyle a�&#305;klanmaya
�al&#305;&#351;&#305;lmaktad&#305;r. &nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hipotirodinin gerek genel olarak demans ve gerekse
de AH ile ili&#351;kisi ortaya konmu&#351;tur.&nbsp; AH ile ili&#351;kisinin
mekanizmas&#305; a&#351;ikar olmasa da potansiyel olarak d�zeltilebilir bir
durum olmas&#305; bak&#305;m&#305;ndan �nemlidir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yorumu yine tart&#305;&#351;mal&#305; olsa da
d�&#351;�k e&#287;itimin ba&#351;l&#305; ba&#351;&#305;na bir risk fakt�r�
oldu&#287;u art&#305;k yerle&#351;mi&#351; bir bilgidir.&nbsp;E&#287;itim
deneyimindeki art&#305;&#351;&#305;n bireyin kognitif rezervinin
geni&#351;lemesine yol a�arak&nbsp;hastal&#305;&#287;&#305;n ortaya
�&#305;k&#305;&#351; e&#351;i&#287;ini y�kseltmesi �ekici bir a�&#305;klama
gibi durmaktad&#305;r.&nbsp;TAPS �al&#305;&#351;mas&#305;nda da d�&#351;�k
e&#287;itim demans i�in bir risk fakt�r� olarak belirlenmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TAPS �al&#305;&#351;mas&#305;nda elektro-manyetik alan
(EMF) maruziyeti de AH i�in bir risk fakt�r� olarak ortaya konmu&#351;tur.
Elektrik�iler, tamirciler, santral operat�rleri, teknisyenleri,
kaynak�&#305;lar, marangozlar, terziler gibi elektrikli aletlerle
�al&#305;&#351;anlar a&#351;&#305;r&#305; d�&#351;�k frekansl&#305; (ELF) EMF
maruziyeti i�in risk alt&#305;nda meslek gruplar&#305;d&#305;r. Bizim
�al&#305;&#351;mam&#305;z&#305; da i�eren ELF-EMF maruziyeti ve AH
ili&#351;kisi ile ilgili 12 �al&#305;&#351;man&#305;n meta-analizi olan Garcia
ve arkada&#351;lar&#305;n&#305;n 2008 tarihli makalelerinde bu ili&#351;kinin
ba&#287;&#305;ms&#305;z bir risk oldu&#287;u kabullenilmekle birlikte mevcut
�al&#305;&#351;malarda maruziyet dozu ile risk art&#305;&#351;&#305; ve
maruziyet ile cinsiyetlerin ili&#351;kisinin belirlenememi&#351; olmas&#305;
dolay&#305;s&#305;yla daha fazla �al&#305;&#351;man&#305;n �neminin alt&#305;
�izilmi&#351;tir. Maruz kal&#305;nan di&#287;er toksik ve zararl&#305; durumlar
aras&#305;nda organik ��z�c�ler, aluminyum ve genel anestezi �n plana
�&#305;kar gibi g�r�nmektedir.&nbsp; Ancak bunlar&#305;n yerle&#351;mi&#351;
tutarl&#305;l&#305;kta bulgular oldu&#287;u s�ylenemez. Sigara i�enlerde,
kolinerjik nikotinik resept�rlerin �st reg�lasyonu ve bunun sonucu olarak
A&#946; d�zeylerinin d�&#351;mesi ile a�&#305;klanan bi�imde AH�nin daha az
g�r�ld�&#287;� bulgusu, ba&#351;lang&#305;�ta sigara i�enlerin ileri
ya&#351;lara gelmeden di&#287;er hastal&#305;klar nedeniyle �lmeleri ve
vask�ler demansa daha yatk&#305;n olmalar&#305; &#351;eklinde metodolojik
olarak ele&#351;tirilmi&#351;ken, son zamanlardaki Rotterdam ve New York �al&#305;&#351;malar&#305;nda
tam tersine AH riskini bir ka� kez artt&#305;rd&#305;&#287;&#305; y�n�nde
bulgular elde edilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ayr&#305; bir alt ba&#351;l&#305;kta
tart&#305;&#351;&#305;lacak olan otozomal dominan ge�i&#351;li familyal AH
olgular&#305; yan&#305;s&#305;ra, ailede demans �yk�s� AH i�in kendi
ba&#351;&#305;na bir risk fakt�r�d�r.&nbsp;AH�li hastalar&#305;n
karde&#351;lerinde ya&#351;am boyu hastal&#305;k riski beklentisi ikiye
katlanarak %23�ten %48�e �&#305;kar.&nbsp; Monozigotik ikizlerde dizigot
ikizlere oranla AH birlikteli&#287;i anlaml&#305; oranda
fazlad&#305;r.&nbsp;APOE-&#949;4 aleli ile AH ili&#351;kisi &quot;genetik&quot;
altba&#351;l&#305;&#287;&#305; alt&#305;nda tart&#305;&#351;&#305;lacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yine genetik ba&#351;l&#305;&#287;&#305;
alt&#305;nda s�z edilecek olan Down sendromu ve AH ili&#351;kisi
yan&#305;s&#305;ra, Down sendromu aile �yk�s� AH riskini 2 ila 3 misli
artt&#305;rmaktad&#305;r.&nbsp; Ayr&#305;ca enteresan bir bulgu olarak, Down sendromlu
�ocuk do&#287;uran annelerin AH riskinin, di&#287;er tiplerde mental retarde
�ocuklar do&#287;uran annelere g�re 5 misli artmas&#305;d&#305;r.&nbsp; Bu
farkl&#305;l&#305;k anne ya&#351;&#305;n&#305;n do&#287;umda 35�in alt&#305;nda
oldu&#287;u durumlarda ortaya �&#305;kmaktad&#305;r.&nbsp; Down
babalar&#305;nda AH i�in ayr&#305;ca bir risk s�z konusu de&#287;ildir.&nbsp;
Bu bulgu, AH geli&#351;tirmek ve 35 ya&#351;&#305;n&#305;n alt&#305;nda Down
sendromlu �ocuk do&#287;urmak aras&#305;nda payla&#351;&#305;lan bir genetik
yatk&#305;nl&#305;k olas&#305;l&#305;&#287;&#305; y�n�nde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kafa travmas&#305; �yk�s� ile AH aras&#305;nda
ili&#351;ki bildiren �nemli �al&#305;&#351;malar olmakla birlikte (�rn.,
EURODEM) bunu reddedenler de vard&#305;r (�rn., Rotterdam
�al&#305;&#351;mas&#305; ve Kanada Sa&#287;l&#305;k ve Ya&#351;lanma
�al&#305;&#351;mas&#305;). Bilin� kayb&#305;na neden olmu&#351; &#351;iddetteki
kafa travmalar&#305;n&#305;n bir risk fakt�r� olarak de&#287;erlendirilmesi mevcut
�al&#305;&#351;malardaki �eli&#351;ik sonu�lar&#305; a&#351;abilir.
APOE-&#949;4 y�k� ile kafa travmas&#305;n&#305;n AH�nin ba&#351;lang&#305;�
ya&#351;&#305; �zerine birlikte etkisi oldu&#287;unu ileri s�ren
�al&#305;&#351;malar&nbsp; mevcuttur.&nbsp; Bir �al&#305;&#351;mada ise tek
ba&#351;&#305;na etkisiz g�r�n�rken, normalde iki misli artm&#305;&#351; olan
APOE-&#949;4 heterozigotlar&#305;n&#305;n riskini 10 misline
artt&#305;rd&#305;&#287;&#305; ortaya konmu&#351;tur.&nbsp; Kafa travmas&#305;n&#305;n
etkisinin &#946;-amiloid metabolizmas&#305; �zerinden olmas&#305; muhtemel
g�r�nmektedir. Dementia pugilistica geli&#351;tiren boks�rlerin otopsilerinde
saptanan gev&#351;ek neokortikal amiloid plaklar bu varsay&#305;m&#305;
destekler niteliktedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�z ge�mi&#351;te 10 y&#305;la kadar geriye giden
tedavi gerektirmi&#351; bir depresyon �yk�s� AH riskini 3 kat
artt&#305;r&#305;r.&nbsp; Depresyonun hastal&#305;&#287;&#305;n erken bir
g�sterisi oldu&#287;unu iddia eden �al&#305;&#351;malar vard&#305;r.&nbsp;Jorm
taraf&#305;ndan yap&#305;lan 2001 tarihli meta-analizde
ya&#351;l&#305;l&#305;kta depresyon �zge�mi&#351;inin demans geli&#351;tirme
riskini ikiye katlad&#305;&#287;&#305; bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K&#305;s&#305;tl&#305; sosyal ili&#351;kiler
Kungsholmen, &#304;sve� ve Kuzey Manhattan, ABD gibi �nemli toplum temelli
kesitsel ve uzunlamas&#305;na g�zlem �al&#305;&#351;malar&#305;nda
ba&#287;&#305;ms&#305;z bir risk fakt�r� olarak ortaya konmu&#351;tur. Sosyal
ili&#351;kiler akraba ve arkada&#351; ili&#351;kilerinin zenginli&#287;i,
sinema, lokanta, kl�p, dernek faaliyetleri ama�l&#305; soka&#287;a
�&#305;kmalar olarak �zetlenebilir. Honolulu-Asya Ya&#351;lanma
�al&#305;&#351;mas&#305;�nda bu risk orta ya&#351;lar&#305;ndan itibaren sosyal
aktiviteleri d�&#351;en bireylerle s&#305;n&#305;rl&#305; bulunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Vask�ler olaylar aras&#305;nda miyokard iskemisi,
hipertansiyon, diyabet ve inme �yk�s� ile metabolik sendrom mevcudiyetinin AH
riskini anlaml&#305; bi�imde artt&#305;rd&#305;&#287;&#305; bir �ok
�al&#305;&#351;mada g�sterilmi&#351;tir.&nbsp; Bu bulgular o denli g��l�d�r ki,
daha yak&#305;n zamanlara kadar 2. s&#305;kl&#305;kta demans nedeni olarak
g�sterilen vask�ler demans&#305;n AH�den ba&#287;&#305;ms&#305;z bir antite
olarak varl&#305;&#287;&#305; bile son y&#305;llarda tart&#305;&#351;ma konusu
olmu&#351;tur. Ayn&#305; zamanda bir inme risk fakt�r� olan y�ksek plazma
homosistein d�zeyinin AH i�in de ba&#287;&#305;ms&#305;z bir risk fakt�r�
oldu&#287;u bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K���k kafa �evresi ile AH aras&#305;nda baz&#305;
�al&#305;&#351;malarda g�sterilen ili&#351;ki, e&#287;itim ile olan
ili&#351;kide oldu&#287;u gibi kognitif rezerv teorisiyle a�&#305;klanmaya
�al&#305;&#351;&#305;lmaktad&#305;r. &nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hipotirodinin gerek genel olarak demans ve gerekse
de AH ile ili&#351;kisi ortaya konmu&#351;tur.&nbsp; AH ile ili&#351;kisinin
mekanizmas&#305; a&#351;ikar olmasa da potansiyel olarak d�zeltilebilir bir
durum olmas&#305; bak&#305;m&#305;ndan �nemlidir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Koruyucu fakt�rler</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Epidemiyolojik �al&#305;&#351;malar bir dizi
fakt�rle AH aras&#305;nda, bu fakt�rlerin �koruyucu� olabilece&#287;ini
d�&#351;�nd�recek &#351;ekilde ters bir ili&#351;ki g�stermi&#351;tir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>D�&#351;�k e&#287;itim d�zeyi AH i�in bir riskken,
do&#287;al olarak y�ksek e&#287;itim d�zeyi ve profesyonel aktivite bir
koruyucu olarak ortaya �&#305;kmaktad&#305;r.&nbsp; Benzer bi�imde APOE-&#949;4
aleli risk iken &#949;2 aleli baz&#305; �al&#305;&#351;malarda koruyucu gibi
g�r�nmekteyse de &#949;2�nin bu olumlu rol�, &#949;4��n olumsuz rol� kadar
sa&#287;lam bir bulgu olarak yerle&#351;memi&#351;tir.&nbsp; Birinci durum
yukarda s�zedilen �kognitif rezerv� kavram&#305; ile a�&#305;klan&#305;rken, 2.
durumda &#949;2�nin &#946;-amiloid fragman&#305;n&#305;n temizlenmesinde etkin
bir alternatifi temsil etti&#287;i d�&#351;�n�lmektedir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�zellikle dejeneratif hastal&#305;klarda oksidatif
gerilim ve eksitotoksisite mekanizmalar&#305;n&#305;n a�&#305;klay&#305;c&#305;
olarak devreye girmesinden sonra, bu mekanizmalar&#305; tersine �evirdi&#287;i
iddia edilen terap�tik ajanlar&#305;n pop�laritesi de
artm&#305;&#351;t&#305;r.&nbsp;Anti-oksidanlar aras&#305;nda �zellikle de E
vitamininin koruyucu etkisi �zerinde durulmu&#351;, Rotterdam ve Kanada
Ya&#351;lanma gibi �nemli �al&#305;&#351;malarda C vitaminiyle birlikte bir
koruyucu etkileri varm&#305;&#351; gibi g�r�nse de Washington Heights-Inwood
Columbia �niversitesi Ya&#351;lanma �al&#305;&#351;mas&#305; ve Honolulu
�al&#305;&#351;mas&#305; gibi di&#287;er �nemli �al&#305;&#351;malarda ise bir
etki g�sterilememi&#351;tir.&nbsp;&nbsp;�nceden Sano ve arkada&#351;lar&#305;n&#305;n
(bir klinik �al&#305;&#351;mas&#305;nda (1997) 2000 IU/g�n dozunda E vitamininin
AH�lilerin hastal&#305;k seyirlerini yava&#351;latt&#305;&#287;&#305;n&#305;n
g�sterilmesiyle AH tedavisinin bir par�as&#305; olarak �nerilmekte olan E
vitaminin pop�laritesi daha yak&#305;n tarihli bir �al&#305;&#351;mada
(Petersen ve ark. 2005) MCI�dan demansa d�n�&#351;meyi engelleyemedi&#287;inin
g�r�lmesiyle kaybolmu&#351; gibi durmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Anti-inflamatuar ajan kullananlar aras&#305;nda AH
s&#305;kl&#305;&#287;&#305;n&#305;n daha az oldu&#287;u bir �ok g�zlemsel
�al&#305;&#351;mada g�sterilmi&#351;tir.&nbsp; Bu bulgu, s�z konusu
ajanlar&#305;n AH�deki inflamatuar s�reci tersine �evirmeleri &#351;eklinde
yorumlanm&#305;&#351;t&#305;r. Ancak, �zg�l olarak sa&#287;l&#305;kl&#305;
ya&#351;l&#305;larda demans geli&#351;imini engellemek veya AH�lilerde
hastal&#305;k seyrini yava&#351;latmak ama�l&#305; tasarlanan anti-inflamatuar
klinik �al&#305;&#351;malar&#305; ba&#351;ar&#305;l&#305; olamam&#305;&#351;t&#305;r.&nbsp;
�strojen kullanan post-menapozal kad&#305;nlarda AH�nin daha az g�r�lmesi,
�strojenin koruyuculu&#287;u �zerine yo&#287;un bir tart&#305;&#351;ma
ba&#351;latm&#305;&#351;t&#305;r.&nbsp; Ancak, Kad&#305;n
Sa&#287;l&#305;&#287;&#305; &#304;nisiyatifi �al&#305;&#351;mas&#305;nda
ya&#351;l&#305; kad&#305;nlarda �strojen replasman&#305;n&#305;n jinekolojik
kanserlerde artman&#305;n yan&#305;s&#305;ra, ayr&#305;ca demans riskini
d�&#351;�rmek bir yana tam tersine artt&#305;rd&#305;&#287;&#305;
bulunmu&#351;tur. Yine, kolesterol d�&#351;�r�c� ila�lar, �zellikle de statin
grubu kullananlarda AH prevalans&#305; kullanmayanlara g�re daha
d�&#351;�kt�r.&nbsp; Son zamanlarda bu etkinin kolesterol d�&#351;�r�c� etkinin
�tesinde, statinlerin do&#287;rudan &#945;-sekretaz proteolitik yolunu
uyararak, sAPP olu&#351;umunu artt&#305;rmalar&#305;yla ilintili oldu&#287;una
ili&#351;kin deneysel deliller bulunmu&#351;tur.&nbsp; Yine de, AH�lilerde
klinik �al&#305;&#351;malarda s&#305;nanan statin tedavisinin faydas&#305;
g�sterilememi&#351;tir. Anti-hipertansif ve anti-diabetiklerin vask�ler risk
fakt�rlerinin kontrol� arac&#305;l&#305;&#287;&#305;yla demansa kar&#351;&#305;
koruyucu olabilece&#287;i sa&#287;duyuyla da �&#305;kar&#305;mlanabilir.
Nitekim, bu �ng�r� anti-hipertansifler a�&#305;s&#305;ndan bir ka� prospektif
�al&#305;&#351;mada do&#287;rulanm&#305;&#351;t&#305;r. &#304;ns�lin degrade
edici enzimin (IDE) A&#946; klirensinde bir &#351;aperon olarak i&#351;lev
g�rd�&#287;� bilinmektedir. &#304;nsuline diren�li tip II diyabetiklerde, IDE
beyinde i&#351;lev g�rmek yerine periferde artan ins�lini par�alamak i�in
kullan&#305;lmaktad&#305;r. Dolay&#305;s&#305;yla, �zg�l olarak ins�lin
direncini d�&#351;�rerek i&#351;lev g�ren peroksizom proliferat�r� ile aktive
resept�r gamma (PPAR-&#947;) agonistleri s&#305;n&#305;f&#305;
anti-diyabetikler vask�ler risk kontrol� yan&#305;s&#305;ra potansiyel olarak
�zg�l anti-Alzheimer etki de g�sterebilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bir�ok �al&#305;&#351;mada hafif-orta alkol
t�ketiminin koruyuculu&#287;u bildirilmi&#351;, giderek bu etkinin bir U
e&#287;risi sergiledi&#287;i y�ksek t�ketimde kayboldu&#287;u ileri
s�r�lm�&#351;t�r. Alkoll� i�kiler i�inde �zellikle k&#305;rm&#305;z&#305;
&#351;arap �zerinde durulmaktad&#305;r. K&#305;rm&#305;z&#305;
&#351;arab&#305;n i�erdi&#287;i polifenoller ve �zellikle de bir uzun �m�r
fakt�r� olarak A&#946;�n&#305;n etkilerini tersine �eviren sirtuin
sinyallemesinde rol oynayan resveratrol son zamanlar&#305;n ilgi
oda&#287;&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Akdeniz diyeti bir koruyucu fakt�r olarak son
y&#305;llardaki en pop�ler �evresel fakt�r ara&#351;t&#305;rma
konular&#305;ndan biridir. Akdeniz diyeti (MeDi) ile tah&#305;llar, sebzeler,
meyvalar, peynir, s�t, �zellikle bal&#305;k, zeytinya&#287;&#305; ve
k&#305;rm&#305;z&#305; &#351;araptan zengin bir diyet kastedilmektedir.
Columbia �niversitesi MeDi �al&#305;&#351;mas&#305;, New York�ta MeDi uyumuna
g�re d�&#351;�k, orta ve y�ksek olarak
s&#305;n&#305;fland&#305;rd&#305;&#287;&#305; 1393 normal
ya&#351;l&#305;n&#305;n MCI ve 482 MCI�l&#305;n&#305;n demans geli&#351;tirme
sonlanma noktalar&#305;nda y�ksek uyum grubunun d�&#351;�k uyum grubuna g�re
avantajl&#305; oldu&#287;unu g�stermi&#351;tir. Rotterdam ve Chicago
Sa&#287;l&#305;k ve Ya&#351;lanma Projesi gibi 2 b�y�k �al&#305;&#351;mada
bal&#305;k t�ketiminin daha yava&#351; kognitif bozulmayla ili&#351;kisi
g�sterilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son olarak, zihinsel ve fiziksel aktivitenin
koruyuculu&#287;undan s�zedilebilir. Osteoporotik Frakt�rler
�al&#305;&#351;mas&#305;�nda uzunlamas&#305;na izlenen 6000 65 ya&#351; �zeri
kad&#305;n aras&#305;nda en fazla y�r�yen �st �eyrek, en az y�r�yen alt
�eyrekle kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda, 6-8
y&#305;l sonra daha az kognitif kay&#305;p sergilemekteydiler. Colcombe ve
Kramer�in meta-analizinde (2003) egzersize tabi tutulan sedanter
ya&#351;l&#305;lar&#305;n tutulmayanlarla kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda
k&#305;sa s�reli kognitif d�zelme sergiledikleri ortaya konmu&#351;tur.
Fiziksel aktivite bir yandan vask�ler riskin kontrolu
arac&#305;l&#305;&#287;&#305;yla, di&#287;er yandan da e&#287;itim i�in
oldu&#287;u gibi zengin uyarana maruz kalman&#305;n kognitif rezervi
artt&#305;rmas&#305; yoluyla etki ediyor olabilir. �ok say&#305;da
�al&#305;&#351;ma, okumak, sanatsal faaliyette bulunmak, oyun oynamak gibi
zihinsel aktivite g�steren ya&#351;l&#305;lar&#305;n AH geli&#351;tirme
risklerinin daha d�&#351;�k oldu&#287;unu ileri s�rmektedir. Wilson ve
arkada&#351;lar&#305; Chicago�da ortalama 5.3 y&#305;l izledikleri 4000
ya&#351;l&#305; aras&#305;nda, kognitif olarak stim�le edici faaliyetlere daha
s&#305;k kat&#305;lan ya&#351;l&#305;lar&#305;n daha d�&#351;�k ihtimalle
kognitif bozulma sergilediklerini g�sterdiler. Zihinsel aktivite de daha zengin
kognitif rezerv olu&#351;turarak etki ediyor olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 13.</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; Alzheimer
Hastal&#305;&#287;&#305;�nda Rol Oynayan Fakt�rler<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=300 valign=top style='width:225.15pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Risk fakt�rleri</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=266 valign=top style='width:199.45pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Koruyucu fakt�rler</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width=300 valign=top style='width:225.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Ya&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Kad&#305;n cinsiyet</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; D�&#351;�k e&#287;itim</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Ailede demans �yk�s�</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Genetik etkenler (APOE-&#949;4)</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Bilin� kay&#305;pl&#305; kafa
  travmas&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Down sendromu</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Maj�r depresyon �yk�s�</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Vask�ler olaylar</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Plazma homosistein d�zeyi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; K���k kafa �evresi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Hipotiroidi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Baz&#305; toksik ve zararl&#305;
  durumlara maruz kalma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=266 valign=top style='width:199.45pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  layout-grid-mode:char;text-autospace:ideograph-numeric'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;
  Y�ksek e&#287;itim</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; APOE-&#949;2 </span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Anti-oksidan
  kullan&#305;m&#305; (?)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;
  Anti-inflammatuar kullan&#305;m&#305; (?)</span><span lang=FI
  style='font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; �strojen
  kullan&#305;m&#305; (?)</span><span lang=FI style='font-family:Tahoma;
  mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Statin
  kullan&#305;m&#305; (?)</span><span lang=FI style='font-family:Tahoma;
  mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;
  K&#305;rm&#305;z&#305; &#351;arap</span><span lang=FI style='font-family:
  Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Akdeniz diyeti</span><span
  lang=FI style='font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp; Fiziksel ve
  zihinsel aktivite</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genetik</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH�de genetik fakt�rler b�y�k oranda
hastal&#305;&#287;&#305;n geli&#351;imi i�in �evresel fakt�rlere bir
yatk&#305;nl&#305;k zemini yaratacak &#351;ekilde birer risk fakt�r� niteli&#287;indedirler.&nbsp;
AH bu �zelli&#287;iyle Huntington hastal&#305;&#287;&#305;nda oldu&#287;u gibi
Mendelyen yasalar&#305;n etkisinde basit&nbsp; genetik belirlenimli de&#287;il
de, genetik ve �evresel fakt�rlerin karma&#351;&#305;k bir etkile&#351;imi
sonucu ortaya �&#305;kan kompleks n�rolojik hastal&#305;klardand&#305;r.&nbsp;
Yine de, t�m AH olgular&#305;n&#305;n uluslararas&#305; literat�rde %5�ine
yakla&#351;an bir oran&#305; basit Mendelyen otozomal dominant ge�i&#351;le
hastal&#305;&#287;a yakalan&#305;rlar.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genetik a�&#305;dan genel olarak kompleks
n�rolojik bir hastal&#305;k olarak nitelenmesinin yan&#305;s&#305;ra, AH
Mendelyen ge�i&#351; a�&#305;s&#305;ndan da heterojenite g�steren
polijenik/multialelik bir hastal&#305;kt&#305;r: birden fazla kromozomdaki gen
lokuslar&#305;n&#305;n �ok say&#305;da farkl&#305; mutasyonlar&#305; ayn&#305;
hastal&#305;&#287;a yola�ar.&nbsp; Otozomal dominant (OD) ge�i&#351;ten sorumlu
olan &#351;imdiye kadar 3 ayr&#305; gen bulunmu&#351;tur: amiloid prek�rs�r
protein (APP) geni (<i>APP, </i>21. kromozom), presenilin 1 geni (<i>PSEN1, </i>14.
kromozom) ve presenilin 2 geni (<i>PSEN2, </i>1. kromozom).&nbsp;&nbsp; Bu
genlerin kodlad&#305;&#287;&#305; 3 protein de normal i&#351;levleri �ok iyi
bilinmeyen, n�ronal plastisitede rol oynad&#305;klar&#305; y�n�nde
varsay&#305;mlar ileri s�r�len transmembran proteinlerdir.&nbsp; An&#305;lan
genlerdeki mutasyonlar her durumda APP proteolizini A&#946;
fragman&#305;n&#305;n �retiminin art&#305;&#351;&#305;na neden olacak yola
kayd&#305;r&#305;rlar.&nbsp; <i>APP</i> mutasyonu ta&#351;&#305;yan aileler �ok
az say&#305;da olsa da, bu mutasyonlar bir yandan amiloid metabolizmas&#305;
�zerinden hastal&#305;&#287;&#305;n patogenezine &#305;&#351;&#305;k tutarken,
bir yandan da Down sendromu ile AH aras&#305;ndaki ili&#351;kiyi de
ayd&#305;nlatm&#305;&#351;t&#305;r.&nbsp; Bilindi&#287;i gibi Down sendromlular
21. kromozomun 3 kopyas&#305;n&#305; ta&#351;&#305;rlar (21 trizomisi).&nbsp;
Dolay&#305;s&#305;yla, �m�rleri boyunca APP proteolizinden �retilecek daha
fazla A&#946;�y&#305; temizlemek zorundad&#305;rlar. Bu hastalar 30�lu
ya&#351;lardan itibaren hemen daima AH�nin n�ropatolojik
de&#287;i&#351;ikliklerini g�stermeye ba&#351;larlar.&nbsp;&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>OD-AH�liler tipik olarak erken
ba&#351;lang&#305;�l&#305; (60 ya&#351; �ncesi) hastal&#305;&#287;a
sahiptirler. OD-AH ile ili&#351;kilendirilen ilk mutasyon John Hardy
taraf&#305;ndan 1991 y&#305;l&#305;nda bildirilen <i>APP�</i>nin
yanl&#305;&#351; anlaml&#305; (missense)<i> </i>bir mutasyonudur (V717I).
Enteresan bi�imde, ayn&#305; gendeki bir ba&#351;ka mutasyon bir y&#305;l �nce
Hollandal&#305; tipi amiloidozlu serebral hemoraji ile
ili&#351;kilendirilmi&#351;ti (G693Q). Biriken veriler serebral amiloid
anjiyopatiye neden olan mutasyonlar&#305;n APP�nin </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-amiloid
b�lgesinin i�inde k�melenirken, OD-AH�ye neden olanlar&#305;n biri
d&#305;&#351;&#305;nda t�m�n�n </span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
kesim b�lgesini tutarak A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
�retimini artt&#305;rd&#305;klar&#305;, bir mutasyonun ise </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
kesim b�lgesinde hem A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, hem
de A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><sub><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>42</span></sub><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> �retimini
artt&#305;rd&#305;&#287;&#305;n&#305; g�stermektedir.&nbsp; St. George Hyslop
1995 y&#305;l&#305;nda <i>PSEN1 </i>genini klonlayarak bu gendeki AH�ye neden
olan mutasyonu tan&#305;mlad&#305;. Bu genin kodlad&#305;&#287;&#305;
Presenilin 1 proteininin (PS1) APP�nin </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
proteolizine ve ayn&#305; zamanda embriyogenez s&#305;ras&#305;nda n�ral
geli&#351;imde temel sinyalleme sistemi olan NOTCH sinyalizasyonuna
arac&#305;l&#305;k eden bir transmembran protein oldu&#287;u
anla&#351;&#305;ld&#305;. Ayn&#305; y&#305;l i�inde bu kez Schellenberg grubu
taraf&#305;ndan PS1 ile %80 homoloji ta&#351;&#305;yan Presenilin 2 (PS2)
proteinini kodlayan <i>PSEN2</i> geninde OD-AH�ye neden olan mutasyon
tan&#305;mland&#305;. G�n�m�ze kadar 76 ailede 28 ayr&#305; <i>APP</i>, 361
ailede 164 ayr&#305; <i>PSEN1</i> ve 18 ailede 10 ayr&#305; <i>PSEN2 </i>mutasyonu
bildirilmi&#351;tir. Her 2 gendeki mutasyonlar da </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivitesini etkileyerek A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n daha toksik formu olan A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
�retiminin artmas&#305;na neden olmaktad&#305;rlar. OH-AH aileleri gen�
ya&#351;ta ortaya �&#305;kmalar&#305; (<i>PS1, </i>25-60 ya&#351;; <i>APP,</i>
40-65 ya&#351;; <i>PSEN2</i>, 45-84 ya&#351;) yan&#305;s&#305;ra, bellek
d&#305;&#351;&#305; bir �ekirdek sendromla ve/veya erken davran&#305;&#351;sal
�zellikler, miyoklonus ve n�betler &#351;eklinde atipik klinik tablolarla da
�&#305;kabilirler. AH�nin ilk bildirilen olgusunun erken
ba&#351;lang&#305;�l&#305;, davran&#305;&#351;sal belirtilerin �n planda oldu&#287;u
bir tabloya sahip oldu&#287;u hat&#305;rland&#305;&#287;&#305;nda Auguste
D.�nin b�ylesi bir genetik varyasyona sahip olmas&#305; ihtimali �zerinde
durulmakla birlikte bu olgunun saklanan dokusundan yak&#305;n tarihlerde
yap&#305;lan bir �al&#305;&#351;mada <i>PSEN1 </i>mutasyonu
ta&#351;&#305;mad&#305;&#287;&#305; ve <i>APOE</i> genotipinin </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3/</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
oldu&#287;u bulunmu&#351;tur. Genel olarak <i>PSEN1</i> aileleri <i>APP </i>ailelerine
g�re daha atipik ve daha k&#305;sa s�reli ve a&#287;&#305;r demans
sergilerlerken, <i>PSEN2 </i>aileleri daha fazla sporadik AH�ye benzeyen ve
daha yava&#351; seyirli hastal&#305;k tablolar&#305;na sahiptirler.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#350;imdiye kadar tan&#305;mlanan
mutasyonlar familyal AH�nin %50�si kadar&#305;n&#305; olu&#351;tururlar ve <i>PSEN2</i>�nin
tan&#305;mlanmas&#305; �zerinden ge�en 15 y&#305;la ve yo&#287;un
ara&#351;t&#305;rmalara ra&#287;men yeni bir Mendelyen ge�i&#351; geninin
bulunamamas&#305; dikkat �ekicidir. An&#305;lan 3 genle
ba&#287;lant&#305;land&#305;r&#305;lamayan AH aileleri oldu&#287;una g�re hen�z
bulunmayan genler ve otozomal dominant olmayan ge�i&#351; bi�imleri ileri
s�r�lebilir.&nbsp; �zellikle hen�z hi� otozomal resesif ge�i&#351;
bildirilmemi&#351; olan bu hastal&#305;kta akraba evliliklerinin s&#305;k
g�r�ld�&#287;� �lkemiz b�ylesi bir bulu&#351; i�in potansiyel
ta&#351;&#305;maktad&#305;r. </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>ApoE proteinini kodlayan gen (<i>APOE</i>,
19. kromozom) mutasyonlar&#305;yla do&#287;rudan belirleyici de&#287;il fakat
polimorfizmiyle sporadik AH�de risk fakt�r� olarak ortaya konmu&#351;tur.&nbsp;
Kolesterol�n ta&#351;&#305;nmas&#305;nda rol oynayan bir protein olan ApoE,
toplam 299 rezid�s�n�n ikisinde arjinin ve/veya sistein bulunmas&#305;yla
farkl&#305;la&#351;an �� ayr&#305; alelik forma sahiptir: </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3 ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp;
Kuzey Amerika ve Kuzey Avrupa�dan normal pop�lasyonlarda en s&#305;k </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
(%70-80) g�r�l�rken, </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4��n
s&#305;kl&#305;&#287;&#305; %10-20, </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2�ninki ise
%5-10�dur.&nbsp; AH�de </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 s&#305;kl&#305;&#287;&#305;
ikiye katlanarak %40-50�ye ula&#351;&#305;r.&nbsp; </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 AH
riskini doza ba&#287;l&#305; bir &#351;ekilde artt&#305;r&#305;r ve
hastal&#305;k ba&#351;lang&#305;� ya&#351;&#305;n&#305; azalt&#305;r.&nbsp;
AlzGene veritaban&#305;nda (2007) beyazlar ve Japonlarda </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
heterozigotlar&#305;nda AH riski, </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
homozigotlar&#305;na g�re ihtimaliyet oranlar&#305; (OR�ler)
s&#305;ras&#305;yla 3 ila 4 olacak &#351;ekilde artm&#305;&#351;t&#305;r.&nbsp;</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
homozigotlar&#305;nda hastal&#305;k heterozigotlar&#305;na g�re daha erken
ba&#351;lar ve risk, OR�ler ayn&#305; gruplarda bu kez s&#305;ras&#305;yla 11.8
ve 21.8 olacak &#351;ekilde artar.&nbsp;Ayr&#305;ca, OR-AH�de de </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 varl&#305;&#287;&#305;
hastal&#305;k ba&#351;lang&#305;� ya&#351;&#305;n&#305; erkene
al&#305;r.&nbsp;Bir yatk&#305;nl&#305;k geni olan ApoE�nin </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4��n�n
varl&#305;&#287;&#305; hastal&#305;k ba&#351;lang&#305;c&#305; i�in ne zorunlu
ne de yeterlidir. Bununla birlikte </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
homozigotlar&#305;n&#305;n ya&#351;am boyu k�m�latif risklerinin %90
oldu&#287;u hesaplanm&#305;&#351;t&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
s&#305;kl&#305;&#287;&#305; ve patolojik rol� i�in co&#287;rafi
farkl&#305;l&#305;klar ileri s�r�lm�&#351;t�r. Bizim de
kat&#305;ld&#305;&#287;&#305;m&#305;z bir g�r�&#351;e g�re Avrupa�da kuzeyden
g�neye s&#305;kl&#305;&#287;&#305; azalacak &#351;ekilde bir gradyan mevcuttur.
�rne&#287;in, </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 s&#305;kl&#305;&#287;&#305;
normal pop�lasyonda kuzeyde Finlandiya�da %24 bulunurken, g�neyde Yunanistan�da
%5.6 gibi k���k bir orana kadar inmektedir.&nbsp; Biz TAPS
�al&#305;&#351;mas&#305;n&#305;n olgu-kontroll� k&#305;sm&#305;nda </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
s&#305;kl&#305;&#287;&#305;n&#305; normal kontrollerde %8.2, buna
kar&#351;&#305;l&#305;k AH grubunda %14.7 bulduk. </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 OR,
2.21 gibi AlzGene�de bildirilenlerden daha d�&#351;�k olmakla birlikte yine de
anlaml&#305; bulundu. ApoE alel s&#305;kl&#305;&#287;&#305;n&#305; d�nya
�ap&#305;nda bir meta-analizde ele alan Corbo ve Scacchi (1999) bu gradyan ve
&#949;4��n bir AH riski olu&#351;turmas&#305;nda g�zlenen etnik ve co&#287;rafi
farkl&#305;l&#305;klar i�in akla yak&#305;n bir a�&#305;klamada bulundular:
&#949;3, Akdeniz Havzas&#305; gibi kadim bir tar&#305;m
uygarl&#305;&#287;&#305;na sahip insan topluluklar&#305;nda en s&#305;k alel
gibi durmaktad&#305;r (%84.9-%89.8). Atalar&#305;n aleli denebilecek olan
&#949;4, Pigmeler (%40.7), Bantular (%37.0), Malezya ve Avustralya aborjinleri
(%24.0 ve %26.0), Papual&#305;lar (%36.8) ve Lapplar (%31.0) gibi
avc&#305;-toplay&#305;c&#305; ekonominin hala mevcut, besin
kaynaklar&#305;n&#305;n g�reli olarak k&#305;s&#305;tl&#305; oldu&#287;u
halklarda s&#305;k olsa da ba&#351;ta Sahra-alt&#305; halklarda olmak �zere bir
AH riski de&#287;ildir. Yazarlar, &#949;4��n Bat&#305;l&#305; diyet, daha uzun
ya&#351;am s�releri gibi �a&#287;da&#351; �evresel ko&#351;ullara
maruziyetinin, baz&#305; i&#351;levsel �zelliklerine dayanarak onu AH i�in bir
yatk&#305;nl&#305;k aleli haline d�n�&#351;t�rm�&#351; olabilece&#287;ini ileri
s�rd�ler. </span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#949;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>4��n hastal&#305;&#287;&#305;n patogenezindeki rol� tam
anlam&#305;yla ortaya konamam&#305;&#351; olsa da, gerek A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
klirensinde ve n�ronal plastisitede rejenerasyon ve onar&#305;mda rol oynayan
APOE�nin, bu rol�nde </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4��n, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2 ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3�e
g�re daha ba&#351;ar&#305;s&#305;z oldu&#287;una ili&#351;kin deliller
vard&#305;r.&nbsp; <i>ApoE </i>nakavt farelerde sinaptik yo&#287;unlukta
ya&#351;a ba&#287;&#305;ml&#305; bir azalma g�r�l�r.&nbsp; Kafa travmas&#305;,
serebro-vask�ler hastal&#305;k gibi beyin hasarlar&#305;ndan&nbsp; sonra </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
ta&#351;&#305;y&#305;c&#305;lar&#305; daha k�t� prognoz
g�sterirler.&nbsp;&nbsp;&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#350;imdiye kadar incelenen <i>APOE-</i></span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
d&#305;&#351;&#305; hi� bir polimorfizmin etki b�y�kl�&#287;� </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
OR�lerine yakla&#351;amam&#305;&#351;t&#305;r. Bertram ve
arkada&#351;lar&#305;n&#305;n AlzGene veritaban&#305;n&#305; kullanarak
yapt&#305;klar&#305; bir meta-analizde (2007) ba&#287;lant&#305; analiziyle o
zamana kadar 69 gende bildirilen 127 polimorfizm incelenerek 13 gendeki 20
polimorfizm pozitif olarak de&#287;erlendirilmi&#351; ve ortalama risk OR�leri
1.25, ortalama koruyucu OR�leri 0.85 olarak bulunmu&#351;tur. Bu 20 polimorfizm
aras&#305;ndan �zellikle anjiyo-tensin converting enzim (<i>ACE</i>), GRB2
asosiye ba&#287;lay&#305;c&#305; protein 2 (<i>GAB2) </i>ve transferrin<i> </i>(<i>TF</i>)
genlerindeki polimorfizmler k���k etkilerine ra&#287;men en az 10
�al&#305;&#351;mada do&#287;rulanm&#305;&#351; g�reli olarak b�y�k �rneklem
say&#305;lar&#305;yla dikkate de&#287;er ek risk fakt�rleri olabilirler. Son
zamanlarda �st�nde durulan ba&#351;ka bir yatk&#305;nl&#305;k geni de sortilin
ili&#351;kili resept�r genidir (<i>SORL1). </i>SORL1 APP�nin h�cre y�zeyinden
Golgi-endoplazmik retikulum kompleksine naklinde rol oynad&#305;&#287;&#305;
bilinmektedir. SORL1 ifadesinin azalmas&#305; A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
art&#305;&#351;&#305;na neden olmaktad&#305;r. Lee ve
arkada&#351;lar&#305;n&#305;n g�zden ge�irdi&#287;i �zere b�y�k �rneklemlerdeki
alelik asosiasyon �al&#305;&#351;mas&#305;nda 1.4 ila 2.2 aras&#305;nda OR�ler
saptanm&#305;&#351;t&#305;r. Genom Boyu Asosiasyon �al&#305;&#351;mas&#305;
(GWAS) ba&#287;lant&#305; analizinden farkl&#305; olarak bir genetik lokus ile
hastal&#305;&#287;&#305;n ili&#351;kisini �nceden teorik olarak varsaymak
gerekmeksizin, binlerce hastal&#305;k b�y�k hasta �rneklemlerini&nbsp;
kontrollerle t�m genomun analizi arac&#305;l&#305;&#287;&#305;yla
kar&#351;&#305;la&#351;t&#305;r&#305;p hastal&#305;k grubunda anlaml&#305; olarak
daha s&#305;k g�r�len varyasyonlar&#305; ortaya koymaya dayan&#305;yor. 2009
y&#305;l&#305;nda tamamlanan 2 b�y�k GWAS �al&#305;&#351;mas&#305;n&#305;n
ilkinde 5000�i a&#351;k&#305;n hasta ve 10000�i a&#351;k&#305;n kontrol�n
analizinde Harold ve arkada&#351;lar&#305; clusterin (�nceden <i>APOJ</i>
olarak bilinen) geni (<i>CLU</i>) ve 11. kromozomda bulunan
phosphatidylinositol ba&#287;layan clathrin asamble proteini geni<i> </i>(<i>PICALM</i>)<i>
</i>ile anlaml&#305; ili&#351;kiler bildirdiler. Nature Genetics�in ayn&#305;
say&#305;s&#305;nda yay&#305;nlanan 2. GWAS �al&#305;&#351;mas&#305;nda
5000�den fazla hasta ve kontrol bireylerinde Lambert ve arkada&#351;lar&#305;
8. kromozomda bulunan <i>CLU</i>�daki lokusu do&#287;rularken, bu kez 1.
kromozomdaki kompleman bile&#351;eni resept�r� 1 geninde (<i>CR1) </i>bir lokus
daha g�sterdiler. Bu 3 genin kodlad&#305;&#287;&#305; proteinlerin de A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
klirensinde rol oynad&#305;&#287;&#305; d�&#351;�n�lmektedir. �yle g�r�n�yor
ki, her &#351;eye ra&#287;men yeni yatk&#305;nl&#305;k genlerinin
ara&#351;t&#305;r&#305;lmas&#305; ve bulunanlar&#305;n do&#287;rulanmas&#305;na
y�nelik yo&#287;un �abalar s�recektir. Bu b�l�m�n bir �zeti i�in <b>Tablo 14</b>�e
bak&#305;n&#305;z.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 14. </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n geneti&#287;i<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.65pt;border-collapse:collapse;border:none;mso-border-alt:
 solid black 1.0pt;mso-padding-alt:0cm 0cm 0cm 0cm;mso-border-insideh:1.0pt solid black;
 mso-border-insidev:1.0pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gen
  ve Proteini</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kromozom</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Mekanizma</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Etki</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Risk</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>APP � </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Amiloid prek�rs�r protein</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>21</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Mutasyon/ Duplikasyon</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946;40 ve A&#946;42 �retiminde art&#305;&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Tam penetrans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>PSEN1 �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Presenilin 1 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>14</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Mutasyon</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946;42 �retiminde art&#305;&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Tam penetrans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>PSEN2 �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Presenilin 2 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Mutasyon</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946;42 �retiminde art&#305;&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Tam penetrans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>APOE � </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Apolipoprotein E </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>19</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>&#949;2, &#949;3, &#949;4</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>&#949;4: 3.68 (3.30-4.11)</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>&#949;3: 0.62 (0.45-0.85)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>ACE �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Anjiotensin I converting enzim</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>17</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>C, T</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.83 (0.72-0.95)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>GAB2 �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>GRB2 asosiye ba&#287;lay&#305;c&#305; protein 2</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>11</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, G</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.85 (0.76-0.94)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>TF �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Transferrin</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>3</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>C2, C1</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1.18 (1.06-1.31)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>SORL1 �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Sortilin ili&#351;kili resept�r</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>11</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, C</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; �retiminde artma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1.10 (1.03-1.17)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>CLU �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Clusterin</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>8</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, C</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.86 (0.82-0.89)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>PICALM �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Phosphatydinilinositol ba&#287;lay&#305;c&#305; klatrin asamble
  proteini</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>11</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>C, T</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.87 (0.83-0.91)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>CR1 �</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Kompleman bile&#351;eni (3b/4b) resept�r� 1</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, C</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1.18 (1.09-1.28)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n otozomal dominan ge�i&#351;li
formlar&#305;ndan sorumlu 3 gen ile yatk&#305;nl&#305;k geni <i>APOE </i>yan&#305;s&#305;ra
2010 Nisan ay&#305; itibariyle AlzGene veritaban&#305;ndaki (</span><span
style='font-family:Tahoma'><a href="http://www.alzgene.org/"><span lang=TR
style='mso-ansi-language:TR'>www.alzgene.org</span></a></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>) pozitif
�al&#305;&#351;malar aras&#305;nda en az 10 �al&#305;&#351;ma ve 10000�e
yakla&#351;an �rneklem b�y�kl�klerine sahip olan aday yatk&#305;nl&#305;k
genleri (<i>ACE, GAB2, TF, SORL1</i>) ile genom boyu asosiasyon
�al&#305;&#351;malar&#305;nda yak&#305;n tarihlerde ortaya konulan aday
yatk&#305;nl&#305;k genleri (<i>CLU, PICALM, CR1</i>) g�sterilmi&#351;tir.
Risk, ihtimaliyet oranlar&#305; (OR�ler) ve parantez i�lerinde %95 g�venilirlik
aral&#305;klar&#305; ile g�sterilmi&#351;tir.<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�ROPATOLOJ&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH�nin klinik tan&#305;da ba&#351;vurulabilecek
patognomik bir i&#351;aretleyicisi olmad&#305;&#287;&#305; gibi patolojik
tan&#305;s&#305; da benzer bir g��l�k ta&#351;&#305;r.&nbsp; Pick
cisimciklerinin varl&#305;&#287;&#305; PiH kesin tan&#305;s&#305; i�in gerekli
ve yeterli ko&#351;uldur.&nbsp; Oysa ki, AH kesin tan&#305;s&#305; i�in
patolojik olarak n�rofibriler yumaklar (NFY) ve senil ya da amiloid
plaklar&#305;n (AP) saptanmas&#305; gerekli ancak yeterli de&#287;ildir.&nbsp;
Her iki lezyon da normal ya&#351;lanmada oldu&#287;u gibi bir dizi ba&#351;ka
dejeneratif hastal&#305;kda da g�r�lebilir.&nbsp; AH�nin kesin tan&#305;s&#305;
i�in patolog bu iki lezyonun varl&#305;&#287;&#305;n&#305; saptaman&#305;n
yan&#305;s&#305;ra&nbsp; belli bir n�roanatomik da&#287;&#305;l&#305;mda ve
belli miktarlarda olduklar&#305;n&#305; da g�stermelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerde demansa d�n�&#351;ecek olsun ya da
olmas&#305;n normal insanlar 60 ya&#351;lar&#305;ndan itibaren neokortikal
gev&#351;ek plaklar ve bazen limbik NFY�ler geli&#351;tirmeye
ba&#351;larlar.&nbsp; Ancak titiz kliniko-anatomik korelasyon
�al&#305;&#351;malar&#305; NFY�lerin neokorteks, AP�lerin ise n�ritik veya sert
plak bi�imiyle limbik sistemde g�r�n�r olmalar&#305;n&#305;n AH i�in %100�e
yakla&#351;an duyarl&#305;l&#305;k ve �zg�ll�k g�sterdi&#287;ini ortaya
koymaktad&#305;r.&nbsp; A&#351;a&#287;&#305;da daha iyi g�r�lece&#287;i gibi,
NFY�lerin limbik sistemde birikip neokortekse ge�i&#351;i ve giderek
neokortekste yayg&#305;nl&#305;k g�stermeye ba&#351;lamas&#305;, normal ya&#351;lanma-MCI-giderek
a&#287;&#305;rla&#351;an demans devaml&#305;l&#305;&#287;&#305;n&#305;n
patolojik korelat&#305; gibi durmaktad&#305;r.&nbsp; Yine klinik evreyle
say&#305;sal ve b�lgesel a�&#305;dan korelasyon g�stermemekle birlikte
gev&#351;ekten n�ritike do&#287;ru bi�imini de&#287;i&#351;tirip limbik
sistemde g�r�l�r hale gelen AP hemen daima AH�yi MCI�dan ay&#305;ran �zelliktir
denebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>NFY&nbsp; ve AP�lerin yan&#305;s&#305;ra
gliozis-inflamasyon, n�ron ve sinaps kay&#305;plar&#305;, aksonal ve dendritik
morfolojik de&#287;i&#351;iklikler, kortikal kolinerjik innervasyon ve
di&#287;er n�rotransmitter sistemlerinde kay&#305;plar AH n�ropatolojisinin bile&#351;enlerini
olu&#351;tururlar <b>(Tablo 15).</b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 15.</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> AH N�ropatolojisi</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=315 valign=top style='width:236.0pt;border:solid black 1.0pt;
  padding:7.0pt 7.0pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�rofibriler
  yumaklar (NFY)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid plaklar (AP)</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�ron kayb&#305;</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dendritik ve aksonal
  de&#287;i&#351;iklikler</span><span lang=DA style='font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinaps kayb&#305;</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gliozis - inflamasyon</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik innervasyonun
  kayb&#305;</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er n�rotransmitter
  kay&#305;plar&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�rofibriler yumaklar</span></b><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>NFY�lerin <b>(&#350;ekil 10)</b> temel
bile&#351;eni hiperfosforile t (tau) proteinidir.&nbsp; Tau 17. kromozom
taraf&#305;ndan kodlanan mikrot�b�l asosiye proteinler (MAP) ailesinden bir
proteindir.&nbsp;Mikrot�b�ller �zellikle aksonlarda yerle&#351;ir.
Mikrot�b�llerin stabilizasyonu, sitoskeletal b�t�nl�k ve kargo vezik�llerinin
aksonal nakliyesinde �nemli roller oynar.&nbsp; Kargo vezik�lleri eskiyen
yap&#305;lar&#305;n replasman&#305; ve sinaptik aktivite i�in gerekli protein
ve enzimleri i�erir. Mikrot�b�ller tau-tubulin etkile&#351;imi ile stabilize
olabilen labil yap&#305;lard&#305;r. Bu etkile&#351;im tau proteininin
izoformuna ve fosforilizasyon durumuna ba&#287;l&#305;d&#305;r. Tau proteini
karboksi ucunda mikrot�b�llere ba&#287;lanma b�lgesi say&#305;s&#305;na g�re
��� 3 tekrar (3R), ��� ise d�rt tekrar (4R) ta&#351;&#305;yan toplam 6 izoforma
sahiptir. 4R tau mikrot�b�l stabilizasyonunda daha etkindir. &#304;kincil
mesajc&#305;lar&#305;n uyar&#305;m&#305; post-sinaptik n�rondaki t�m
intrasel�ler proteinleri oldu&#287;u gibi tauyu da protein kinazlar&#305;n
aktivitesiyle fosforile eder. Fosforile tau mikrot�b�lden ayr&#305;l&#305;r. Yine
b�t�n fosforile intrasel�ler proteinler gibi tau da i&#351;lev bittikten sonra
fosfatazlar arac&#305;l&#305;&#287;&#305;yla defosforile edilmelidir ki yeniden
mikrot�b�le ba&#287;lanabilsin. Fosforile taunun defosforilasyonundan
ba&#351;l&#305;ca sorumlu fosfataz protein fosfataz 2A�d&#305;r (PP2A). AH
patogenezinde hiperaktif kinazlar ve/veya hipoaktif fosfatazlar tau proteininin
hiperfosforilizasyonuna yola�arak mikrot�b�llere ba&#287;lanma yetene&#287;ini
bozarlar.&nbsp; Bu kinazlar aras&#305;nda �zellikle glikojen sentetaz kinaz 3</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n (GSK-3</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)
yaln&#305;z AH�de de&#287;il, di&#287;er taupatilerde de patolojik
hiperfosforilasyondan sorumlu olan enzim oldu&#287;u �zerinde
durulmaktad&#305;r. Ba&#287;lanmam&#305;&#351; hiperfosforile tau monomerleri
fiziksel konformasyonlar&#305;n&#305; de&#287;i&#351;tirerek kendi �zerlerine
katlan&#305;rlar (patolojik hatal&#305; katlanma) ve toksik oligomerlere
d�n�&#351;�rler. Tau oligomerleri bir sonraki a&#351;amada&nbsp;yine toksik
��z�lemeyen �ift sarmall&#305; filamanlara (PHF) polimerize olurlar.&nbsp;
PHF�ler &#305;s&#305; &#351;oku proteinleri ve ba&#351;l&#305;ca ubikutin
proteozom sistemlerinin devreye girmesiyle giderek intran�ronal NFY�ler
&#351;eklinde kondanse olurlar (<b>&#350;ekil 11</b>).&nbsp; NFY�lerin toksik
PHF�lerin etkisini s&#305;n&#305;rlamaya �al&#305;&#351;an bir savunma
mekanizmas&#305; oldu&#287;u giderek ge�erlilik kazanan bir g�r�&#351;t�r.
Yetersiz bir savunma olan NFY ile sonunda h�cre iskeleti b�t�nl�&#287;� ve
aksonal nakliye bozularak h�cre �l�m� meydana gelir.&nbsp; H�cre �l�m�yle
ortaya �&#305;kan ekstrasel�ler NFY�ye </span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>hayalet yumak� ad&#305; verilir. NFY�den hayalet
yuma&#287;a ge�i&#351;in y&#305;llar&#305; kapsayan uzun bir s�re� oldu&#287;u
d�&#351;�n�lmektedir.&nbsp;&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span style='font-size:10.0pt;font-family:Tahoma'><a
href="demans10.JPG"><span lang=TR style='mso-ansi-language:TR'>&#350;ekil 10.</span></a></span></b><b><span
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ntrasel�ler
N�rofibriler Yumak</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>(Kaynak: </span><span style='font-size:10.0pt;font-family:
Tahoma'><a href="http://www-medlib.med.utah.edu/WebPath/CNSHTML/CNS094.html"><span
lang=TR style='mso-ansi-language:TR'>http://www-edlib.med.utah.edu/WebPath/CNSHTML/CNS094.html</span></a></span><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>NFY�ler beyinde rasgele de&#287;il
fakat belli bir b�lgesel yatk&#305;nl&#305;&#287;&#305; yans&#305;tacak &#351;ekilde
yerle&#351;irler.&nbsp; Normal ya&#351;l&#305;l&#305;k s�recinde limbik
(entorhinal ve hippokampal) NFY say&#305;s&#305;yla kronolojik ya&#351;
aras&#305;nda korelasyon g�sterilmi&#351;tir. Braak ve Braak�&#305;n I ve II.
evrelerine kar&#351;&#305;l&#305;k gelen bu a&#351;aman&#305;n
sa&#287;l&#305;kl&#305; ya&#351;lanmadan ya&#351;la ilintili unutkanl&#305;&#287;a
(AAMI) ge�i&#351;in n�ral altyap&#305;s&#305; oldu&#287;u ileri s�r�lebilir. En
erken de&#287;i&#351;iklikler entorhinal korteksin (ECx) II. molek�ler
tabakas&#305;nda olu&#351;maktad&#305;r. ECx limbik sistemin d&#305;&#351;
d�nyayla aray�z� olarak de&#287;erlendirilebilir. Hat&#305;rlanmak �zere
kaydedilmesi gereken her t�rl� yeni bilgi limbik sisteme ECx II
arac&#305;l&#305;&#287;&#305;yla girer ve bu tabakadaki n�ronlar&#305;n
aksonlar&#305; perforan yolu olu&#351;turarak ECx�i hippokampal formasyonun
giri&#351; kap&#305;s&#305; denilebilecek olan dentat girusunun (DG) gran�ler
tabakas&#305;na ba&#287;larlar. DG epizodik (otobiyografik) bellek sistemindeki
bilgi i&#351;lemenin n�ral altyap&#305;s&#305; olan 2 kapal&#305; devrenin
yolaklar&#305;n&#305; ta&#351;&#305;r: lokal intrensek hippokampal devre ve
geni&#351; boyutlu Papez devresi (<b>&#350;ekil 12</b>). Her iki devre de
nihayetinde subikulum arac&#305;l&#305;&#287;&#305;yla&nbsp; ECx alt tabakalar&#305;na
(IV-VI) ba&#287;lanarak kapanacak ve ECx IV-VI i&#351;lenmi&#351; limbik
bilgiyi multimodal asosiasyon kortekslerine geri bildirebilecektir.
&#304;ntrensek hippokampal devre i�inde DG yosunsu lifler
arac&#305;l&#305;&#287;&#305;yla Ammon boynuzunun 3. sekt�r�n�n (CA3) piramidal
tabakas&#305;na ba&#287;lan&#305;r. Shaffer kollateralleri bu kez CA3�� CA1�e
ba&#287;larlar. CA1 ise subikuluma ba&#287;lan&#305;r. Subikulum hippokampal
formasyonun bu kez �&#305;k&#305;&#351; kap&#305;s&#305; konumundad&#305;r ve
yukarda de&#287;inildi&#287;i gibi her 2 devrenin de sonland&#305;&#287;&#305;
yap&#305;d&#305;r. Papez devresi ise DG�den fimbria-fornix
arac&#305;l&#305;&#287;&#305;yla hipotalamusun mamiller cisimciklerine (CM)
olan ba&#287;lant&#305;yla ba&#351;lar. CM, mamillo-talamik traktus (MTT)
arac&#305;&#287;&#305;yla talamusun limbik �ekirdekleri de denilen anterior
grup �ekirdeklerine ba&#287;lan&#305;r.&nbsp; Talamus anterior grubu posterior
singulat girusla (pCG), pCG ise retrosplenial girusla (rSG)
ba&#287;lant&#305;l&#305;d&#305;r. rSG�den subikuluma olan
ba&#287;lant&#305;larla Papez devresi kapan&#305;r. AH�de n�rodejenerasyonun
a&#287;&#305;rl&#305;&#287;&#305; ve s�resiyle paralel bi�imde NFY�nin �nceden
g�r�ld�&#287;� bir b�lgedeki say&#305;s&#305; artarken o b�lgeyle
ba&#287;lant&#305;l&#305; olan kom&#351;u b�lgeye transsinaptik olarak
yay&#305;l&#305;r.&nbsp; Dolay&#305;s&#305;yla, ECx II dejenerasyonuyla DG
diskoneksiyonu ve bunun sonucunda meydana gelen ve sadece CA3��n sahip
oldu&#287;u ve girdilerinin %95�ini ol&#305;u&#351;turan oto-asosiyatif
liflerince sa&#287;lanan kompansatuar CA3 a&#351;&#305;r&#305; aktivitesinin
sonucu olan de&#287;i&#351;erek reorganize olan intrensek hippokampal devre
AAMI�daki bellek bozuklu&#287;unun n�ral temeli olabilir. Braak ve Braak, I�den
VI�ya s&#305;ralad&#305;klar&#305; evreler boyunca NFY�lerin entorhinal
kortekste g�r�lmeye ba&#351;lay&#305;p �nce hippokampus ve sonra da paralimbik
alanlara, sonunda da heteromodal neokortikal alanlara yay&#305;l&#305;p
say&#305;lar&#305;n&#305;n art&#305;&#351;&#305;n&#305; izleyen bir evreleme
sistemi geli&#351;tirdiler.&nbsp; Mesulam, Braak ve Braak sistemine paralel bir
klinokopatolojik korelasyon evrelemesi �nererek (<b>&#350;ekil 13</b>) NFY
yay&#305;l&#305;m&#305;n&#305; normal ya&#351;lanmadan MCI, hafif ve
a&#287;&#305;r demans evreleri s�reklili&#287;i i�inde izler. Bu evreler
boyunca intrensek hippokampal devrenin ve Papez devresi
yap&#305;lar&#305;n&#305;n giderek daha fazla NFY ile y�klendikleri ilerleyici
s�re� AH�nin AAMI-MCI-demans s�reklili&#287;i boyunca merkezi ilerleyici bellek
bozuklu&#287;u fenotipinin de a�&#305;klamas&#305;d&#305;r.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AH�nin yerle&#351;ik tedavisi i�inde
yeralan ajanlardan biri olan memantinin in vitro olarak PP2A agonizmas&#305;
yapt&#305;&#287;&#305;na dair deliller AH�lilerle yap&#305;lan k���k bir
�al&#305;&#351;mada �al&#305;&#351;ma sonunda BOS fosfo-tau d�zeylerinde
g�sterilen d�&#351;me ile desteklenmi&#351;tir. GSK3</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
inhibit�rleri (�rne&#287;in, lityum, valproat, thiadiazolidindionlar [TDZD�ler:
NP-13])&nbsp; ve mikrot�b�l stabilizat�rleri (�rne&#287;in, paclitaxel,
davunetide [AL-108]) erken klinik geli&#351;im a&#351;amas&#305;ndaki anti-tau
stratejiler aras&#305;ndad&#305;r. Fosfo-tau immunizasyonuna ili&#351;kin
ba&#351;ar&#305;l&#305; bir pre-klinik �al&#305;&#351;ma mevcuttur .</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans11.JPG">&#350;ekil 11.<span
style='font-weight:normal'>&nbsp;</span></a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Mikrot�b�l
asosiye tau proteinin NFY�ye evrimi</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�� veya d�rt tekrar b�lgesinden mikrot�b�le
ba&#287;l&#305; olan tau proteini hiperaktif kinazlar (�zellikle GSK3&#946;)
ve/veya hipoaktif fosfatazlar&#305;n (�zellikle PP2A) varl&#305;&#287;&#305;nda
hiperfosforile olarak mikrot�b�llerden serbestler. Serbest tau patolojik olarak
katlanarak oligomerle&#351;ir. Oligomerler �ift sarmall&#305; filamanlara (PHF)
kondanse olurlar. PHF ise &#305;s&#305; &#351;oku proteinleri (�zellikle HSP90)
ve proteozomal ubikutinizasyon sistemi arac&#305;l&#305;&#287;&#305;yla
NFY�lere hapsolunurlar.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar:
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>GSK3&#946;: glikojen sentetaz kinaz 3&#946;; HSP: &#305;s&#305; &#351;oku
proteini; MAP: mikrot�b�l asosiye protein; NFY: n�rofibriler yumak; P: fosfor;
PHF: �ift sarmall&#305; filaman; PP2A: protein fosfataz 2A</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans12.JPG">&#350;ekil 12.</a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
&#304;ntrensek hippokampal ve Papez devreleri</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multimodal
asosiasyon alanlar&#305; ECx�in �st tabakalar&#305; ile ileri besleme
ba&#287;lant&#305;lar&#305;na sahiptir. ECx II molek�ler tabaka perforan yol
arac&#305;l&#305;&#287;&#305;yla hippokampal formasyonun giri&#351;
kap&#305;s&#305; DG�nin gran�ler tabakas&#305;na ba&#287;lan&#305;r. DG fornix
arac&#305;l&#305;&#287;&#305;yla Papez, yosunsu lifler
arac&#305;l&#305;&#287;&#305;yla intrensek hippokampal devreyi
ba&#351;lat&#305;r. Her 2 devre de hippokampal formasyonun �&#305;k&#305;&#351;
kap&#305;s&#305; olan subikulumun �zerine d�ner. Subikulum ECx alt
tabakalar&#305; arac&#305;l&#305;&#287;&#305;yla multimodal asosiasyon
kortekslerine limbik geri besleme yapar. CA3��n %95 girdisi kendi
oto-asosiyatif lifleri arac&#305;l&#305;&#287;&#305;ylad&#305;r. Perforan yol
CA3�e bir kollateral verir. ECx III�den CA1 ve subikuluma do&#287;rudan
ba&#287;lant&#305;lar mevcuttur.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar:
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Ant. Th: talamus anterior grup �ekirdekler;<b> </b>CA1 ve 3: cornu ammonis
1 ve 3; CM: corpus mamillare; DG: dentat girus; ECx: entorhinal
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; korteks; pCG: posterior singulat girus; rSG:
retrosplenial girus.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans13.JPG">&#350;ekil 13.</a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR;mso-bidi-font-weight:bold'><span
style='mso-spacerun:yes'>�</span>N�rofibriler yumaklar&#305;n zaman ve uzamsal
ilerleyi&#351;i. Kaynak 29�dan modifiye edilmi&#351;tir. </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'>+ say&#305;s&#305; ve giderek koyula&#351;an renk gradyan&#305;
artan NFY y�k�n� temsil etmektedir. AAMI: Ya&#351;la ilintili bellek bozuklu&#287;u;
MCI: Hafif kognitif bozukluk.&nbsp;</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid plaklar ve Amiloid-</span></b><b><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span></b><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Fizyopatolojisi</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AH�deki ikinci temel n�ropatolojik
de&#287;i&#351;iklik olan ve NFY�lerin tersine y�kleri hastal&#305;k &#351;iddetiyle
korele etmeyen senil plaklar&#305;n (<b>&#350;ekil 14</b>) amiloid maddelere
y�ksek afiniteli Kongo k&#305;rm&#305;z&#305;s&#305; ile
boyand&#305;&#287;&#305; 1927�de Divry taraf&#305;ndan g�sterilmi&#351;, bir
dizi farkl&#305; morfolojik yap&#305;da olsalar da ana bile&#351;enlerinin
amiloid beta peptidi (A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>) oldu&#287;u 1984�te Glenner
ve Wong taraf&#305;ndan bildirilmi&#351;tir (yani, senil plak = amiloid
plak).&nbsp; Yukarda genetik b�l�m�nde s�zedildi&#287;i gibi A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, 21.
kromozomda kodlanan ve i&#351;levi tam olarak
anla&#351;&#305;lamam&#305;&#351;sa da bir sinaptik adhezyon proteini
oldu&#287;u d�&#351;�n�len bir transmembran protein olan amiloid prek�rs�r
proteininin (APP) metabolizma �r�nlerindendir.&nbsp; APP geninin
yokedildi&#287;i transjenik farelerde (APP nakavt) n�ral plastisitede rol�
olabilece&#287;ini d�&#351;�nd�ren &#305;l&#305;ml&#305; bulgular mevcuttur.&nbsp;
APP yoklu&#287;u onun gibi davranan ve �amiloid prek�rs�r benzeri proteinler�
ad&#305; verilen APLP1 ve APLP2 taraf&#305;ndan kompanse ediliyor olabilir.
Nitekim, APP/APLP2 �ifte nakavtlar sa&#287; kalamamaktad&#305;r. </span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B�t�n transmembran proteinlerde
oldu&#287;u gibi APP�nin de bir h�crei�i karboksi ucu (CT), bir membran kateden
par�as&#305;, bir de h�cred&#305;&#351;&#305; amino ucu (NT) vard&#305;r (<b>&#350;ekil
15</b>).&nbsp; 770, 751 ve 695 rezid�l�k 3 alternatif ba&#287;lanm&#305;&#351;
izoformu olan APP�nin intramembran�z par�as&#305; 700-723. rezid�lere rastlar. </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-amiloid,
671 ila 711-713. rezid�ler aras&#305;nda yeralan 40 veya 42 rezid�l�k distal
k&#305;sm&#305; ekstrasel�ler, proksimal k&#305;sm&#305; intramembran�z
yerle&#351;mi&#351; bir par�as&#305;d&#305;r.&nbsp; APP bir dizi proteolitik
enzimle&nbsp; kesilerek metabolize edilir.&nbsp;Bu enzimlere </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
adlar&#305; verilir.&nbsp; </span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
APP�yi tam da A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>n&#305;n ortalar&#305;na raslayan 687. ekstrasel�ler
b�lgede keser.&nbsp;Bu kesim sonunda distalde parenkime at&#305;lan ��z�lebilir
APP ya da sAPP</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ad&#305; verilen ekstrasel�ler
par�a olu&#351;urken geride hala membrana ba&#287;l&#305; 83 rezid�l�k
C-teminal fragman&#305;-</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> (CTF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)
kal&#305;r.&nbsp; sAPP</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>n&#305;n h�cre k�lt�rlerinde n�rotrofik etkileri
bulunmu&#351; ve APP nakavt transjeniklerdeki plastisite defisitlerini geri
�evirdikleri g�sterilmi&#351;tir.&nbsp; Oysa ki, alternatif distal kesimi yapan
</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>-sekretaz enzimi APP�yi A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>y&#305; salim b&#305;rakacak
&#351;ekilde, ekstrasel�ler b�lgede </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz&#305;n
daha distalinden 671. pozisyondan keserek akson budanmas&#305; ve
dejenerasyonuna neden oldu&#287;u d�&#351;�n�len distal par�a sAPP</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>y&#305; parenkime atar ve geride salim
A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> fragman&#305;n&#305; da i�eren 99 rezid�l�k membrana
ba&#287;l&#305; CTF-</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>y&#305; b&#305;rak&#305;r. Proksimal kesme ise
intramembran�z b�lgede a&#287;&#305;rl&#305;kla 711, daha az olarak 713.
pozisyondan </span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#947;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>-sekretaz enzimi
arac&#305;l&#305;&#287;&#305;ylad&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz CTF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>y&#305; kesti&#287;inde bu kez
parenkime A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'>�</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>n&#305;n
budanm&#305;&#351; ve zarars&#305;z p3 ad&#305; verilen
par�ac&#305;&#287;&#305; at&#305;l&#305;rken, geride kalan CTF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
taraf&#305;ndan biraz daha proksimalde, </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> pozisyonundan
(720/721) bir kez daha kesilmesiyle n�kleer sinyallemede rol
oynad&#305;&#287;&#305; bulunan amiloid intrasel�ler domeni (AICD) isimli
fragman sitoplazmaya sal&#305;n&#305;r.&nbsp; Buna kar&#351;&#305;l&#305;k, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
CTF-</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'>�</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>y&#305;
kesti&#287;inde 711 veya 713. pozisyonlardan kesilmeye g�re daha
a&#287;&#305;rl&#305;kla A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, daha
az oranda da, daha toksik formu olan A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>fragman&#305;,
yani klirensi ba&#351;ar&#305;yla sa&#287;lanamazsa amiloid plaklarda birikecek
materyel ortaya �&#305;kar.&nbsp; Normal ya&#351;lanmada </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivitesi bask&#305;nken, AH�de denge </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
alternatifine kaymaktad&#305;r. Yine yukarda genetik b�l�m�nde s�zedildi&#287;i
gibi OD-AH �zellikle A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�retimini
artt&#305;r&#305;rken ba&#351;ta APOE olmak �zere b�t�n yatk&#305;nl&#305;k
genleri A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> klirensini etkileyerek risk olu&#351;turmakta veya
koruyucu olmaktad&#305;rlar.&nbsp; </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivitesini �ok say&#305;da transmembran proteinin proteolizinde g�revli olan
bir disintegrin ve metalloproteinaz (ADAM) ailesinden bir dizi
metalloproteinaz&#305;n yerine getirdi&#287;i bilinmektedir. Bunlar
aras&#305;nda en aktiflerinden biri ADAM17 olarak da bilinen t�m�r nekrotizan
fakt�r-</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#945;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> �evirici enzim (TACE), di&#287;eri ADAM10�dur. </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz&#305;n
son y&#305;llarda 11. kromozomdaki geni de bulunarak karakterize edilmi&#351;
ve BACE (beta-site APP cleaving enzyme) ad&#305; verilmi&#351;tir.&nbsp; BACE
nakavt farelerde kayda de&#287;er bir de&#287;i&#351;iklik olmamakla birlikte
APP/PS1 gibi son derece virulan bir AH transjeni&#287;i ile
�aprazla&#351;t&#305;r&#305;lan BACE nakavt farelerin soyunda, plak birikimi
i�in BACE�in temel �nemde oldu&#287;unu g�sterecek &#351;ekilde plak birikimi
olmamaktad&#305;r. Bu da </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz inhibisyonunu �ekici
bir tedavi hedefi k&#305;lmaktad&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz&#305;n
ise aktif b�lgesinde presenilini de i�eren ayr&#305;ca nikastrin, APH-1 ve
PEN-2 isimli proteinlerden olu&#351;an bir proteaz kompleksi oldu&#287;u
bilinmektedir. Daha �nce de s�zedildi&#287;i gibi PS1 ayn&#305; zamanda
n�ro-geli&#351;imde temel olan NOTCH sinyalizasyonunda da rol oynamaktad&#305;r
ve PS1 nakavt fareler a&#287;&#305;r geli&#351;imsel kusurlar sergileyerek
sa&#287; kalamamaktad&#305;rlar.&nbsp;</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Parenkimdeki A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
monomerleri kendi ba&#351;&#305;na zarars&#305;zd&#305;r ve mikroglia
taraf&#305;ndan do&#287;rudan fagositoza maruz b&#305;rak&#305;ld&#305;klar&#305;
gibi APOE alelik formlar&#305;, ins�lin degrade edici enzim (IDE), </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2-makroglobulin
(</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#945;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>2-MG), neprilizin ve matriks metalloproteinaz (MMP) gibi
proteinleri i�eren bir dizi �&#351;aperon molek�le� ba&#287;lan&#305;p,
d�&#351;�k dansiteli lipoprotein resept�r� ili&#351;kili protein (LRP-1)
arac&#305;l&#305;&#287;&#305;yla astrosit ve n�ronlara internalize edilerek
otofaji ve proteozomal degradasyona maruz b&#305;rak&#305;l&#305;rlar. LRP1
farkl&#305; h�cre tiplerinde A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n internalizasyonu i�in bir
kap&#305;c&#305; olarak d�&#351;�n�lebilir ve nitekim vask�ler endotelinden
sirk�lasyona aktar&#305;l&#305;rak temizlenmeye de arac&#305;l&#305;k eder.
Degradasyon ve klirens arac&#305;l&#305;&#287;&#305;yla ba&#351;a
�&#305;k&#305;lamayan miktarlardaki monomerler bir araya gelerek dimer ve
trimerler &#351;eklinde ��z�lebilir A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomerlerini olu&#351;turacaklard&#305;r. Oligomerler par�alanarak �amiloid
betadan t�reyen dif�ze olabilen ligandlara� (ADDL�ler) de&#287;i&#351;ebilirler
veya toplanmay&#305; s�rd�rerek bir sonraki a&#351;amada art&#305;k ��z�lemeyen
protofibrilleri ve giderek toksik fibrilleri olu&#351;tururlar. ADDL�ler
aras&#305;nda NT�de ilk 2 resid�s� budanm&#305;&#351; ve piroglutamatla
de&#287;i&#351;tirilmi&#351; A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> [A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
(3(pE)-42)] toksik potansiyeli ve birikime yatk&#305;nl&#305;&#287;&#305; en
fazla bi�im olarak ilgi �ekmeye ba&#351;lam&#305;&#351;t&#305;r. A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
fragman&#305;n&#305;n �nce oligomerizasyonu, sonra da fibrilizasyonuna amino
ucuna yak&#305;n bir konumda bulunan a&#287;&#305;r metal
ba&#287;lay&#305;c&#305; b�lgelerinin arac&#305;l&#305;k etti&#287;i
d�&#351;�n�lmektedir. Buna g�re, Cu<sup>++ </sup>ba&#287;lanmas&#305;
oligomerizasyon, Zn<sup>++ </sup>ba&#287;lanmas&#305; fibrilizasyon i�in
gereklidir. Zn<sup>++ </sup>yan&#305;s&#305;ra metal ba&#287;lay&#305;c&#305;
b�lgenin yak&#305;nlar&#305;ndaki proteoglikan polisakkarid makromolek�lleri
ba&#287;layan ba&#351;ka bir b�lgenin de fibrilojenezde etkili oldu&#287;u
bildirilmi&#351;tir. Fibriler A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> plaklara
�hapsedilecektir�.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#304;lk birikim NFY�lerin tersine
limbik sistemde de&#287;il, neokortekste ve gev&#351;ek (dif�z) plaklar
&#351;eklindedir.&nbsp;Bu plaklardaki amiloidin b�y�k �o&#287;unlukla fibriler
de&#287;il gran�ler A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomerlerini i�erdikleri
bulunmu&#351;tur. Gev&#351;ek plaklar kognitif bozukluk geli&#351;tirmeden
�lm�&#351; olan ya&#351;l&#305; beyinlerinde de b�y�k miktarlarda g�r�lebilir.
Ayr&#305;ca AH�lilerde hastal&#305;&#287;&#305;n semptomatolojisine katk&#305;da
bulundu&#287;u d�&#351;�n�lmeyen striatum, talamus ve serebellum gibi
b�lgelerde �evrelerinde gliozis ve n�ritik sitopatolojik
de&#287;i&#351;iklikler olmaks&#305;z&#305;n g�r�lebilirler. Ayr&#305;ca, �ok
say&#305;da immunositokimyasal �al&#305;&#351;ma ile gev&#351;ek plak
i�eri&#287;inin daha toksik ve birikime yatk&#305;n ba&#351;l&#305;ca A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> formu
oldu&#287;unu g�r�lm�&#351;t�r. Dolay&#305;s&#305;yla, plak olu&#351;umu A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
monomerinden birikime do&#287;ru giden bir patogenetik mekanizman&#305;n daha
olgun bir evresinden �ok hastal&#305;&#287;&#305;n demans �ncesi
a&#351;amas&#305;ndaki bir savunma mekanizmas&#305; olarak d�&#351;�n�lebilir:
degradasyon ve klirens mekanizmalar&#305;yla A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ile&nbsp;
ba&#351;a �&#305;k&#305;lmakta bu mekanizmalar A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>i�in
yetersiz kald&#305;&#287;&#305;nda plak formasyonu yoluna gidilmektedir. Buna
kar&#351;&#305;l&#305;k di&#287;er plak formu olan kat&#305; (kompakt) plaklar
�ekirde&#287;ini beta katlanm&#305;&#351; fibriler A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n olu&#351;turdu&#287;u
plaklard&#305;r, Bu a&#351;amadan sonra dejenere n�ritler i�eren kat&#305;
plaklara n�ritik plaklar ad&#305; verilir.&nbsp; N�ritik plaklar immun
cevab&#305; tetikleyerek mikroglia ve astrosit aktivasyonu ile TNF-&#945; ve
IL-&#946; gibi sitokinlerin sal&#305;n&#305;m&#305;, kompleman aktivasyonu ve
serbest radikal olu&#351;umuna neden olurlar. Bu immun aktivasyon
n�rotoksisitenin ba&#351;l&#305;ca etmenlerindendir gibi durmaktad&#305;r.
N�ritik plaklar yaln&#305;zca demansl&#305; beyinlerde g�r�l�r.&nbsp; N�ritik
bile&#351;en sinaptik art&#305;k ve n�rofilamanlardan olu&#351;ur ve �o&#287;u
ayn&#305; zamanda t-PHF i�in de pozitif immunoreaksiyon g�sterir.&nbsp; PHF(+)
plaklarda n�ritik bile&#351;enin NFY i�eren akson kal&#305;nt&#305;lar&#305;
oldu&#287;u s�ylenebilir.&nbsp; B�ylelikle b�lgesel olarak farkl&#305;
ba&#351;lang&#305;� yatk&#305;nl&#305;klar&#305;na sahip olan NFY ve AP�ler
hastal&#305;&#287;&#305;n seyri i�inde PHF(+) plaklarla birlikte yan yana
gelmi&#351; olurlar.&nbsp;N�ritik plaklar tam boy A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ve A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nin
her ikisini de i�erdikleri gibi ADDL�leri de i�erirler. Bunlar aras&#305;nda
yukarda en toksik oldu&#287;u s�ylenilen amino ucundan budanm&#305;&#351; A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
(3(pE)-42 formu demans &#351;iddetine korele edecek &#351;ekilde Braak ve Braak
evre IV-VI boyunca n�ritik plak kompozisyonundaki oran&#305; giderek artar. Bu
bulgu da yaln&#305;zca demansl&#305; beyinlerde g�r�len bu daha olgun plak
formunun da bizzat kendisinin bir tetik�i olmas&#305;ndan �ok alternatif
savunma mekanizmalar&#305;n&#305;n �ok yetersiz kald&#305;&#287;&#305;
n�rodejenerasyonun bu ileri a&#351;amalar&#305;na �zg� bir ek savunma
giri&#351;imi oldu&#287;unu d�&#351;�nd�rmektedir. Son zamanlarda
A&#946;�n&#305;n �zellikle A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> (3(pE)-42
formu ile agrezom ad&#305; verilen intran�ronal birikintilerde birikti&#287;ine
dair �al&#305;&#351;malar artmaktad&#305;r. Bu �al&#305;&#351;malar sonucunda
intran�ronal birikimin sinaps ve n�ron kayb&#305;na neden olan, ekstrasel�ler
plak birikimini �nceleyen erken bir fenomen oldu&#287;u ileri s�r�lm�&#351;t�r.
Bu yeni bulgular &#305;&#351;&#305;&#287;&#305;nda A&#946; monomerinden n�ritik
pla&#287;a do&#287;ru evrim eski perspektifle oldu&#287;u gibi giderek daha
zararl&#305; bir forma do&#287;ru �izgisel bir evrilme &#351;eklinde de&#287;il
de toksik A&#946; oligomeri ile farkl&#305; a&#351;amalarda ba&#351;a
�&#305;kma stratejileri olarak g�r�lmelidir. Degrade edilemeyen toksik
A&#946;�n&#305;n fibrilizasyonu ve sonras&#305;nda da plaklara hapsolunmas&#305;
toksisitesinin giderilmesine y�nelik �nlemler olmakla birlikte, bu ��z�lemeyen
birikintilerle ��z�n�r oligomerik formlar aras&#305;nda s�rekli bir dinamik
dengenin mevcudiyeti asl&#305;nda bu formlar&#305;n toksik bi�imler i�in
s�rekli bir rezervuar i&#351;levi g�rmeleri anlam&#305;na gelmektedir. A&#946;
oligomerinin yola�t&#305;&#287;&#305; sinaptik disfonksiyon ve giderek n�ron
kayb&#305;n&#305; �nceleyen ve a&#351;an sinaps kayb&#305; mekanizmalar&#305;na
a&#351;a&#287;&#305;da de&#287;inilecektir.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AP y�k�n�n AH�de demans
&#351;iddetiyle korele etmedi&#287;ini g�steren n�ropatolojik
�al&#305;&#351;malar&#305;n �tesinde, PIB�den ba&#351;layarak PET amiloid ligandlar&#305;n&#305;n
geli&#351;tirilmesinden sonra AP y�k�n�n bir k&#305;s&#305;m kognitif
yak&#305;nmas&#305; olmayan ya&#351;l&#305;lar ve bir k&#305;s&#305;m
MCI�l&#305;larda AH tan&#305;s&#305; alm&#305;&#351; demansl&#305;lar d�zeyine
yakla&#351;t&#305;&#287;&#305;, hatta AP y�k� a�&#305;s&#305;ndan AH�ye
benzeyen MCI</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'>�</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>l&#305;lar&#305;n
uzunlamas&#305;na izlemlerinde demansa d�n�&#351;t�kleri, bir kez demans
geli&#351;tikten sonra ise AP y�k�n�n fazlaca de&#287;i&#351;medi&#287;i ortaya
konmu&#351;tur. PET ile �l��len amiloid y�k� esas olarak MCI�dan da �nce
pre-klinik a&#351;amada ilerleyici olarak art&#305;yor, pre-demans MCI ve
demans a&#351;amalar&#305;nda ise b�y�k �l��de de&#287;i&#351;meyecek denge
durumuna ula&#351;&#305;yor gibi durmaktad&#305;r.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> monomerinin
�retiminin engellenmesinden ba&#351;layarak t�m ��z�lebilir ve ��z�lemez
formlar&#305;n&#305;n klirensini desteklemek gelece&#287;in temel tedavi
stratejisi gibi durmaktad&#305;r. APP proteolizini non-amiloidojenik y�ne
kayd&#305;rmak ama�l&#305; bir spesifik </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivat�r� (NP-17) ilk kez klinik �al&#305;&#351;ma evresine kadar
ula&#351;m&#305;&#351;t&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
inhibisyonu yukarda s�zedilen nedenlerle daha �ekici bir hedef gibi g�r�nse de
spesifik k���k molek�ll� ajanlar&#305;n geli&#351;tirilmesi a�&#305;s&#305;ndan
geride kalm&#305;&#351;t&#305;r. Yak&#305;n tarihlerde bir ajan (CTS-21166) ilk
kez bir faz I �al&#305;&#351;mada ba&#351;ar&#305;yla s&#305;nanm&#305;&#351;,
bir di&#287;eri i�in de (HPP854) faz I �al&#305;&#351;mas&#305; i�in ba&#351;vuruda
bulunuldu&#287;u bildirilmi&#351;tir. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
inhibisyonu hedefi, yine yukarda s&#305;ralanan nedenlerle problemli gibi
g�r�nse de s&#305;nanan b�yle bir ajan (flurizan) faz III�e kadar gelip bu
noktada tak&#305;lm&#305;&#351;, di&#287;eri (semagacestat) ise halen olduk�a
b�y�k boyutlu bir faz III�te s&#305;nanmaktad&#305;r. Do&#287;al klirens
mekanizmalar&#305; yetersiz kald&#305;&#287;&#305;nda immunizasyon
arac&#305;l&#305;&#287;&#305;yla ba&#351;a �&#305;kma �abas&#305; �ekici bir
hedeftir. Nitekim, tam boy A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> peptidine
kar&#351;&#305; geli&#351;tirilen antijenle ba&#351;lat&#305;lan bir faz IIa
�al&#305;&#351;mas&#305; (AN1792) hastalar&#305;n bir b�l�m�nde geli&#351;en
meningoensefalit nedeniyle durduruldu. �len bir olgunun otopsisinde
anti-amiloid etki i�in tetiklenen h�moral immunite cevab&#305;
yan&#305;s&#305;ra inflamasyonun nedeninin ayr&#305;ca tetiklenen T-h�cre
cevab&#305; oldu&#287;u ileri s�r�ld�. H�cresel immuniteyi tetiklemeden sadece
h�moral immuniteyi tetikleyecek bir y�ntem �zerinde �al&#305;&#351;an
ara&#351;t&#305;r&#305;c&#305;lar sonunda h�cresel cevab&#305;n A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>nin C-terminaline kar&#351;&#305;
geli&#351;ti&#287;ini, N-terminalini i�eren 5-6 rezid�l�k budanm&#305;&#351;
epitoplar&#305;n terap�tik olarak yeterli h�moral cevaba neden oldu&#287;unu
buldular. Sonras&#305;nda humanize monoklonal A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
antikorlar&#305;yla pasif immunizasyonun da ba&#351;ar&#305; &#351;ans&#305;
y�ksek bir m�dahele bi�imi oldu&#287;u ortaya kondu. Halen �ok say&#305;da
aktif (�rne&#287;in, ACC-001, CAD106, V-950) ve pasif (�rne&#287;in,
bapineuzumab, LY2062430) immunizasyon ajan&#305; klinik �al&#305;&#351;malar&#305;n
�e&#351;itli evrelerinde s&#305;nanmaktad&#305;r. Sekretaz mod�lasyonu ve
immunizasyonun yan&#305;s&#305;ra A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> monomerinin
toksik olgun bi�imlerine d�n�&#351;mesini engelleme stratejileri de
denenmektedir. Anti-oligomerizat�rler aras&#305;nda s&#305;n&#305;flanan
tramiprosat isimli molek�l b�y�k umutlarla geldi&#287;i faz III��
a&#351;amam&#305;&#351;t&#305;r. Di&#287;er bir
anti-oligomerizasyon/fibrillizasyon y�ntemi </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-katlanman&#305;n
arac&#305;lar&#305;ndan a&#287;&#305;r metal ba&#287;lay&#305;c&#305; b�lgenin
inhibisyonudur. Metalloprotein zay&#305;flat&#305;c&#305; ajanlar (MPAC�ler)
b�ylesi ajanlard&#305;r. Bunlar aras&#305;nda clioquinol (PBT-1) toksik
metaboliti bertaraf edilemedi&#287;i i�in geli&#351;imi durdurulduysa da benzer
bir molek�l olan PBT-2�nin faz II �al&#305;&#351;malar&#305; s�rd�r�lmekteydi.
Exebryl ve scyllo-inositol (ELND005/AZD-103) isimli molek�ller klinik
�al&#305;&#351;malarda s&#305;nanmakta olan di&#287;er k���k molek�ll�
anti-fibrillizat�rler aras&#305;ndad&#305;rlar.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans14.JPG">&#350;ekil 14.</a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Amiloid Plak (Kaynak: </span><span style='font-size:10.0pt;font-family:Tahoma'><a
href="http://www-medlib.med.utah.edu/WebPath/CNSHTML/CNS090.html"><span
lang=TR style='mso-ansi-language:TR'>http://www-edlib.med.utah.edu/WebPath/CNSHTML/CNS090.html</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans15.JPG">&#350;ekil 15.</a> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>APP proteolizi
ve A&#946; birikimi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:48.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid
prek�rs�r protein (APP) 770 aminoasidlik (aa) bir transmembran (TM) proteindir.
700 ve 723. aa�lar membran&#305; kateden par�as&#305;na rasgelir. A&#946;
karboksi ucuna (CT) yak&#305;n 40-42 aa�l&#305;k bir fragman&#305;d&#305;r.
A&#946;�n&#305;n 700 ila 711-713. aa�lara kar&#351;&#305;l&#305;k gelen
k&#305;sm&#305; membran i�inde (transmembran domen � TMD), 671 ila 699. aa�lar
aras&#305;nda kalan k&#305;sm&#305; ise ekstrasel�ler (jukstamembran domen �
JMD) yerle&#351;imlidir. APP proteolizi distalde ekstrasel�ler par�ada
amiloidojenik veya non-amiloidojenik olarak yap&#305;l&#305;r. Amiloidojenik
proteoliz A&#946; fragman&#305;n&#305; salim b&#305;rakacak &#351;ekilde 671.
pozisyondan &#946;-sekretaz kesimiyle ba&#351;lat&#305;l&#305;r. Bu kesim amino
ucunda (NT) akson budanmas&#305;nda rol oynad&#305;&#287;&#305; bulunan
sAPP&#946; ve CT�de membrana ba&#287;l&#305; 99 aa�l&#305;k (C99) fragman&#305;
olu&#351;turur. Non-amiloidojenik proteoliz ise APP�yi A&#946;-JMD i�inden,
687. pozisyondan kesen &#945;-sekretaz arac&#305;l&#305;&#287;&#305;yla
ba&#351;lar. Bu kesim de NT�de n�rotrofik etkileri bilinen sAPP&#945; ve CT�de
yine membrana ba&#287;l&#305; 83 aa�l&#305;k (C83) fragman&#305;
olu&#351;turur. C99 ve C83 intramembran�z par�ada &#947;-sekretaz kompleksi
(GS) ile bir dizi ard&#305;&#351;&#305;k kesimden ge�er. &#304;lk kesim &#949;
kesimi ad&#305; verilen 720 veya 721. pozisyonda meydana gelir. Olu&#351;an
49-50 aa�l&#305;k APP intrasel�ler domeni (AICD) isimli fragman&#305;n h�cre
�ekirde&#287;ine transloke olarak protein sentezini destekledi&#287;i
bilinmektedir. &#304;kinci kesim &#950; kesimidir ve 717 veya 718. pozisyonda
ve nihayet 3. kesim olan &#947; kesimi 711 veya 713. pozisyondad&#305;r. Bu son
kesim non-amiloidojenik C83�te ise ortama 24-26 aa�l&#305;k inert bir
budanm&#305;&#351; A&#946; par�ac&#305;&#287;&#305; olan p3, amiloidojenik
C99�da ise 40-42 aa�l&#305;k salim bir A&#946; fragman&#305; �retir. GS APP�nin
yan&#305;s&#305;ra bir dizi TM proteinin daha proteolizinden sorumlu olan bir
aspartil proteaz kompleksidir. Aktif katalitik b�lgesi presenilin 1 veya 2
(PSEN) olmak �zere 4 ayr&#305; proteinin bile&#351;imidir (Pen-2, Nicastrin,
Aph1B). GS�nin di&#287;er �nemli proteolitik hedefi n�ro-geli&#351;imde �nemli
rol oynayan NOTCH proteinidir. GS kesimi sonras&#305; NOTCH intrasel�ler domeni
(NICD) ad&#305; verilen fragman, gen ifadesini ve h�cresel farkl&#305;la&#351;may&#305;
ba&#351;latmak �zere nukleusa transloke olur. Ortama sal&#305;nan A&#946;
monomerli mikroglial fagositozla temizlenebilecekleri gibi &#351;aperon
molek�ller taraf&#305;ndan vask�ler endotelden klirensi sa&#287;lanabilir veya
yine &#351;aperon molek�ller taraf&#305;ndan lizozomal veya proteozomal
degradasyona maruz kalacaklar&#305; n�ronlar ve astrositler i�ine sokulur. Bu
y�ntemlerin her hangi biriyle ortamdan uzakla&#351;t&#305;r&#305;lamayan,
�zellikle de potansiyel olarak daha toksik form olan A&#946;<sub>42 </sub>gev&#351;ek
plaklarda birikir. Bu son savunma mekanizmas&#305; da ba&#351;ar&#305;s&#305;z
kald&#305;&#287;&#305; takdirde A&#946; monomeri ��z�lebilir oligomerler
halinde bir araya gelir. ��z�lebilir oligomer bir dizi sinaptik disfonksiyon
mekanizmas&#305;n&#305; tetikleyerek AH�nin en erken fizyopatolojik
�zelli&#287;i olan LTP depresyonuna neden olur. Oligomerler daha toksik
ADDL�lere budanabilecekleri gibi ��z�lemeyen A&#946; fibrillerine do&#287;ru da
evrilebilirler. A&#946; fibrilleri de h�cre y&#305;k&#305;nt&#305; �r�nleri
olan distrofik n�ritlerle birlikte n�ritik plaklarda hapsedilirler. Fibriler
A&#946; gibi n�ritik plaklar da kararl&#305; yap&#305;lar olmaktan �ok toksik
oligomerler i�in bir t�r rezervuar i&#351;levi g�rmektedirler. N�ritik plaklar
�evrelerinde oksidatif gerilim yan&#305;s&#305;ra aktive mikroglia
arac&#305;l&#305;&#287;&#305;yla inflammasyona yola�arlar.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�ron kayb&#305;</span></b><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AH�de n�ron kayb&#305; entorhinal
korteksten ba&#351;lar ve limbik sistemi terketti&#287;inde superior temporal
sulkusta tespit edilebilir.&nbsp;&nbsp; N�ron kayb&#305;n&#305;n zaman i�inde
ilerleme ve anatomik yatk&#305;nl&#305;k tarz&#305; genel anlamda NFY�nin
tarz&#305;na benzese ve NFY ile n�ron say&#305;lar&#305;n&#305;n
aras&#305;nda&nbsp; anlaml&#305; negatif korelasyonlar saptansa da, n�ron
�l�m�nden tek ba&#351;&#305;na NFY�ler sorumlu tutulamaz.&nbsp; Subkortikal
�ekirdekler gibi NFY�lerin bulundu&#287;u b�lgelerde ille de n�ron
kayb&#305;n&#305;n olmas&#305; gerekmedi&#287;i gibi, NFY�lerin az say&#305;da
oldu&#287;u ya da hi� bulunmad&#305;&#287;&#305; b�lgelerde de a&#287;&#305;r
n�ron kayb&#305; g�r�lebilir.&nbsp; Amiloid n�rotoksisitesinin neden
oldu&#287;u sinaps kayb&#305; ve transsinaptik dejenerasyon h�cre �l�m�nde rol
oynad&#305;&#287;&#305; d�&#351;�n�len di&#287;er etmenlerdir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik kay&#305;p</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B�t�n korteksin kolinerjik
innervasyonu temel limbik yap&#305;lardan biri olan bazal �nbeyindeki Meynert
�ekirde&#287;inden sa&#287;lan&#305;r.&nbsp; Bu innervasyon dikkat ve bellek
i&#351;levlerinin optimal s�rd�r�lebilmesi a�&#305;s&#305;ndan b�y�k �nem
ta&#351;&#305;r.&nbsp; Tau hiperfosforilazasyonun ilk g�r�ld�&#287;� alanlardan
biri de Meynert �ekirde&#287;idir.&nbsp; AH�de limbik alanlardaki yayg&#305;n
NFY formasyonu ve n�ron kayb&#305; Meynert&nbsp; �ekirde&#287;ini de
etkiler.&nbsp; Kolinerjik aksonlar&#305;n kayb&#305; di&#287;er patolojik
�zellikler gibi bir b�lgesel yatk&#305;nl&#305;k g�sterir.&nbsp; Lokal intern�ronlardan
sa&#287;lanan striatal kolinerjik innervasyon ve talamusun beyinsap&#305;
pedink�lopontin �ekirdek kaynakl&#305; kolinerjik innervasyonu
etkilenmedi&#287;i gibi, etkilenen Meynert kaynakl&#305; kolinerjik innervasyon
da ayn&#305; tarz&#305; yans&#305;t&#305;r: kortekste en fazla etkilenen
b�lgeler limbik ve asosiasyon korteksleri iken, primer sensoryal ve motor
korteksler g�reli olarak salim kal&#305;rlar.&nbsp;&nbsp;&nbsp;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik buton da denilen
pre-sinaptik kolinerjik terminalde kolin asetil transferaz enzimi (ChAT) bir
yandan mitokondrilerden asetil koenzim A arac&#305;l&#305;&#287;&#305; ile
serbestlenen kolinden, di&#287;er yandan da y�ksek afiniteli kolin geri
al&#305;n&#305;m sistemi arac&#305;l&#305;&#287;&#305;yla al&#305;nan kolinden
asetil kolin (ACh) �retir.&nbsp;&nbsp; ACh molek�lleri vezik�llere paketlenip
depolarizasyonu izleyerek sinaptik aral&#305;&#287;a salg&#305;lan&#305;r.&nbsp;
Sinaptik aral&#305;kta dif�zyonla ilerleyen ACh post-sinaptik membranda
nikotinik resept�rlere ba&#287;lanarak do&#287;rudan, muskarinik resept�rlere
ba&#287;lanarak ise G-proteini ili&#351;kili ikincil mesajc&#305;lar �zerinden
etkisini g�sterir.&nbsp; Nikotinik etkilerin h�crenin
uyar&#305;labilirli&#287;ini artt&#305;rarak dikkat tonusunun
sa&#287;lanmas&#305;nda rol oynad&#305;&#287;&#305;, muskarinik etkilerin ise
kal&#305;c&#305; sinaptik de&#287;i&#351;ikliklerle yeni bilginin
depolanmas&#305; &#351;eklindeki n�roplastisite mekanizmalar&#305;n&#305;n
unsuru oldu&#287;u bilinmektedir.&nbsp; Beyinde </span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7 nikotinik
resept�rler (</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7nAChR) pre-sinaptik
yerle&#351;imlidir ve uyar&#305;lmalar&#305; ACh�nin pre-sinaptik akson
terminalinden sal&#305;n&#305;m&#305;n&#305; artt&#305;r&#305;rken yine
pre-sinaptik muskarinik 2 ACh resept�rleri (M2AChR) tam tersine ACh
sal&#305;n&#305;m&#305; inhibe ederler. AH�nin erken d�neminde </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7nAChR</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>de kompansatuar bir art&#305;&#351;
s�z konusuyken pre-sinaptik denge giderek nikotinik aleyhine ve muskarinik
lehine d�nmeye ba&#351;lar. Post-sinaptik membranda bulunan ve her ikisi de AH
s�recinde erken d�nemde kaybolmaya ba&#351;layan M1AChR ve hem pre- hem de
post-sinaptik yerle&#351;mi&#351; olan </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2nAChR�lerin
uyar&#305;lmas&#305; yukarda de&#287;inilen h&#305;zl&#305; (nikotinik) ve
yava&#351; (muskarinik) kolinerjik n�rotransmisyona arac&#305;l&#305;k eder.
Hem nikotinik, hem de muskarinik stim�lasyon kayb&#305;n&#305;n gerek </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
etkinli&#287;inin azalmas&#305;yla A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
olu&#351;umunun artmas&#305; ve gerekse de GSK-3</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
etkinli&#287;inin artmas&#305;yla taunun patolojik fosforilizasyonunun da
artmas&#305; &#351;eklinde in vitro etkileri g�sterilmi&#351;, di&#287;er
yandan A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'>�</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>n&#305;n </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7nAChR
blokaj&#305; �zerinden ACh�n&#305;n sentez, sal&#305;n&#305;m ve post-sinaptik
etkinli&#287;ini azaltabilece&#287;i de ortaya konmu&#351;tur.&nbsp;Bu durum A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ve
kolinerjik kayb&#305;n birbirlerini pozitif geri besledikleri bir
k&#305;s&#305;r d�ng� olu&#351;turmaktad&#305;r. Muskarinik kolinerjik
n�rotransmisyonun tetikledi&#287;i fosfoinositol sistemi �zerinden
anti-Alzheimer mekanizmalar <b>&#350;ekil 16 ve 17</b> de g�sterilmi&#351;tir.
Bu mekanizmalar </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2 ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7
nikotinik ile M1 muskarinik agonizman&#305;n bir tedavi hedefi olarak �nemini
g�stermektedir ve bunlar&#305;n t�m�ne ili&#351;kin terap�tik ajanlar, doz
k&#305;s&#305;tlayan gastro-intestinal yan etkilerinin sundu&#287;u b�y�k g��l�klere
ra&#287;men klinik �al&#305;&#351;malarda ilerlemeye
�al&#305;&#351;maktad&#305;rlar (�rne&#287;in, s&#305;ras&#305;yla TC-1734, MEM
3454, AF267B). M2 antagonizmas&#305;n&#305;n hayvan modellerinde M1
agonizmas&#305;na benzer anti-AH etkileri g�sterilmi&#351;tir.
Asetilkolinesteraz (AChE) enzimi katalitik iyonik k&#305;sm&#305;n&#305;n
aktivitesiyle ACh�yi asetat ve koline hidrolize ederek ACh�nin post-sinaptik
aktivitesini durdurur.&nbsp;AChE�nin di&#287;er yandan periferik aniyonik
k&#305;sm&#305; arac&#305;l&#305;&#287;&#305;yla A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomerleriyle olu&#351;turduklar&#305; fibriler kompleksin de tek
ba&#351;&#305;na oligomerinkini a&#351;an toksik etkileri g�sterilmi&#351;tir.
AChE inhibit�rleri AH tedavisinin ilk yerle&#351;ik ajanlar&#305; olarak
terap�tik cephanede �oktan yerlerini alm&#305;&#351;lard&#305;r. Klasik
katalitik b�lge inhibisyonu yan&#305;s&#305;ra periferik b�lge inhibisyonu da
yapabilen ajanlar (�rne&#287;in, NP-61) erken klinik geli&#351;im
a&#351;amas&#305;ndad&#305;rlar. �strojen limbik n�ronlarda sinaptogeneze
katk&#305;da bulunup n�roplastisitede rol oynarken, Meynert�te ACh �retimine de
katk&#305;da bulunur.&nbsp; Post-menapozal kad&#305;nlarda �strojen replasman&#305;n&#305;n
koruyucu etkisi an&#305;lan i&#351;levleri dolay&#305;s&#305;yla olabilir.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans16.JPG">&#350;ekil 16.</a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Kolinerjik
sinaps<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kolinerjik Sinaps.Pre-sinaptik akson terminalinde ChAT,
asetil CoA arac&#305;l&#305;&#287;&#305;yla kolini asetilleyerek ACh olu&#351;turur.
ACh vezik�ller i�ine paketlenerek sinaps aral&#305;&#287;&#305;na sal&#305;n&#305;r.
Presinaptik nikotinik </span><span style='font-size:10.0pt;font-family:Tahoma'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7
resept�rlerinin uyar&#305;lmas&#305; ACh sal&#305;n&#305;m&#305;n&#305; stim�le
ederken (ye&#351;il ok), muskarinik M2 resept�rlerinin uyar&#305;lmas&#305;
inhibe eder (k&#305;rm&#305;z&#305; �ubuk). Sinaptik aral&#305;&#287;a sal&#305;nan
ACh post-sinaptik nikotinik </span><span style='font-size:10.0pt;font-family:
Tahoma'>&#945;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>4</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2
resept�rleriyle ba&#287;land&#305;&#287;&#305;nda Na<sup>4</sup> kanal&#305; a�&#305;l&#305;r
ve i�eriye Na<sup>+ </sup>girerek dikkatten sorumlu h&#305;zl&#305; kolinerjik
n�rotransmisyonu ba&#351;lat&#305;r. Muskarinik M1 resept�rlerine ba&#287;lanan
ACh, resept�re ba&#287;l&#305; Gq proteinini aktive ederek PLC�yi fosforiller.
Fosforile PLC bir yandan ikincil mesajc&#305;lardan membrana ba&#287;l&#305;
diasil gliserol� (DAG) aktive ederek PKC�yi do&#287;rudan fosforillerken, di&#287;er
yandan da fosfoinositol difosfattan (PIP<sub>2</sub>) inositol trifosfat (IP<sub>3</sub>)
�reterek endoplazmik retikulumdaki (ER) kendi resept�r�ne ba&#287;lanacak di&#287;er
ikincil mesajc&#305;y&#305; h�cre i�ine salar. IP<sub>3</sub>,<sub> </sub>ER�den
Ca<sup>++ </sup><span style='mso-spacerun:yes'>�</span>sal&#305;n&#305;m&#305;n&#305;
sa&#287;lar ve artan intrasel�ler Ca<sup>++ </sup>b�ylece daha fazla PKC�yi
dolayl&#305;</span><span lang=TR style='font-size:10.0pt;mso-bidi-font-size:
12.0pt;font-family:Tahoma;mso-ansi-language:TR'> yoldan fosforillemi&#351;
olur. Fosforile PKC, mitojen aktive protein kinaz (MAPK) arac&#305;l&#305;&#287;&#305;yla
n�kleer transkripsiyonu devreye sokar ve �&#287;renmenin temeli olan yeni
sinaps yap&#305;m&#305;na arac&#305;l&#305;k eder. Sinaps aral&#305;&#287;&#305;nda
i&#351;levi biten ACh, AChE arac&#305;l&#305;&#287;&#305;yla asetat ve koline
par�alan&#305;r. Kolin pre-sinaptik terminalden kolin ta&#351;&#305;y&#305;c&#305;s&#305;
arac&#305;&#287;&#305;yla geri al&#305;n&#305;r</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=ListParagraph0CxSp&#304;lk style='text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#350;ekil
17. </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AH�li sinapsta A</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�n&#305;n anti-glutamaterjik ve
anti-plastisite etkiler<b><o:p></o:p></b></span></p>

<p class=ListParagraph0CxSpOrta style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans17a.JPG">&#350;ekil 17a.</a> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Glutamaterjik
sinaps, GABA-erjik olan&#305;n tersine AH�de<b style='mso-bidi-font-weight:
normal'> </b>erken d�nemde sald&#305;r&#305; alt&#305;ndad&#305;r. APP�nin
amiloidojenik proteolizi sonras&#305; ortamdan temizlenemeyen ��z�n�r A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomeri
post-sinaptik membranda bir dizi patolojik zinciri tetikler. Bunlar&#305;n
sonucunda, �nce NMDA, sonra da AMPA olmak �zere glutamaterjik (GluR) sinapslar
endositozla kaybedilir. Sonu�ta glutamaterjik aktiviteye dayanan ve
�&#287;renmenin molek�ler mekanizmas&#305; olan uzun s�reli potansiasyon (LTP)
giderek azal&#305;rken, uzun s�reli depresyon (LTD) artar. Bu etkinin GluR ile
do&#287;rudan etkile&#351;imle de&#287;il fakat ba&#351;ka bir transmembran
protein (TMP) olan bir arac&#305; �st�nden oldu&#287;una dair deliller
mevcuttur. Bu arac&#305;lardan biri olarak normal TMP prion proteini (PrP<sup>c</sup>)
g�sterilmi&#351;tir. Di&#287;eri ise yaln&#305;zca glutamaterjik<span
style='mso-spacerun:yes'>� </span>sinapslarda bulunan ve GluR stabilitesini
sa&#287;layan neuroglin 1�dir. Neuroglin 1-A</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> kompleksinin Wnt sinyalizasyonunu
ba&#351;latacak ligand&#305;n resept�r�ne ba&#287;lanmas&#305;n&#305; engelledi&#287;i,
bunun sonucunda da GSK3</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-Axin-APC�den
olu&#351;an �y&#305;k&#305;m kompleksi�nin inhibe edilemeyerek bir n�kleer
transkripsiyon fakt�r� olan </span><span style='font-size:10.0pt;font-family:
Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>-kateninin i&#351;levini g�remeden
y&#305;k&#305;ld&#305;&#287;&#305; bilinmektedir. ��z�n�r A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomeri
ileri glikasyon son �r�nleri resept�r� (RAGE) ile de etkle&#351;ir. N�ronal
membranda etkile&#351;im temel inflammatuar sinyalizasyon olan NF</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#954;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B
sinyalizasyonunu tetikler ve b�ylelikle ortama inflammatuar sitokinler
sal&#305;n&#305;r. A</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
fagositozu i�in aktive olmu&#351; mikroglia da RAGE-A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
etkile&#351;imi ile sal&#305;nan inflammatuar sitokinlerin bir di&#287;er
kayna&#287;&#305;d&#305;r. Bir TMP olan RAGE, bu t�r proteinlerin
proteolizinden sorumlu olan bir metalloproteinaz olan ADAM10
arac&#305;l&#305;&#287;&#305;yla kesilerek parenkime sal&#305;nan ��z�n�r RAGE
(sRAGE) olu&#351;ur. sRAGE de A</span><span style='font-size:10.0pt;font-family:
Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> ba&#287;lar, ancak art&#305;k membrana ba&#287;l&#305;
olmad&#305;&#287;&#305;ndan bir patolojik zinciri ba&#351;latman&#305;n tam
tersine A</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�y&#305;
n�tralize eden bir i&#351;lev g�r�r. A</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> d�&#351;�k yo&#287;unluklu
lipoprotein resept�r� 1 (LRP1) arac&#305;l&#305;&#287;&#305;yla kan-beyin
bariyerinden dola&#351;&#305;ma verilir. Vask�ler endotel membran&#305;ndaki
RAGE A</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�y&#305;
yeniden beyne al&#305;rken, dola&#351;&#305;mdaki sRAGE A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
ba&#287;layarak buna kar&#351;&#305;t �al&#305;&#351;&#305;r. Dolay&#305;s&#305;yla,
RAGE antagonistleri ve sRAGE agonistlerinin potansiyel anti-AH farmakolojik
stratejiler oldu&#287;u s�ylenebilir. Yerle&#351;ik tedavi stratejilerinden
biri olan memantinin bilinen etki mekanizmas&#305; NMDAr�da Mg<sup>++ </sup>t&#305;kac&#305;
i&#351;levi g�rerek mevcut Ca<sup>++ </sup>s&#305;z&#305;nt&#305;s&#305;
kaynaklar&#305;ndan birini engellemek iken h�cre i�inde de hiperfosforile tauyu
par�alayacak fosfataz agonizmas&#305; yapt&#305;&#287;&#305;na dair de deliller
vard&#305;r.<o:p></o:p></span></p>

<p class=ListParagraph0CxSpOrta style='text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=ListParagraph0CxSpSon style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans17b.JPG">&#350;ekil 17b.</a> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik
sinaps da AH�de erken tehdit alti&#305;ndad&#305;r. ��z�n�r A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomerleri
pre-sinaptik membranda asetil kolin (ACh) sal&#305;n&#305;m&#305;n&#305; inhibe
eden M2 muskarinik resept�rlere de&#287;il de, tam tersine
sal&#305;n&#305;m&#305; artt&#305;ran </span><span style='font-size:10.0pt;
font-family:Tahoma'>&#945;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>7 ve </span><span style='font-size:
10.0pt;font-family:Tahoma'>&#945;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2 nikotinik resept�rlere
ba&#287;lanarak kolinerjik n�rotransmisyonu azalt&#305;rlar. M2 antagonizmas&#305;
ve/veya </span><span style='font-size:10.0pt;font-family:Tahoma'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7 ve </span><span
style='font-size:10.0pt;font-family:Tahoma'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2
agonizmas&#305; yapan ajanlar bu dengeyi tersine �evirebilirler. Post-sinaptik
M1 kolinerjik aktivite gibi insulin sinyalizasyonu da protein kinaz C (PKC)
fosforillenmesi �zerinden anti-AH etkiler (ADAM17 aktivasyonu, </span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz ve
GSK3</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
inhibisyonu) g�sterir. </span><span style='font-size:10.0pt;font-family:Tahoma'>Dolay&#305;s&#305;yla,
M1 agonistleri ve insulin potansiyel anti-AH etkilere sahiptirler. Asetil kolin
esteraz&#305;n (AChE) periferik k&#305;sm&#305;na ba&#287;lanan A&#946; ile
olu&#351;turdu&#287;u kompleksin oligomerin toksisite arac&#305;lar&#305;ndan
biri oldu&#287;u g�sterilmi&#351;tir. Dolay&#305;s&#305;yla, katalitik
k&#305;sma ba&#287;lanan klasik inhibit�rlerden farkl&#305; olarak ayr&#305;ca
periferik k&#305;sm&#305; da bloke edecek �dual inhibit�rler� daha g��l� bir
anti-AH etki g�sterebilirler. DNA onar&#305;m&#305;yla g�revli sirtuin
sinyalizasyonunun A&#946; ile tam tersi etkilere sahip oldu&#287;u
bilinmektedir. &#304;ntrasel�ler A&#946; sirtuin sinyalizasyonunda rol oynayan
ba&#351;l&#305;ca molek�llerden biri olan SIRT1�i inhibe ederken, bir TMP olan
fraktalcine�nin (CX3CL1), �rne&#287;in k&#305;rm&#305;z&#305; &#351;arapta da
bulunan bir polifenol olan rosveratrol ile uyar&#305;lmas&#305; CX3CL1�in,
ayn&#305; zamanda APP�nin non-amiloidojenik proteolizini sa&#287;layan
ADAM17�yi aktive etmesini sa&#287;lamakta, bunun sonucunda aktive olan SIRT1
ise RAGE�i kesecek ADAM10�u aktive ederek pro-inflammatuar NF&#954;B
sinyalizasyonunu durdururken, di&#287;er yandan da pro-plastisite n�kleer
transkripsiyon fakt�rlerini harekete ge�irmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinaps kayb&#305;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Sinaps kayb&#305; kortikal biyopsi
�rneklerinde klinik demans a&#287;&#305;rl&#305;&#287;&#305;yla, n�ron
kayb&#305;ndan dahi daha kuvvetli en y�ksek korelasyon g�steren yap&#305;sal
de&#287;i&#351;ikliklerin ba&#351;&#305;nda gelir.&nbsp; Sinaptofizin gibi
sinaptik proteinlerin miktarlar&#305;n&#305;n da demans
a&#287;&#305;rl&#305;&#287;&#305;yla korele etti&#287;i g�sterilmi&#351;tir.&nbsp;
Sinaps kayb&#305; ba&#351;lang&#305;�ta NFY ve n�ron �l�m�n�n anterograd
Wallerian dejenerasyon sonucu sekonder etkisi ile a�&#305;klansa da, primer
hasar&#305;n �zellikle de intrasel�ler ��z�lebilir A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomeri arac&#305;l&#305;&#287;&#305;yla sinapslara olmas&#305; ve
bozuklu&#287;un retrograd olarak h�cre g�vdesine ta&#351;&#305;narak, NFY
olu&#351;umu ve nihayetinde h�cre �l�m�ne yola�mas&#305; art&#305;k daha
muhtemel g�r�nmektedir. </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>��z�lebilir A&#946; oligomerinin
toksisitesi ve neden oldu&#287;u erken sinaptik disfonksiyon �zerine odaklanan
son �al&#305;&#351;malar ��z�lemez fibriler formun veya daha olgun
plaklar&#305;n parenkimde oynad&#305;&#287;&#305; rol yerine toksik ��z�lebilir
oligomerin h�cre y�zeyinde uygun bir resept�r bulup ba&#287;land&#305;ktan
sonra veya membrandan intrasel�ler mesafeye ge�tikten sonra ba&#351;latt&#305;&#287;&#305;
bir dizi zincirleme reaksiyonun do&#287;as&#305;n&#305; ayd&#305;nlatmaya
ba&#351;lam&#305;&#351;t&#305;r. Bu mekanizmalar&#305;n
basamaklar&#305;n&#305;n ayn&#305; zamanda nedene y�nelik tedavi hedefleri de
olu&#351;turmalar&#305; heyecan vericidir. Bu �al&#305;&#351;malar&#305;n
ortakla&#351;t&#305;&#287;&#305; bir nokta A&#946; oligomerinin
ba&#351;lang&#305;�ta inhibit�r GABA-erjik sinapslar&#305; salim b&#305;rak&#305;rken
eksitat�r glutamaterjik sinapslarda de&#287;i&#351;ikliklere neden olmas&#305;,
buna ba&#287;l&#305; olarak �&#287;renmenin temelini te&#351;kil eden molek�ler
mekanizma olan uzun s�reli potansiasyonu (LTP) bask&#305;larken, uzun s�reli
depresyonu (LDP) te&#351;vik etmesidir. Inestrosa grubu oligomerin eksitat�r
sinapslarda NMDA resept�r� stabilitesini sa&#287;layan neurogilin 1 ile
etkile&#351;irken inhibit�r sinapslardaki neurogilin 2 ile
etkile&#351;medi&#287;ini g�sterdiler. Ayn&#305;
ara&#351;t&#305;r&#305;c&#305;lar bu etkile&#351;imin embryogenez gibi bir dizi
di&#287;er i&#351;levleri yan&#305;s&#305;ra akson rehberli&#287;inden sorumlu
Wnt sinyalizasyonunu bozdu&#287;u ve AH�de bu sinyalizasyonun son �r�n� olan
n�kleer transkripsiyon fakt�r� &#946;-katenin miktarlar&#305;n&#305;n
azald&#305;&#287;&#305; buldular. Bu etkile&#351;im sonunda NMDA ve AMPA resept�rlerinin
postsinaptik membrandan endositozla kayb&#305;na yola�ar. Resept�rlerin
kayb&#305;yla sinaps atrofiye u&#287;rar. Wnt sinyalizasyonunu aktive eden
ligandlar A&#946;�n&#305;n tetikledi&#287;i sinaptik de&#287;i&#351;iklikleri
geri �evirebilmektedir.&nbsp; Wnt sinyalizasyonu sinaptik �z-savunma
mekanizmalar&#305;ndan biridir. AH i�in de ba&#351;l&#305;ca risk fakt�r� olan
bu sinaptik �z-savunma mekanizmalar&#305; ya&#351;lanmayla birlikte
zay&#305;flamaya ba&#351;larlar. &#350;ekil 17a�dan A &#946;�n&#305;n neden
oldu&#287;u glutamaterjik sinaptik disfonksiyon ve Wnt sinyalizasyonu &#351;ematik
olarak g�sterilmi&#351;tir.<span style='mso-spacerun:yes'>� </span>Bu
sinyalizasyon mekanizmalar&#305;ndan bir di&#287;eri de sirtuin
sinyalizasyonudur. Sirtuinler proteinlerin asetil grubunu kald&#305;rarak
(deasetilaz) ve ADP-riboziltransferaz i&#351;levleri g�ren bir uzun �m�r
fakt�r�d�r. SIRT1 ve SIRT2 isimli sirtuinlerin DNA onar&#305;m&#305;nda rol
ald&#305;&#287;&#305;, aktivitelerinin ya&#351;lanmayla birlikte
zay&#305;flad&#305;&#287;&#305; g�sterilmi&#351;tir. A&#946; oligomerlerinin
SIRT1 aktivitesini bozarken tersine k&#305;rm&#305;z&#305; &#351;arapta da
bulunan bir polifenol olan resveratrol gibi maddelerle SIRT1 geninin aktivasyonu
m�mk�n oldu&#287;u gibi bir sitokin proteini olan fraktalkinin (CX3CL1)
aktivitesinin artt&#305;r&#305;lmas&#305; AH�de azalan SIRT1 aktivitesini
artt&#305;rmakta ve b�ylelikle aktive olmu&#351; NF-&#954;B sinyalizasyonu
inhibe edilerek tetiklenen inflamatuar s�re� tersine �evrilebilmektedir. Bu
g�zlemler AH�de birer terap�tik ajan olarak resveratrol ve CX3CL1
agonizmas&#305;n&#305; g�ndeme getirmi&#351;tir. NF-&#954;B sinyalizasyonu
�zerinden inflamatuar de&#287;i&#351;ikliklere a&#351;a&#287;&#305;daki ilgili
b�l�mde daha ayr&#305;nt&#305;yla de&#287;inilecektir. Serebral ins�lin sinyallemesi
ve A&#946; oligomerinin h�cre y�zeyine ba&#287;land&#305;ktan sonra tetikledi&#287;i
mekanizmalar da birbirinin tam tersi gibi g�r�n�yor. Serebral ins�lin
sinyallemesi sinaptik enerji homeostaz&#305;ndan sorumludur. N�ronlarda bir
tirosin kinaz resept�r� gibi i&#351;lev g�ren ins�lin resept�rlerine (IR)
ba&#287;lanan ins�lin&nbsp; fosfadidilinositol-3-kinaz (PI3K) �zerinden
nihayetinde protein kinaz C�yi aktive ederek a&#351;a&#287;&#305;da �kolinerjik
kay&#305;p� b�l�m�nde daha ayr&#305;nt&#305;yla s�zedilen ve <b>&#350;ekil 17b�</b>de
&#351;ematik olarak g�sterilen anti-AH mekanizmalar&#305; tetikler. AH
hastalar&#305;n&#305;n bir b�l�m� y�ksek a�l&#305;k ins�lin d�zeylerine
sahiptir (periferik diren�). FDG-PET ile de g�sterilen n�ronal glukoz
kullan&#305;m&#305; bozuklu&#287;u (hipometabolizma AH�de g�reli erken bir
�zelliktir ve demans &#351;iddetiyle korele eder. AH�li hastalar&#305;n bir
b�l�m�nde n�ronal IR�ler, glukoz ta&#351;&#305;y&#305;c&#305; proteinler ve
di&#287;er ins�lin yola&#287;&#305; ilintili bile&#351;enler azal&#305;r
(santral diren�). A&#946; dendritik IR�leri azalt&#305;rken ins�lin oligomerin
tetikledi&#287;i LTP bask&#305;lanmas&#305; ve sinaptik kayb&#305; tersine
�evirir. Bu bulgular ins�lin sinyallemesini etkileyen ajanlar&#305; AH�nin
potansiyel terap�tik ajanlar&#305; durumuna getirmi&#351;tir. Periferik ins�lin
direnci d�&#351;�rerek IDE�nin periferiden ziyade MSS�de bir &#351;aperon
molek�l olarak kullan&#305;lmas&#305;n&#305; ama�layan varsay&#305;mlar&#305;n
s&#305;nanmas&#305; PPAR-&#947; agonistlerini (rosiglitazon ve pioglitazon)
klinik �al&#305;&#351;malar&#305;n olgun evrelerine kadar getirmi&#351;tir. Son
olarak, do&#287;rudan ins�linin intranazal yoldan MSS�ye verilmesi halen
s�rmekte olan bir faz II �al&#305;&#351;mada (SNIFF �al&#305;&#351;mas&#305;)
s&#305;nanmaktad&#305;r. A&#946;�n&#305;n LTP depresyonu yapacak &#351;ekilde
NMDA resept�rlerine ba&#287;lanmas&#305; ve nihayet �nce glutamaterjik NMDA
sonra da glutamaterjik AMPA resept�rlerinin endositozla kaybolmas&#305;
bilinmekle birlikte bunun do&#287;rudan A&#946;�n&#305;n resept�re
ba&#287;lanmas&#305;yla de&#287;il fakat bilinmeyen bir transmembran proteine
ba&#287;lan&#305;p bir kompleks olu&#351;turduktan sonra ger�ekle&#351;ti&#287;i
ileri s�r�lmekteydi. Yak&#305;n tarihte bu bilinmeyen transmembran proteinin
prion proteini (PrP<sup>c</sup>) oldu&#287;u ileri s�r�ld�.
Ara&#351;t&#305;r&#305;c&#305;lar A&#946;�n&#305;n 350 transmembran protein
aras&#305;ndan bask&#305;n olarak PrP<sup>c</sup>�ye
ba&#287;land&#305;&#287;&#305;n&#305; g�sterdiler. &#304;lk bak&#305;&#351;ta
bu durum &#351;a&#351;&#305;rt&#305;c&#305; ��nk� bu i&#351;levi bilinmeyen
proteinin proteolitik kesimi ve sonras&#305;nda hatal&#305; katlanarak fiziksel
konformasyonunu de&#287;i&#351;tirmesi (PrP<sup>Sc</sup>) ve birikmesi bir
ba&#351;ka n�rodejeneratif hastal&#305;klar grubuna, yani i�lerinde
Creutzfeldt-Jacob hastal&#305;&#287;&#305;n&#305;n da bulundu&#287;u prion
hastal&#305;klar&#305;na yola�makta. PrP<sup>c</sup>�ye AH patogenezinde
atfedilen bu temel rol do&#287;ruland&#305;&#287;&#305; takdirde 2 b�y�k
n�rodejeneratif hastal&#305;&#287;&#305;n ayd&#305;nlat&#305;lmas&#305;nda
�nemli bir d�n�m noktas&#305; olabilir.
Ara&#351;t&#305;r&#305;c&#305;lar&#305;n �al&#305;&#351;malar&#305; olduk�a
ikna edici g�r�nmektedir. PrP nakavt transjenik farelerde A&#946; ile LTP
supresyonu ger�ekle&#351;miyor. Son derece virulan bir transjenik model olan
APP/PSEN mutantlar&#305;n PrP nakavtlarla �aprazlanan soyunda
sa&#287;kal&#305;m art&#305;yor, APP/PSEN Tg�lerdeki tipik pasif ka�&#305;nma
�&#287;renme bozukluklar&#305; g�r�nm�yor ve mekansal �&#287;renmeleri
do&#287;al tip farelere benzer d�zeyde normal oluyor. Buna
kar&#351;&#305;l&#305;k A&#946;-Prp<sup>c </sup>kompleksi NMDA resept�rlerinin
tipik endositozuna yol a�t&#305;klar&#305; gibi bu farelerde dentritik diken
kayb&#305;, n�ritik distrofi ve sonunda h�cre kayb&#305; gibi AH�nin di&#287;er
tipik sinaptik patolojisinin t�m� g�r�l�yor. Son olarak, intrasel�ler
A&#946;�n&#305;n mitokondriyal stabiliteyi de bozup apoptozu tetikleyecek
reaktif oksijen t�rlerinin (ROS) olu&#351;umuna neden oldu&#287;u bilinmekte.
AH�li beyinlerde mitokondriyal membran stabilitesinden sorumlu f�zyon
proteinleri dynaminlerin ve bunlar&#305;n aras&#305;nda �zellikle de DLP1�in
d�zeyi d�&#351;mekte, bunun sonucunda intrasel�ler mitokondri
da&#287;&#305;l&#305;m&#305; bozulmakta, say&#305;lar&#305; azalmakta ve bu
durum sonunda dentritik diken say&#305;s&#305;n&#305; azalt&#305;p sinaps
kayb&#305;na yola�makta. Tersine, deneysel modellerde DLP1 a&#351;&#305;r&#305;
ifadesi ADDL ile tetiklenen mitokondriyal de&#287;i&#351;iklikleri tersine
�evirmekte. Dimebon isimli eski bir anti-histaminik molek�l�n AH�de
i&#351;levsiz kald&#305;&#287;&#305; g�sterilen mitokondriyal delikleri
kapatarak i&#351;lev g�rd�&#287;�ne dair pre-klinik deliller sonras&#305; halen
olgun klinik �al&#305;&#351;malarda etkinli&#287;i s&#305;nanmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gliozis ve &#304;nflamasyon</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Gliozis AH n�ropatolojisinin bir
ba&#351;ka �zelli&#287;idir.&nbsp; A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n n�ritik plaklarda birikiminin mikroglial
ve astroglial h�creleri aktive etti&#287;i AH patogenezinde g�reli ge� bir olay
olarak �teden beri iyi bilinmektedir. Mikroglial aktivasyon sitokinlerin
salg&#305;lanmas&#305;, akut faz reaktanlar&#305; ve kompleman&#305;n aktive
edilmesiyle inflamasyonu harete ge�irir.&nbsp; Son zamanlarda plaklardan
ba&#287;&#305;ms&#305;z olarak do&#287;rudan A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomerinin ileri glikasyon son �r�nleri resept�r� (RAGE) ile ba&#287;lanarak
MSS�deki ba&#351;l&#305;ca pro-inflamatuar sinyalleme sistemi olan aktive B
h�crelerinin kappa hafif zincir&nbsp; g��lendiricisi n�kleer fakt�r�n� (NF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B)
tetiklemesinin AH�de erken bir fenomen olarak inflamasyona
yola�mas&#305;n&#305;n �zerinde durulmaktad&#305;r. NF-&#954;B infeksiyona
immun cevapta DNA transkripsiyonunu d�zenleyen bir protein kompleksidir.
Sinaptik plastisite ve bellek i&#351;levlerinde de rol� g�sterilmi&#351;tir.
Kanser, �e&#351;itli inflamatuar ve otoimmun hastal&#305;klar ve AH�de
NF-&#954;B sinyallemesi yolundan sapar. RAGE immunoglobulin s�per
familyas&#305;na dahil bir transmembran resept�r proteindir. &#304;leri
glikasyon son �r�nleri (AGE�ler) ya&#351;lanma yan&#305;s&#305;ra diabetik hiperglisemi
gibi patolojik durumlarda glikozillenme ile ba&#351;layan bir dizi kimyasal
reaksiyonun nihai �r�nleri olan ligandlard&#305;r. RAGE, AGE�ler
yan&#305;s&#305;ra A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, HMGB1, s100, Mac-1 gibi bir
dizi ba&#351;ka ligand&#305; ba&#287;layarak diabet komplikasyonlar&#305;yla
birlikte, AH, multipl skleroz, inme gibi n�rolojik hastal&#305;klar, romatoid
artrit, ateroskleroz, koroner kalp hastal&#305;&#287;&#305; gibi sistemik
hastal&#305;klarda rol oynad&#305;&#287;&#305; bulunmu&#351;tur. Tam uzunlukta
RAGE (flRAGE) bir transmembran protein iken alternatif d�&#287;�mlenme ile �retilen
&#351;ekli olan endojen sekretuar RAGE (esRAGE) ve RAGE�in proteoliziyle ortaya
�&#305;kan enzimatik kesilmi&#351; RAGE (ecRAGE) RAGE�in ��z�n�r bi�imleridir
(sRAGE). sRAGE de flRAGE gibi ligand ba&#287;lar, ancak h�cre y�zeyine
ba&#287;l&#305; olmad&#305;&#287;&#305; i�in NF-</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B gibi
sinyalizasyon tetiklenmesine neden olmad&#305;&#287;&#305; gibi flRAGE�e ba&#287;lanarak
pro-inflamatuar zinciri ba&#351;latacak olan ligandlar&#305; kendine
ba&#287;layarak bir tampon i&#351;levi g�r�r. Ya&#351;lanma s�reci gibi AH�nin
de flRAGE d�zeylerinin art&#305;p sRAGE d�zeylerinin d�&#351;t�&#287;� s�re�ler
oldu&#287;u d�&#351;�n�lebilir. sRAGE ayn&#305; zamanda sirk�lasyonda bulunur
ve artm&#305;&#351; d�zeyleri daha fazla A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n LRP1 arac&#305;l&#305;&#287;&#305;yla
kan-beyin bariyerinden dola&#351;&#305;ma aktar&#305;ld&#305;&#287;&#305; bir
k�vet (sink) etkisiyle A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>n&#305;n klirensine kar&#351;&#305;l&#305;k gelir. Bu
g�zlemler bir tedavi hedefi olarak flRAGE inhibit�rleri (�rne&#287;in, TTP488)
ve/veya sRAGE-mimetiklerini (TTP4000) g�ndeme getirmi&#351;tir. NF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B
sinyalizasyonunun A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-RAGE etkile&#351;imi ile
tetiklenmesinin yan&#305;s&#305;ra, yukarda de&#287;inildi&#287;i gibi A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n yola�t&#305;&#287;&#305;
SIRT1 inaktivasyonu da devreye giren NF-</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B
sinyalizasyonunun �zerindeki denetimi kald&#305;rarak bir pozitif geribildirim
etkisi yapmaktad&#305;r. RAGE etkileri &#350;ekil 17a ve 17b�de &#351;ematik
olarak g�sterilmi&#351;tir. &#304;nflamasyonun, serbest radikallerin ortaya
�&#305;k&#305;&#351;&#305;, oksidatif gerilim, kalsiyum homeostaz&#305; ve
mitokondriyal membranda bozulmalar ile birlikte gitti&#287;i
d�&#351;�n�lmektedir.&nbsp; Astrositler butiril kolin esteraz (BChE) gibi
normalde aktivitesi ihmal edilecek d�zeyde olan bir dizi molek�l�n de
kayna&#287;&#305;d&#305;r ve dolay&#305;yla da gliozis asetil kolinin
par�alanmas&#305;nda da alternatif yolu devreye sokmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er n�rotransmitter
kay&#305;plar&#305;</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Serotoninerjik kay&#305;p</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AH�de serotoninerjik (5-HT-erjik)
dorsal raphe �ekirde&#287;inde Meynert d�zeyinde olmasa bile kayda de&#287;er
n�ron kayb&#305; ve kalan n�ronlarda NFY�ler g�r�l�r.&nbsp; Kortikal 5-HT-erjik
akson terminallerinde 5-HT�nin sal&#305;n&#305;m&#305; ve geri
al&#305;n&#305;m&#305; ciddi d�zeyde bozulmu&#351;tur.&nbsp;AH�de 5-HT-erjik
kay&#305;pla depresyon ve sald&#305;rgan davran&#305;&#351;&#305;n korelasyonu
bildirilmektedir.&nbsp;5-HT geri al&#305;n&#305;m blokerlerinin (SSRI) AH�deki
depresyon ve agresyonun tedavisindeki rasyoneli bu g�zlemlere
dayanmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Dorsal raphede bildirilen bu
kay&#305;p ve pre-sinaptik serotonerjik aktivitedeki bu eksikliklere
ra&#287;men AH�de serotonerjik sistemin hiperaktif olabilece&#287;ine dair
g�r�&#351;ler mevcuttur. Bu sa&#287;duyuya kar&#351;&#305;t gibi g�r�nen
durumun nedeni farkl&#305; post-sinaptik 5-HT resept�rlerinin i&#351;levsel
farkl&#305;l&#305;klar&#305; ve yerle&#351;imleri ile ilintildir. Bunlar
aras&#305;nda 5-HT1a ve 5-HT6 resept�rler siklik AMP�nin
intrasel�lerd�zeylerini azaltarak ve dolay&#305;s&#305;yla plastisite
kar&#351;&#305;t&#305; bir mekanizmayla i&#351;lev g�r�rler. Her iki resept�r
tipi de limbik sistemde zengin bulunur. 5-HT6 �zellikle glutamaterjik ve
kolinerjik n�ronlar&#305; do&#287;rudan inhibe edecek pozisyonda bulunan
GABA-erjik n�ronlarda zengindir. Bu bulgulardan yola �&#305;karak 5-HT1A ve
5-HT6 antagonistleri AH i�in klinik �al&#305;&#351;malarda s&#305;nanmaya
ba&#351;lanm&#305;&#351;t&#305;r (�rn., ilki i�in SRA333 ve WAY100635, ikincisi
i�in SB-742457 ve SAM-351). </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Spesifik 5-HT antagonizmas&#305;
arac&#305;l&#305;&#287;&#305;yla cAMP intrasel�ler d�zeylerinin
azalt&#305;lmas&#305;na kar&#351;&#305; durman&#305;n pro-plastisie etkilerinin
g�sterilmesinden sonra cAMP�y&#305; y&#305;kan enzim olan fosfodiesteraz&#305;n
(PDE) inhibisyonunun terap�tik poyansiyeli �zerinde durulmu&#351;tur.
Pre-klinik �al&#305;&#351;malarda g��l� pro-kognitif ve pro-plastisite etkileri
g�r�len PDE4 inhibit�rleri erken klinik �al&#305;&#351;malara
ula&#351;m&#305;&#351; durumdad&#305;r (�rn., AVE8112 ve MEM 1414).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Noradrenerjik kay&#305;p</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Beyinsap&#305;ndaki noradrenerjik
(NA-erjik) �ekirdek olan locus ceruleus�ta (LC) da dorsal raphe benzeri bir
n�ronal kay&#305;p ve NFY olu&#351;umu g�zlenir.&nbsp;LC�deki patoloji se�ici
yatk&#305;nl&#305;&#287;a uygun bi�imde LC�nin kortikal projeksiyonlar&#305;
olan anterior ve medyal b�l�mlerini etkilerken spinal ve serebellar
projeksiyonlar&#305; i�eren kaudal ve lateral b�l�mleri salim
kal&#305;r.&nbsp;NA-erjik kayb&#305;n klinik kar&#351;&#305;l&#305;&#287;&#305;
iyi belirlenmemi&#351;tir.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Dopaminerjik kay&#305;p</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AH ileri evrelerinde parkinsonizm
s&#305;rad&#305;&#351;&#305; bir olgu de&#287;ildir.&nbsp;Bu olgular&#305;n
patolojik kar&#351;&#305;l&#305;&#287;&#305; b�y�k s&#305;kl&#305;kla
substantia nigra pars compacta (SNc) dopaminerjik (DA-erjik) n�ronlar&#305;nda
kay&#305;p ve Lewy cisimcikleridir (LC).&nbsp; LCD kendine �zg� bir antite olarak
ortaya �&#305;km&#305;&#351;ken LCD ve AH�nin i�i�e ge�ti&#287;i durumlar olan
hem NFY-AP hem de kortikal Lewy cisimciklerinin sonucu olan klinik
durumlar&#305;n LCD mi yoksa AH�nin Lewy varyant&#305; (AH-LV) olarak m&#305;
adland&#305;r&#305;laca&#287;&#305; tart&#305;&#351;mal&#305;d&#305;r. LC�ler
ve NFY-AP birlikteli&#287;i i�in 2 ayr&#305; n�ropatolojik �r�nt�
s&#305;n&#305;fland&#305;rmaya yard&#305;mc&#305; olabilir. LC�ler gerek
sporadik ve gerekse de familyal AH�de en s&#305;k amigdalada ve %60�a
yakla&#351;an bir oranda g�r�l�rler. Di&#287;er limbik alanlar, �zellikle de
periamigdaloid ve entorhinal korteks amigdaladan sonra en s&#305;k g�r�ld�kleri
yerlerdir. LCD�ye �zg� neokortikal ve beyinsap&#305; yerle&#351;imi �ok daha
seyrektir. Buna kar&#351;&#305;l&#305;k LCD�de yayg&#305;n neokortikal ve
beyinsap&#305; yerle&#351;imine de&#287;i&#351;ken miktarlarda AH tipi patoloji
e&#351;lik edebilir. </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Alzheimer Hastal&#305;&#287;&#305;n&#305;n Nedenselli&#287;i
�zerine Son De&#287;erlendirmeler</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH ara&#351;t&#305;rmac&#305;lar&#305; plaklar ve
yumaklar temelinde, hangisinin birincil rol� oynad&#305;&#287;&#305; �zerine
nerdeyse uzla&#351;maz iki kampa b�y�k �l��de ayr&#305;lm&#305;&#351;
durumdad&#305;rlar.&nbsp; Bu kampla&#351;man&#305;n dinsel fanatizme
benzerli&#287;ine ince bir ele&#351;tiriyle de, tau patolojisini
(yumaklar&#305;) �n plana alanlara tauistler, &#946;-amiloid patolojisini
alanlara ise baptistler dendi&#287;i olmu&#351;tur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ger�ekten de, ancak demans evresinde
tan&#305;nabilen hastal&#305;&#287;&#305;n klinik evreleri NFY
yay&#305;l&#305;m&#305;yla �ok iyi korele ederken, AP ile korelasyonun
olmamas&#305; tauistlerin temel tezi olurken, g�sterilen b�t�n genetik
bozukluklar&#305;n A&#946; �zerinden etkisini g�stermesi, buna
kar&#351;&#305;l&#305;k tau mutasyonlar&#305;n&#305;n AH d&#305;&#351;&#305;
dejenerasyonlara neden olmas&#305; baptistlerce tezlerinin
kan&#305;t&#305;&nbsp; gibi sunulmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G�n�m�zde ilk bak&#305;&#351;ta baptizm
tart&#305;&#351;mas&#305;z bir zafer kazanm&#305;&#351; g�r�nmekte ve amiloidin
hastal&#305;&#287;&#305;n tetik�isi oldu&#287;u, buna kar&#351;&#305;l&#305;k
tau patolojisinin bir epifenomen oldu&#287;u art&#305;k egemen g�r�&#351;
olarak yerle&#351;mi&#351; durumda. Tetik�i amiloid oldu&#287;una g�re bunun
do&#287;al sonucu olarak neredeyse t�m nedene y�nelik tedavi �abalar&#305;
anti-amiloid stratejilere vakfedilmi&#351; durumda. Bu �aban&#305;n temel
rasyoneli, tetik�i ortadan kald&#305;r&#305;ld&#305;&#287;&#305; takdirde ona
sekonder olarak geli&#351;en fizyopatolojik de&#287;i&#351;iklikler, tau da
dahil olmak �zere d�zelecektir &#351;eklinde �zetlenebilir. Yeni
y�zy&#305;l&#305;n ilk ony&#305;l&#305;nda bu �abalar&#305;n
yaratt&#305;&#287;&#305; b�y�k heyecan ve iyimserlik, klinik
�al&#305;&#351;malarda nihai geli&#351;im a&#351;amas&#305;na kadar gelen hi�
bir anti-amiloid aday molek�l�n ipi g�&#287;�sleyememesiyle, b�y�k maddi ve
moral kay&#305;plarla birlikte birbiri ard&#305;na hayal
k&#305;r&#305;kl&#305;klar&#305;na d�n�&#351;m�&#351;t�r. Bunlar aras&#305;nda
�zellikle de A&#946; antijeniyle ilk aktif immunizasyon
�al&#305;&#351;mas&#305; olan ve kat&#305;l&#305;mc&#305;lar aras&#305;nda
geli&#351;en meningoensefalit olgular&#305; nedeniyle durdurulan AN1792
�al&#305;&#351;mas&#305; temel varsay&#305;m&#305;n s&#305;nanmas&#305;
a�&#305;s&#305;ndan �&#287;retici olmu&#351;tur. Kat&#305;l&#305;mc&#305;lar
aras&#305;ndan �len olgular&#305;n otopsilerinde serebral plak y�k�nde (hem
gev&#351;ek, hem de sert plaklar) kayda de&#287;er bir azalmaya kar&#351;&#305;n
NFY y�k�nde bir farkl&#305;l&#305;k izlenmemi&#351;tir. Dahas&#305;, bu
�al&#305;&#351;maya kat&#305;l&#305;p da yeterli antikor geli&#351;tiren
hastalar&#305;n uzun s�reli izlemleri de dahil olmak �zere, �ok say&#305;da
farkl&#305; anti-amiloid tedavi �al&#305;&#351;malar&#305;na kat&#305;lan hi�
bir hasta grubunda bildirilen yararlanman&#305;n b�y�kl�&#287;� amiloid
hipotezinden yola �&#305;karak beklenilece&#287;i gibi dramatik
olmam&#305;&#351;, plaseboya kar&#351;&#305; farkl&#305; sonlan&#305;m
�l��tleri a�&#305;s&#305;ndan ancak marjinal yararlar ifade edilmi&#351;tir.
&#304;lk ony&#305;l&#305;n sonunda bu durum en militan baptistler aras&#305;nda
dahi orijinal g�r�&#351;e y�nelik bir skeptisizmle birlikte g�r�&#351;�n
revizyonu taleplerinin ileri s�r�lmesine neden olmu&#351;tur.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu kafa
kar&#305;&#351;&#305;kl&#305;&#287;&#305;n&#305;n nedeni AH�nin yukarda
�zetlenmeye �al&#305;&#351;&#305;lan s�rekli de&#287;i&#351;en dinamik
do&#287;as&#305;na kar&#351;&#305;n hastal&#305;&#287;&#305; tan&#305;ma,
�tetik�ilik� kavram&#305;n&#305; anlama gibi bir dizi etmene indirgenebilir.
Her &#351;eyden �nce &#351;imdiki durumda Alzheimer hastas&#305;
dendi&#287;inde demansl&#305; bir ki&#351;i anla&#351;&#305;lmakta ve bu t�rden
�al&#305;&#351;malar demansl&#305; hastalar toplanarak yap&#305;lmaktad&#305;r.
Daha �nce g�zden ge�irildi&#287;i gibi demans AH�nin olduk�a ileri bir evresine
kar&#351;&#305;l&#305;k gelmektedir ve bu ileri evrede amiloidle ba&#351;a
�&#305;kmak yeterli olmamaktad&#305;r. Alzheimerli beyin, ordular&#305;n
s�rekli yeniden mevzilendi&#287;i bir sava&#351; alan&#305; gibi
d�&#351;�n�lebilir. Demans a&#351;amas&#305; bu sava&#351;&#305;n art&#305;k
b�y�k �l��de kaybedildi&#287;i bir evreye kar&#351;&#305;l&#305;k gelmektedir.
�yle g�r�n�yor ki bu sava&#351;&#305;n ba&#351;lang&#305;c&#305;nda
savunman&#305;n hen�z ba&#351;ar&#305;l&#305; oldu&#287;u d�nemde kolay degrade
edilebilen A&#946;<sub>40</sub>�&#305;n g�venlik kuvvetleri olarak
d�&#351;�n�lebilecek &#351;aperon molek�ller arac&#305;l&#305;&#287;&#305;yla
klirensini sa&#287;lamak ve kolay ba&#351;a �&#305;k&#305;lamayan daha
sald&#305;rgan A&#946;<sub>42</sub>�yi gev&#351;ek plaklarda hapsetmek temel
savunma stratejisidir. B�ylesi bir ��at&#305;&#351;man&#305;n� hen�z hi� bir
kognitif yak&#305;nmas&#305; olmayan bir ya&#351;l&#305;n&#305;n beyninde
s�rmekte oldu&#287;u ileri s�r�lebilir (AH�nin pre-klinik evresi). &#304;lk
savunma mevzilerinin d�&#351;meye ba&#351;lamas&#305;yla sald&#305;rgan&#305;n
A&#946; (3(pE)-42 gibi daha elit birlikleri h�cre i�ine girip sinapslar&#305;
�ld�rmeye ba&#351;layacak ve bu kez savunma bunlar&#305; �l� sinaps
art&#305;klar&#305;n&#305; da i�eren daha maliyetli ekstrasel�ler n�ritik
plaklara ve intrasel�ler agrezomlara hapsetmeye �al&#305;&#351;acakt&#305;r. Bu
a&#351;amada savunma da ins�lin, sirtuin, WnT, sRAGE gibi kendi elit
birliklerini devreye sokarak sald&#305;r&#305;ya g�&#287;�s germeye
�al&#305;&#351;acakt&#305;r. &#304;lk savunman&#305;n b�ylesi ��kmesinin
kar&#351;&#305;l&#305;&#287;&#305; AH�nin pre-demans veya MCI a&#351;amas&#305;
olarak d�&#351;�n�lebilir. Bu ikinci savunma mevzisi de ��kecek olursa bu kez
tau da sald&#305;rgan&#305;n 2. elit birli&#287;i olarak devreye girecek ve en
ba&#351;ar&#305;l&#305; oldu&#287;u sava&#351; alan&#305; olan limbik sistemden
ba&#351;layarak n�ronlar&#305; �ld�rmeye ba&#351;layacakt&#305;r. Bu ���nc�
a&#351;ama AH�nin demans evresidir ve tau yeni mevziler kazan&#305;p
yay&#305;ld&#305;k�a savunma da giderek &#351;iddetlenen demans maliyetini
�demek pahas&#305;na, sonuna kadar direnebilece&#287;i en tahkim edilmi&#351;
b�lgeleri olan primer sensori-motor alanlara do&#287;ru geri �ekilecektir. Bu
senaryoya g�re bir �tetik�i� tan&#305;mlamak gerekiyorsa bu A&#946; de&#287;il
fakat n�ronun ba&#351;l&#305;ca katili olan taudur gibi durmaktad&#305;r.
A&#946;�y&#305; ise tetik�iyi tutan sponsor olarak d�&#351;�nebiliriz. Bu
senaryoya g�re AH�den korunman&#305;n yolu sponsorun tetik�iyi bulmas&#305;na
engel olmak gibi durmaktad&#305;r. �yleyse, hastal&#305;&#287;&#305; demans
�ncesi a&#351;amas&#305;nda, hatta pre-klinik d�neminde tan&#305;mak art&#305;k
bir zorunluluk olmu&#351;tur. �yle g�r�n�yor ki AH�nin bu demans �ncesi
evreleri yeterli duyarl&#305;l&#305;k ve �zg�ll�kte belirlenip
tan&#305;nd&#305;ktan sonra �e&#351;itli anti-amiloid stratejileri bu erken
a&#351;amalarda denemek, bu ilk savunma kaybedildi&#287;inde veya zaten
hastal&#305;k gecikmi&#351; demans a&#351;amas&#305;nda
tan&#305;nd&#305;&#287;&#305;nda bu kez ba&#351;l&#305;ca anti-tau stratejilere
y�nelmek gerekecektir. �n�m�zdeki ony&#305;l&#305;n genetik ve �evresel olarak
AH riski ta&#351;&#305;yan normal ya&#351;l&#305; bireylerin ve ger�ekte
prodromal AH olan AAMI ve MCI�l&#305; bireylerin biyo-i&#351;aretleyici
kombinezonlar&#305;yla hassasiyetle ay&#305;rtedilip anti-amiloid tedavi klinik
�al&#305;&#351;malar&#305;na dahil edilece&#287;i ve AH demans&#305; i�in
ba&#351;ar&#305;l&#305; anti-tau ajanlar&#305;n geli&#351;tirilece&#287;i bir
d�nem olaca&#287;&#305;n&#305; ileri s�rmek bir kehanet
olmayacakt&#305;r.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam, AH�nin nedenselli&#287;i i�in baptizm ve
tauizm d&#305;&#351;&#305;nda kalan ve hastal&#305;&#287;&#305;n
ya&#351;l&#305;l&#305;k riskiyle n�roanatomik yatk&#305;nl&#305;k
tarz&#305;n&#305; gayet iyi a�&#305;klayan �n�roplastisite yetmezli&#287;i� teorisini
ileri s�rm�&#351;t�r (Mesulam, 2000, Mesulam, 1999). Bu hipoteze g�re AH �zetle,
genetik ve �evresel etkilerle ya&#351;am boyunca artarak biriken plastisite
y�k�n�n art&#305;k kald&#305;r&#305;lamaz olmas&#305; ile normal
ya&#351;lanmadan sapman&#305;n sonu�lar&#305;d&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�roplastisite, MSS�nin yeni ya&#351;ant&#305;lama
ve doku hasar&#305;na kar&#351;&#305; verdi&#287;i yap&#305;sal tepkileri
i�erir.&nbsp; N�ronun post-mitotik bir h�cre olmas&#305; dolay&#305;s&#305;yla,
h�cre yenilenmesi �zelli&#287;i olmayan MSS�de ontogenezin intra-uterin ve
do&#287;um sonras&#305; ergenlik boyunca da s�recek l d�nemlerinde&nbsp; b�y�k
bir dinamizm g�r�l�r.&nbsp; Genetik olarak belirlenen ve s&#305;n&#305;rlanan
&nbsp;bir �er�evede, daha intra-uterin d�nemden ba&#351;layarak �evresel
uyaranlar&#305;n mod�latuar etkisi alt&#305;nda n�ral geli&#351;imin temel
mekanizmalar&#305; olan n�rogenez, n�ral migrasyon, n�ral eliminasyon ve
stabilizasyon, sinaptogenez ve aksonal miyelinizasyon ilerleyici bir &#351;ekilde
tamamlan&#305;r.&nbsp; Eri&#351;kin MSS�ye ait mimari tamamlanmadan �nce,
n�roplastisitenin nerdeyse s&#305;n&#305;rs&#305;z potansiyeli ile, genetik
olarak verilenin �er�evesi i�ine, o bireyin maruz kald&#305;&#287;&#305;, hi�
bir zaman ba&#351;ka bir bireyle tam anlam&#305;yla �rt�&#351;meyecek olan,
emsalsiz ya&#351;ant&#305; par�alar&#305;n&#305;n temsili, yukarda an&#305;lan
mekanizmalarla, ki&#351;ili&#287;i de olu&#351;turmak �zere
yerle&#351;ir.&nbsp; Eri&#351;kin MSS�nin plastik dinamizmi geli&#351;imsel
a&#351;amadaki d�zeyini yitirir.&nbsp; Geli&#351;imsel d�nemde her kritik yeni
ya&#351;ant&#305;lama ki&#351;ili&#287;i olu&#351;turacak yeni bir yap&#305;ta&#351;&#305;
olarak MSS�ye kaydedilirken, eri&#351;kin d�nemde art&#305;k kritik ya&#351;am
deneyimleri bu denli b�y�k de&#287;i&#351;ikliklere yola�maz. Geli&#351;imsel
d�nemde bir hemisferektomiyi tolere edebilecek durumda olan MSS, eri&#351;kinli&#287;e
ula&#351;t&#305;ktan sonra bir hemisferin �ok daha s&#305;n&#305;rl&#305; bir
alan&#305;ndaki hasar sonucu a&#287;&#305;r d�zeyde sakatlanabilir.&nbsp;&nbsp;
Yine de, n�roplastisite eri&#351;kin d�nemle birlikte t�mden durmaz.&nbsp; Yeni
�&#287;renme, a&#351;&#305;nma ve hasar onar&#305;m&#305; ama�l&#305; olarak
MSS�nin belli b�lgelerinde daha belirgin olmak �zere devam eder.&nbsp; Bunlar
aksonal tomurcuklanma, dendritik dallanma, yeni sinaps olu&#351;umu
(sinaptogenez) ve varolan sinaps&#305;n yeniden &#351;ekillenmesi (sinaptik
�remodeling�) ve uzun s�reli potensiasyon (LTP) olarak
s&#305;ralanabilir.&nbsp; Bu mekanizmalar yeni ya&#351;ant&#305;lar&#305;n
temsili ihtiyac&#305;na kar&#351;&#305; ya&#351;ant&#305;lama
ba&#287;&#305;ml&#305; plastisite ile a&#351;&#305;nma, y&#305;pranma ve hasara
cevap olan reaktif veya kompansatuar plastisitenin temel
mekanizmalar&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam varsay&#305;m&#305;n&#305; bilinen AH ile
ilintili t�m risk fakt�rleri ve patolojik �r�nlerin n�roplastisiteye m�dahale
etti&#287;ine ili&#351;kin delillerle desteklemektedir.&nbsp; N�roplastisite
potansiyeli, AH�de NFY olu&#351;umunun yay&#305;l&#305;m&#305; ile �rt�&#351;�r
bi�imde en y�ksek limbik sistemde iken, azalan s&#305;rayla paralimbik
yap&#305;lar, asoasiasyon neokorteksi ve en az da primer sensoryel-motor
korteksler &#351;eklinde kendini g�sterir.<b>&nbsp; </b><i>MAP-</i></span><i><span
style='font-family:Tahoma;mso-fareast-font-family:Batang'>&#964;</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> �retimi ve
fosforilizasyonunda art&#305;&#351; plastik de&#287;i&#351;iklikler s�recinin
temel i&#351;lemlerindendir.&nbsp; �zellikle plastisite y�k�n�n y�ksek
oldu&#287;u b�lgelerde kinaz-fosfataz d�ng�s�n�n dengesinin bozulmas&#305;
plastik talep kar&#351;&#305;s&#305;nda fosforillenmi&#351; taunun g�revi
bitti&#287;inde defosforilizasyonunun sa&#287;lanamayarak yukarda
s�zedildi&#287;i gibi patolojik katlanmas&#305;na ve birikim e&#287;ilimi
g�steren oligomerlere d�n�&#351;mesine neden olmaktad&#305;r.&nbsp; <i>APP</i>,
daha �nce de s�zedildi&#287;i gibi, eri&#351;kin beyninde ba&#351;l&#305;ca sinaptik
b�t�nl�&#287;�n korunmas&#305; olmak �zere, n�roplastisitedeki rol� deneysel
olarak g�sterilmi&#351; bir membran proteinidir.&nbsp; APP proteolizi sonucunda
&#945;-sekretaz ile kesilen �r�n olan sAPP�nin de n�rit b�y�mesi ve LTP�deki
rol� bilinmektedir.&nbsp; Buna kar&#351;&#305;l&#305;k, &#946; sekretazla
alternatif kesim sonucu olu&#351;an A&#946; fragman&#305; n�rotoksiktir,
aksonal tomurcuklanma ve LTP�yi inhibe eder.&nbsp; &#946;-sekretaz&#305;n
distal amino terminal �r�n� olan sAPP&#946;�n&#305;n da akson budanmas&#305;
tarz&#305; anti-plastisite etkisinden yukarda s�zedilmi&#351;ti. PS1�in, n�rogenezde
�ok �nemli i&#351;levi olan Notch proteini ile etkile&#351;erek i&#351;lev
g�rd�&#287;�ne de de&#287;inilmi&#351;ti. Bu etkile&#351;imin eri&#351;kin
beyninde plastisite y�kseltici etkileri g�sterilmi&#351;tir.&nbsp; PS1 ve PS2
mutasyonlar&#305; APP proteolizini A&#946; yoluna kayd&#305;rmak yan&#305;
s&#305;ra, Notch ile an&#305;lan etkile&#351;imi g�steremeyen bozuk �r�nlere
yol a�arak da plastisite potansiyelini bask&#305;l&#305;yor olabilir.&nbsp;
Kolesterol ve fosfolipidlerin transsel�ler naklinde rol oynayan ve
dolay&#305;s&#305;yla aksonal b�y�me ve sinaptogeneze katk&#305;da
bulundu&#287;u d�&#351;�n�lebilecek<b> </b><i>ApoE�</i>nin plastisite ile&nbsp;
ili&#351;kisine daha �nce de&#287;inilmi&#351;ti.&nbsp; Buna g�re ApoE-&#949;4
plastisiteyi bask&#305;larken, ApoE-&#949;3 ve &#949;2 y�kseltici etki
g�stermektedir.&nbsp; Yine <i>�strojenin </i>n�rotrofik etkilerine
de&#287;inilmi&#351;ti.&nbsp; <b>Ya&#351; </b>AH i�in temel risk
fakt�r�d�r.&nbsp; Uzun �m�r do&#287;al olarak hem ya&#351;ant&#305;lama
ba&#287;&#305;ml&#305; plastisite, hem de a&#351;&#305;nma, y&#305;pranma ve
hasarlanman&#305;n artmas&#305;yla kompansatuar plastisite ihtiyac&#305;n&#305;
artt&#305;rmaktad&#305;r.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Dolay&#305;s&#305;yla da ya&#351;la birlikte artan
bu ihtiyac&#305; kar&#351;&#305;lamak i�in gerek &#964; fosforilasyonunda ve
gerekse de APP ekspresyonundaki adaptif art&#305;&#351;la birlikte denge ne
kadar plastisite y�kseltici fakt�rler lehine ise o kadar AH patolojisinden
korunulabilmekte, tersine durumda ise bir yandan serbest &#964; polimerlerinden
NFY olu&#351;umu, di&#287;er yandan&nbsp; da A&#946;�n&#305;n �nce gev&#351;ek
plaklarda birikmesi, sonras&#305;nda da bunlar&#305;n kat&#305; plaklara
d�n�&#351;mesi artmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�a&#287;da&#351; uygarl&#305;k tek bir bireyin
optimal adaptasyonu i�in y�ksek bir kognitif kapasite, �zellikle de bellek
kapasitesi talep etmektedir.&nbsp; �a&#287;da&#351; insan genetik
yap&#305;s&#305;n&#305;, o d�nemin do&#287;al �evresine adaptasyon i�in
seleksiyona u&#287;ram&#305;&#351; 30.000 y&#305;l �nceki
avc&#305;-toplay&#305;c&#305; uygarl&#305;&#287;&#305;n&#305;n Homo
sapiensinden miras alm&#305;&#351;t&#305;r.&nbsp; Avc&#305;-toplay&#305;c&#305;
uygarl&#305;&#287;&#305;na k&#305;yasla gerek bireysel olarak uzayan �m�r ve
gerekse de sosyal olarak nicel ve nitel a�&#305;lardan ola&#287;an�st�
de&#287;i&#351;en ko&#351;ullar n�roplastisite y�k�n�
ta&#351;&#305;n&#305;lamaz hale getirerek AH�yi modern insanl&#305;k durumunun
ka�&#305;n&#305;lmaz bir e&#351;lik�isi yapmaktad&#305;r.&nbsp; Bu perspektifle
bak&#305;ld&#305;&#287;&#305;nda yukarda resmedilen sava&#351; senaryosunun
taraflar&#305; da pro-plastisite ve anti-plastisite g��ler olmaktad&#305;r.
Dolay&#305;s&#305;yla, n�roplastisite y�k�ne odaklan&#305;lmayan uzun �m�r veya
AH kesin tedavisi d�&#351;leri de anlams&#305;zla&#351;maktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TEDAV&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH�de mevcut ve deneysel tedavilere toplu bir
bak&#305;&#351; i�in <b>Tablo 16�</b> ya bak&#305;n&#305;z.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><a href="tablo16.JPG">Tablo 16.</a>
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n yerle&#351;ik ve potansiyel tedavi
stratejileri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif Semptomatik Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Halen tedavinin �ekirde&#287;ini&nbsp;
kolinesteraz inhibit�rleri (ChE&#304;�ler) ve memantin ile kognitif semptomatik
tedavi olu&#351;turmaktad&#305;r.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kolinesteraz &#304;nhibit�rleri</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Takrinin (Cognex<sup>�</sup>) 1993
y&#305;l&#305;nda Amerika Besin ve &#304;la� &#304;daresi (FDA) taraf&#305;ndan
Alzheimer hastal&#305;&#287;&#305;n&#305;n tedavisi i�in
ruhsatland&#305;r&#305;lmas&#305; o zamana kadar tedavi edilemez kategoride
kabul edilen bir hastal&#305;k i�in ilk onaylanm&#305;&#351; tedavi olmas&#305;
anlam&#305;na geliyordu.&nbsp; AH tedavisinde bir ilac&#305;n FDA onay&#305;
almas&#305; i�in yaln&#305;zca bir k&#305;s&#305;m kognitif sonlan&#305;m
�l��t�nde de&#287;il, klinik olarak da g�zlenebilir bir etkisinin olmas&#305;
(GYA�lar ile davran&#305;&#351; �zerine ve genel klinik izlenim olarak) ve bu
etkisini en az 6 ayl&#305;k bir s�re i�inde korurken g�venilir de olmas&#305;
gerekmektedir.&nbsp; Bu ruhsat takrinin 1987�de ba&#351;lad&#305;&#287;&#305;
klinik �al&#305;&#351;malar s&#305;navlar&#305;ndan sonunda ge�ti&#287;ini
sembolize ediyordu ayn&#305; zamanda.&nbsp; Ancak bir yandan gastro-intestinal
yan etkilerinin &#351;iddeti etkili doza �&#305;kmay&#305;
s&#305;n&#305;rlarken, bir yandan da hepatotoksisite nedeniyle haftal&#305;k
karaci&#287;er enzimleri taramas&#305; zorunlulu&#287;u kullan&#305;m&#305;
iyiden iyiye g��le&#351;tirmekteydi.&nbsp;&nbsp; 1990�lar&#305;n 2. yar&#305;s&#305;ndan
itibaren yan etki profili a�&#305;s&#305;ndan daha kullan&#305;&#351;l&#305;
ChE&#304;�lerin birbiri ard&#305;na ruhsatland&#305;r&#305;lmas&#305; takrinin
piyasa �mr�n�n �ok k&#305;sa olmas&#305;na neden oldu.&nbsp; Yine de AH
tedavisinde �ilk g�z a&#287;r&#305;s&#305;� olma onuru ebediyyen takrine ait
olacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Donepezil (Aricept<sup>�</sup>), rivastigmin
(Exelon<sup>�</sup>) ve galantamin (Remynil<sup>�</sup>) s&#305;nanan �ok
say&#305;da ChE&#304;�den &#351;imdiye kadar ruhsatlananlard&#305;r.&nbsp;
Bunlar&#305;n hepsi de �lkemizde mevcuttur ve ilk ikisinin �ok say&#305;da
jenerik muadili de �&#305;km&#305;&#351;t&#305;r. &#350;imdiye kadar piyasaya
verilmi&#351; olsun olmas&#305;n klinik �al&#305;&#351;malarda d�zg�n bi�imde
s&#305;nanan t�m ChE&#304;�ler ba&#351;ar&#305;l&#305; olmu&#351;tur. B�t�n
CHE&#304;�ler i�in klinik �al&#305;&#351;malarda genel olarak s�ylenebilecek
olan ortak etki plaseboya g�re anlaml&#305; farkl&#305;l&#305;&#287;&#305;n
yan&#305;s&#305;ra, sonlan&#305;m �l��tlerinin zaman i�indeki de&#287;i&#351;im
e&#287;rileri izlendi&#287;inde 6. ayda plasebo grubu k�t�le&#351;mi&#351;ken,
k�t�le&#351;meksizin hala ba&#351;lang&#305;� noktas&#305;nda olma ve 1.
y&#305;lda ba&#351;lang&#305;� noktas&#305;na g�re k�t�le&#351;meye
kar&#351;&#305;n ChE&#304; �ncesi d�nemin uzunlamas&#305;na izlemlerdeki
bozulma h&#305;zlar&#305;na referansla (�tarihsel plasebo�) daha iyi durumda
olmakt&#305;r.&nbsp;Plasebo grubundayken 6. ayda a�&#305;k etiketli uzatma
evresinde aktif ilaca ge�irilen hastalar ba&#351;lang&#305;�ta d�zelseler de
sonras&#305;nda bozulmaya ba&#351;larlar ve e&#287;rileri hi� bir zaman
ba&#351;tan beri aktif grupta olanlar&#305;n e&#287;risini kesmeden izlem
boyunca paralel olarak bozulurlar.&nbsp; Dolay&#305;s&#305;yla, ChE&#304;�lerin
hastaya yakla&#351;&#305;k 1 y&#305;l kazand&#305;rd&#305;&#287;&#305; ve
tan&#305; konulduktan sonra ilaca ne kadar erken ba&#351;lan&#305;rsa o kadar
iyi oldu&#287;u s�ylenebilir.&nbsp;Donepezil (FDA onay&#305; 1996) g�nde tek
doz (prospekt�s bilgisi ak&#351;amlar&#305; �nerirken biz birimimizde bazen
uykuyu bozmas&#305; ve fazik fizyolojik kolinerjik aktiviteyle uyumu nedeniyle
sabahlar&#305; tercih ediyoruz), 5 ila 10 mg tabletler &#351;eklinde
kullan&#305;lan selektif bir ChE&#304;�dir.&nbsp;Her 2 dozu da etkin olmakla
birlikte y�ksek dozun etkinli&#287;i de daha y�ksektir. Ba&#351;ta G&#304;S�e
ait olanlar olmak �zere, yan etkileriyle ba&#351; edebilmek i�in 4 haftada
titrasyonla y�ksek doza �&#305;kmak uygundur. Yak&#305;n tarihlerde piyasaya
verilen a&#287;&#305;zda eriyen &#351;ekli yutma g��l�&#287;� de olan �zellikle
ileri evre hastalarda yararl&#305; olmaktad&#305;r. Rivastigmin (FDA onay&#305;
1997) 1.5, 3, 4.5 ve 6 mg�l&#305;k kaps�ller &#351;eklinde
piyasadad&#305;r.&nbsp; B�tiril kolin esteraz (BuChE) inhibisyonu etkisi de
olan ve g�nde iki kez kullan&#305;lan rivastigminin en d�&#351;�k etkili dozu 6
mg/g�n olmak �zere, 4�er haftal&#305;k titrasyonlarla 12 mg/g�n�e y�kseltilmesi
hedeflenmektedir.&nbsp;Renksiz ve kokusuz s&#305;v&#305; &#351;ekli ila�
kullanmay&#305; reddeden hastalarda kullan&#305;m&#305;
kolayla&#351;t&#305;rm&#305;&#351;t&#305;r. AChE&#304;�lerin kafa kafaya
kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305; en kaliteli �al&#305;&#351;ma
olan, b�y�k boyutlu ve uzun s�reli EXCEED isimli �al&#305;&#351;mada ikinci
y&#305;l&#305;n sonunda rivastigmin 2 ikincil sonlan&#305;m �l��t�nde (demans
evrelendirmesi ve GYA�lar) donepezile �st�n bulunmu&#351;sa da donepezil de ilk
4 ayl&#305;k titrasyon d�neminde rivastigmine k&#305;yasla anlaml&#305; �l��de
daha iyi tolere edilmi&#351;tir. Birincil sonlan&#305;m �l��t� (kognitif)
a�&#305;s&#305;ndan her 2 ilac&#305; kullananlar&#305;n da yakla&#351;&#305;k
%35�i 2. y&#305;l&#305;n sonunda ba&#351;lang&#305;� noktalar&#305;ndan daha
iyi durumdayd&#305;lar. Rivastigmin yak&#305;nlarda deriden emilen bant
formunun oral formuna e&#351;de&#287;er etkinli&#287;i ve plaseboya yak&#305;n
tolerabilitesini g�sterdi&#287;i IDEAL �al&#305;&#351;mas&#305;yla kayda
de&#287;er bir yenilik getirmi&#351; oldu. &#304;lki 6mg/g�n, ikincisi 12mg/g�n
klasik dozlar&#305;na e&#351;it 5 ve 10cm<sup>2 </sup>dozlar&#305;yla piyasada
olan bant &#351;ekli de 4 haftada titre edilmelidir.&nbsp; Galantamin (FDA
onay&#305; 2001) 8, 16 ve 24 mg/g�n aral&#305;&#287;&#305;nda g�nde iki doz
&#351;eklinde kullan&#305;lan ve pre-sinaptik allosterik nikotinik resept�r
mod�lasyonu etkisi de olan bir ChE&#304;�dir.&nbsp; �nce s&#305;v&#305;
&#351;ekli, daha sonra da yava&#351; emilen kaps�l formu piyasaya
verilmi&#351;tir. S&#305;v&#305; form hala g�nde 2 doz &#351;eklinde 4�er
haftal&#305;k titrasyonla �nce etkisiz 8mg/g�n ile ba&#351;lan&#305;p, 4 hafta
sonra etkin oldu&#287;u ilk doz d�zeyi olan 16mg/g�n, son olarak da kompliyans
sa&#287;lanabildi&#287;i takdirde 24mg/g�n d�zeyine
�&#305;k&#305;lmal&#305;d&#305;r. Kaps�l formu g�nde tek doz benzer titrasyon
&#351;emas&#305;yla artt&#305;r&#305;lmal&#305;d&#305;r. En d�&#351;�k dozdan
ba&#351;lay&#305;p 4 haftal&#305;k aral&#305;klarla y�kselindi&#287;inde ���
i�in de ortak problem olan bulant&#305;-kusma ile ba&#351;a �&#305;kmak daha
kolay olmaktad&#305;r.&nbsp;ChE&#304;�ler hafif ve orta evre AH�de
kullan&#305;m i�in ruhsatlanm&#305;&#351; olsa da a&#287;&#305;r evrede
yararlar&#305;na ili&#351;kin gerek klinik �al&#305;&#351;ma ve gerekse de
kendi deneyimizden anekdotal deliller bulunmaktad&#305;r.&nbsp;
&#304;la�lar&#305;n etkisizlik ve kesilme kararlar&#305;na ili&#351;kin �ok
a&#351;ikar g�stergeler olmasa da, d�zenli kullan&#305;lan ilaca
kar&#351;&#305;n y&#305;l i�inde s�rekli k�t�le&#351;me g�zlemleri sonucunda
kesme karar&#305; verilebilir.&nbsp; Yine gerek bizim deneyimimiz ve gerekse
birinden di&#287;erine ge�i&#351; verileri (�switch data�), ila�lardan biri
kesildi&#287;inde di&#287;erinin kullan&#305;lmaya ba&#351;lanmas&#305;n&#305;n
hastalar&#305;n %50�sinde yararl&#305; olabildi&#287;ini g�stermektedir
.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ChE&#304;�lerin non-kognitif ya da
davran&#305;&#351;sal belirtiler �zerindeki olumlu etkileri de
bildirilmektedir.&nbsp;&nbsp; Buna bir sonraki b�l�mde de&#287;inilecektir.
ChE&#304;�ler b�y�k �l��de hafif-orta evre hastalarda
�al&#305;&#351;&#305;lm&#305;&#351; ve bu evrelerde kullan&#305;m i�in
endikasyon alm&#305;&#351;lard&#305;r. Bununla birlikte, orta-a&#287;&#305;r
evre �al&#305;&#351;malar&#305; da genellikle pozitiftir. G�n�m�ze kadar
biriken verilerin kapsaml&#305; bir g�zden ge�irmesi i�in Cochrane
veritaban&#305;na bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Memantin</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ChE&#304;�lerden sonra bu kez farkl&#305; bir etki
mekanizmas&#305;na sahip olan bir ajan daha onay alm&#305;&#351;, b�ylece
kolinerjik n�rotransmisyonun yan&#305;s&#305;ra glutamaterjik n�rotransmisyonun
da NMDA resept�r mod�lasyonu arac&#305;l&#305;&#287;&#305;yla d�zenlenmesinin
AH�de bir tedavi stratejisi olabilece&#287;i
kan&#305;tlanm&#305;&#351;t&#305;r. Memantin (FDA onay&#305; 2003) d�&#351;�k
afiniteli bir NMDA resept�r antagonistidir. Memantinin bozuk Alzheimer
sinaps&#305;nda post-sinaptik NMDA resept�r�nde magnezyum t&#305;kac&#305;
g�revi yaparak patolojik intrasel�ler kalsiyum birikimini engelledi&#287;i
bilinmektedir. Buna kar&#351;&#305;l&#305;k, NMDA antagonizmini geri
d�n�&#351;�ms�z de&#287;il fakat d�&#351;�k afiniteyle
yapt&#305;&#287;&#305;ndan, NMDA resept�rleri arac&#305;l&#305;kl&#305; normal
glutamaterjik n�rotransmisyon i�in gerekli olan depolarizan bir uyaranla
magnezyumun yapaca&#287;&#305; gibi resept�r� terketmekte ve b�ylelikle de LTP
mekanizmas&#305;na engel olmamaktad&#305;r. LTP bozuklu&#287;unun AH
fizyopatolojisinin erken ve temel �zelliklerinden biri oldu&#287;una yukarda
de&#287;inilmi&#351;ti. Memantinin 10mg�l&#305;k tablet &#351;eklinde piyasaya
verilmi&#351;tir ve g�nde 2 doz kullan&#305;lacak &#351;ekilde, haftada
5mg�l&#305;k art&#305;&#351;larla 4. haftada 20mg/g�n dozuna ula&#351;&#305;l&#305;r.
Sonradan bu g�nl�k dozun gece tek doz verilmesinin de tolerabiliteyi
bozmad&#305;&#287;&#305;, buna kar&#351;&#305;l&#305;k bir k&#305;s&#305;m
hastada g�r�lebilen g�nd�z sedasyonuyla ba&#351;a �&#305;kmay&#305;
kolayla&#351;t&#305;rd&#305;&#287;&#305; g�r�lm�&#351;t�r. &#304;zleyerek,
memantinin de s&#305;v&#305; formu 10 damla = 5mg olacak &#351;ekilde
geli&#351;tirilmi&#351; ve ChE&#304;�lerde oldu&#287;u gibi yutma g��l�&#287;�
ve ila� reddi olan hastalarda kullan&#305;m kolayl&#305;&#287;&#305;
sa&#287;lam&#305;&#351;t&#305;r. Yine de g�nl�k toplam doza 40 damlayla
ula&#351;&#305;lmas&#305; bir g��l�k nedeniyken bu sorun da yeni piyasaya
verilen pompal&#305; s&#305;v&#305; formuyla a&#351;&#305;lm&#305;&#351; gibi
g�r�nmektedir. Bu yeni formda bir bardak su i�ine akacak &#351;ekilde pompa
d�zene&#287;ine bir kez bas&#305;&#351; 5 mg e&#351;de&#287;eri memantin
sa&#287;lamaktad&#305;r. ChE&#304;�lerin oldu&#287;u gibi memantinin de
non-kognitif, davran&#305;&#351;sal etkileri mevcuttur ve bunlara
a&#351;a&#287;&#305;da de&#287;inilecektir. G�n�m�ze kadar biriken verilerin
son sistematik metaanalizi i�in Cochrane veritaban&#305;na bak&#305;n&#305;z. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH�de mevcut tedaviler olan ChE&#304;�ler ve
memantinin etkileri genel olarak m�tevazi g�r�nse de bu tedavilerin
eri&#351;ilebilir olmas&#305;ndan itibaren hasta ve yak&#305;nlar&#305;n&#305;n
ya&#351;am kalitelerine katk&#305;lar&#305; oldu&#287;u ku&#351;kusuzdur. Bu
y�nde �zellikle de end�stri sponsorlu&#287;unda olmayan, ABD�nin 2 ayr&#305;
m�kemmeliyet merkezi diyebilece&#287;imiz Alzheimer merkezinden gelen 2
ba&#287;&#305;ms&#305;z �al&#305;&#351;man&#305;n verileri olduk�a �nemlidir.
Bunlar&#305;n ilkinde Boston, Massachusetts General Hospital Alzheimer
Merkezi�nin 1990-2005 y&#305;llar&#305; aras&#305;ndaki verileri analiz
edilmi&#351;. Bu 15 y&#305;l&#305;n ba&#351;lar&#305; ila�s&#305;z d�nem,
ortalar&#305; sadece ChE&#304;�lere eri&#351;ilebilen d�nem ve sonlar&#305; ise
ChE&#304; memantin kombinasyonunun m�mk�n oldu&#287;u d�nemdir. Bu
�al&#305;&#351;man&#305;n sonu�lar&#305;, ortalama 30 ay izlenen 382 hastada, kognitif
ve fonksiyonel sonlan&#305;m �l��tleri a�&#305;s&#305;ndan solo ChE&#304;
kullanan grubun ila�s&#305;z gruptan daha iyi, ChE&#304;+memantin kombinasyon
tedavisi kullanan grubun ise her ikisinden de daha iyi oldu&#287;u y�n�ndedir.
&#304;kincisinde Pittsburgh �niversitesi Alzheimer Merkezi�nin 1983-2006
aras&#305; verileri analiz edilmi&#351;tir. Bu 23 y&#305;ll&#305;k d�nem de
benzer &#351;ekilde ila�s&#305;z, tek ba&#351;&#305;na ChE&#304;�li ve
kombinasyon tedavili d�nemler olarak ayr&#305;labiliyor. Bu kez bak&#305;mevine
yat&#305;r&#305;lma bir sonlan&#305;m �l��t� olarak al&#305;nm&#305;&#351; ve
ortalama 60 ay izlenen hastalarda solo ChE&#304;�nin ila�s&#305;z gruba g�re bu
s�reyi geciktirdi&#287;i, kombinasyon tedavisinin ise yine her ikisine g�re
daha dageciktirdi&#287;i g�sterilmi&#351;tir .<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Non-Kognitif Semptomatik Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ChE&#304;�lerin �zellikle hal�sinasyon ve
hezeyanlar &#351;eklindeki psikotik belirtilere, ajitasyon ve apatiye iyi
gelebildi&#287;i g�sterilmi&#351;tir.&nbsp; Benzer &#351;ekilde, memantinin de
psikotik belirtilere ve �zellikle de ajitasyona iyi geldi&#287;i
g�sterilmi&#351;tir, Biriken verilerin analizi memantinin mevcut ajitasyonu
kontrol alt&#305;na alabildi&#287;i gibi uzunlamas&#305;na izlemde ila�
kullanan hastalarda daha az ajitasyon ortaya �&#305;kt&#305;&#287;&#305;
g�zlemlenmi&#351;tir. Dolay&#305;s&#305;yla da, bu an&#305;lan belirtilerin
&#351;iddetleri anti-psikotiklerle derhal m�dahaleyi gerektirmedi&#287;i
durumlarda yeni ba&#351;lan&#305;lan bir ChE&#304;�nin ve/veya memantinin
onlar&#305;n �zerine muhtemel etkisini de&#287;erlendirmekle gereksiz ila�
kullan&#305;m&#305;n&#305;n da �n�ne ge�ilmi&#351; olur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Depresyon, mani ve anksiyete gibi duygudurum
bozukluklar&#305; AH�de s&#305;kt&#305;r.&nbsp; Depresyon tedavisinde �ncelikle
bu ya&#351; grubunda s&#305;k kullan&#305;lan ve depresyonu bizzat ortaya
�&#305;karabilecek veya &#351;iddetlendirebilecek olan reserpin,
&#945;-metil-dopa, &#946;-blokerler gibi anti-hipertansifler kesilerek kalsiyum
kanal blokerleri veya ACE inhibit�rleri gibi daha uygun ila�lara ge�ilmelidir.&nbsp;
Trisiklik anti-depresanlar anti-kolinerjik yan etkileri nedeniyle se�ilmemesi
gereken gruptur.&nbsp; SSRI grubundan ila�lar, venlafaksin, mirtazapin,
duloksetin gibi yeni ku&#351;ak hem serotonin, hem de norepinefrin
gerial&#305;m blokeri olan (SNRI) anti-depresanlar g�venle kullan&#305;labilir.&nbsp;
Tam bir mani olduk�a seyrek olsa da emosyonel labilite, iritabilite ve �fori
gibi �zellikleri bazen tedavi gerektirebilir.&nbsp; Bu durumda lityum,
karbamazepin ve valproat gibi duygudurum stabilizat�rleri
kullan&#305;labilir.&nbsp; Lityum ve valproat&#305;n GSK3&#946; inhibit�r�
olarak potansiyel i&#351;levleri klinik �al&#305;&#351;malarda
s&#305;nanmaktad&#305;r. Anksiyete tedavisinde �ok gerekmedik�e kognitif
depresan etkileri nedeniyle benzodiazepinlerden
ka�&#305;n&#305;lmal&#305;d&#305;r.&nbsp; SSRI�lar ve trazodon bu ama�la
�ncelikle se�ilebilir.&nbsp; Etkisiz kald&#305;&#287;&#305;nda lorazepam
(Ativan<sup>�</sup>) veya alprozalam (Xanax<sup>�</sup>) gibi k&#305;sa etkili
benzodiazepinler se�ilebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hezeyan ve hal�sinasyon gibi psikotik belirtilerin
tedavisinde ekstrapiramidal ve anti-kolinerjik yan etkilerden
ar&#305;nm&#305;&#351;l&#305;k ba&#351;l&#305;ca tercih nedenidir.&nbsp; Bu
nedenle atipik n�roleptikler �ncelikle tercih edilenlerdir.&nbsp; Risperidon
(Risperdal<sup>�</sup>) ve olanzapinin (Zyprexa<sup>�</sup>) ekstrapiramidal
yan etki potansiyelleri onlar&#305; ger�ek anlamda birer atipik olarak
s&#305;n&#305;flamay&#305; engellemektedir.&nbsp; Risperidonun aktif metaboliti
olan paliperidol (Invega<sup>�</sup>) yak&#305;n zamanlarda piyasaya
verilmi&#351;tir ve tek doz kullan&#305;labilen bu ajan&#305;n ger�ek bir
atipik oldu&#287;u, kilo ald&#305;rmad&#305;&#287;&#305; ve sedasyona neden
olmad&#305;&#287;&#305; ileri s�r�lmektedir. Klozapin&nbsp; (Leponex<sup>�</sup>)
�ok etkili bir atipik olsa da kemik ili&#287;i bask&#305;lama potansiyeli
nedeniyle haftal&#305;k l�kosit say&#305;mlar&#305;n&#305;n getirdi&#287;i
g��l�k kullan&#305;m&#305;n&#305; s&#305;n&#305;rlamaktad&#305;r.&nbsp;
Atipikler aras&#305;nda ketiapin (Seroquel<sup>�</sup>) di&#287;erleri i�in
s&#305;ralanan k&#305;s&#305;tlamalardan ar&#305;nm&#305;&#351; ve geni&#351;
bir g�venlik aral&#305;&#287;&#305;nda rahatl&#305;kla
kullan&#305;labilmektedir.&nbsp; Di&#287;erleriyle k&#305;yaslanamayacak kadar
ucuz olmas&#305; d�&#351;�k dozlarda haloperidol� (Norodol<sup>�</sup>) tipik
bir n�roleptik olsa da hala bir se�enek olarak korunmas&#305;na neden
olmaktad&#305;r.&nbsp; Demansta psikoz tedavisinde �ok d�&#351;�k dozlarda
ba&#351;lay&#305;p optimal dozu olguya g�re uyarlamak esast&#305;r.&nbsp; Dozun
t�m�n� ya da b�y�k b�l�m�n� g�nd�z sedasyonundan ka�&#305;nmak amac&#305;yla
geceleri vermek uygun olur.&nbsp; Ketiapin 50 ila 100 mg�l&#305;k dozlarda
genellikle etkin olurken, 400 mg/g�n d�zeylerine �&#305;karmak da gerekebilir.&nbsp;
Risperidon 0.5 ila 1 mg, seyrek olarak da 2 mg/g�n dozlar&#305;nda
kulan&#305;l&#305;r. Paliperidol ile demansl&#305; pop�lasyonda yeterli tecr�be
olmamakla birlikte en d�&#351;�k dozu olan 3 mg denebilir. Olanzapin dozu 2.5-5
mg, bazen 10 mg/g�n�d�r; bir klinik �al&#305;&#351;mada 15 mg/g�n�den itibaren
etkinli&#287;inin paradoksal olarak d�&#351;t�&#287;�
g�sterilmi&#351;tir.&nbsp; Klozapin 6.25 mg ila 50 mg/g�n dozlar&#305;nda
yeterli etkinlik g�sterse de bazen 200 mg/g�n dozlar&#305;na kadar �&#305;kmak
gerekebilmektedir.&nbsp; Haloperidol dozu 1 ila 3 mg/g�n aras&#305;nda
de&#287;i&#351;ebilir ve damla &#351;eklinde kullan&#305;m&#305; bir avantaj
olarak d�&#351;�n�lebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ajitasyon ve sald&#305;rganl&#305;&#287;&#305;n
tedavisinde yine atipik n�roleptikler ilk se�imlerdir. Ajitasyon i�in bazen tek
ba&#351;&#305;na trazodonla ba&#351;lay&#305;p cevap al&#305;nmazsa
n�roleptikleri tercih etmek bir se�enek olabilir.&nbsp;Karbamazepin, valproat
ve lityum da tek ba&#351;&#305;na ya da ilave tedavi olarak denenebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;mpulsivite ve d�rt� kontrol
kusurlar&#305;n&#305;n tedavisinde �ncelikle SSRI�lar
denenir.&nbsp;Hiperseks�alite i�in ayr&#305;ca anti-androjen ajanlar
kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Uykusuzluk tedavisinde ila�tan �nce yatmadan bir
s�re �nce i�ilecek &#305;l&#305;k s�t �nerilmelidir.&nbsp;Ger�ekte bir
anti-depresan olan trazodon (Desyrel<sup>�</sup>) 50-200 mg dozlar&#305;
aras&#305;nda yatmadan 1 saat �nce verildi&#287;inde olduk�a etkin bir sedatif
etki g�sterir.&nbsp; Mirtazapin (Remeron<sup>�</sup>) yatmadan �nce � tablet (15mg)
dozunda benzer etkiye sahiptir.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Non-Farmakolojik Tedavi</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tedaviye non-farmakolojik yakla&#351;&#305;m hasta
ve hasta yak&#305;n&#305; ile kurulan ve hastal&#305;kla ba&#351;a �&#305;kmaya
y�nelik ila� d&#305;&#351;&#305; etkile&#351;imin b�t�n�n� i�ermektedir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bunlar farkl&#305; ba&#351;l&#305;klarda
s&#305;ralanabilece&#287;i gibi hastal&#305;k evrelerine g�re de
farkl&#305;l&#305;k g�sterir.&nbsp; Evresel perspektif &#351;�yle
�zetlenebilir:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Erken evrede</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> hastal&#305;k hasta ve hasta
yak&#305;n&#305;na k�lt�re uyumlu bir &#351;ekilde anla&#351;&#305;labilir bir
&#351;ekilde aktar&#305;l&#305;r ve hastal&#305;&#287;&#305;n m�mk�n
oldu&#287;unca ayr&#305;nt&#305;l&#305; bir &#351;ekilde kavranaca&#287;&#305;
internet, Alzheimer dernek ve vak&#305;flar&#305;n&#305;n ve benzeri
kaynaklar&#305;n dergi, bro&#351;�r, kitap gibi bilgilendirici
yay&#305;nlar&#305;n&#305;n okunmas&#305; te&#351;vik edilir.&nbsp;Hastayla
vesayet meselelerini de i�erecek &#351;ekilde, gelece&#287;in ger�ek�i bir
bi�imde tasarlanmas&#305;na y�nelik tart&#305;&#351;&#305;lmaya gayret
edilir.&nbsp;Hobiler ve sosyal ili&#351;kileri s�rd�rmenin �nemi
aktar&#305;l&#305;r.&nbsp;Araba kullanmay&#305; s�rd�rmenin
sak&#305;ncalar&#305;ndan s�zedilir.&nbsp;Hasta yak&#305;n&#305;na destek gruplar&#305;
hakk&#305;nda bilgi verilir ve dernek aktivitelerinde yer almas&#305;
do&#287;rultusunda cesaretlendirilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Orta evrede</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> hasta ve hasta
yak&#305;n&#305;na yaln&#305;z soka&#287;a �&#305;kman&#305;n
sak&#305;ncalar&#305; anlat&#305;l&#305;r.&nbsp; Mali ve bunun gibi hukuksal
i&#351;lerde art&#305;k vesayetin zorunlulu&#287;u aktar&#305;l&#305;r.&nbsp;
Ev ayg&#305;tlar&#305;n&#305; kullanmadaki g��l�kler ve kaza ihtimalleri g�zden
ge�irilir.&nbsp; Giyinmek, y&#305;kanmak ve sofra davran&#305;&#351;&#305; gibi
g��l�kler ele al&#305;n&#305;r.&nbsp; Art&#305;k yaln&#305;z
ya&#351;amamas&#305; y�n�nde te&#351;vik edilir ve alternatifler ele
al&#305;n&#305;r.&nbsp; Psikotik belirtiler mevcutsa �evresel m�dahalelerle
ba&#351;a �&#305;k&#305;lmas&#305;na gayret edilir.&nbsp; Sfinkter kontrol�n�
artt&#305;r&#305;c&#305; y�ntemler �zerinde durulur.&nbsp; Bu t�r
kurulu&#351;lar o �evrede mevcut oldu&#287;unda g�nd�z bak&#305;m evlerinin
de&#287;erlendirilmesi te&#351;vik edilir.&nbsp; Hasta yak&#305;n&#305; y�k�
g�zden ge�irilir ve muhtemel bir depresyona kar&#351;&#305; �nlem
al&#305;n&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;leri evrede</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> hasta yak&#305;n&#305;yla
su�luluk duygular&#305;, hastal&#305;k y�k� ve kay&#305;p �zerine
tart&#305;&#351;&#305;l&#305;r.&nbsp;Evde profesyonel yard&#305;m ve bir �tesi
olarak kal&#305;c&#305; bir bak&#305;mevine nakil �zerine
tart&#305;&#351;&#305;l&#305;r ve te&#351;vik edilir.&nbsp;Yatak yaralar&#305;,
kontrakt�rler, �riner ve solunum sistemi infeksiyonlar&#305; riskleri konusunda
uyar&#305;l&#305;r.&nbsp; Sonda ile beslenme gereklili&#287;i ele
al&#305;n&#305;r.&nbsp; Nihayet terminal bak&#305;m ve �l�m meseleleri �zerinde
durulur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Spesifik m�dahale alanlar&#305; ise
a&#351;a&#287;&#305;daki &#351;ekilde s&#305;ralanabilir:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel performans a�&#305;s&#305;ndan
s�zel ipu�lar&#305;ndan fiziksel olarak g�stermeye kadar de&#287;i&#351;en
kademeli yard&#305;m&#305;n demansl&#305; hastan&#305;n g�nl�k
performans&#305;n&#305; artt&#305;rd&#305;&#287;&#305;
g�sterilmi&#351;tir.&nbsp; Davran&#305;&#351; modifikasyonu ile tuvaletin
uyar&#305;lmas&#305; veya saatlerinin �nceden belirlenmesi kuru kalmay&#305;
te&#351;vik eder.&nbsp; U&#287;ra&#351;&#305; rehabilitasyonu kognitif performans,
psikososyal i&#351;levsellik ve emosyonel dengeyi d�zeltir.&nbsp;
I&#351;&#305;&#287;&#305;n azalt&#305;lmas&#305; ve seslerin s�k�net verici bir
duruma getirilmesi gibi �evresel manip�lasyonlar&#305;n yeme
davran&#305;&#351;&#305;n&#305; artt&#305;rd&#305;&#287;&#305;
g�sterilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal problemler a�&#305;s&#305;ndan
banyo ve sofra s&#305;ras&#305;nda m�zi&#287;in ajitasyon ve
sald&#305;rganl&#305;&#287;&#305; azaltt&#305;&#287;&#305;
g�sterilmi&#351;tir.&nbsp; Mevcudiyetin sim�layonu tedavisi ad&#305; verilen
aile �yelerinin ses ve g�r�nt� kay&#305;tlar&#305;n&#305;n dinletilmesi veya
izletilmesinin de benzer etkisi oldu&#287;una ili&#351;kin bildirimler
vard&#305;r.&nbsp; Y�r�y�&#351; ve benzeri hafif egzersizler
gezinme-ad&#305;mlama davran&#305;&#351;&#305;n&#305;n �n�ne ge�ebilir.&nbsp;
Psikotik belirtiler sald&#305;rganl&#305;k, ka�ma veya yemeyi reddetme gibi
tehlikeli veya a&#351;&#305;r&#305; s&#305;k&#305;nt&#305; verici &#351;iddette
de&#287;ilse yeniden y�nlendirme (konuyu de&#287;i&#351;tirme) en iyi ba&#351;a
�&#305;kma yoludur.&nbsp; Ajitasyon ve sald&#305;rganl&#305;k i�in de yeniden
y�nlendirme, dikkatini �elme ve aktivite tedavisi etkili olabilir.&nbsp;
�ncelikle e&#287;er ay&#305;rt edilebiliyorsa ajitasyonu tetikleyen olay&#305;n
�n�ne ge�ilmeye �al&#305;&#351;&#305;lmal&#305;d&#305;r (�rne&#287;in, aynadaki
�yabanc&#305;� g�r�nt�den �rk�p kavga eden hasta i�in aynalar&#305;n
kald&#305;r&#305;lmas&#305;).&nbsp; Kahve, �ay gibi uyar&#305;c&#305;lar&#305;n
ak&#351;am i�ilmemesine �zen g�sterilmelidir, onlar&#305;n yerine i�ilecek
&#305;l&#305;k s�t uykusuzlu&#287;un �n�ne ge�ebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hasta yak&#305;nlar&#305; i�in hastal&#305;k
hakk&#305;nda k&#305;sa ve uzun s�reli e&#287;itim programlar&#305;n&#305;n
s&#305;k&#305;nt&#305;y&#305; azaltan ve nihai evreyi geciktiren etkileri kesin
bir bi�imde g�sterilmi&#351;tir.&nbsp; Hasta yak&#305;n&#305; destek
gruplar&#305;n&#305;n emosyonel denge a�&#305;s&#305;ndan b�y�k �nemi
vard&#305;r.&nbsp; Bilgisayar a&#287;lar&#305;, telefon deste&#287;i
e&#287;itim i�in kullan&#305;lacak se�eneklerdir.&nbsp; G�nd�z bak&#305;m
evlerinin hasta yak&#305;n&#305; y�k� a�&#305;s&#305;ndan olumlu etkisi
ku&#351;kusuzdur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALZHEIMER DI&#350;I DEMANSLAR</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALZHEIMER DI&#350;I DEJENERATIF DEMANSLAR</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Lewy Cisimcikli Demans<a name="_ftnref2"> </a></span></b><span
style='mso-bookmark:_ftnref2'></span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Friedrich Lewy, 1923 y&#305;l&#305;nda parkinsonizmi
olan ve hemen nerdeyse yar&#305;s&#305;nda demans&#305;n da var oldu&#287;u
k���k bir hasta serisinde daha sonra kendi ad&#305;yla an&#305;lmaya
ba&#351;lanan sitoplazmik inkl�zyonlar&#305; tan&#305;mlam&#305;&#351;t&#305;r.
Sonraki 50 y&#305;l i�erisinde Lewy cisimci&#287;i-demans birlikteli&#287;i ile
ilgili sadece tek tek olgu bildirimleri mevcuttur. Ancak, 1980�li
y&#305;llarda, demans&#305; olan bir grup hastada n�ropatolojik olarak kortikal
Lewy cisimciklerinin g�sterilmesinden sonra, d�nyan&#305;n farkl&#305;
merkezlerinden hasta serileri bildirilir olmu&#351;tur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Lewy cisimcikli demans (LCD) tan&#305;m&#305; ilk
kez 1996 y&#305;l&#305;nda &#351;u anki LCD Birli&#287;i�nin Birinci
Uluslararas&#305; �al&#305;&#351;tay&#305;�nda
kullan&#305;lm&#305;&#351;t&#305;r (McKeith<i> et al. </i>, 1996). Bu
�al&#305;&#351;taydan �nce demanstaki Lewy cisimciklerinin
varl&#305;&#287;&#305;, diff�z Lewy cisimcik hastal&#305;&#287;&#305;,
Alzheimer hastal&#305;&#287;&#305;n&#305;n Lewy cisimcikli varyant&#305;
(AHLCV), Lewy cisimcik tipli senil demans ve Alzheimer
hastal&#305;&#287;&#305;na e&#351;lik eden Lewy cisimcik
hastal&#305;&#287;&#305; gibi farkl&#305; terimlerle ifade edilmi&#351;tir.
Yukarda �Alzheimer Hastal&#305;&#287;&#305;� b�l�m�n�n �Dopaminerjik
Kay&#305;p� alt ba&#351;l&#305;&#287;&#305;nda
tart&#305;&#351;&#305;ld&#305;&#287;&#305; gibi AHLCV�yi AH n�ropatolojisine
s&#305;n&#305;rl&#305; limbik LC�lerin (amigdala, peri-amigdalar ve entorhinal
korteksler) e&#351;lik etmesi durumunda kullan&#305;p, neokortikal ve
beyinsap&#305; LC�lere de&#287;i&#351;en oranlarda AH n�ropatolojisinin
(bask&#305;n olarak amiloid plaklar) e&#351;lik etmesi durumunda vurgunun LCD
�zerinde olmas&#305; daha uygun gibi g�r�nmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Baz&#305;
merkezlerin demanslar aras&#305;nda s&#305;kl&#305;k a�&#305;s&#305;ndan AH�den
sonra 2. s&#305;ray&#305; VaD veya FTD�ye vermelerine kar&#351;&#305;n LCD�nin
ikinci s&#305;ray&#305; ald&#305;&#287;&#305; daha yayg&#305;n bir kab�l g�rmektedir
(McKeith<i> et al. </i>, 2004). Populasyon temelli �al&#305;&#351;malar&#305;n
g�zden ge�irildi&#287;i bir meta-analizde LCD prevelans&#305; %0.1-5.0
aras&#305;nda, demanslar aras&#305;nda s&#305;kl&#305;&#287;&#305; ise
%1.7-30.5 aras&#305;nda de&#287;i&#351;mektedir. Yukarda AH b�l�m�nde s�zedilen
TAPS �al&#305;&#351;mas&#305;nda Kad&#305;k�y�de 70 ya&#351; �zeri 1019
ya&#351;l&#305;n&#305;n tarand&#305;&#287;&#305; prevelans
�al&#305;&#351;mas&#305;nda saptanan toplam 93 demans olgusunun 70�i PRAD ve
PosAD tan&#305;lar&#305; alan toplam AH olgular&#305; iken LCD (toplam muhtemel
ve m�mk�n LCD) 9 olgu ile 2. s&#305;rada yer alm&#305;&#351;t&#305;. Otopsi
serilerinde de benzer &#351;ekilde bu oran %15 ile 25 aras&#305;ndad&#305;r.
Insidans, Cache County �al&#305;&#351;mas&#305;nda izlenen 65 ya&#351; �zeri
5092 birey aras&#305;nda y&#305;lda 6 yeni LCD olgusu ile %0.1 olarak
saptanm&#305;&#351;t&#305;. Cinsiyetin bir risk fakt�r� olarak niteli&#287;i
�ok a&#351;ikar olmasa da n�ropatolojik olarak ayn&#305; zamanda kesin AH
tan&#305; kriterlerini dolduran beyinsap&#305; LC�li 85 otopsi olgusunda saf
AH�li 192 olgunun tam tersine erkek bask&#305;nl&#305;&#287;&#305;
bildirilmi&#351;tir. Yukarda s�z edilen meta-analizde ya&#351;&#305;n LCD i�in de
bir risk fakt�r� oldu&#287;u, buna kar&#351;&#305;l&#305;k Brezilya ve Sri
Lanka kentleri ile Japonya k&#305;rsal alan&#305;ndan ayn&#305; prevelans
rakamlar&#305;n&#305;n bildirilmi&#351; olmas&#305;na dayan&#305;larak �evresel
fakt�rlerin rol� olmad&#305;&#287;&#305; ifade edilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.4pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Klinik
Tablo:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LCD de
Alzheimer hastal&#305;&#287;&#305;na benzer tarzda, senil d�nemde sinsi
ba&#351;lang&#305;�l&#305;, kronik progresif seyirli, genellikle belirgin
g�rsel-mekansal ve y�r�t�c� fonksiyonlarda bozulman&#305;n �n planda
oldu&#287;u bir demans tablosudur. LCD tan&#305;s&#305; alan hastalar&#305;n
kolinesteraz inhibit�rlerine yan&#305;t&#305;n&#305;n iyi olmas&#305; ve
n�roleptiklere a&#351;&#305;r&#305; hassasiyetleri nedeniyle farmakolojik
yakla&#351;&#305;m a�&#305;s&#305;ndan ve ayn&#305; zamanda seyrinin ve
prognozunun di&#287;er demans tiplerinden farkl&#305; olmas&#305; nedeniyle
LCD�nin klinik olarak do&#287;ru tan&#305;nmas&#305; �nemlidir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Son
y&#305;llarda edinilen bilgilerden sonra, LCD�nin klinik ve patolojik tan&#305;
kriterleri i�in, McKeith ve arkada&#351;lar&#305; taraf&#305;ndan 1996
y&#305;l&#305;nda tan&#305;mlanan uzla&#351;&#305; kriterlerinin kabul
edilebilir bir �zg�ll�&#287;�n�n olmas&#305;na ra&#287;men
duyarl&#305;l&#305;&#287;&#305;n&#305;n suboptimal olmas&#305; ve bununla
beraber temel �zelliklerden olan zihinsel i&#351;levlerde dalgalanman&#305;n
tan&#305;nmas&#305;ndaki zorluklar ve temel �zelliklerin (g�rsel
hal�sinasyonlar, seyirde dalgalanma ve parkinsonizm) ���n�n bir arada
d�&#351;�k s&#305;kl&#305;kta g�r�l�yor olmas&#305; nedeniyle tan&#305;
kriterlerinde revizyon yap&#305;lmas&#305; ihtiyac&#305; do&#287;mu&#351;tur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>McKeith
ve arkada&#351;lar&#305; taraf&#305;ndan 2005 y&#305;l&#305;nda yay&#305;nlanan
yeni uzla&#351;&#305; kriterleri Tablo 17�de belirtilmi&#351;tir (McKeith<i> et
al. </i>, 2005). Revize edilmi&#351; kriterlerde �nceki merkezi, �ekirdek ve
destekleyici �zellikler kategorilerine klinik ve inceleme bulgular&#305;ndan
olu&#351;an i&#351;aretleyici �zellikler eklenmi&#351;tir.
&#304;&#351;aretleyici �zellikler di&#287;er demans tiplerine g�re anlaml&#305;
olarak daha s&#305;k g�r�l�rken, destekleyici �zellikler ise s&#305;kl&#305;kla
g�r�l�r ancak �zg�ll�kleri azd&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LCD�de
ilerleyici engellili&#287;in sebebi hem kognitif bozuklu&#287;a hem de
n�ropsikiyatrik, motor, uyku ve otonomik bozukluklara ba&#287;l&#305;
olabilmesine ra&#287;men zihinsel bozulma tan&#305; i�in gerek
&#351;artt&#305;r. LCD demans&#305;n kardinal (kognitif ve i&#351;levsel
bozukluk olarak demans ve g�rsel hal�sinasyonlar) ve ikincil alanlar&#305;ndan
(spontan parkinsonizm, REM-uykusu davran&#305;&#351; bozuklu&#287;u [RUDB],
inkontinans) �zelliklerin daha ilk evrelerden itibaren g�r�lebildi&#287;i
demanslar aras&#305;nda en zengin sunuma sahip olan&#305;d&#305;r. Merkezi
�zelli&#287;e ek olarak �� �ekirdek �zellikten ikisinin mevcudiyeti �muhtemel
LCD�, birinin mevcudiyeti ise �m�mk�n LCD� tan&#305;s&#305; i�in esast&#305;r
(Bkz. Tablo 17). Bir veya daha fazla �ekirdek �zelli&#287;in
varl&#305;&#287;&#305;na, i&#351;aretleyici �zelliklerden bir veya daha
fazlas&#305;n&#305;n e&#351;lik etmesi durumunda tan&#305; �muhtemel LCD�
olabilir. Buna kar&#351;&#305;n �ekirdek �zellliklerden hi�birisinin
olmamas&#305; durumunda, i&#351;aretleyici �zelliklerden bir veya daha
fazlas&#305;n&#305;n olmas&#305; ise �m�mk�n LCD� tan&#305;s&#305; i�in
yeterlidir. Ancak �muhtemel LCD� tan&#305;s&#305; tek ba&#351;&#305;na
i&#351;aretleyici �zelliklere dayanarak konmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Her ��
�ekirdek �zellik i�in de yeni kriterlerde fazlaca de&#287;i&#351;iklik
belirtilmemesine ra&#287;men, tan&#305; ve semptomlar&#305;n &#351;iddetini
de&#287;erlendirmek i�in klinik de&#287;erlendirmede daha geli&#351;mi&#351;
metodlar&#305;n kullan&#305;m&#305; �nerilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Merkezi
�zellik</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hastan&#305;n
sosyal ya da i&#351; hayat&#305;ndaki fonksiyonelli&#287;ini etkileyen
ilerleyici bir kognitif bozulma olmal&#305;d&#305;r. Bu kognitif kay&#305;p
erken evrede �zellikle karma&#351;&#305;k dikkat, g�rsel-mekansal ve y�r�t�c�
i&#351;levlerde bozulma ile karakterizedir. Y�r�t�c� i&#351;levler; planlama,
soyut d�&#351;�nme yetene&#287;i, yarg&#305;lama, i�g�r�, karar verme gibi
amaca y�nelik hareketler i�in �nemli olan kognitif i&#351;lemleri i�erir.
Hastal&#305;&#287;&#305;n erken evresinde g�reli olarak daha az olan bellek ile
ilgili yak&#305;nmalar ve muayene bulgular&#305; ancak hastal&#305;k ilerledik�e
a&#351;ikar hale gelir. Episodik bellek ile ilgili testlerdeki
performanslar&#305; (�oktan se�meli ile hat&#305;rlamalar&#305; serbest
hat&#305;rlamadan iyidir) AH�si olan hastalara g�re daha iyidir. Ayr&#305;ca
s�zel bellek testlerinde g�rsel bellek testlerine g�re daha iyi performans
g�sterirler. Erken ve �n planda g�rsel-mekansal bozukluk LCD i�in tipiktir.
MMSE�de AH�ye k&#305;yasla g�reli y�ksek puan alabilen, hatta demans i�in kesme
puan&#305;n&#305;n �zerinde kalan bir hastan&#305;n kesi&#351;en
be&#351;genlerden puan kaybetmesi �zellikle ay&#305;t ettiricidir. G�rsel-mekansal
bozuklu&#287;un &#351;iddeti erken d�nemde posterior kortikal atrofide izlenen
&#351;iddette bir simultanagnoziye neden olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�ekirdek
�zellikler</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dalgalanma:</span></i></b><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Klinik pratikte
�ekirdek kriterler aras&#305;nda en zor karakterize edilebileni zihinsel
i&#351;levlerdeki dalgalanmalard&#305;r.&nbsp; Bu kriter i�in
uyan&#305;kl&#305;k durumu veya kognitif ve i&#351;levsel performansta
dakikalar, saatlerden, g�nler, haftalara kadar de&#287;i&#351;en s�relerde,
hasta yak&#305;n&#305; ve bazen de hekim i�in a&#351;ikar kayda de&#287;er
dalgalanmalar ge�erli say&#305;lmal&#305;d&#305;r. Bununla birlikte dalgalanma
kriterinin varl&#305;&#287;&#305; veya yoklu&#287;unun saptanmas&#305;n&#305;n
sadece �yk�yle de&#287;erlendirmeciler aras&#305; g�venilirli&#287;inin �ok
y�ksek olmad&#305;&#287;&#305; ve dalgalanmaya �zg� geli&#351;tirilmi&#351;
�l�eklerin kullan&#305;m&#305;n&#305;n �nerildi&#287;i
unutulmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>G�rsel
hal�sinasyonlar:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Hastal&#305;&#287;&#305;n genellikle erken evrelerinde
g�r�len tekrarlay&#305;c&#305; canl&#305;, renkli, kompleks g�rsel
hal�sinasyonlar tan&#305; i�in �ekirdek �zelliklerden ikincisidir. G�rsel
hal�sinasyonlar&#305; olan LCD�li hastalar&#305;n, hal�sinasyonlar&#305;
olmayan grup ile kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda
g�rsel-alg&#305;sal bozulmalar&#305; daha belirgindir. SPECT g�r�nt�lemelerinde
oksipital kortekste tutulum azalm&#305;&#351;t&#305;r. G�rsel
hal�sinasyonlar&#305; olan posterior kortikal atrofili (PKA) grubun, olmayan
PKA�l&#305;lara g�re bunlar&#305;n ger�ekte LCD olduklar&#305;n&#305; d�&#351;�nd�recek
&#351;ekilde daha fazla parkinsonizm ve RUDB�ye sahip olduklar&#305;
g�sterilmi&#351;tir. Otopsi �al&#305;&#351;malar&#305;nda, g�rsel
hal�sinasyonlar&#305; olan vakalarda, g�rsel kompleks imajlar&#305;n jenerat�r�
oldu&#287;u bilinen anterior ve inferior temporal lob ve amigdalada Lewy cisimciklerinin
artm&#305;&#351; oldu&#287;u bildirilmi&#351;tir. G�rsel hal�sinasyonlar&#305;
olan hastalarda kortikal asetilkolin defisitleri daha belirgindir ve bu durum
belki de kolinerjik tedaviye daha iyi yan&#305;t&#305;n nedeni olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Parkinsonizm:</span></i></b><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> LCD�de ekstrapiramidal
motor bulgular&#305;n a&#287;&#305;rl&#305;&#287;&#305; genellikle demans&#305;
olsun veya olmas&#305;n benzer ya&#351; grubundaki Parkinson
hastalar&#305;ndaki (PH) motor bulgular&#305;n
a&#287;&#305;rl&#305;&#287;&#305;na benzer &#351;ekilde olabilece&#287;i gibi
daha geri planda ve hafif de olabilir. PH�n&#305;n ay&#305;rdedici asimetrik
sunumu belirgin olmayabilir.&nbsp;LCD�de post�ral instabilite, y�r�y�&#351;
bozuklu&#287;u, bradimimi gibi aksiyal tutulum demanss&#305;z PH�l&#305;lara
g�re daha belirgindir. &#304;stirahat tremoru daha az g�r�l�r. Parkinsonizmin
L-Dopa cevab&#305; �ok iyi olmayabilir. Miyoklonus, tedavi gerektirmeyecek
kadar hafif bir parkinsonizm, tremorun yoklu&#287;u, L-Dopa
cevaps&#305;zl&#305;&#287;&#305; �zelliklerinden birinin LCD�de PH�ya g�re 10
kat daha muhtemel oldu&#287;u bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;aretleyici
�zellikler<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>REM
uyku davran&#305;&#351; bozuklu&#287;u: </span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;RUDB demans ve
parkinsonizmden �ok �nce ba&#351;lam&#305;&#351; olabilir. RUDB spesifik bir
sin�kleopati (PH, MSA, LCD) e&#351;lik�isidir ve nadiren di&#287;er dejeneratif
hastal&#305;klarda g�r�l�r. RUDB LCD�ye e&#351;lik eden a&#351;&#305;r&#305;
g�nd�z uyuklamas&#305; gibi di&#287;er uyku bozukluklar&#305;yla birlikte
zihinsel i&#351;levlerdeki dalgalanmalara katk&#305;da bulunuyor olabilir. RUDB
�yk�s� polisomnografi ile do&#287;rulanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�roleptik
a&#351;&#305;r&#305; duyarl&#305;l&#305;&#287;&#305;:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> N�roleptik
duyarl&#305;l&#305;k reaksiyonlar&#305;yla birlikte olan y�ksek mortalite ve
morbidite nedeniyle, D2 resept�r bloke edici ajanlar tan&#305; veya tedavi
amac&#305;yla kullan&#305;lmamal&#305;d&#305;r. LCD�li hastalar ve demans&#305;
olsun olmas&#305;n PH�l&#305;lar �zellikle tipik n�roleptiklere
kar&#351;&#305;, demansta kullan&#305;lmaya al&#305;&#351;&#305;lan �ok
d�&#351;�k dozlar&#305;na dahi a&#351;&#305;r&#305; duyarl&#305;l&#305;k
g�sterirler ve a&#287;&#305;r, akut bir akinetik-rijid tablo
geli&#351;tirebilirler. Bu durum habis n�roleptik sendrom &#351;iddetinde
olabilir ve ketiapin ile dahi bildirilmi&#351;tir. Ancak LCD tan&#305;s&#305;
alan hastalar&#305;n yakla&#351;&#305;k %50�sinde tipik veya atipik
antipsikotik ajanlar almalar&#305;na ra&#287;men belirgin yan etki
bildirilmemesine dayanarak, n�roleptik duyarl&#305;l&#305;&#287;&#305;n&#305;n
olmamas&#305; LCD tan&#305;s&#305;n&#305; d&#305;&#351;lamazken varl&#305;&#287;&#305;
ise tan&#305;y&#305; kuvvetle destekler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; g�r�nt�lemesi:</span></i></b><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; fonksiyonel g�r�nt�lemesi, nigrostriatal
dopaminerjik sistemin b�t�nl�&#287;�n� tan&#305;mlar. FP-CIT, beta-CIT, IPT,
TRODAT gibi spesifik ligandlarla yap&#305;lan dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; g�r�nt�lemesi, presinaptik n�ronal
dejenerasyon i�in i&#351;aretleyici olabilirler. LCD�de striatal dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; aktivitesi d�&#351;�k iken, Alzheimer
hastal&#305;&#287;&#305;nda normaldir. &#304;diopatik PH, MSA ve PSP�de de
bozuk olabilece&#287;i g�z �n�nde tutulmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Destekleyici
�zellikler:<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Destekleyici
�zellikler LCD�de s&#305;kl&#305;kla g�r�l�r ancak �zg�ll�kleri �ekirdek ve
i&#351;aretleyici �zellikler kadar y�ksek de&#287;ildir.
Hastal&#305;&#287;&#305;n erken d�neminde ortostatik hipotansiyon, �riner
inkontinans, n�rokardiyovask�ler insitabilite, konstipasyon, impotans gibi
otonomik semptomlar g�r�lebilir. Otonomik disfonksiyon ayn&#305; zamanda
baz&#305; hastalarda g�r�lebilen tekrarlayan d�&#351;meler, senkop ve ge�ici
bilin� kayb&#305;n&#305;n geli&#351;mesine de katk&#305; da bulunuyor olabilir.
Sistematize hezeyanlar ve depresyon hastal&#305;&#287;&#305;n herhangi bir
d�neminde g�r�lebilir.&nbsp; Hezeyanlar i�inde misidentifikasyon ve Capgras
hezeyan&#305; �zellikle s&#305;kt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#350;u
anki bilgilerin &#305;&#351;&#305;&#287;&#305;nda, LCD tan&#305;s&#305;n&#305;
desteklemek i�in klinik olarak uygulanabilir genotipik veya beyin omurilik
s&#305;v&#305;s&#305; i&#351;aretleyicisi yoktur. Beyin manyetik rezonans
g�r�nt�leme (MRG)�de, hippokampal ve medial temporal lob vol�mlerinin
korunmu&#351; olmas&#305;, putamende atrofi ve MRG�de oksipital atrofi
olmaks&#305;z&#305;n SPECT ve PET ile oksipital hipoperf�zyon ve hipometabolizman&#305;n
g�r�lmesi tan&#305; i�in yard&#305;mc&#305;d&#305;r. Yukarda s�z&nbsp;
edildi&#287;i gibi MRG�de PKA tarz&#305; oksipito-parietal atrofi sergileyen
hastalar aras&#305;nda g�rsel hal�sinasyonlar kuvvetle LCD d�&#351;�nd�rse de
rasgele se�ilmi&#351; LCD�liler yap&#305;sal MRG�de posteriyor atrofi
tarz&#305; a�&#305;s&#305;ndan ay&#305;rt edilemeyebilirler.
[I-123]-metaiodobenzyl guanidine (MIBG) ile yap&#305;lan ve postganglionik
sempatik kardiak innervasyon hakk&#305;nda bilgi veren sintigrafi LCD�de
anormaldir ve AH�den ay&#305;rmada �zg�ll�k ve duyarl&#305;l&#305;&#287;&#305;
y�ksektir. Ba&#351;ka bir �al&#305;&#351;mada bu ayr&#305;m&#305;n �zellikle de
a&#351;ikar ortostatik hipotansiyonu olan hastalarda parkinsonizm
olmaks&#305;z&#305;n da a&#351;ikar oldu&#287;u g�sterilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sa&#287;kal&#305;m
AH�ye k&#305;yasla daha k&#305;sa gibi durmaktad&#305;r. Bu ama�la
yap&#305;lm&#305;&#351; yak&#305;n tarihli b�y�k bir �al&#305;&#351;mada LCD ve
PH demansl&#305; (PHD) otopsi do&#287;rulamal&#305; 243 olgunun retrospektif
analizinde medyan sa&#287;kal&#305;m&#305;n 5 y&#305;l oldu&#287;u
bildirilmi&#351;tir. PHD�liler LCD�lilere g�re daha uzun sa&#287;kal&#305;ma
sahiptiler. Ba&#351;lang&#305;�ta a&#351;ikar dalgalanma k�t� sonlan&#305;m&#305;
en iyi �ng�ren �zellik olarak belirlenmi&#351;tir. AH�ye g�re sa&#287;kal&#305;m&#305;n
k&#305;salmas&#305;n&#305;n, �zellikle motor ve otonom bozukluklar olmak �zere,
LCD�nin zengin klinik sunumunun engellili&#287;i �ok daha fazla
artt&#305;rmas&#305; nedeniyle oldu&#287;u ileri s�r�lebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>N�ropatoloji</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:red;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>N�ropatolojik olarak tabloya ad&#305;n&#305; veren intrasel�ler Lewy cisimcikleri
(LC) ba&#351;l&#305;ca �zelliktir.&nbsp; LC�ler, intran�ronal sitoplazmik,
eozinofilik, sferik, filamant�z inkl�zyon cisimcikleridir. LC�lerin temel
bile&#351;eni 4. kromozomda kodlanan ve i&#351;levi �ok iyi
ayd&#305;nlat&#305;lamasa da aksonal nakilde rol oynad&#305;&#287;&#305;
d�&#351;�n�len ve a&#287;&#305;rl&#305;kla akson sonlanmalar&#305;nda lokalize
olan, dolay&#305;s&#305;yla sinaptik b�t�nl�&#287;�n korunmas&#305;
&#351;eklinde bir plastisite rol� de oldu&#287;u d�&#351;�n�len
&#945;-sin�klein isimli proteindir.&nbsp;LC�ler, &#945;-sin�kleinin anormal
katlanmas&#305; ve fosforilasyonu sonras&#305;nda olu&#351;urlar. &#945;-sin�klein
imm�n boyamas&#305; geli&#351;tirildikten sonra hematoksilen-eozin ile
se�ilemeyen neokortikal LC�leri de ay&#305;rt etmek m�mk�n olmu&#351;tur.&nbsp;
PH�da a&#287;&#305;rl&#305;kl&#305; olarak subtantia nigran&#305;n DA-erjik
h�cre g�vdelerini i�eren pars compactas&#305;na s&#305;n&#305;rl&#305; olan LC
ve Lewy n�ritleri, LCD�de beyin sap&#305;na ilave olarak limbik-paralimbik
sistem ve neokortekste birikir. Bununla birlikte saf LCD&nbsp; n�ropatolojisi
t�m LCD klinik fenotipinin k���k bir b�l�m�nden sorumludur.&nbsp; Klinik olarak
LCD tan&#305;s&#305; alan hastalar&#305;n postmortem
�al&#305;&#351;malar&#305;nda&nbsp; AH patolojisi de s&#305;kl&#305;kla bir
arada g�r�lmekte ve hem nomenklat�r� (AH�nin Lewy cisimcikli varyant&#305;,
yayg&#305;n Lewy cismci&#287;i hastal&#305;&#287;&#305; gibi) hem de klinik
fenotipi bulan&#305;kla&#351;t&#305;rmaktad&#305;r. �rne&#287;in, daha belirgin
olarak neokortikal Alzheimer tipi patolojisi olan LCD hastalar&#305;nda, klasik
LCD klinik bulgular&#305; da daha hafiftir. LCD�li hastalarda en s&#305;k
g�r�len Alzheimer patolojisi amiloid plaklar iken NFY daha seyrektir. NFY�ler
g�r�ld�&#287;� takdirde, AH�yle k&#305;yasla daha d�&#351;�k Braak ve Braak
evrelerinde, a&#287;&#305;rl&#305;kla limbik ve paralimbik alanlarda, AP�ler de
n�ritik de olsalar, genellikle PHF (-) ve neokortekse s&#305;n&#305;rl&#305;
olma e&#287;ilimi ta&#351;&#305;maktad&#305;rlar.&nbsp; Ayr&#305;ca, LCD�deki
AP�ler �evresinde mikroglial aktivasyon ve inflamasyona da AH�ye k&#305;yasla
�ok daha az rastland&#305;&#287;&#305; ileri s�r�lmektedir.&nbsp;Hippokampal
CA2 ve CA3 b�lgelerinde g�r�len ubik�tin pozitif n�ritik dejenerasyonun da
AH�de g�r�lmeyen LCD�ye �zg� bir patolojik �zellik oldu&#287;u ileri
s�r�lmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>LCD n�rokimyasal olarak kortikal kolinerjik i&#351;aretleyiciler ve
nigrostriatal dopamin kayb&#305; ile karakterizedir. Raphe �ekirde&#287;i ve
locus ceruleus�taki n�ron kayb&#305; ve gliozis serotonin ve norepinefrin
azalmas&#305;na neden olur ve duygu durum, dikkat ve uyan&#305;kl&#305;ktaki
dalgalanmalar&#305; a�&#305;klayabilir. Meynert �ekirde&#287;indeki kolinerjik
n�ron kayb&#305; da bellek, dikkat, uyan&#305;kl&#305;&#287;&#305;n derecesi ve
belki de dalgalanmalar&#305; anlaml&#305; olarak etkileyebilir. Meynert
�ekirde&#287;indeki dejenerasyona ek olarak ba&#351;l&#305;ca i&#351;levi
diurnal ritmin d�zenlenmesi olan talamik kolinerjik innervasyonun
kayna&#287;&#305; pedinculo-pontin �ekirdek de AH�den farkl&#305; olarak
dejenerasyona kat&#305;l&#305;r.&nbsp;An&#305;lan beyin sap&#305;
n�rotransmitter kay&#305;plar&#305;n&#305;n LCD�ye �zg� parasomni, parkinsonizm
ve otonom sinir sistemi belirtilerinden sorumlu oldu&#287;u d�&#351;�n�lmektedir.&nbsp;
ChAT aktivitesi ile belirlenen neokortikal kolinerjik kay&#305;p AH�ye g�re �ok
daha belirgindir.&nbsp; Bu kayb&#305;n genel olarak demans &#351;iddetiyle,
�zel olarak temporal lober kayb&#305;n ise davran&#305;&#351;sal belirtilerle
korelasyonu bildirilmi&#351;tir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>��z�nemeyip biriken fibriler &#945;-sin�kleinin, LCD�nin yan&#305;
s&#305;ra bir dizi dejeneratif hastal&#305;kta daha temel patolojik
i&#351;aretleyici oldu&#287;unun g�sterilmesi sonras&#305;nda bu grup <i>&#945;-sin�kleopatiler
</i>olarak adland&#305;r&#305;lmaya ba&#351;lanm&#305;&#351;t&#305;r.&nbsp;
Bunlar aras&#305;nda LCD�den ayr&#305; bir antite olup olmad&#305;&#287;&#305;
tart&#305;&#351;mal&#305; olan PH demans&#305; �ncelikle say&#305;labilir.&nbsp;
K&#305;sa s�re �ncesine kadar bir PH-AH �rt�&#351;mesi oldu&#287;u
d�&#351;�n�len idyopatik PH�da sonradan geli&#351;en demans&#305;n, art&#305;k
beyin sap&#305; tipi LC hastal&#305;&#287;&#305;n&#305;n zamanla kortikal tip
LC�ye yayg&#305;nla&#351;mas&#305; sonucu geli&#351;ti&#287;ine dair bir
g�r�&#351; birli&#287;i olu&#351;maktad&#305;r.&nbsp;&#945;-sin�klein fibriler
birikimleri MSA�da glial inkl�zyonlar &#351;eklinde g�r�lmektedir.&nbsp;Glial
&#945;-sin�klein inkl�zyonlar&#305; LCD ve PH�da ge� evrelerde g�r�l�rken,
MSA�da klinik fenotipten sorumlu patolojik de&#287;i&#351;iklik gibi
durmaktad&#305;r.&nbsp;Hallervorden-Spatz hastal&#305;&#287;&#305;nda n�ronal
ve glial inkl�zyonlar&#305;n yan&#305;s&#305;ra aksonal sferoidler i�inde de
g�r�l�rler. Bir �al&#305;&#351;mada otonomik ganglionlarda ilerleyici
dejenerasyonla giden saf otonomik yetmezlik de&nbsp;bir &#945;-sin�kleopati
olarak tarif edilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans18.JPG">&#350;ekil 18.</a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Lewy
Cisimci&#287;i. Solda substantia nigra�da �evresinde halosuyla intran�ronal
eosinofilik inkl�zyon izlenirken sa&#287;da ise kortekste ubikitin (+), halosu
se�ilmeyen intran�ronal inkl�zyon izlenmekte (Kaynak: </span><span
style='font-size:10.0pt;font-family:Tahoma'><a
href="http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass5.htm"><span
lang=TR style='mso-ansi-language:TR'>http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass5.htm</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 17.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Muhtemel ve M�mk�n LCD Klinik
Tan&#305;s&#305; i�in G�zden Ge�irilmi&#351; Yeni Uzla&#351;&#305; Kriterleri <i>(McKeith
et al. , 2005)<o:p></o:p></i></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1)&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Merkezi �zellik</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Muhtemel veya
m�mk�n LCD tan&#305;s&#305; i�in gereklidir):<b> </b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demans; Normal
sosyal ya da mesleki i&#351;levselli&#287;i etkileyecek
a&#287;&#305;rl&#305;kta ilerleyici kognitif bozulma.&nbsp; Erken evrelerde
bellek bozuklu&#287;u bask&#305;n ve kal&#305;c&#305; d�zeyde olmayabilir,
fakat ilerlemeyle birlikte a&#351;ikar hale gelir.&nbsp; Dikkat,
frontal-subkortikal yetenekler ve vizuo-spasyal i&#351;levleri �l�en
testlerdeki bozulmalar �n planda olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2)&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�ekirdek �zellikler</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(�� temel
�zellikten ikisinin mevcudiyeti �muhtemel DLB�, birinin mevcudiyeti ise �m�mk�n
DLB� tan&#305;s&#305; i�in esast&#305;r): <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
Dikkat ve uyan&#305;kl&#305;kta ciddi de&#287;i&#351;ikliklerle birlikte giden
zihinsel i&#351;levlerde dalgalanma. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:46.4pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
Tipik olarak iyi forme ve ayr&#305;nt&#305;l&#305;, tekrarlay&#305;c&#305;
g�rsel hal�sinasyonlar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:46.4pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;
Parkinsonizmin motor �zelliklerinin kendili&#287;inden mevcudiyeti<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3)&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&#304;&#351;aretleyici �zellikler</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Bu
�zelliklerden bir veya daha fazlas&#305; yine bir veya&nbsp; daha fazla
�ekirdek �zelli&#287;in varl&#305;&#287;&#305;nda, tan&#305; muhtemel LCD
olabilir. Ancak �ekirdek �zelliklerden hi�birisi yoksa, bu �zelliklerden bir
veya daha fazlas&#305;n&#305;n olmas&#305; m�mk�n LCD tan&#305;s&#305; i�in
yeterlidir. Muhtemel LCD tan&#305;s&#305; ise tek ba&#351;&#305;na
i&#351;aretleyici �zelliklere dayanarak konmamal&#305;d&#305;r.)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
REM uyku davran&#305;&#351; bozuklu&#287;u<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
A&#287;&#305;r n�roleptik duyarl&#305;l&#305;&#287;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;
SPECT veya PET g�r�nt�lemeleriyle g�sterilebilen bazal gangliada d�&#351;�k dopamin
ta&#351;&#305;y&#305;c&#305; tutulumu<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4)&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Destekleyici �zellikler </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:21.3pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>(Genellikle vard&#305;r fakat tan&#305;sal
�zg�ll�&#287;� kan&#305;tlanmam&#305;&#351;t&#305;r.):<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
Tekrarlayan d�&#351;meler ve senkop<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
Ge�ici a�&#305;klanamayan bilin� kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;A&#287;&#305;r
otonomik disfonksiyon (ortostatik hipotansiyon, �riner inkontinans gibi)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>d.&nbsp;&nbsp;
Di&#287;er modalitelerde hal�sinasyonlar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>e.&nbsp;&nbsp;
Sistematize hezeyanlar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>f.&nbsp;&nbsp;&nbsp;&nbsp;Depresyon<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>g.&nbsp;&nbsp;
BT/MRG�de medial temporal lob yap&#305;lar&#305;n&#305;n g�reli olarak
korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>h.&nbsp;&nbsp;
SPECT ve PET�de oksipital aktivitede azalma ile birlikte genel olarak
d�&#351;�k tutulum<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>i.&nbsp;&nbsp;&nbsp;&nbsp;MIBG
myokard sintigrafisinin bozuk (d�&#351;�k tutulum) olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>j.&nbsp;&nbsp;&nbsp;&nbsp;EEG�de
belirgin yava&#351; dalga aktivitesi ile birlikte temporal loblarda ge�ici
keskin dalgalar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>LCD tan&#305;s&#305; ihtimali
a&#351;a&#287;&#305;dakilerin mevcudiyeti durumunda azal&#305;r:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
Fokal n�rolojik bulgular veya beyin g�r�nt�lemesinde serebrovask�ler olaya ait
bir delil varsa<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
Klinik tabloya tamamen ya da k&#305;smen neden olabilecek ba&#351;ka bir
fiziksel hastal&#305;k veya beyin bozuklu&#287;unun varl&#305;&#287;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;
E&#287;er parkinsonizm ilk kez a&#287;&#305;r demans evresinde ortaya
�&#305;karsa<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Semptomlar&#305;n zamansal s&#305;ralan&#305;m&#305;:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>LCD
tan&#305;s&#305;, demans parkinsonizmden (e&#287;er varsa) �nce veya birlikte
ortaya �&#305;kar ise d�&#351;�n�lmelidir. Parkinson hastal&#305;&#287;&#305;
demans&#305; (PHD) terimi, yerle&#351;mi&#351; Parkinson
hastal&#305;&#287;&#305; ba&#287;lam&#305;nda olu&#351;an demans&#305;
tan&#305;mlamak i�in kullan&#305;lmal&#305;d&#305;r. Pratik uygulamada, klinik
durum i�in en uygun terim kullan&#305;lmal&#305;d&#305;r ve Lewy cisimcik
hastal&#305;&#287;&#305; gibi genelleyici terimler s&#305;kl&#305;kla
yard&#305;mc&#305;d&#305;r. LCD ve PHD ayr&#305;m&#305; yap&#305;lmas&#305;
gereken ara&#351;t&#305;rma projelerinde ise demans&#305;n
ba&#351;lang&#305;c&#305; ile parkinsonizm aras&#305;ndaki 1 y&#305;l
kural&#305;, LCD tan&#305;s&#305; i�in hala �nerilmeye devam edilmektedir.
Klinikopatolojik ve tedavi �al&#305;&#351;malar&#305; gibi di&#287;er
ara&#351;t&#305;rma projelerinde ise her iki klinik fenotipinin de
alfa-sin�kleopati veya Lewy cisimcik hastal&#305;&#287;&#305; gibi daha
geni&#351; kategoriler alt&#305;nda toplanmalr&#305; d�&#351;�n�lebilir.<o:p></o:p></span></p>

<div style='margin-left:21.3pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LCD
tedavisi klinisyen i�in zor ve karma&#351;&#305;kt&#305;r. Non-motor semptomlar
i�in etkili olan&nbsp; tedaviler, motor fonksiyonlar&#305;
k�t�le&#351;tirebilir veya benzer &#351;ekilde tersi de m�mk�nd�r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Non-farmakolojik
yakla&#351;&#305;m:</span></i></b><i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Non-farmakolojik
yakla&#351;&#305;mlar, LCD�li hastalar&#305;n pek �ok semptomlar&#305;nda ve
fonksiyonel kay&#305;plar&#305;nda yararl&#305; olabilirler, ancak hen�z bu konu
sistematik olarak de&#287;erlendirilmemi&#351;tir. G�rsel hal�sinasyonlar ve
kognitif k�t�le&#351;me, dikkat ve uyan&#305;kl&#305;&#287;&#305;n az
oldu&#287;u zamanlarda daha a&#287;&#305;r olabilir. Bu nedenle sosyal
ili&#351;kilerin artt&#305;r&#305;lmas&#305; gibi yakla&#351;&#305;mlarla
uyan&#305;kl&#305;&#287;&#305;n ve dikkatin artt&#305;r&#305;lmas&#305; yararl&#305;
olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Farmakolojik
yakla&#351;&#305;m:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Motor
bulgular:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> LCD�de parkinsonizmin L-Dopa cevab&#305;n&#305;n iyi olmamas&#305; ve
DA-erjiklerin psikotik belirtileri artt&#305;rma riskine kar&#351;&#305;n
hastan&#305;n kendisine optimize edilmi&#351; bir anti-parkinson tedaviden
yararlan&#305;p yararlanmayaca&#287;&#305; tetkik edilmelidir.&nbsp; L-dopa
d�&#351;�k dozlarda ba&#351;lan&#305;p, yava&#351; doz art&#305;&#351;&#305;
yap&#305;larak psikiyatrik semptomlar&#305;n artmas&#305;n&#305; engellemek
amac&#305;yla gerekli olan minimum dozda kullan&#305;lmal&#305;d&#305;r.
Antikolinerjiklerden ka�&#305;n&#305;lmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�ropsikiyatrik
semptomlar: </span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>G�rsel hal�sinasyonlar en s&#305;k g�r�len psikiyatrik semptomlard&#305;r.
Farmakolojik yakla&#351;&#305;m&#305;n gerekti&#287;i durumlarda atipik
antipsikotikler ve kolinesteraz inhibit�rleri (ChE&#304;) d�&#351;�n�lmelidir.
ChE&#304;�lerin davran&#305;&#351;sal belirtiler �zerindeki olumlu etkisi ilk
kez LCD�li hastalarla yap&#305;lan bir klinik �al&#305;&#351;mada ortaya
konmu&#351;tur.&nbsp; Dolay&#305;s&#305;yla, yeni bir hastada kognitif tedavi
ama�l&#305; ba&#351;lanan ChE&#304;, n�roleptik tedaviye kar&#351;&#305;
geli&#351;ebilecek a&#351;&#305;r&#305; duyarl&#305;l&#305;k da g�z �n�ne
al&#305;narak g�rsel hal�sinasyonlar ve di&#287;er psikotik belirtilerin
tedavisi i�in bir s�re tek ba&#351;&#305;na b&#305;rak&#305;labilir.&nbsp;
Cevap al&#305;namad&#305;&#287;&#305; takdirde atipik n�roleptikler, onlarla
dahi a&#351;&#305;r&#305; duyarl&#305;l&#305;&#287;&#305;n
geli&#351;ebilece&#287;ine dair anekdotal bildiriler de hesaba kat&#305;larak
dikkatle kullan&#305;labilir.&nbsp; AH tedavisine benzer dozlarda kullan&#305;lmak
ko&#351;uluyla ketiapin, olanzapin, klozapin s&#305;ras&#305;yla
se�ilebilir.&nbsp;Tipik antipsikotiklerin kullan&#305;m&#305;ndan
ka�&#305;n&#305;lmal&#305;d&#305;r. Depresyon da s&#305;k g�r�len bir
semptomdur ancak anti-depresan kullan&#305;m&#305; ile ilgili sistematize bir
�al&#305;&#351;ma yoktur. SSRI veya SNRI�lar kullan&#305;labilir. Ancak
antikolinerjik etkileri nedeniyle trisiklik antidepresanlardan
ka�&#305;n&#305;lmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Uyku
bozukluklar&#305;: </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>RUDB yatmadan �nce verilen 0.25 mg klonazepam, 3 mg
melatonin veya 12.5 mg ketiapin ile ba&#351;lanacak dozlarla tedavi edilebilir.
Doz art&#305;&#351;&#305; her zaman yava&#351; yap&#305;lmal&#305; ve yan
etkiler a�&#305;s&#305;ndan dikkatli olunmal&#305;d&#305;r.
A&#351;&#305;r&#305; g�nd�z uyuklamas&#305; zihinsel performans&#305;n
d�&#351;mesine katk&#305;da bulunabilir. Tedavide sabah ve �&#287;len
dozlar&#305; &#351;eklinde, 100-400mg aras&#305; kullan&#305;lacak modafinil
ile yarar sa&#287;lan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kognitif
semptomlar: </span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>LCD tedavisinde a&#287;&#305;r kolinerjik yetmezli&#287;in de
d�&#351;�nd�rece&#287;i gibi, kolinerjik temelli tedavi, en az&#305;ndan halen
elimizde bulunan ChE&#304;�lerle AH�ye benzer bi�imde yararl&#305;
olabilir.&nbsp;LCD�de Cochrane K�t�phanesi taraf&#305;ndan de&#287;erlendirmeye
al&#305;nan tek rasgele kontroll� klinik �al&#305;&#351;ma olan McKeith
�al&#305;&#351;mas&#305;nda rivastigminin baz&#305; kognitif �l��tlerdeki
�st�nl�&#287;�ne ra&#287;men sonu�lar etkinlik a�&#305;s&#305;ndan yeterince
ikna edici bulunmam&#305;&#351;t&#305;r. Buna kar&#351;&#305;l&#305;k
rivastigmin EXPRESS isimli ba&#351;ar&#305;l&#305; klinik �al&#305;&#351;mas&#305;na
dayanarak PHD tedavisi i�in, FDA onay&#305; alm&#305;&#351;t&#305;r ve
dolay&#305;s&#305;yla da LCD i�in de d�&#351;�n�lebilir. Memantin tek bir
�al&#305;&#351;mada (Emre 2010) sadece global �l��de plaseboya �st�n
bulunmu&#351;tur. Kullan&#305;m&#305; d�&#351;�n�lebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Parkinson
Hastal&#305;&#287;&#305; Demans&#305; </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Parkinson hastal&#305;&#287;&#305; uzun
y&#305;llar i�in saf bir motor bozukluk olarak tasarland&#305;ktan sonra zaman
i�inde non-motor bozukluklar ve bunlar i�inde a&#287;&#305;rl&#305;kl&#305; bir
yeri olan kognitif bozukluklar kaydedilir olmu&#351;tur. Giderek yeterince uzun
s�rm�&#351; bir PH�da kognitif bozulman&#305;n belli bir &#351;ddeti olarak
demans&#305;n nerdeyse ka�&#305;n&#305;lmaz oldu&#287;u g�zlenmi&#351;tir. Bu
klinik g�zlemler b�y�k �l��de hastal&#305;&#287;&#305;n n�robiyolojisi ve
patogenezinin kavranmas&#305;ndaki geli&#351;meler sayesinde m�mk�n olmu&#351;tur.
<span style='color:black'>Alfa-sin�kleinin SNc�deki Lewy cisimcikleri (LC�ler)
i�inde biriken ana protein oldu&#287;unun bulunmas&#305; ve alfa-sin�klein
imm�nhistokimyas&#305;n&#305;n geli&#351;tirilmesinden sonra, nigral LC�lerin
�evresindeki karakteristik haloyu ta&#351;&#305;mad&#305;klar&#305; i�in klasik
boyamayla g�sterilemeyen kortikal LC�ler de g�sterilebilir hale gelmi&#351;tir.
&#304;zleyen �al&#305;&#351;malarda kortikal LC�lerin demans &#351;iddetiyle
korelasyon g�steren ana patolojik bulgu oldu&#287;u
saptanm&#305;&#351;t&#305;r. Braak ve arkada&#351;lar&#305;n&#305;n
anatomo-klinik korelasyon �al&#305;&#351;malar&#305;nda (halen
tart&#305;&#351;mal&#305; olsa da) alfa-sin�klein patolojisinin kaudo-rostral
bir ilerleyi&#351;le beyinsap&#305;ndan limbik ve heteromodal asosiasyon
kortekslerine do&#287;ru y�kseldi&#287;inin g�sterilmesiyle PH�da
demans&#305;n&nbsp; neden ge� d�nemde ortaya �&#305;kt&#305;&#287;&#305;
sorusunun cevab&#305; da teorik bir temele kavu&#351;mu&#351;tur.</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Belirli kriterlere g�re se�ilmi&#351; 12 prevelans
�al&#305;&#351;mas&#305;n&#305; sistematik olarak g�zden ge�iren bir
meta-analizde PHD�n&#305;n kesitsel nokta prevelans&#305;n&#305;n %25-30
oran&#305;nda oldu&#287;u bildirilmi&#351;tir. Toplum-tabanl&#305; prospektif
bir �al&#305;&#351;mada, Aarsland ve arkada&#351;lar&#305;
ba&#351;lang&#305;�,&nbsp; 4 y&#305;l ve 8 y&#305;l sonraki PHD kumulatif
prevelans&#305;n&#305; s&#305;ras&#305;yla %26, %51, %78 olarak
bildirmi&#351;lerdir. Di&#287;er �al&#305;&#351;malarda ba&#351;lang&#305;�ta
demans&#305; olmayan Parkinson hastalar&#305;nda 4 y&#305;l sonunda %42, bir
di&#287;erinde ise 15 y&#305;l i�inde %48 oran&#305;nda demans
geli&#351;ti&#287;i bildirilmi&#351;tir. Sa&#287;kal&#305;mdan
etkilenmedi&#287;i i�in prevelans �l��mlerine g�re daha sa&#287;l&#305;kl&#305;
olan insidans hesaplamalar&#305;nda �� ila be&#351; y&#305;ll&#305;k izlem
s�resinde PH�da insidans&#305;n kontrol grubuna g�re 4-6 kat daha fazla
artt&#305;&#287;&#305; izlenmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHD i�in en �nemli risk fakt�rleri ileri ya&#351;,
uzun hastal&#305;k s�resi ve a&#287;&#305;r motor �z�rl�l�kt�r (�zellikle
bradikinezi-rijidite ve aksiyel semptomlar). �zellikle ileri ya&#351; ve
a&#287;&#305;r motor bulgular&#305; olan hastalar gen� ya&#351; ve daha hafif
motor bulgular&#305; olan hastalara k&#305;yasla yakla&#351;&#305;k 10 kat
kadar artm&#305;&#351; bir demans riski g�sterirler. De&#287;i&#351;ik
�al&#305;&#351;malarda bildirilen, ancak her zaman do&#287;rulanamayan
di&#287;er risk fakt�rleri aras&#305;nda &#351;unlar say&#305;labilir: PH
ba&#351;lang&#305;c&#305;n&#305;n ileri ya&#351;ta olmas&#305;, akinetik-dominan
tipte PH, konu&#351;ma bozuklu&#287;u ve post�ral insitabilite gibi aksiyel
tutulum bulgular&#305;n&#305;n belirgin olmas&#305;, levodopa ile tedavi
esnas&#305;nda hal�sinasyonlar&#305;n ve psikozun erken d�nemde ortaya
�&#305;kmas&#305;, depresyonun varl&#305;&#287;&#305;, hastan&#305;n ilk
muayenesindeki mini-mental durum muayenesi puan&#305;n&#305;n d�&#351;�k
olmas&#305; ve y�r�t�c� i&#351;levler (�zellikle s�zel
ak&#305;c&#305;l&#305;k), g�rsel-mekansal i&#351;levler ve bellek
fonksiyonlar&#305;nda hafif de olsa i&#351;lev bozukluklar&#305;n&#305;n
varl&#305;&#287;&#305;. &#304;ki y&#305;ll&#305;k prospektif bir
�al&#305;&#351;mada post�ral insitabilite ve y�r�me g��l�&#287;� fenotipi
bulunan hastalarda tremor-dominan gruba k&#305;yasla PHD ortaya �&#305;kma
riskinin daha y�ksek ve kognitif bozulma oran&#305;n&#305;n daha
h&#305;zl&#305; oldu&#287;u bulunmu&#351;tur. Bir ba&#351;ka
�al&#305;&#351;mada ba&#351;lang&#305;�ta tremor-dominan bir fenotip g�steren
hastalar&#305;n demans geli&#351;mesinden �nce tremor dominans&#305;n&#305;
kaybedip akinetik-rijid belirtilerin �n plana �&#305;kt&#305;&#287;&#305;
saptanm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Klinik �zellikler&nbsp; </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genel seyri itibar&#305;yla PHD sinsi
ba&#351;lang&#305;�l&#305; ve yava&#351; ilerleyici bir demans tablosu ile
karakterizedir. Tipik klinik �zellikler �n planda bir y�r�t�c� i&#351;lev
bozuklu&#287;uyla birlikte dikkatte ve g�rsel mekansal i&#351;levlerde erken
d�nemlerden itibaren bozulma (s&#305;kl&#305;kla demans&#305;n genel
&#351;iddetinden daha a&#287;&#305;r �l��de), genelde tan&#305;man&#305;n
korundu&#287;u daha hafif bir episodik bellek bozuklu&#287;u, kelime
ak&#305;c&#305;l&#305;&#287;&#305; ve kelime bulma zorlu&#287;u
d&#305;&#351;&#305;nda g�reli olarak korunmu&#351; temel lingusitik
i&#351;levleri i�erir. Bu kognitif profile s&#305;kl&#305;kla apati,
hal�sinasyon ve hezeyanlar gibi davran&#305;&#351;sal semptomlar e&#351;lik
eder. Ba&#351;lang&#305;�ta zihinsel alandaki bozulmalar motor bulgulara
odaklanan hekimin ve hasta yak&#305;nlar&#305;n&#305;n dikkatini �ekmeyebilir.
Subjektif olarak hastalar s&#305;kl&#305;kla dikkat ve konsantrasyon
g��l�klerinden, yak&#305;n olaylar&#305; iyi
hat&#305;rlayamad&#305;klar&#305;ndan, alg&#305;laman&#305;n ve d�&#351;�ncenin
yava&#351;lamas&#305;ndan, c�mleyi ba&#351;latmakta ve do&#287;ru kelimeleri
bulmakta g��l�klerden bahsederler. Giderek �nce hesap yapma, banka ve finans
i&#351;lerini y�r�tme, kar&#305;&#351;&#305;k ila� &#351;emalar&#305;n&#305;
uygulama gibi daha karma&#351;&#305;k i&#351;levlerde, zamanla da daha temel
g�nl�k ya&#351;am i&#351;levlerinde bozulma g�r�l�r. Hastalar kendilerine ya da
�stlendikleri g�revleri yapmak i�in uzun zaman harcarlar, ya da hi� yapamazlar.
Karar vermede, i&#351;leri ba&#351;latmada, ailevi ve sosyal aktivitelere
kat&#305;lmakta zorluk �ekerler, giderek artan apatiden dolay&#305; bu tip
aktivitelere ve hobilerine ilgileri ve spontaniteleri azal&#305;r. S&#305;k bir
bulgu g�ni�i uyuklamalar&#305;n artmas&#305;, g�nd�z-gece ritminin tersine
d�nmeye ba&#351;lamas&#305;d&#305;r. Demans&#305;n ileri evrelerinde bu
belirtiler iyice belirginle&#351;ir, konu&#351;ma giderek k�t�le&#351;ir, ileri
dizartrik ve anla&#351;&#305;lmaz hale gelebilir; hasta konu&#351;may&#305; kesti&#287;inde
ne anlatt&#305;&#287;&#305;n&#305; ve nerede kald&#305;&#287;&#305;n&#305;
hat&#305;rlamayabilir. Son evrelerde hasta s&#305;kl&#305;kla inkontinan,
yata&#287;a veya tekerlekli sandalyeye ba&#287;&#305;ml&#305; haldedir.
N�ropsikolojik profil a�&#305;s&#305;ndan PHD klasik olarak y�r�t�c� i&#351;lev
bozuklu&#287;unun �n planda oldu&#287;u , �diseksekutif� tipte bir demans
tablosudur. Ancak baz&#305; hastalarda ileri, limbik tipte bellek
bozuklu&#287;unun �n planda oldu&#287;u Alzheimer tipi bir demans tablosunun
belirtileri tabloya kat&#305;labilir ya da �n plana ge�ebilir. Bu hastalar
b�y�k olas&#305;l&#305;kla her iki tip patolojinin de&#287;i&#351;ik oranlarda
bir arada oldu&#287;u karma-patolojili tablolar&#305; temsil ederler.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>N�ropsikolojik muayenede kompleks,
y�neltilmi&#351; dikkatte bozulma anlam&#305;ndaki y�r�t�c� i&#351;lev
bozuklu&#287;u, s�zel ak&#305;c&#305;l&#305;kta azalma ve psikomotor
h&#305;zdaki yava&#351;lama en erken saptanan �zelliklerdir. AH ile k&#305;yasland&#305;&#287;&#305;nda
PHD�de daha fazla apati, daha belirgin kognitif yava&#351;lama (bradifreni),
dikkatte daha a&#287;&#305;r ve daha dalgalanan bir bozulma vard&#305;r.
Y�r�t�c� i&#351;lev bozuklu&#287;u erkenden ortaya �&#305;kar ve hastal&#305;k
ilerledik�e daha belirgin hale gelir. PHD�de belle&#287;in t�m �&#287;eleri
(�al&#305;&#351;ma belle&#287;i, a�&#305;k bellek, verbal ve g�rsel
modalitelerde �rt�k haz&#305;rlama belle&#287;i, prosed�rel �&#287;renme)
bozulmu&#351;tur. �&#287;renme testlerinde ve g�nl�k hayatta spontan geri
�a&#287;&#305;rma AH�ye benzer &#351;ekilde bozulmu&#351;ken se�enekler
aras&#305;ndan tan&#305;ma veya ipu�lar&#305;ndan yararlanarak hat&#305;rlama
daha iyidir. Erken ve belirgin g�rsel-mekansal i&#351;lev bozuklu&#287;u
PHD�nin di&#287;er bir �nemli �zelli&#287;idir, bu bozukluk .AH�ye k&#305;yasla
daha a&#287;&#305;rd&#305;r. Temel dil i&#351;levleri PHD�de b�y�k �l��de
korunmu&#351;tur. Dil ba&#287;lam&#305;nda en s&#305;k g�r�len sorunlar&#305;
spontan kelime bulma g��l�&#287;� ve s�zel ak&#305;c&#305;l&#305;kta bozulma
olu&#351;turur. Baz&#305; yazarlara g�re y�r�t�c� i&#351;lev disfonksiyonuna
ba&#287;l&#305;, i�e d�n�k dikkat ve arama stratejilerinde bozulma sonucu
ortaya �&#305;kan, b�ylelikle de dil i&#351;levlerinde ger�ek bir
bozulmay&#305; yans&#305;tmayan bu belirtiler AH�dekinden daha ciddi boyutta
olabilirler. AH�ye ba&#287;l&#305; demans tablosuyla PHD tablosu
aras&#305;ndaki bu farkl&#305;l&#305;klara kar&#351;&#305;n PHD ile Lewy
Cisimcikli Demans tablolar&#305; b�y�k �l��de �rt�&#351;�rler. LCD�nin temel
�zelliklerinden biri olan mental performansta g�nden g�ne veya g�n i�inde
ortaya �&#305;kan dalgalanmalar PHD i�in de olduk�a tipiktirler. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHD�de davran&#305;&#351;sal problemler ve
ki&#351;ilik de&#287;i&#351;iklikleri olduk�a s&#305;kt&#305;r. NPI
kullan&#305;larak yap&#305;lan bir �al&#305;&#351;mada PHD olan hastalar&#305;n
%89�unda bir veya daha fazla psikiyatrik semptom bulundu&#287;u
saptanm&#305;&#351;t&#305;r. En s&#305;k g�r�len&nbsp; n�ropsikiyatrik
semptomlar depresyon, hal�sinasyonlar, apati, anksiyete ve hezeyanlard&#305;r.
Depresyon ya da depresif belirtiler hastalar&#305;n en az %50�sinde g�r�l�p
hastal&#305;&#287;&#305;n seyri esnas&#305;nda herhangi bir zamanda ortaya
�&#305;karlar. Hal�sinasyonlar genelde g�rsel nitelikte olup iyi
&#351;ekillenmi&#351; insan (s&#305;kl&#305;kla �ocuklar, bazen
tan&#305;d&#305;k bazen da tan&#305;nmayan kad&#305;n ve erkekler), hayvan veya
bitki g�r�nt�lerinden olu&#351;ur ve LCD�de g�r�lenlere benzerler. Kap&#305; ya
da zil sesi, veya ismin �a&#287;r&#305;lmas&#305; &#351;eklinde duysal
hal�sinasyonlar daha nadirdir; multi-modal hal�sinasyonlar ise �ok nadir
g�r�l�rler. &#304;�g�r� s&#305;kl&#305;kla korunurken bazen bozulur ve
hal�sinasyonlar korkutucu bir nitelik kazan&#305;rlar. Hezeyanlar en s&#305;k
�phantom boarder� (evde bir yabanc&#305;n&#305;n oldu&#287;u hissi),
hastan&#305;n arkas&#305;nda ya da yan&#305;nda birisinin durdu&#287;u hissi,
bir g�lgenin ge�ti&#287;i d�&#351;�ncesi, aldatma hezeyanlar&#305; olarak
ortaya �&#305;karlar. Hastalar bazen evlerinin kendi evleri
olmad&#305;&#287;&#305;, ya da yak&#305;nlar&#305;n&#305;n (s&#305;kl&#305;kla
e&#351;lerin) kendi yak&#305;n&#305; olmad&#305;&#287;&#305; hissine
kap&#305;labilir ve �eve� gitmek isteyebilirler. Hal�sinasyonlar ve hezeyanlar
dopaminerjik ila�lar&#305;n al&#305;m&#305;ndan sonra ortaya �&#305;kabilir ya
da belirginle&#351;ebilirler. Bu durum PHD olan ya da demans geli&#351;tirmekte
olan hastalarda daha erken, daha kolay ve daha d�&#351;�k dozlarda ortaya
�&#305;karlar. Erken d�nemlerden itibaren g�r�len ve PHD�nin �nemli bir
�zelli&#287;i olan apati hastal&#305;k ilerledik�e daha da belirginle&#351;ir,
ileri evrelerde hastalar spontanite ve motivasyonlar&#305;n&#305; tamamen
yitirip g�n�n b�y�k k&#305;sm&#305;n&#305; uyuyarak ya da bir k�&#351;ede
oturarak ge�irirler. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHD�de motor fenotip s&#305;kl&#305;kla simetrik
bradikinezi, rijiidite ve post�ral instabilitenin �n planda oldu&#287;u
akinetik-rijid formdur. Daha �nce tremor-dominans&#305; g�steren hastalarda
zamanla tremor tamamen ortadan kalkabilir. PHD�de levodopa cevab&#305;n&#305;n
giderek azald&#305;&#287;&#305; d�&#351;�n�l�r. Ancak bu g�zlem en az
k&#305;smen non-dopaminerjik bulgular&#305;n giderek �n plana ge�mesiyle
a�&#305;klanabilir. LCD hastalar&#305;na benzer &#351;ekilde �l�mle
sonlanabilecek n�roleptik duyarl&#305;l&#305;&#287;&#305; PHD&nbsp;
hastalar&#305;nda da bildirilmi&#351;tir. Uyku ile ilgili bozukluklardan
artm&#305;&#351; g�n uykusu yan&#305;nda REM uykusu davran&#305;&#351;
bozuklu&#287;u da PHD�de s&#305;k g�r�len �zelliklerden birisidir. Bu belirti
demans&#305; olmayan hastalarda da ortaya �&#305;kabilmekle birlikte demansl&#305;
hastalarda muhtemelen daha s&#305;kt&#305;r ve bilinen bir Parkinson
hastas&#305;nda yeni olarak ortaya �&#305;kmas&#305; kognitif bozulman&#305;n
�n habercisi olabilir. Kapsaml&#305; ve
kar&#351;&#305;la&#351;t&#305;rmal&#305; olarak ara&#351;t&#305;r&#305;lmamalar&#305;na
kar&#351;&#305;n ortostatik hipotansiyon, senkop, d�&#351;meler, barsak ve
mesane bozukluklar&#305;, kalp at&#305;m h&#305;z&#305;nda azalma, seks�el
disfonksiyon gibi otonomik bozukluklar&#305;n demans&#305; olan hastalarda daha
s&#305;k g�r�ld�&#287;� d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>N�ropatoloji ve Fizyopatoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHD�de asandan modulat�r sistemlerin hemen
hepsinde h�cre ve innervasyon kayb&#305; bildirilmi&#351;tir. De&#287;i&#351;ik
�al&#305;&#351;malarda kolinerjik, dopaminerjik, noradrenerjik ve
serotoninerjik monoaminerjik sistemlerin etkilendi&#287;i bulunmu&#351;tur.
Kolinerjik kay&#305;plar d&#305;&#351;&#305;ndaki bulgular ve bunlar&#305;n
demans ile ba&#287;lant&#305;s&#305; net olarak g�sterilmemi&#351; olmakla
birlikte bu kay&#305;plar&#305;n t�m� de demans&#305;n de&#287;i&#351;ik
belirtilerinin ortaya �&#305;kmas&#305;na katk&#305;da bulunabilirler.
�rne&#287;in, dopaminerjik kay&#305;p frontostriatal
ba&#287;lant&#305;lar&#305;n normal �al&#305;&#351;mas&#305;n&#305; bozarak
y�r�t�c� i&#351;levlerde ve �al&#305;&#351;ma belle&#287;inde bozulma
yapabilir. Ancak PHD�deki kognitif bozuklu&#287;un biyokimyasal k�keni olarak
en sistemli &#351;ekilde g�sterilebilen bulgu kolinerjik innervasyondaki
azalmad&#305;r. Bu azalma anatomik, biyokimyasal ve fonksiyonel
�al&#305;&#351;malarda g�sterilmi&#351; olup AH�de g�r�lenden daha fazla
orandad&#305;r (g�zden ge�irme i�in bkz. Emre, 2007). Yap&#305;sal olarak bazal
�nbeyni innerve eden Meynert�in n�kleus bazalisindeki kolinerjik h�crelerin
say&#305;s&#305;n&#305;n azald&#305;&#287;&#305; saptanm&#305;&#351;t&#305;r.
Biyokimyasal olarak asetilkolin yap&#305;lmas&#305;n&#305; sa&#287;layan enzim
olan kolinasetiltransferaz aktivitesinin PHD olan hastalar&#305;n korteksinde
demans&#305; olmayan Parkinson hastalar&#305;na g�re daha fazla oranda
azald&#305;&#287;&#305;, bu azalman&#305;n �zellikle frontal ve temporal
kortekslerde daha belirgin oldu&#287;u bulunmu&#351;tur. Kolinerjik
i&#351;aretleyiciler ile yap&#305;lan fonksiyonel g�r�nt�leme
�al&#305;&#351;malar&#305;nda benzer &#351;ekilde kolinerjik aktivitenin PHD
olan hastalarda olmayanlara ve AH olanlara k&#305;yasla daha �ok
azald&#305;&#287;&#305;, bu azalman&#305;n miktar&#305;n&#305;n kognitif
tutulumun, �zellikle de y�r�t�c� i&#351;levlerdeki bozuklu&#287;un miktar&#305;
ile orant&#305;l&#305; oldu&#287;u saptanm&#305;&#351;t&#305;r. T�m
biyokimyasal bulgular birlikte ele al&#305;nd&#305;&#287;&#305;nda dopaminerjik
eksikli&#287;in y�r�t�c� i&#351;lev ve �al&#305;&#351;ma belle&#287;i
bozuklu&#287;una, kolinerjik eksikli&#287;in bellek, dikkat ve y�r�t�c�
i&#351;levlerde bozuklu&#287;a, noradrenerjik eksikli&#287;in dikkat
bozuklu&#287;una, serotoninerjik eksikli&#287;in ise affektif bozuklu&#287;a
katk&#305;da bulunabilece&#287;i �ne s�r�lm�&#351;t�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Zamansal geli&#351;im i�inde PHD�nin
n�ro-patolojik kar&#351;&#305;l&#305;&#287;&#305; olarak �� tip patoloji
sorumlu tutulmu&#351;tur. Bunlar a) subkortikal �ekirdeklerin, �zellikle
mediyal substantia nigran&#305;n dejenerasyonu, b) AH-tipi patoloji (amiloid
plaklar ve n�rofibriler yumaklar) c) Lewy cisimci&#287;i (LC) patolojisidir.
Her bir patoloji i�in demanstan sorumlu ana mekanizma oldu&#287;unu g�steren
farkl&#305; �al&#305;&#351;malar vard&#305;r. Ancak son 10 y&#305;lda
yap&#305;lan, de&#287;i&#351;ik patolojilerin e&#351; zamanl&#305; olarak
de&#287;erlendirildi&#287;i, �zellikle de LC patolojisini saptamak i�in daha
hassas bir y�ntem olan alfa-sin�klein imm�nhistokimyas&#305; kullan&#305;lan
�al&#305;&#351;malarda altta yatan ana patolojinin kortikal ve limbik alanlarda
h�cre kayb&#305; ve LC-tipinde dejenerasyon oldu&#287;u g�sterilmi&#351;tir. Bu
�al&#305;&#351;malarda LC patolojisi, kognitif bozuklukla en yak&#305;n
korelasyon g�steren bulgudur; buna s&#305;kl&#305;kla AH-tipi patoloji
e&#351;lik etmekte, ancak nadiren patolojik olarak AH tan&#305;s&#305;n&#305;
koydurmaya yetecek miktarda olmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genetik
�zellikler</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi PH�n&#305;n nadir
nedenlerinden olan alfa-sin�klein geninde triplikasyon mutasyonu
ta&#351;&#305;yan ailelerde PH motor semptomlar&#305;n&#305;n yan&#305;nda,
bazen erken d�nemden itibaren demans g�r�lebilirken, gen duplikasyonu olan
ailelerde bu durum ya hi� olmamakta ya da nadir g�r�lmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;
Kriterleri</span></b><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD�nin klinik tan&#305;
kriterleri (bkz. Tablo 18) �Movement Disorders Society��nin
olu&#351;turdu&#287;u bir �al&#305;&#351;ma Grubu taraf&#305;ndan 2007
y&#305;l&#305;nda yay&#305;nlanm&#305;&#351;t&#305;r (Emre<i> et al. </i>,
2007). Bu grup taraf&#305;ndan tan&#305;mlanan PHD�nin klinik �zellikleri, bu
�zelliklerin varl&#305;&#287;&#305; ya da yoklu&#287;una
dayand&#305;r&#305;larak tan&#305;mlanan �muhtemel PHD� ve �m�mk�n PHD�
tan&#305; kriterleri Tablo 18�de g�sterilmi&#351;lerdir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD tan&#305;s&#305; temel
prensipleri itibar&#305;yla herhangi bir hastada demans tan&#305;s&#305; koymaktan
farkl&#305; de&#287;ildir. &#304;lk a&#351;amada demans&#305; taklit edebilen
di&#287;er durumlar&#305;n ekarte edilmesi gerekir. Bu durumlar demans
seviyesinde olmayan kognitif tutulumu, sistemik hastal&#305;klar ya da ila� yan
etkisi olarak ortaya �&#305;kabilen akut-uzam&#305;&#351; konf�zyonu ve depresyonu
i�erir. Bu durumlar ekarte edilp demans tan&#305;s&#305; konulduktan sonra
ikinci a&#351;ama ay&#305;r&#305;c&#305; tan&#305;y&#305; olu&#351;turur. Bu
a&#351;amada demans ve Parkinsonsizm belirtilerinin bir arada olabilece&#287;i
di&#287;er hastal&#305;klar (progresif supran�kleer fel�, kortikobazal dejenerasyon,
vask�ler demans, normal bas&#305;n�l&#305; hidrosefali ve LCD gibi)
d�&#351;�n�lmeli, Parkinson hastal&#305;&#287;&#305;na eklenebilecek subdural
hematom, B-12 eksikl&#287;i gibi di&#287;er nedenler de g�z ard&#305;
edilmemelidir. T�m bu durumlar ekarte edilmesine kar&#351;&#305;n tan&#305;da
bazen g��l�klerle kar&#351;&#305;la&#351;&#305;labilir. �rne&#287;in, ileri
derecede motor ve konu&#351;ma bozuklu&#287;unun kognitif y&#305;k&#305;mla �st
�ste binmesi, depressif belirtielerin e&#351;lik etmesi, olas&#305; ila� yan
etkilerinin tabloyu kar&#305;&#351;t&#305;rd&#305;&#287;&#305; durumlarda
tan&#305;&nbsp; g��le&#351;ebilir. Ayr&#305;nt&#305;l&#305; bir �yk�, t�m
kognitif alanlar&#305; i�eren mental muayene, di&#287;er hastal&#305;klar&#305;
d&#305;&#351;layan laboratuar incelemeleri ile yukar&#305;da s�z� edilen PHD
klinik tan&#305; kriterlerinin dikkatlice uygulanmas&#305; tan&#305;y&#305;
kolayla&#351;t&#305;r&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD i�in �zg�l bir
n�rog�r�nt�leme bulgusu yoktur. BT ve MRG gibi yap&#305;sal g�r�nt�lemelerde
daha ziyade beynin posterior b�lgelerinde atrofi dikkat �eker; hippokampal ve
medyal-temporal atrofi e&#351;lik edebilmesine kar&#351;&#305;n AH�de g�r�len
kadar s&#305;k ve a&#287;&#305;r de&#287;ildir. Fonksiyonel g�r�nt�lemede SPECT
ve PET incelemelerinde frontal ve temporoparietal kortekste hipoperf�zyon
bulunur; ancak bu bulgu AH�de de ortaya �&#305;kabildi&#287;i i�in �zg�l
de&#287;ildir ve tek bir hastan&#305;n ay&#305;r&#305;c&#305;
tan&#305;s&#305;na katk&#305; sa&#287;lamaz. Presinaptik dopaminerjik terminallerin
yo&#287;unlu&#287;unu g�steren �dopamin ta&#351;&#305;y&#305;c&#305;�
(DAT)&nbsp; SPECT incelemesinde PHD ve LCD hastalar&#305;nda striatal DAT
tutulumunda azalma g�r�l�rken AH�de bu tutulum normaldir. B�ylelikle bu y�ntem
ekstrapiramidal bulgular geli&#351;tiren Alzheimer hastalar&#305;n&#305;n
(�rn., n�roleptik yan etkisine ba&#287;l&#305;) PHD ve LCD hastalar&#305;ndan
ay&#305;rd edilmesinde yard&#305;mc&#305; olabilir. Nihayet AH i�in
geli&#351;tirilen PET ile amiloid g�r�nt�lemede LCD gruplar&#305; AH2liler gibi
amiloid pozitif bulunurken PHD gruplar&#305; demanss&#305;z kontroller gibi
amiloid negatif bulunmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD d�&#351;�n�len bir hastada
farmakolojik tedaviye ba&#351;lamadan �nce zihinsel bozuklu&#287;u
tetikleyebilecek di&#287;er fakt�rler d&#305;&#351;lanmal&#305;d&#305;r. Bu
ba&#287;lamda sistemik hastal&#305;klar, �zellikle yeni ba&#351;lanan veya dozu
artt&#305;r&#305;lan ila�lar g�zden ge�irilmeli, hasta antikolinerjik,
trisiklik antidepresan veya benzodiazepin grubundan bir ila� kullan&#305;yorsa
bu ila�lar kesilmelidir. Dopaminerjik ila�lar hal�sinasyon,&nbsp; hezeyan gibi
psikotik belirtileri ve konf�zyonu artt&#305;rabilecekleri i�in �zellikle
agonistlerin dozu azalt&#305;lmal&#305; ya da bunlar kesilmeli, tedavi m�mk�n
oldu&#287;u kadar yeterli dozda yal&#305;n levodopa preparatlar&#305;na
indirgenmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD�de kolinerjik
eksikli&#287;in tan&#305;mlanmas&#305;ndan sonra mevcut t�m kolinesteraz
inhibit�rleri (rivastigmin, donepezil, galantamin) �o&#287;unlukla k���k
�apl&#305; ve a�&#305;k �al&#305;&#351;malarda olmak �zere bu grup hastalarda
denenmi&#351;, t�m �al&#305;&#351;malarda belirli&nbsp; �l��de olumlu etkiler
tan&#305;mlanm&#305;&#351;t&#305;r. Bu �al&#305;&#351;malar&#305;n en
b�y�&#287;� ve kapsaml&#305;s&#305; rivastigmin ile yap&#305;lan EXPRESS
�al&#305;&#351;mas&#305;d&#305;r ve pozitif sonu�lanm&#305;&#351;t&#305;r (Emre<i>
et al. </i>, 2004). Di&#287;er asetilkolinesteraz inhibit�rlerden donepezil ile
de b�y�k �apl&#305; bir �al&#305;&#351;ma yap&#305;lm&#305;&#351;, belirli
�l�eklerde plasebodan �st�n oldu&#287;u bildirilmi&#351;, ancak bu
�al&#305;&#351;ma hen�z yay&#305;nlanmam&#305;&#351;t&#305;r. EXPRESS
�al&#305;&#351;mas&#305;n&#305;n sonu�lar&#305;na dayanarak rivastigmin PHD�de
ilk �zg�l tedavi olarak ruhsatland&#305;r&#305;lm&#305;&#351;t&#305;r. LCD
tedavisinde an&#305;lan Emre �al&#305;&#351;mas&#305;nda memantin PHD grubunda
da klinik de&#287;erlendirme �l��t�nde plaseboya �st�n bulunmu&#351;tur.
Kullan&#305;m&#305; d�&#351;�n�lebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Non-kognitif belirtilerin
tedavisi de LCD�ye benzerdir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 18:
Parkinson hastal&#305;&#287;&#305; demans&#305;n&#305;n �zellikleri (Emre et
al. 2007)<o:p></o:p></span></b></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>I. Temel
�zellikler</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1. Tan&#305;s&#305; �Queen
Square Beyin Bankas&#305;� Kriterlerine g�re konulmu&#351; Parkinson
Hastal&#305;&#287;&#305;n&#305;n varl&#305;&#287;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2. Sinsi olarak ba&#351;layan,
yava&#351; ilerleyen, tan&#305;s&#305; �yk�, klinik ve mental muayene
bulgular&#305; ile konan, a&#351;a&#287;&#305;daki &#351;ekilde
tan&#305;mlanm&#305;&#351; demans sendromunun varl&#305;&#287;&#305;:<o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l4 level1 lfo3;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Birden
     fazla kognitif alanda bozulma</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l4 level1 lfo3;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu
     alanlarda premorbid d�zeye g�re bir d�&#351;�&#351; </span><span
     style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l4 level1 lfo3;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kognitif
     bozukluklar&#305;n g�nl�k hayat&#305; (sosyal, mesleki veya ki&#351;isel
     bak&#305;m) etkileyecek a&#287;&#305;rl&#305;kta olmas&#305; (motor veya
     otonomik bozuklu&#287;a atfedilen bozukluktan ba&#287;&#305;ms&#305;z
     olarak) </span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>II. E&#351;lik
eden klinik �zelikler</span></b><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1. Kognitif �zellikler</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dikkat</span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
     Bozulmu&#351;. Spontan ve odaklanm&#305;&#351; dikkatte bozulma, dikkat
     testlerinde&nbsp; k�t� performans; performans g�n i�inde veya g�nden g�ne
     dalgalanabilir.</span><span lang=DA style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�r�t�c�
     &#304;&#351;levler</span></u><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>: Bozulmu&#351;. Bozukluk
     ba&#351;lama, planlama, konsept olu&#351;turma, kural bulma, kural
     de&#287;i&#351;tirme veya koruma testlerinde olabilir;
     yava&#351;lam&#305;&#351; mental h&#305;z (bradifreni) </span><span
     lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�rsel-mekansal
     i&#351;levler</span></u><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>: Bozulmu&#351;. Bozulma g�rsel-mekansal
     i&#351;levler, g�rsel-mekansal oryantasyon, g�rsel alg&#305; veya
     yap&#305;land&#305;rma testlerinde g�r�lebilir</span><span lang=DA
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek</span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
     Bozulmu&#351;. Bozulma yak&#305;n ge�mi&#351;teki olaylar&#305;n serbest
     hat&#305;rlanmas&#305; veya yeni bilgileri �&#287;renme testlerinde
     g�r�lebilir; hat&#305;rlama genellikle ipucuyla d�zelir, tan&#305;ma
     genellikle serbest hat&#305;rlamadan daha iyidir</span><span lang=DA
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dil</span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
     Ana fonksiyonlar b�y�k oranda korunmu&#351;. Kelime bulma g��l�kleri ve
     kompleks c�mleleri anlamada bozulma olabilir. <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2. Davran&#305;&#351;sal
�zellikler</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Apati:
     Spontanitenin azalmas&#305;; motivasyonun, ilginin ve iradi
     davran&#305;&#351;lar&#305;n kayb&#305;</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;ilikte
     ve duygu durumda, depresif �zellikler ve anksiyeteyi i�eren
     de&#287;i&#351;iklikler </span><span style='font-size:10.0pt;font-family:
     Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hal�sinasyonlar;
     �o&#287;unlukla g�rsel, genellikle kompleks, ki&#351;i, hayvan veya
     objelerin iyi &#351;ekillenmi&#351; g�r�nt�leri</span><span
     style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hezeyanlar;
     genellikle paranoid �zellikte, aldat&#305;lma veya ba&#351;ka birinin
     varl&#305;&#287;&#305; (evde istenmeyen misafirlerin
     varl&#305;&#287;&#305;) gibi hezeyanlar</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#351;&#305;r&#305;
     g�nd�z uyuklamalar&#305;</span><span style='font-size:10.0pt;font-family:
     Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>III. Parkinson Hastal&#305;&#287;&#305;
demans&#305;n&#305; d&#305;&#351;latt&#305;rmayan, ancak tan&#305;y&#305;
ku&#351;kuda b&#305;rakan �zellikler</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.45pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.15pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Demans&#305;n sebebi olduklar&#305; d�&#351;�n�lmeyen, ancak kognitif
bozuklu&#287;a neden olabilecek di&#287;er anormalliklerin
varl&#305;&#287;&#305;, �rn. g�r�nt�lemede anlaml&#305; vask�ler hastal&#305;k
varl&#305;&#287;&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.45pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.15pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Motor ve kognitif semptomlar&#305;n geli&#351;imi aras&#305;ndaki zaman
ili&#351;kisinin bilinmemesi</span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:3.3pt;margin-bottom:.0001pt;text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>IV. Mental bozuklu&#287;un nedeni olabilecek di&#287;er
hastal&#305;klar&#305;n veya bozukluklar&#305;n mevcudiyeti, bunlar&#305;n
varl&#305;&#287;&#305;nda Parkinson hastal&#305;&#287;&#305; demans&#305;
tan&#305;s&#305;n&#305; koymak m�mk�n olmaz</span></b><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l35 level1 lfo12;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kognitif
     ve davran&#305;&#351;sal semptomlar&#305;n a&#351;a&#287;&#305;daki
     nedenler �er�evesinde ortaya �&#305;kmas&#305;</span><span
     style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akut konf�zyon&nbsp;&nbsp; </span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Sistemik hastal&#305;klar veya anormallikler</span><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;la� intoksikasyonu&nbsp; &nbsp;</span><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
DSM IV�e g�re maj�r depresyon </span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.45pt;text-align:justify;text-indent:
-14.15pt'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NINDS-ARIEN&nbsp; kriterlerine g�re
�Muhtemel Vask�ler Demans� ile uyumlu �zellikler</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>Muhtemel
Parkinson Hastal&#305;&#287;&#305; Demans&#305;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A. Temel �zellik: Her iki temel
�zellik de bulunmal&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B. E&#351;lik eden klinik
�zellikler:</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l27 level1 lfo15;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D�rt
     kognitif alan&#305;n en az ikisinde, tipik profil g�steren bozulma
     (dikkatte dalgalanan bozulma, y�r�t�c� i&#351;levlerde bozulma, g�rsel-mekansal
     i&#351;levlerde bozulma ve serbest hat&#305;rlama belle&#287;inde
     bozulma-genellikle ipucu ile d�zelme)</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l27 level1 lfo15;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal
     semptomlardan (apati, depresif ve anksiy�z duygudurum, hal�sinasyonlar,
     hezeyanlar, a&#351;&#305;r&#305; g�nd�z uyuklamas&#305;) en az birinin
     varl&#305;&#287;&#305; muhtemel&nbsp; Parkinson Hastal&#305;&#287;&#305;
     Demans&#305; tan&#305;s&#305;n&#305; destekler, ancak
     davran&#305;&#351;sal semptomlar&#305;n olmamas&#305; tan&#305;y&#305;
     d&#305;&#351;latmaz</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>C. Grup III�de yer alan
�zelliklerin olmamas&#305;</span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D. Grup IV�de yer alan
�zelliklerin olmamas&#305;</span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>M�mk�n
Parkinson Hastal&#305;&#287;&#305; Demans&#305;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A. Temel �zellik: Her iki temel
�zellik de olmal&#305;</span><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B. E&#351;lik eden klinik
�zellikler:</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l46 level1 lfo18;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Birden
     fazla alanda var olan kognitif bozuklu&#287;un atipik profili; �rn. dikkat
     korunmu&#351; iken saf depo-hasar&#305; bi�iminde amnezi (bellek ipucuyla
     veya tan&#305;ma g�revleri ile d�zelmiyor) veya reseptif tipte (ak&#305;c&#305;)
     afazi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l46 level1 lfo18;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal
     semptomlar olabilir veya olmayabilir </span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>VEYA</span><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>C. Grup III�de yer alan
�zelliklerden bir veya daha fazlas&#305;n&#305;n varl&#305;&#287;&#305; </span><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D. Grup IV�de yer alan
�zelliklerin olmamas&#305;<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Frontotemporal Demans</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Arnold Pick ilk kez
1892 y&#305;l&#305;nda �Afazi ve Beynin Senil Atrofisi Aras&#305;ndaki
&#304;li&#351;ki �zerine� isimli makalesinde,&nbsp; Alzheimer�in Auguste
D.�sinden 14 y&#305;l �nce, n�rodejeneratif hastal&#305;klar&#305;n 3. b�y�k
grubunu olu&#351;turan ve g�n�m�zde son olarak (&#351;imdilik)
�frontotemporolobar deenerasyonlar� (FTLD) olarak adland&#305;r&#305;lan ancak
bu terimin patolojiye daha yak&#305;n olan
�a&#287;r&#305;&#351;&#305;mlar&#305;yla olsa gerek klinikte �oklukla bir
�nceki ismi olan �frontotemporal demans� (FTD) olarak an&#305;lan fokal
atrofilerin ilk olgusunu bildirdi. O s&#305;rada Prag�da �niversite Psikiyatri
B�l�m��n�n direkt�r� olan Pick ba&#351;ka bir August�u, August H. isimli olguyu
�zetle &#351;�yle tan&#305;mlam&#305;&#351;t&#305;: ��yk� konu&#351;ma
bozuklu&#287;unun yava&#351; geli&#351;ti&#287;ini d�&#351;�nd�r�yor ...Sol
hemisferin, �zellikle de sol temporal lobun giruslar&#305;nda a&#287;&#305;r
bir atrofi mevcuttu. Her hangi bir fokal hastal&#305;k saptanmad&#305;��yle
g�r�n�yor ki, belli bir zaman par�as&#305;nda geli&#351;mi&#351;,
a&#351;a&#287;&#305; yukar&#305; keskin bir bi�imde s&#305;n&#305;rlanabilen
bir afazi t�r� mevcuttur ve muhtemelen de basit nitelikte,
s&#305;n&#305;rlar&#305; belirlenebilir beyin de&#287;i&#351;iklikleriyle
ili&#351;kilendirilebilir��. Bu paragraf g�n�m�zde semantik demans olarak
bilinen sol temporopolar atrofiye ba&#287;l&#305; ilerleyici afazi alt tipinin
bundan nerdeyse 120 y&#305;l �nce yap&#305;lm&#305;&#351; m�kemmel bir
tan&#305;m&#305;n&#305; i�ermektedir. �Eri&#351;kinlerin Primer Progresif
Demans&#305; �zerine� isimli, 1904 tarihli bir sonraki yay&#305;n&#305;nda ise
bu kez de davran&#305;&#351;sal varyant&#305; ilk kez tarif edecektir: �41
ya&#351;&#305;nda bir ev han&#305;m&#305; yava&#351; yava&#351;
de&#287;i&#351;ti. �zensiz ve sakar bir hale geldi� ola&#287;an i&#351;lerini
s�rd�rm�yor, �ocuklar&#305;n&#305;n bak&#305;m&#305;n&#305; yapm&#305;yor,
giysilerini ya da yatak �ar&#351;aflar&#305;n&#305; de&#287;i&#351;tirmiyor,
sa�lar&#305;n&#305; taram&#305;yordu. &#304;&#351;lerini bitirmeden
b&#305;rak&#305;yor ve tembel tembel oturuyordu. Her hangi bir sohbet
ba&#351;latm&#305;yor, sorular&#305; tekrarl&#305;yor, stereotipik
e&#287;ilimli cevaplar veriyor ve s&#305;kl&#305;kla persevere ediyordu. Tek
kayg&#305;s&#305; bedeniydi, bitlenmeden ve a�l&#305;ktan yak&#305;n&#305;yor
ve daima yemek talep ediyordu. Al&#305;&#351;&#305;lmad&#305;k �fke krizleri
oluyor, �ocuklar&#305;na s�zel olarak &#351;iddet g�steriyor veya
�ocuklar&#305;na veya inekler dahil yak&#305;n&#305;nda ne varsa onlara
vuruyordu��. Pick�in �al&#305;&#351;malar&#305;yla ilerleyici
davran&#305;&#351;sal belirtiler ve ilerleyici afaziden olu&#351;an bu
antitenin n�ropatolojisi intran�ronal glob�ler arjirofilik inkl�zyonlu
cisimcikler (Pick cisimcikleri-PiC) ve balonla&#351;m&#305;&#351; &#351;i&#351;
n�ronlar (Pick h�creleri-PiHc), y�zeyel kortikal spongioz, glioz, n�ron
kayb&#305; olarak tan&#305;mlanm&#305;&#351;t&#305;. PiC terimini ilk Alzheimer
1911 y&#305;l&#305;nda kullanm&#305;&#351;t&#305;r. Bu antite 1922�de Gans
taraf&#305;ndan �Pick atrofisi� ve nihayet 1926�da Onari ve Spatz
taraf&#305;ndan �Pick hastal&#305;&#287;&#305;� olarak
adland&#305;r&#305;ld&#305; (kapsaml&#305; bir g�zden ge�irme i�in bkz. Binetti
2001). Gans hastal&#305;&#287;&#305;n bask&#305;n ailevi �zelli&#287;inden de
ilk kez s�zediyordu. Yak&#305;n tarihlerin �nmli �al&#305;&#351;malar&#305;ndan
birinde 1974�te Cenevre Beyin Bankas&#305;�ndan 40 olguluk bir PiH serisi
bildirildi. Klinik olarak davran&#305;&#351;sal art&#305; dilsel bir sendrom veya
y�r�t�c� bozukluk art&#305; parkinsonizm olarak �zetlenebilecek 2 tarzda
sunulmu&#351; olan bu seride ilk sunum temporo-orbitofrontal, ikincisi frontal
konveksite atrofisi ile ili&#351;kiliydi. &#304;lk atrofi tarz&#305;n&#305;
sergileyen 10 olguda PiC ve PiHC birlikte g�r�l�rken 8 olguda ikisinin birden
olmad&#305;&#287;&#305; sadece gliozis mevcuttu. &#304;kinci tarz atrofi
tarz&#305;n&#305; sergileyen 10 olguda PiC olmaks&#305;z&#305;n sadece PiHC, 4
olguda ise yine sadece gliozis mevcuttu. Cummings ve Duchen 1981�de bilgisayarl&#305;
tomografinin erken d�nemlerinde 5 a&#287;&#305;r anterior temporal atrofili PiH
olgusu bildirdiler. T�m�nde de atrofi PiC ile ili&#351;kiliydi ve
amigdalay&#305; i�ine almaktayd&#305;. Davran&#305;&#351;sal �zellikleri
�Kluver-Bucy sendromu� unsurlar&#305; olarak �zetlediler. Dilsel
bozukluklar&#305;n da �n planda oldu&#287;unu, bellek ve mekansal oryantasyonun
g�reli korunmu&#351; oldu&#287;unu vurgulayarak bu klinik tablonun PiH�in bu
varyant&#305; i�in ay&#305;rt edici olabilece&#287;ini ileri s�rd�ler.
&#304;zleyen y&#305;llarda, ba&#351;l&#305;ca daha sonra yay&#305;nlanacak ilk
kriterler dizisine de isimlerini verecek olan &#304;sve�ten Lund,
&#304;ngiltere�den Manchester gruplar&#305;ndan
ara&#351;t&#305;r&#305;c&#305;lar&#305;n bir dizi �al&#305;&#351;mas&#305;yla,
PiC ve PiHc�nin bu antitenin s&#305;k g�r�len bir bile&#351;eni
olmad&#305;&#287;&#305; gerek�esiyle, Pick�in ismi kald&#305;r&#305;larak
atrofi tarz&#305; (fronto-temporal) antitenin ad&#305; haline geldi. Bu
�al&#305;&#351;malar �zetle frontal lob demans&#305;n&#305;n (FLD) AH�den
ay&#305;rt edilebilir bir sendrom oldu&#287;unu, t�m demanslar&#305;n
%15-20�sini kapsad&#305;&#287;&#305;n&#305;, olgular&#305;n �o&#287;unda PiC
bulunmad&#305;&#287;&#305;n&#305; ileri s�rmekteydi. Ge�en y�zy&#305;l&#305;n
son 10 y&#305;l&#305;na egemen olan bu 2 grup 1994�te bir araya gelerek �Manchester-Lund
Fronto-temporal Demans (FTD) Kriterleri� olarak an&#305;lacak ilk tan&#305;
kriterleri dizisini yay&#305;nlad&#305;lar. Bu kriterlerde
davran&#305;&#351;sal �zellikler ayr&#305;nt&#305;l&#305; bir &#351;ekilde
tan&#305;mlan&#305;rken, dilsel �zelliklerin olduk�a y�zeysel bir
tan&#305;m&#305;na rastlan&#305;r. Parkinsonizm ve ALS bulgular&#305;n&#305;n
g�r�lebilece&#287;i vurgulan&#305;r. Erken inkontinans, normal EEG ve
g�r�nt�lemede frontal, anterior temporal veya bunlar&#305;n kombinasyonunun bu
tan&#305;ya �zg� oldu&#287;unun alt&#305; �izilir. Erken ba&#351;lang&#305;� ve
s&#305;k aile �yk�s� AH�yle kontrast olu&#351;turan �yk� �zellikleri olarak
belirlenir. Nihayet, 1998�de Lund ve Manchester gruplar&#305;na Frans&#305;z,
Kanadal&#305; ve ABD, California�dan ara&#351;t&#305;r&#305;c&#305;lar&#305;n
kat&#305;l&#305;m&#305;yla isim bir kez daha de&#287;i&#351;tirilip bug�nk�
haline getirilir: FTLD (Neary<i> et al. </i>, 1998). Bu yeni kriterler
dizisinde (bkz. Tablo 19), yukarda �demans sendromlar&#305;n&#305;n
fenomenolojik ayr&#305;r&#305;c&#305; tan&#305;s&#305;� b�l�m�nde �progresif
afazi� ve �progresif y�r�t�c�/davran&#305;&#351;sal bozukluk� alt
ba&#351;l&#305;klar&#305;nda ayr&#305;nt&#305;s&#305;yla
tart&#305;&#351;&#305;lan davran&#305;&#351;sal varyant FTD (FTDdv), ilerleyici
tutuk afazi (PNFA) ve semantik demans (SD) bi�imlerinde 3 farkl&#305; sunumunun
ayr&#305;nt&#305;l&#305; tan&#305;mlar&#305; s&#305;ralanm&#305;&#351;t&#305;r.
FTLD �Uzla&#351;&#305;m� Kriterleri�nin yazarlar&#305; aras&#305;nda bulunan
Kertesz Pick isminin bir klinik tan&#305; olarak ortadan
kald&#305;r&#305;l&#305;p sadece PiC�lerin g�r�nd�&#287;�, klinik
kar&#351;&#305;&#287;&#305; m�phem ve dolay&#305;s&#305;yla tan&#305;s&#305;
�ok g�� ender bir histopatolojik tan&#305;ya indirgenmesine ba&#351;tan beri
itiraz etmekteydi. Kertesz, ilk kez 1994�te �primer progresif afazi (PPA), FLD,
PPA-ALS ve KBD gibi fokal kortikal dejenerasyonlarla karakterize n�rodejeneratif
hastal&#305;klar&#305;� Pick Kompleksi (PK) terimiyle adland&#305;rarak Pick
eponimini yeniden canland&#305;rmay&#305; �nerdi. Bu �neri yayg&#305;n kabul
g�rmese de Kertesz &#305;srar&#305;n&#305; s�rd�rd�. Zaman i�inde Kertesz i�in
PK dilsel ve davran&#305;&#351;sal bile&#351;enlerle birlikte, KBD ve PSP�yi
i�eren bir motor bile&#351;en de i�eren bir klinik spektrum haline geldi.
Klinik sunumlar bu bile&#351;enlerden biriyle ba&#351;lay&#305;p seyir boyunca
izole kalabildikleri gibi daha s&#305;kl&#305;kla di&#287;er bile&#351;enlerden
�zelliklerin de kat&#305;ld&#305;&#287;&#305; karma sendromlar haline
d�n�&#351;mektedir. PK spektrumunu olu&#351;turan antitelerin �ng�r�lebilir
n�ropatolojik ve genetik kar&#351;&#305;l&#305;klar&#305; oldu&#287;unu ileri
s�rd� (yeni y�zy&#305;ldaki bir dizi Kertesz g�zden ge�irmeleri i�in bkz.
Kertesz, 2007, Kertesz, 2003, Kertesz).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�ok say&#305;da
prevelans �al&#305;&#351;mas&#305; olmasa da Cambridge, &#304;ngiltere
�al&#305;&#351;mas&#305;nda FTD�nin pre-senil d�nemde (45-64 ya&#351;) AH kadar
s&#305;k olabilece&#287;ini g�steren bulgular elde edilmi&#351;tir. Rochester,
Minnesota, ABD�den gelen tek insidans rakamlar&#305; (100,000 ki&#351;ilik
n�fusta y&#305;lda yeni olgu) 40-49 ya&#351; aral&#305;&#287;&#305;nda 2.2,
50-59 aral&#305;&#287;&#305;nda 3.3 ve 60-69 aral&#305;&#287;&#305;nda 8.9
&#351;eklindedir. Daha ya&#351;l&#305; aral&#305;k dahil edilmemi&#351;tir.
Genellikle cinsiyetleri e&#351;it etkiledi&#287;i g�r�&#351;� hakimken,
Cambridge �al&#305;&#351;mas&#305;nda �rneklemin %82�si erkeklerdi. Ortalama
hastal&#305;k s�resi AH�ye g�re biraz daha k&#305;sa, 8 y&#305;ld&#305;r
(aral&#305;k 2-20 y&#305;l). ALS e&#351;li&#287;i sa&#287;kal&#305;m&#305; 3
y&#305;la kadar k&#305;salt&#305;r. Hastalar&#305;n %40�&#305;n&#305;n 1.
derece akrabalar&#305;nda benzer hastal&#305;k �yk�s� vard&#305;r ve
bunlar&#305;n en az yar&#305;s&#305; otozomal dominan tarzda bir ge�i&#351;
sergilerler. Familyal ve sporadik olgular aras&#305;nda AH i�in mutad olan
ba&#351;lang&#305;� ya&#351;&#305; fark&#305; yoktur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>FTLD�nin alt gruplar&#305;n&#305;n prevelans ve
insidanslar&#305; spesifik olarak
�al&#305;&#351;&#305;lmam&#305;&#351;t&#305;r. PNFA�n&#305;n t�m FTLD�nin %10
ila 35�ini olu&#351;turdu&#287;u ileri s�r�lm�&#351;t�r. Bir
�al&#305;&#351;mada ba&#351;lang&#305;� ya&#351;&#305;n&#305;n di&#287;er FTLD
alt gruplar&#305;ndan anlaml&#305; olarak daha ge� oldu&#287;u fakat
sa&#287;kal&#305;m&#305;n farkl&#305; olmad&#305;&#287;&#305; bulunmu&#351;tur.
SD t�m FTLD�nin %15-25�ini olu&#351;turur ve ba&#351;lang&#305;� ya&#351;&#305;
ve sa&#287;kal&#305;m a�&#305;s&#305;ndan tipik FTD�den farkl&#305;l&#305;k
g�stermez. Belirlenmi&#351; ve yerle&#351;mi&#351; risk fakt�rleri oldu&#287;u
s�ylenemez. Sadece <i>MAPT</i> geninin H1 haplotipine sahip olmak bir genetik
risk olarak ileri s�r�lm�&#351; ve H1/H1 homozigot genotipi PSP ve KBD i�in bir
risk olu&#351;turdu&#287;u do&#287;rulanm&#305;&#351;t&#305;r. Genetik olmayan
risk fakt�rleri aras&#305;nda da sadece kafa travmas&#305; �yk�s� tek bir
�al&#305;&#351;mada FTLD ile anlaml&#305; ili&#351;kili bulunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Klinik Tablo</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PK perspektifi ile motor vayant da dahil
edildi&#287;inde bir davran&#305;&#351;sal varyant (FTDdv), kendi i�inde PNFA
ve SD olarak da ayr&#305;lan bir dilsel varyant (SD sol ve sa&#287; temporal varyantlar
olarak bir kez daha ayr&#305;labilir) ve yine kendi i�inde asimetrik
parkinsonizm-progresif apraksi tarz&#305;nda KBD sendromu ve vertikal
bak&#305;&#351; felci-aksiyel parkinsonizm-a&#287;&#305;r post�ral imbalans
&#351;eklinde PSP sendromu &#351;eklinde ayr&#305;labilecek bir motor varyant
ay&#305;rt edilir. �zellikle FTDdv ve PNFA�ta ALS e&#351;lik etti&#287;inde
FTD-ALS�den s�zedilir. Bu klinik sunumlar&#305;n ayr&#305;nt&#305;l&#305;
�zellikleri yukarda �Progresif Afazi�, �Progresif
Y�r�t�c�/Davran&#305;&#351;sal Bozukluk� ve �Progresif Apraksi� b�l�mlerinde
ayr&#305;nt&#305;yla tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genetik</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tau geni (<i>MAPT</i>) </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Familyal FTD ile <i>MAPT </i>geni
ili&#351;kisi ilk kez 1994�te<i> </i>bir ailenin kromozom 17�de <i>MAPT </i>genini
i�eren q21-22 b�lgesine anlaml&#305; bir ba&#287;lant&#305;n&#305;n
varl&#305;&#287;&#305;n&#305;n bulunmas&#305;yla g�sterilmi&#351;tir.
Sonras&#305;nda 1996�da o zamana kadar ayn&#305; ba&#287;lant&#305;n&#305;n
saptand&#305;&#287;&#305; 13 geni&#351; aileyi tan&#305;mlamak �zere
ger�ekle&#351;tirilen bir uzla&#351;&#305;m toplant&#305;s&#305;nda �Kromozom
17�ye ba&#287;l&#305; fronto-temporal demans ve parkinsonizm (FTDP-17)� terimi
�nerilmi&#351;tir. &#304;ki y&#305;l sonra FTDP-17 ailellerinde ilk <i>MAPT</i>
mutasyonlar&#305; 3 ayr&#305; grup taraf&#305;ndan bildirildi. Ge�en
y&#305;llar i�inde toplam 132 ailede 44 farkl&#305; mutasyon
bildirilmi&#351;tir. <i>MAPT </i>mutasyonlu olgular t�m FTLD
olgular&#305;n&#305;n %5-10�unu, familyal FTD�nin ise %10-20�sini
olu&#351;turur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Fakl&#305; <i>MAPT </i>mutasyonlu
aileler PK�n&#305;n t�m varyantlar&#305;n&#305; i�eren olduk�a geni&#351; bir
fenotipik varyasyon sergilerler. Bu durum bazen ayn&#305; mutasyona sahip bir
ailenin farkl&#305; �yelerinin fenotipik de&#287;i&#351;kenli&#287;i olarak da
g�r�l�r. En s&#305;k g�r�len mutasyon P301L hatal&#305; anlaml&#305; mutasyonu
s&#305;kl&#305;kla 45-65 aras&#305;nda ba&#351;lar ve ba&#351;lang&#305;�
ya&#351;&#305; hi� bir zaman 70�i a&#351;maz. <i>MAPT</i> mutasyonu PSP ve KBD
fenotipi sergileyen hastalarda da bildirilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>MAPT </span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>mutasyonlar&#305;
bir dizi farkl&#305; tau patolojisine yola�ar. Bunlar&#305;n ilki
ba&#351;l&#305;ca 4R taudan olu&#351;an, AH�ye benzemeyen n�rofibriler inkl�zyonlard&#305;r
ve 4R tau mikrot�b�l ba&#287;lanmas&#305;n&#305; etkileyen veya 4R/3R
oran&#305;n&#305; artt&#305;ran ekson 10 mutasyonlar&#305; sonucu g�r�l�rler
(en s&#305;k olan P301L ilkine neden olur). Bu birikintilerde AH NFY�lerinin
PHF�lerinden morfolojik farkl&#305;l&#305;klar izlenir. Hem n�ronlar hem de
glia etkilenir. Buna kar&#351;&#305;l&#305;k, ekson 9, 11, 12 ve 13
mutasyonlar&#305; 3R ve 4R tauyu birlikte etkiler ve ya NFY-PHF�lere ya da
PiC�lere benzeyen inkl�zyonlar yarat&#305;r. Glial etkilenme daha azd&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Progranulin geni (<i>PGRN)</i></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Yeni y�zy&#305;ldan itibaren giderek artan
g�zlemler 17q21�e ba&#287;lant&#305;land&#305;&#287;&#305; halde b�t�n �abalara
ra&#287;men <i>MAPT</i> mutasyonu bulunamayan ve ayn&#305; zamanda da tau
patolojisi sergilemeyip sadece ubikuitin immunoreaktivitesi g�steren (Ub+T-)
ailelerin say&#305;s&#305;n&#305;n FTD-17-tau ailelerini a&#351;maya
ba&#351;lad&#305;&#287;&#305;n&#305; ortaya koydu. Sonunda 2006 i�inde 2
ayr&#305; grup taraf&#305;ndan bu Ub+T- FTD-17 ailelerinden sorumlu genin
progranulin geni (<i>PGRN</i>) oldu&#287;unu buldular. Bu genin
kodlad&#305;&#287;&#305; progranulin proteini bir b�y�me fakt�r�d�r ve
geli&#351;im, yara onar&#305;m&#305;, inflammasyon ve t�m�r olu&#351;umu gibi
bir dizi farkl&#305; s�re�le ili&#351;kilendirilmi&#351;tir. Bildirilen
mutasyonlar&#305;n t�m� s&#305;f&#305;r mutasyonlard&#305;r ve muhtemelen
proteinin i&#351;lev yitimine neden olarak etki etmektedirler. K&#305;sa s�re
�nce ke&#351;fedilmesine ra&#287;men &#351;imdiye kadar toplam 212 ailede 68
farkl&#305; mutasyon bildirilmi&#351;tir. T�m FTLD�lerin %5-10�unu familyal
FTD�lerin ise %15-25�ini olu&#351;turduklar&#305; tahmin edilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;lang&#305;� ya&#351;&#305;
ayn&#305; aile i�inde dahi olduk�a de&#287;i&#351;kendir (38-79 aras&#305;).
Klinik olarak FTDdv yan&#305;s&#305;ra PNFA fenotipi ve KBD fenotipi bildirilmi&#351;tir.
Mesulam dil bozukluklar&#305; kendi PPA tan&#305;m&#305; ile uyumlu 2 ailede
yine <i>PGRN </i>mutasyonu bildirmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PGRN</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
mutasyonlar&#305; n�ropatolojik olarak y�zeyel kortikal tabakalarda spongiform
de&#287;i&#351;ikliklerle Ub+T- inkl�zyonlara yola�ar. Bunlar genellikle n�ronlar&#305;n
sitoplazmalar&#305;nda olmakla birlikte (NCI�lar), intran�kleer de olabilirler
(NII<i>). </i>Distrofik n�ritler (DN) de g�r�l�r. PGRN�nin bulunmas&#305;ndan
k&#305;sa zaman sonra bir biri ard&#305;na bildirilen otopsi <i>serilerinde </i>PGRN
mutasyonlu bireylerin beyinlerindeki bilinmeyen ubikuitinize proteinin TDP-43
oldu&#287;u ortaya konmu&#351;tur.&nbsp;TDP-43 ekson atlama ve transkripsiyon
d�zenlemeden sorumlu bir n�kleer proteindir ve 1. kromozomda kodlan&#305;r (<i>TARDP
</i>geni). &#304;zleyerek sporadik Ub+T- FTD�lerin de (FTLD-U) %90�dan
fazlas&#305;n&#305;n transaktif cevapl&#305;-DNA�ya ba&#287;lanan protein 43
(TDP-43) imm�noreaktivitesi g�sterdi&#287;i bulunmu&#351; ve TDP-43
proteinopatileri FTLD�nin de sporadik ve familyal b�y�k bir b�l�m�nden sorumlu
yeni bir proteinopati olarak n�rodejeneratif hastal&#305;klar
s&#305;n&#305;flamas&#305;na dahil edilmi&#351;tir. <i>PGRN </i>mutasyonu
ilintili familyal FTD-TDP, NCI, NII ve DN inkl�zyonlar&#305; birlikte
g�stererek FTLD-U subtiplerinden Tip 3 olarak da
s&#305;n&#305;flan&#305;l&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er sorumlu genler</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Daha 1987 gibi erken bir tarihte
tan&#305;mlanm&#305;&#351; olan ve bask&#305;n olarak davran&#305;&#351;sal
de&#287;i&#351;iklikler ve bir �l��de dilsel �zellikler ve geri planda KBD
benzeri motor �zellikler sergileyen geni&#351; bir Danimarka ailesinde
ba&#287;lant&#305; analizi kromozom 3�� i&#351;aretlemi&#351;ti. Geninin
bulunmas&#305; i�in bir 10 y&#305;l ge�mesi gerekti: kromatin modifiye edici
protein veya di&#287;er ismiyle y�kl� multivesik�ler protein 2B geni (<i>CHMP2B</i>).
Bu gendeki mutasyonlar&#305;n CHMP2B�nin h�cresel lokalizasyonunu bozdu&#287;u
g�sterilmi&#351;tir. An&#305;lan bu Danimarkal&#305; aile
d&#305;&#351;&#305;nda &#351;imdiye kadar 2. bir aile bildirilmemi&#351;tir,
dolay&#305;syla FTD-3 kategorisi halen sadece bu orijinal aile ile
s&#305;n&#305;rl&#305;d&#305;r. FTD-3 n�ropatolojik olarak bir&nbsp;
FTLD-U�dur. Ancak, TDP-43 imm�noreaktivitesi g�stermedi&#287;i gibi bu y&#305;l
geriye kalan %10 kadar TDP-43 negatif FTLD-U�larda mevcudiyeti ortaya konan
�fused in� sarkoma proteini (FUS) immunoreaktivitesi de negatiftir. B�ylelikle,
art&#305;k FTLD n�ropatolojisinin %1�inden az&#305;na
s&#305;n&#305;rlanm&#305;&#351; olan FTLD-U kategorisinin tek temsilcisi
burdaki ubikuitinize protein de ke&#351;fedilene kadar FTD-3�t�r diyebiliriz.
Bu gendeki 2 yeni mutasyon daha sonradan saf ailevi ALS ile
ili&#351;kilendirmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Inkl�zyon cisimci&#287;i myoziti (IBM)
ve Paget hastal&#305;&#287;&#305; ile birlikte herediter FTD sergileyen aileler
valosin i�eren proteini (VCP) kodlayan 9. kromozomda p21.1-p12 lokusuna
haritalan&#305;rlar. VCP bir AAA-ATPaz s�perfamilyas&#305; �yesidir ve h�cre
�evrimi kontrol�, membran f�zyonu ve ubikuitin-proteasom degradasyon
yola&#287;&#305; gibi bir dizi h�cresel aktiviteden sorumludur. Watts ve
arkada&#351;lar&#305; toplam 66 hastada bulduklar&#305; 6 farkl&#305; mutasyonu
bildirmi&#351;lerdir. Hastal&#305;k klinik olarak eri&#351;kin
ba&#351;lang&#305;�l&#305; kav&#351;ak tipi myopati, omurga ve kal�a
a&#287;r&#305;lar&#305;yla karakterize Paget hastal&#305;&#287;&#305; ve
k&#305;rkl&#305; ya&#351;larda ba&#351;layan dilsel varyant
a&#287;&#305;rl&#305;kl&#305; FTLD ile karakterizedir. Triad b�t�n
hastalar&#305;n ancak %12�sinde g�r�l�r ve en s&#305;k izole sunum %30 kadar
IBM &#351;eklindedir. Dolay&#305;s&#305;yla bu hastalara daha
s&#305;kl&#305;kla n�rom�sk�ler hastal&#305;klar birimlerinde
rastlan&#305;lmas&#305; beklenir. N�ropatolojik olarak hippokampusun g�reli
kurtuldu&#287;u ba&#351;l&#305;ca neokortikal NII inkl�zyonlar&#305; (Tip 4)
&#351;eklinde FTD-TDP birikintileri g�r�l�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Yak&#305;nlarda FTD-ALS sergileyen 6
Frans&#305;z ailesi kromozom 9p21.3-p13.3�e
ba&#287;lant&#305;land&#305;r&#305;lm&#305;&#351;t&#305;r. 27 aday genin hi�
birinde mutasyon bulunamam&#305;&#351;t&#305;r. Hastalar %32 oran&#305;nda
izole FTD, %29 izole ALS (FALS) ve %39 oran&#305;nda da her ikisinin
bile&#351;imi &#351;eklinde sunulmu&#351;lard&#305;. TDP-43-pozitif NCI�lar
(Tip 2 FTLD-U) korteks ve medulla spinaliste saptand&#305;. Bulunamayan bu
genin t�m FTD-ALS�nin %60�&#305;ndan sorumlu olabilece&#287;i ileri
s�r�lm�&#351;t�r.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Kromozom 1�de kodlana TDP-43 genindeki
mutasyonlar FALS ile ili&#351;kilendirilmi&#351; ve <i>TARDP </i>mutasyonlu
FALS olgular&#305; ALS10 olarak da s&#305;n&#305;flanm&#305;&#351;t&#305;.
Yak&#305;n tarihte ALS olmaks&#305;z&#305;n FTD�ye neden olan 2 ayr&#305; <i>TARDP
</i>mutasyonu bildirildi. Bunlardan ilki FTDdv fenotipi sergileyen bir
kad&#305;nd&#305;. Di&#287;eri ise FTDdv, PSP �zellikleri ve koreye sahipti ve
n�ropatolojik olarak ba&#351;l&#305;ca subkortikal �ekirdekler ve
beyinsap&#305;n&#305;n TDP-43+ inkl�zyonlarla tutulmu&#351; oldu&#287;u
g�r�ld�.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Son olarak, 16. kromozomda kodlanan ve
TDP-43-negatif FTLD-U olgular&#305;n&#305;n b�y�k b�l�m�nde ubkuitinize
edilmi&#351; protein oldu&#287;u �ok yak&#305;nlarda g�sterilmi&#351; olan
�fused in� sarkoma proteini (FUS) genindeki mutasyonlar da FALS
olgular&#305;yla ili&#351;kilendirilmi&#351; ve <i>FUS</i> mutasyonlu FALS
olgular&#305; ALS6 olarak
s&#305;n&#305;fland&#305;r&#305;lm&#305;&#351;t&#305;. Yine yak&#305;n
tarihlerde bir <i>FUS </i>mutasyonlu olgunun FTD-ALS sergiledi&#287;i
bildirildi.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>N�ropatoloji</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>N�ropatolojik olarak makroskopik a�&#305;dan FTLD
antitelerinin ay&#305;r&#305;c&#305; �zelli&#287;i daha �nce de
de&#287;inildi&#287;i gibi lober atrofidir.&nbsp; En s&#305;k olarak asimetrik
fronto-temporal kombine atrofi g�r�l�rken, bunu izole frontal, anterior
temporal ve parietal lob atrofileri izler.&nbsp; Hastal&#305;k ilerledik�e
atrofi tarz&#305; simetrikle&#351;me e&#287;ilimi g�sterir.&nbsp; AH�nin
aksine, tutulum tarz&#305;n&#305;n nas&#305;l ilerleyece&#287;i �nceden kestirilemez.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Mikroskopik olarak tau+ inkl�zyonlar
(FTLD-tau), Ub+T- inkl�zyonlar (FTLD-U) olarak s&#305;n&#305;flan&#305;rlar.
FTLD-U�nun %90�&#305;na yakla&#351;an bir k&#305;sm&#305;nda ubikuitinize
proteinin TDP-43 oldu&#287;u (FTLD-TDP) bulunmu&#351;tur (Neumann<i> et al. </i>,
2006). Geri kalan %10 kadar FTLD-U�nun&nbsp; da �ok yak&#305;nda ubkuitinize
proteiinlerinin FUS oldu&#287;u (FTLD-FUS) bulunmu&#351; ve FTLD-U
s&#305;n&#305;f&#305; hen�z ubikuitinize proteini bulunamayan az say&#305;daki
CHMP2B mutasyonlu familyal FTLD hastas&#305;na s&#305;n&#305;rl&#305;
kalm&#305;&#351;t&#305;r. �ok az say&#305;daki hastada ise ge�en
y�zy&#305;l&#305;n �ay&#305;rtettirici histopatolojisi olmayan demans-DLDH�
veya non-spesifik gliozis tan&#305;m&#305;n&#305; hakedecek &#351;ekilde her
hangi bir inkl�zyon (FTLD-ni) g�r�lmez. T�m�n�n de ortak �zelli&#287;i tutulan
alanlarda saptanan n�ron kayb&#305;, gliozis ve y�zeyel lineer
spongiozistir.&nbsp; FTLD-tauda derin kortikal tabakalarda &#351;i&#351;, balonla&#351;m&#305;&#351;
g�r�n�ml� Pick h�creleri saptanabilir.&nbsp; PiH�in ay&#305;r&#305;c&#305;
�zelli&#287;i olan Pick cisimcikleri n�ronlar&#305;n i�inde g�r�len b�y�k ve
yuvarlak inkl�zyonlard&#305;r (bkz. &#350;ekil 19).&nbsp; Tau antikorlar&#305;yla
farkl&#305; tarzlarda boyanmalar&#305; ve n�rofilamanlar, �ift sarmall&#305; filamanlar,
k&#305;sa d�z ve uzun k&#305;vr&#305;ml&#305; fibriller gibi farkl&#305; eleman
i�erikleriyle, olduk�a homojen bir yap&#305; olan NFY�lerden farkl&#305; olarak
de&#287;i&#351;kenlik g�sterirler.&nbsp; Bunlar PiH�e �zg� olarak Bielschowsky
boyas&#305; ile boyan&#305;rken, Gallyas ile boyanmazlar.&nbsp; Pick cisimciklerine
tutulmam&#305;&#351; neokortikal alanlarda rastlan&#305;lm&#305;yor olsa da
say&#305;lar&#305; atrofiyle korele etmez ve daima atrofik loba k&#305;yasla
hippokampusta daha bol miktarda bulunurlar.&nbsp; Tutularak atrofiye
kat&#305;lan ve Pick cisimciklerinin g�r�lebildi&#287;i subkortikal yap&#305;lar
aras&#305;nda olgudan olguya de&#287;i&#351;ecek &#351;ekilde neostriatum,
medial talamus, daha hafif d�zeyde olmak �zere de substantia nigra, hipotalamus
ve locus coeruleus bulunur.&nbsp; KBD�de n�ronal inkl�zyonlar bazen Pick
cisimciklerini and&#305;rsa da daha �ok halka &#351;eklinde
yumaklard&#305;r.&nbsp; Pick cisimciklerinden farkl&#305; olarak Bielschowsky
ile gayet zay&#305;f boyan&#305;rlarken, bu kez Gallyas ile iyi
boyan&#305;rlar.&nbsp; D�z k&#305;sa fibrillerden olu&#351;urlar.&nbsp; N�ronal
&#964; birikimleri Pick cisimciklerine benzer yap&#305;lardan �ok yayg&#305;n
birikimler ve yumaklar tarz&#305;ndad&#305;rlar.&nbsp; Yayg&#305;n subkortikal
tutulum i�inde substantia nigra n�ronlar&#305;nda kortikobasal cisimcikler de
denilen globoz NFY�ler ay&#305;rt edilir.&nbsp;&nbsp; N�ronal
inkl�zyonlar&#305;n yan&#305; s&#305;ra yayg&#305;n astrositik &#964;
inkl�zyonlar&#305; (GCI�lar) tan&#305; koydurucudur.&nbsp; Bunlara amiloid
i�ermeyen glial plaklar ad&#305; da verilir.&nbsp; Oligodendrogliada da
yayg&#305;n bi�imde &#964; ekspresyonu ve arjirofilik inkl�zyonlar
g�r�l�r.&nbsp; FTLD-TDP inkl�zyonlar&#305; daha �nce s�zedildi&#287;i gibi NCI,
NII ve DN &#351;ekillerinde olur ve bunlar&#305;n biri ya da bir
ka�&#305;n&#305;n bask&#305;nl&#305;&#287;&#305; ve tutulum tarz&#305;na g�re 4
ayr&#305; alt tipe s&#305;n&#305;fland&#305;r&#305;lm&#305;&#351;t&#305;r.
FTLD-FUS atipik FTLD-U (aFTLD-U), bazofilik inkl�zyon cisimci&#287;i
hastal&#305;&#287;&#305; (BIBD) ve n�ronal orta boy filaman inkl�zyonu
hastal&#305;&#287;&#305; (NIFID) alt tiplerini kapsar.&nbsp; Kromozom 17
ilintili FTLD ve di&#287;er ailevi&nbsp; FTLD�ler de sporadik proteinopatilerin
n�ropatolojisini and&#305;r&#305;rlar.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span style='font-size:10.0pt;font-family:Tahoma'><a
href="demans19.JPG"><span lang=TR style='mso-ansi-language:TR'>&#350;ekil 19.</span><span
lang=TR style='mso-ansi-language:TR;font-weight:normal'>&nbsp;</span></a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Pick
Cisimcikleri. Bielschowsky g�m�&#351; boyama ile arjantofilik intrasel�ler
inkl�zyonlar (Kaynak: </span><span style='font-size:10.0pt;font-family:Tahoma'><a
href="http://www.binderlab.northwestern.edu/pickbodies.html"><span lang=TR
style='mso-ansi-language:TR'>http://www.binderlab.northwestern.edu/pickbodies.html</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Nedene y�nelik bir tedavinin
do&#287;al olarak FTLD mekanizmas&#305;nda temel rol� oynayan tau, TDP-43 ve
FUS proteinlerinin patolojik katlanmas&#305;n&#305; engellemeyi hedeflemelidir.
AH�nin mekanizma temelli tedavi staratejillerinden tau hedefli stratejilerin
ilerde FTLD�lerde de kullan&#305;labilece&#287;i d�&#351;�n�lebilir. FTLD�de
mekanizma temelli tedavilerin yerle&#351;ebilmesi i�in farkl&#305; proteinopatilerin
de klinik olarak tan&#305;nabilmesi tabii ki bir zorunluluk olacakt&#305;r.
Baz&#305; bildirimlerde SSRI�lar&#305;n yarar&#305; �zerinde
durulmaktad&#305;r.&nbsp; ChEI�lerin ve memantinin yarar&#305;
g�sterilmemi&#351;tir.&nbsp;�e&#351;itli davran&#305;&#351;sal belirtilerin
tedavisi i�in AH tedavisinde �nerilenlere paralel bir yol izlenebilir.&nbsp;Parkinsonizm
b�y�k �l��de L-dopa�ya cevaps&#305;zsa da erken d�nemde al&#305;nabilecek olan
s&#305;n&#305;rl&#305; cevaptan yararlan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 19. </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Frontotemporal
Lobar Dejenerasyon Klinik Tan&#305; Uzla&#351;&#305; Kriterleri (Neary et al.
1998)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:48.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Liste 1.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
FTD�nin klinik tan&#305; �zellikleri: Klinik profil</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ki&#351;ilik de&#287;i&#351;ikli&#287;i ve sosyal
davran&#305;&#351; bozuklu&#287;u, ba&#351;lang&#305;�ta ve
hastal&#305;&#287;&#305;n seyri boyunca temel �zelliklerdir. Alg&#305;,
mekansal yetenekler, praksis ve belle&#287;e ili&#351;kin enstr�mental i&#351;levler
salim ya da g�reli olarak iyi korunmu&#351;tur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>I. </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Temel tan&#305; �zellikleri</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Sinsi ba&#351;lang&#305;�, yava&#351; seyir<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:7.0cm;margin-bottom:.0001pt;text-align:justify;text-indent:-2.0cm;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sosyal
ki&#351;iler aras&#305; davran&#305;&#351;&#305;n erken d�nemde bozulmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:7.0cm;margin-bottom:.0001pt;text-align:justify;text-indent:-2.0cm;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ki&#351;isel
davran&#305;&#351;&#305;n d�zenlenmesinin erken d�nemde bozulmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erken d�nemde emosyonel k�ntl�k</span><span lang=DE style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>E.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#304;�
g�r�n�n erken d�nemde kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>II. </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Destekleyici tan&#305; �zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Davran&#305;&#351;sal bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ki&#351;isel
hijyen ve kendine bak&#305;mda azalma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zihinsel
rijidite ve esneklik kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
�elinebilirlik ve sebats&#305;zl&#305;k<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hiperoralite
ve beslenme tarz&#305;nda de&#287;i&#351;iklikler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Perseveratif
ve stereotipik davran&#305;&#351;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>6.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kullanma
davran&#305;&#351;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma ve dil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma �&#305;kt&#305;s&#305;nda de&#287;i&#351;iklik<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:213.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>a.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kendili&#287;indenli&#287;in
kayb&#305;, az konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:213.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>b.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bas&#305;n�l&#305; konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stereotipik konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ekolali<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Perseverasyon</span><span lang=DE style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mutizm</span><span lang=DE style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fiziksel bulgular</span><span lang=DE style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;lkel refleksler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;nkontinans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akinezi, rijidite, tremor<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
D�&#351;�k ya da labil kan bas&#305;nc&#305;</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;ncelemeler</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N�ropsikoloji:
a&#287;&#305;r amnezi, afazi veya alg&#305;sal-mekansal bozukluk
olmaks&#305;z&#305;n frontal lob testlerinde anlaml&#305; bozukluk</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elektroensefalografi:
klinik olarak a&#351;ikar demansa kar&#351;&#305;l&#305;k konvansiyonel EEG�nin
normal olmas&#305;</span><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Beyin
g�r�nt�lemesi (yap&#305;sal ve/veya i&#351;levsel): a&#287;&#305;rl&#305;kla
frontal ve/veya anterior temporal bozukluk</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:48.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Liste 2.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Progresif tutuk afazinin klinik tan&#305; �zellikleri: Klinik profil</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:142.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ekspresif dil bozuklu&#287;u ba&#351;lang&#305;�ta ve
hastal&#305;&#287;&#305;n seyri botunca temel �zelliktir.&nbsp; Di&#287;er
bili&#351;sel i&#351;levler salimdir veya g�reli olarak iyi korunmu&#351;lard&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:143.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Temel tan&#305; �zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.&nbsp;&nbsp;&nbsp;&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinsi
ba&#351;lang&#305;�, yava&#351; seyir<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Tutuk
spontan konu&#351;ma ve &#351;unlardan en az biri: agramatizm, fonemik
parafaziler, anomi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:143.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>II.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Destekleyici tan&#305; �zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma ve dil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kekeleme veya oral apraksi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Tekrarlama bozuklu&#287;u<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Aleksi, agrafi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kelime anlam&#305;n&#305;n erken d�nemde korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ge� d�nemde mutizm<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Davran&#305;&#351;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Sosyal
yeteneklerin erken d�nemde korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Ge�
d�nemde FTD�ye benzer davran&#305;&#351;sal de&#287;i&#351;iklikler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Fiziksel
bulgular: ge� d�nemde kontrlateral primitif refleksler, akinezi, rijidite ve
tremor<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&#304;ncelemeler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;N�ropsikoloji:
a&#287;&#305;r amnezi ve alg&#305;sal-mekansal bozukluk olmaks&#305;z&#305;n
tutuk afazi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elektroensefalografi:
normal veya hafif asimetrik yava&#351;lama<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Beyin
g�r�nt�lemesi (yap&#305;sal ve/veya i&#351;levsel): a&#287;&#305;rl&#305;kla
dominan (genellikle sol) hemisferi tutan asimetrik bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-96.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Liste 3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Semantik
afazi ve asosiyatif agnozinin (SD) klinik tan&#305; �zellikleri: Klinik profil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Semantik bozukluk (kelime anlam&#305;n&#305;n ve/veya
nesne kimli&#287;inin anla&#351;&#305;lmas&#305;nda bozulma)
ba&#351;lang&#305;�ta ve hastal&#305;k seyri boyunca temel �zelliktir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Otobiyografik bellek de dahil olmak �zere di&#287;er
bili&#351;sel i&#351;levler salimdir veya g�reli olarak iyi korunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:47.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>I.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Tan&#305; �zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinsi
ba&#351;lang&#305;�, yava&#351; seyir<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerle karakterize dil bozuklu&#287;u:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Progresif,
ak&#305;c&#305;, i�eri&#287;i bo&#351; spontan konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Adland&#305;rma
ve anlama bozuklu&#287;u ile ortaya konan kelime anlam&#305;n&#305;n kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Semantik
parafaziler ve/veya</span><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerle karakterize alg&#305;sal bozukluk:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Prosopagnozi:
a&#351;ina y�zlerin tan&#305;nmas&#305;nda bozulma ve/veya<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Asosiyatif
agnozi: nesne kimli&#287;inin tan&#305;nmas&#305;n&#305;n bozulmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Alg&#305;sal
e&#351;leme ve �izerek kopyalaman&#305;n korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>E.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Tek
kelime tekrarlaman&#305;n korunmu&#351; olmas&#305;</span><span lang=FI
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>F.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Y�ksek
sesle okuma ve dikte ile ortografik olarak d�zg�n kelimeler yazma
yeteneklerinin korunmu&#351; olmas&#305;</span><span lang=FI style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=FI style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>II. </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Destekleyici tan&#305; �zellikleri</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma ve dil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bas&#305;n�l&#305; konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;dyosenkratik kelime kullan&#305;m&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fonemik parafazilerin bulunmay&#305;&#351;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Y�zey disleksi ve disgrafisi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Hesab&#305;n korunmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Davran&#305;&#351;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Sempati ve empatinin kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
K&#305;s&#305;tl&#305; tak&#305;nt&#305;l&#305; u&#287;ra&#351;&#305;lar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Hasislik<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fiziksel bulgular:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primitif
refleksler yoktur veya ge� d�nemde g�r�l�r<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Akinezi,
rijidite ve tremor</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;ncelemeler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
N�ropsikoloji:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:214.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>a.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;Kelime
anlama ve adland&#305;rma ve/veya y�z ve nesne tan&#305;ma bozuklu&#287;uyla
ortaya konan a&#287;&#305;r semantik kay&#305;p<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:214.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>b.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Fonoloji,
sentaks ve elemanter alg&#305;sal s�re�ler, mekansal yetenekler ile g�ndelik
belle&#287;in korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Elektroensefalografi: normal<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:154.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:12.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Beyin
g�r�nt�lemesi (yap&#305;sal ve/veya i&#351;levsel): a&#287;&#305;rl&#305;kla anterior
temporal bozukluk (simetrik veya asimetrik)<o:p></o:p></span></p>

<div style='margin-left:24.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-24.0pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>CREUTZFELDT-JACOB VE DI&#286;ER PRION HASTALIKLARI</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hans Gerhard Creutzfeldt ve Alfons Maria Jakob�un
1920 ve 1921�de ardarda bildirdi&#287;i olgu serilerinin Spielmeyer
taraf&#305;ndan 1922 y&#305;l&#305;nda Creutzfeldt-Jakob
hastal&#305;&#287;&#305; (CJH) olarak adland&#305;r&#305;lmas&#305;
sonras&#305; bunlar&#305;n birbirlerine ve bug�n bilinen &#351;ekliyle CJH�ye
benzerlikleri �ok ku&#351;kuluysa da, art&#305;k s�z konusu hastal&#305;k
tart&#305;&#351;maya yer b&#305;rakmayacak bi�imde an&#305;lan
ara&#351;t&#305;rmac&#305;lar&#305;n isimleri ile an&#305;lmaktad&#305;r.
Gajdusek 1968 y&#305;l&#305;nda deneysel kuru hastal&#305;&#287;&#305; olan
&#351;empanze beyni ve sporadik CJH�s&#305; olan insan beyinlerinden
haz&#305;rlanm&#305;&#351; materyelleri primatlara inok�le ederek bu
hayvanlarda hastal&#305;k geli&#351;tirmeyi ba&#351;arm&#305;&#351; ve
bula&#351;t&#305;r&#305;labilen spongiform ensefalopatiler (TSE)
kavram&#305;n&#305; geli&#351;tirmi&#351;tir. Ayn&#305; y&#305;l i�inde CJH�yi
subakut sklerozan panansefalit tarz&#305; bir �yava&#351; vir�s
hastal&#305;&#287;&#305;� olarak tan&#305;mlam&#305;&#351;t&#305;r. Stanley
Prusiner�in 1982 y&#305;l&#305;nda yava&#351; vir�s kavram&#305;n&#305; yerle
bir edip, CJH�nin nedeni olarak di&#287;er proteinopatilerde oldu&#287;u gibi,
fiziksel konformasyonunu de&#287;i&#351;tirerek patojen haline d�n�&#351;en
(PrP<sup>Sc</sup>) ve bu haliyle bir &#351;ablon olu&#351;turup normal h�cresel
proteini (PrP<sup>c</sup>) kendine benzetmeye ba&#351;lay&#305;p, b�ylelikle
�o&#287;al&#305;p biriken ve bula&#351;abilen bir protein olan prionu (PrP)
bulmas&#305; alan&#305; k�kten de&#287;i&#351;tirmi&#351;ti. Bundan b�yle
ayn&#305; zamanda bula&#351;abilir bir proteinopati olarak prion
hastal&#305;klar&#305;ndan s�z edilecektir. Oesch 1985 y&#305;l&#305;nda PrP<sup>c</sup>�yi
kodlayan geni (<i>PRPN</i>) 20. kromozomda
haritaland&#305;rm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>CJH ve yeni varyant CJH�nin de (nvCJH)
aralar&#305;nda bulundu&#287;u insan prion hastal&#305;klar&#305; (bkz. Tablo
20) %85-90 oran&#305;nda sporadik ortaya �&#305;karlar.&nbsp; Geri kalan %1-2
enfeksiy�z, yani prion hastal&#305;&#287;&#305; g�sterilmi&#351; bir kaynaktan
bula&#351;&#305;c&#305; yolla edinilen ve %5-15�de ailevi, yani 20. kromozomda
kodlanan prion proteini (PrP) geninde bir mutasyon sonucu otozomal dominan
kal&#305;t&#305;mla ge�en &#351;ekillerdir.&nbsp; &#304;nsan prion
hastal&#305;klar&#305;n&#305;n t�m�, hasta beyninden haz&#305;rlanan ekstrenin
bir primata inok�lasyonuyla bu hayvana bula&#351;t&#305;r&#305;labilir.&nbsp;
&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sporadik Prion Hastal&#305;klar&#305;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sporadik fatal insomni son derece nadir bir
hastal&#305;k oldu&#287;u i�in bu ba&#351;l&#305;k sporadik CJH ile pratik
olarak ayn&#305; anlama gelir.&nbsp; Hastal&#305;k co&#287;rafi b�lge, etnik
k�ken veya cinsiyet ay&#305;rd etmeksizin b�t�n d�nyada g�r�lebilmekte ve
y&#305;ll&#305;k s&#305;kl&#305;&#287;&#305; yakla&#351;&#305;k 1/1,000,000
ki&#351;i olarak hesaplanmaktad&#305;r.&nbsp; Bu, �lkemizde kabaca her y&#305;l
65-70 yeni CJH vakas&#305;n&#305;n ortaya �&#305;kt&#305;&#287;&#305;
anlam&#305;na gelmektedir. Ba&#351;lang&#305;� ya&#351;&#305; ortalama
60�d&#305;r.&nbsp; Hastal&#305;k �ok h&#305;zl&#305; seyirlidir.&nbsp; Konu
�zerine uzmanla&#351;m&#305;&#351; b�y�k merkezlerde CJH hastalar&#305;ndan
olu&#351;an geni&#351; vaka serilerinde ortalama hayatta kalman&#305;n 4 ay
kadar oldu&#287;u hesaplanmaktad&#305;r.&nbsp; Belirtilerin
ba&#351;lamas&#305;ndan sonraki 1. y&#305;l i�inde t�m olgular&#305;n
%90�&#305;n&#305;n �lm�&#351; oldu&#287;u kaydedilmi&#351;tir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 20.&nbsp; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion
Hastal&#305;klar&#305;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid black 1.0pt;
 mso-padding-alt:0cm 0cm 0cm 0cm;mso-border-insideh:1.0pt solid black;
 mso-border-insidev:1.0pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width=584 colspan=2 valign=top style='width:437.75pt;border:solid black 1.0pt;
  padding:4.0pt 4.0pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nsan Hastal&#305;klar&#305;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sporadik</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fatal Sporadik Insomnia � FSI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiy�z</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH
  (iyatrojenik)</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>vCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuru</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH
  (ailevi)</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fatal Familyal Insomnia - FFI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gerstmann-Str�ussler-Scheinker
  Hastal&#305;&#287;&#305; (GSS)</span><span lang=DE style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=584 colspan=2 valign=top style='width:437.75pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:4.0pt 4.0pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DE style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hayvan Hastal&#305;klar&#305;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Koyun</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Scrapie</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>S&#305;&#287;&#305;r</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bovin
  Spongiform Ensefalopati (BSE)</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vizon</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bula&#351;abilen
  Vizon Ensefalopatisi (TME)</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Geyik</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik
  Kas Erimesi Hastal&#305;&#287;&#305; (CWD)</span><span lang=FI
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;mso-yfti-lastrow:yes'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kedi</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Felin
  Spongiform Ensefalopati (FSE)</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastal&#305;k olgular&#305;n yakla&#351;&#305;k
%25�inde uykusuzluk, i&#351;tahs&#305;zl&#305;k, kilo kayb&#305;, huzursuzluk,
halsizlik gibi spesifik olmayan prodromal belirtilerle ba&#351;lar.&nbsp;
Prodromal belirtiler olsun olmas&#305;n, ba&#351;lang&#305;�taki ki&#351;ilik
de&#287;i&#351;ikli&#287;i, zihinsel i&#351;levlerde bozulma, ataksi, kortikal
k�rl�kten agnozilere g�rsel i&#351;leme problemleri &#351;eklindeki belirti ve
bulgular, aylar i�inde h&#305;zla a&#287;&#305;r bir demansa ve sonunda
akinetik mutizme yola�ar.&nbsp; Ki&#351;ilik de&#287;i&#351;ikli&#287;i, en
ba&#351;larda ki&#351;inin daha kolay �fkelenir ya da daha hasis olmas&#305;
gibi �nceden getirdi&#287;i ki&#351;ilik �zelliklerinin abart&#305;lmas&#305;
&#351;eklindeyken, giderek FTD �zellikleri �e&#351;itli bile&#351;imlerde
sergilenmeye ba&#351;lar.&nbsp; Hezeyan ve hal�sinasyonlar &#351;eklinde
psikotik �zellikler g�r�lebilir.&nbsp; Kognitif i&#351;levlerde y&#305;k&#305;m
k&#305;sa bir s�re i�in progresif afazi veya kortikal k�rl�&#287;e gidebilen
progresif simultanagnozi benzeri izole kalabilse de zaman i�inde genel bir
y&#305;k&#305;m tablosu yerle&#351;ir.&nbsp; Serebellar ataksi ve
ekstrapiramidal bulgular CJH�nin farkl&#305; alt bi�imlerinde tabloya
�e&#351;itli d�nemlerde kat&#305;l&#305;rlar.&nbsp; Hastal&#305;&#287;&#305;n
orta evrelerinde akustik ve hatta taktil uyaranlarla ortaya
�&#305;kar&#305;labilen irkilme miyoklonisi tan&#305;ya g�� katan klinik
bulgulardand&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastal&#305;k, yukarda an&#305;lan tipik
tarz&#305; yan&#305; s&#305;ra farkl&#305; isimlerle an&#305;lan ve
a&#351;a&#287;&#305;da s�zedilecek prion �su&#351;lar&#305;n&#305;n� tipi <i>PRPN
</i>ve kodon 129 polimorfizmine g�re (prion proteini geninin 129. kodonundaki
metionin veya valin mevcudiyetine g�re) de&#287;i&#351;en klinik tarzlarda da
g�r�lebilir (Tablo 21).&nbsp; Yeni varyant CJH (vCJH), �teden beri bilinen bu
tarzlara g�re �yeni� oldu&#287;u i�in bu &#351;ekilde isimlendirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="tablo21.htm">Tablo 21.</a>
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er Sporadik CJH Klinik Tarzlar&#305;n&#305;n �zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar: </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>AV:
anteroventral �ekirdek; BG: basal ganglia; Cer: serebellum; Cx: korteks; M: metionin;
MD: mediodorsal �ekirdek; PSW: periyodik yava&#351; dalga; V: valin<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Laboratuar incelemeleri tan&#305;y&#305;
kesinle&#351;tirmese de, katk&#305;da bulunur.&nbsp; Elektro-ensefalografi, bir
d�nem i�in hastal&#305;&#287;a �zg� periyodik 1 Hz keskin-dalga komplekslerini
g�sterir (PSW; <b>&#350;ekil 20</b>). PSW ve klinik �zellikleri ba&#351;vuru ve
seyir i�indeki s&#305;kl&#305;klar&#305;n&#305; 209 hastal&#305;k bir Amerikan
serisinde analiz eden bir 1993 �al&#305;&#351;mas&#305;nda miyoklonus
ba&#351;lang&#305;�ta %5 iken seyir s&#305;ras&#305;nda %88�e, ekstrapiramidal
bulgular %1�den %56�ya, serebellar bulgular %33�ten %70�e, g�rsel bulgular
%19�dan %41�e, PSW�nin %0�dan %44�e y�kseldi&#287;i bildirilmi&#351;tir. MRG�de
en y�ksek duyarl&#305;l&#305;kla dif�zyon a&#287;&#305;rl&#305;kl&#305;
g�r�nt�lerde (DWI) ortaya �&#305;kan, zaman i�inde s&#305;ras&#305;yla FLAIR ve
T2 a&#287;&#305;rl&#305;kl&#305; g�r�nt�lerde de beliren kortikal (kortikal
&#351;eritlenme) ve ba&#351;ta bazal ganglia, sonra da talamus olmak �zere
y�ksek sinyal, h&#305;zl&#305; seyirli bir demansta CJH i�in y�ksek
duyarl&#305;l&#305;k ve �zg�ll�k ta&#351;&#305;d&#305;&#287;&#305; �e&#351;itli
�al&#305;&#351;malarda bildirilmi&#351;tir (<b>&#350;ekil 21</b>). Bir Japon
�al&#305;&#351;mas&#305;nda 36 olguda DWI-MRG
duyarl&#305;l&#305;&#287;&#305;&nbsp; %92.3, �zg�ll�&#287;� %93.8, buna
kar&#351;&#305;l&#305;k PSW duyarl&#305;l&#305;&#287;&#305; %50, BOS 14-3-3
protein d�zeyi %84, BOS NSE protein d�zeyi %73.3 bulunmu&#351;tur. Bir Amerikan
�al&#305;&#351;mas&#305;nda ise 40 olguda DWI+FLAIR�in birlikte
duyarl&#305;l&#305;klar&#305; %91, �zg�ll�kleri ise %95 olarak
bildirilmi&#351;tir. Bu bulgunun sadece voltaj kap&#305;l&#305; potasyum
kanalopatili olgular taraf&#305;ndan taklit edilebilece&#287;ine dair bir
bildirim mevcuttur. Manyetik rezonans ya da bilgisayarl&#305; tomografi (BT)
ile kortikal atrofi, bazen de bazal gangliada sinyal de&#287;i&#351;iklikleri
g�r�lebilir.&nbsp; BOS�da n�ronal y&#305;k&#305;m �r�nleri total tau ve 14-3-3
proteinin d�zeylerinin belirgin y�kselmesinin hastal&#305;k i�in y�ksek
duyarl&#305;l&#305;k g�sterdi&#287;i ileri s�r�lmektedir.
Ay&#305;r&#305;c&#305; tan&#305;da di&#287;er h&#305;zl&#305; seyirli demans
nedenleri g�z �n�ne al&#305;nmal&#305;d&#305;r. Yine de ku&#351;kuda
kal&#305;nd&#305;&#287;&#305;nda beyin biyopsisine
ba&#351;vurulmal&#305;d&#305;r.&nbsp; CJH ku&#351;kusuyla yap&#305;lan bir
beyin biyopsisinde 2. kez kullan&#305;lmayacak cerrahi aletler se�ilir.&nbsp;
Mikroskopik olarak spongiform de&#287;i&#351;iklikler, immunhistokimyasal
boyama ile PrP<sup>Sc</sup> reaktivitesi ve Western blot ile proteaza diren�li
PrP<sup>Sc</sup>�nin g�sterilmesi tan&#305; koydurucu olur.&nbsp; Tablo 22�de
g�sterilen tan&#305; kriterleri D�nya Sa&#287;l&#305;k �rg�t� taraf&#305;ndan
1998�de yay&#305;nlanm&#305;&#351;t&#305;r ve MRG ve ba&#351;ta total tau
d�zeyi olmak �zere BOS biyoi&#351;aretleyicilerini i�ermedi&#287;inden demode
olmu&#351; gibi g�r�nmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-indent:36.0pt;
page-break-before:always;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans20.JPG">&#350;ekil 20.<span style='font-weight:normal'>&nbsp;</span></a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Tipik
CJH EEG�si: Periyodik keskin dalga (PSW) aktivitesi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-indent:36.0pt;
page-break-before:always;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans21.JPG">&#350;ekil 21.<span style='font-weight:normal'>&nbsp;</span></a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sporadik
CJH�da MRG.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ki
ayr&#305; sporadik CJH hastas&#305;. a. Subkortikal bask&#305;n tarz: T2
a&#287;&#305;rl&#305;kl&#305; aksiyel kesitte (sol �st) daha belirsiz olan
kaudat ve putaminal hiperintensiteleri, FLAIR koronal kesitte (�st orta) biraz
daha belirginle&#351;iyor ve DWI aksiyel kesitte (�st sa&#287;) en belirgin
hale geliyor.&nbsp; b. Kortikal &#351;eritlenme ve subkortikal y�ksek sinyal
ile birlikte olan tarz: FLAIR aksiyel kesitte (alt sa&#287;) basal ganglia ve
silik talamik hiperintensite DWI aksiyel kesitlerde (alt orta ve alt sa&#287;)
2 yanl&#305; medyal frontal kortikal &#351;eritlenme. (&#304;stanbul T&#305;p
Fak�ltesi N�roloji Anabilim Dal&#305;, Davran&#305;&#351; N�rolojisi ve Hareket
Bozukluklar&#305; Birimi ar&#351;ivinden ).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 22. </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Creutzfeldt-Jacob
hastal&#305;&#287;&#305; i�in D�nya Sa&#287;l&#305;k �rg�t� (WHO) Klinik
Tan&#305; Kriterleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div style='margin-bottom:4.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Muhtemel CJH</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;lerleyici demans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Tipik EEG<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerden en az ikisi:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Miyoklonus<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
G�rsel bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Serebellar bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Piramidal veya ekstrapiramidal bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akinetik mutizm<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>M�mk�n CJH</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#304;lerleyici
demans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Atipik
EEG veya EEG bilgisi mevcut de&#287;il<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerden en az ikisi:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Miyoklonus<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
G�rsel bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Serebellar bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Piramidal veya ekstrapiramidal bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>�&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akinetik mutizm<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demans
s�resi iki y&#305;ldan daha az<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kesin CJH</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Karakteristik
n�ropatoloji<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beyin
dokusunda Western blot analizi ile proteaza diren�li prion proteininin
saptanmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
N�ropatolojik incelemede scrapie ile ilintili fibrillerin saptanmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Hastal&#305;kl&#305; beyin dokusu inok�lat&#305; ile deneysel
bula&#351;man&#305;n g�sterilmesi<o:p></o:p></span></p>

<div style='margin-left:42.55pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-42.55pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiy�z&nbsp; Prion
Hastal&#305;klar&#305;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#304;yatrojenik CJH, kornea nakli
yap&#305;lan, prion bula&#351;m&#305;&#351; cerrahi aletlerle
n�ro&#351;ir�rjikal operasyon ge�iren,&nbsp; infekte derin elektrodlar&#305;n
kullan&#305;ld&#305;&#287;&#305;, insan hipofiz bezi ekstreleri alan veya dura
mater greftlemesi yap&#305;lan ki&#351;ilerde g�sterilmi&#351;tir.&nbsp; Klinik
tablo sporadik hastal&#305;&#287;a �ok benzer.&nbsp; Bula&#351;ma ile
hastal&#305;&#287;&#305;n ortaya �&#305;kmas&#305; aras&#305;nda ge�en s�re
(ink�basyon periyodu), bula&#351;man&#305;n do&#287;rudan beyne (�rne&#287;in
cerrahi gere�ler, dural greftler), ya da sistemik olarak (�rne&#287;in hipofiz
ekstresi) olmas&#305;na ba&#287;l&#305; olarak, 2 ila 40 y&#305;l aras&#305;nda
de&#287;i&#351;ir.&nbsp; Kan ve kan �r�nleri ile hastal&#305;&#287;&#305;n
bula&#351;mas&#305; riski bir endi&#351;e kayna&#287;&#305; olsa da, tam
do&#287;rulanmam&#305;&#351;t&#305;r. Hasta kan&#305;n&#305;n &#351;empanzelere
nakli bu hayvanlarda hastal&#305;&#287;a yol a�mazken, farelerde do&#287;rudan
beyne zerkedilmesiyle hastal&#305;k ortaya
�&#305;km&#305;&#351;t&#305;r.&nbsp;Sonradan vCJH geli&#351;tiren hastalardan
yap&#305;lm&#305;&#351; kan transf�zyonu �yk�leri olan 2 ayr&#305; vCJH olgusu
bildirilmi&#351;tir. Bir �al&#305;&#351;mada, n�ro&#351;ir�rjikal olsun veya
olmas&#305;n, ameliyat say&#305;s&#305; artt&#305;k�a hastal&#305;k riskinin de
artt&#305;&#287;&#305; g�sterilmi&#351;tir.&nbsp;Brown ve arkada&#351;lar&#305;
1974-2000 aras&#305; bildirilmi&#351; olan 267 iyatrojenik CJH olgusunun analizini
bildirdiler. &#304;nk�basyon s�relerinin 30 y&#305;la kadar
�&#305;kabildi&#287;i bu olgular&#305;n 139�u kadavra k�kenli b�y�me hormonu
(74 Frans&#305;z, %0.3-4.4) kullanm&#305;&#351;, 114��ne ise dura mater grefti
(67 Japon, %0.02-0.05) yap&#305;lm&#305;&#351;t&#305;. Dura mater olgular&#305;
kodon <i>PRNP</i>129MM s&#305;k, ink�basyon s�resi k&#305;sa ve klinik olarak
h&#305;zl&#305; seyirli demansa sahiplerdi. Buna kar&#351;&#305;l&#305;k b�y�me
hormonu olgular&#305;nda <i>PRNP</i>kodon129VV s&#305;k, ink�basyon s�resi uzun
ve klinik olarak progresif ataksi sergilenmi&#351;ti.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Kuru, Yeni Gine�de Fore yerlileri
aras&#305;nda tarif edilmi&#351; ve hastal&#305;&#287;a neden oldu&#287;u
kan&#305;tlanan b�lgeye �zg� dinsel rit�elin terkedilmesiyle de art&#305;k
g�r�lmez olmu&#351;tur.&nbsp; Foreliler�in geleneklerine g�re, aile
b�y�&#287;�n�n �l�m�nden sonra, onun bilgeli&#287;ini yeni ku&#351;aklara
ge�irebilmek i�in beyni o ailenin kad&#305;nlar&#305; ve her iki cinsiyetten
�ocuklar&#305; taraf&#305;ndan yenir, ayr&#305;ca beden ve y�ze s�r�l�r.&nbsp;
Etkenin konjonktivalar, deri ve sindirim sisteminden al&#305;nmas&#305;n&#305;
izleyen ink�basyon periyodu sonras&#305;nda, hastal&#305;k s�resi ve klinik
�zellikler a�&#305;lar&#305;ndan sporadik CJH�yi and&#305;ran bir tablo ortaya
�&#305;kar.&nbsp; Hastal&#305;k deneysel olarak &#351;empanzelere de
ge�irilebilmi&#351; ve izleyerek onlar&#305;n da kendi aralar&#305;nda
ta&#351;&#305;nabilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>vCJH, Britanya, Fransa ve
&#304;rlanda�da yakla&#351;&#305;k 50 gen� hastada 1990�lar&#305;n
ortalar&#305;ndan itibaren bildirilmeye ba&#351;lanm&#305;&#351;t&#305;r.&nbsp;
Hen�z ABD�den ve �lkemizden bildirilen olgu yoktur.&nbsp;Birle&#351;ik
Krall&#305;k�ta bildirilen 35 olgunun ortalama ba&#351;lang&#305;�
ya&#351;&#305; 29�dur (aral&#305;k: 18-53).&nbsp;Ayn&#305; seride �l�me kadar
ge�en s�re ortalamas&#305; 16 ayd&#305;r.&nbsp; Hastal&#305;k duysal ve
psikiyatrik belirti ve bulgularla ba&#351;lar.&nbsp; Alt&#305; ay kadar s�ren
bu ba&#351;lang&#305;� evresinden sonra �nce ataksi, sonras&#305;nda da demans,
istemsiz hareketler ve inkontinans gibi �zellikler tabloya
kat&#305;l&#305;rlar.&nbsp; Laboratuarda, sporadik CJH�nin tipik EEG
bulgular&#305; g�r�lmez.&nbsp; BOS�ta 14-3-3 proteini olgular&#305;n %50�sinde
pozitiftir.&nbsp;MRG�de tipik pulvinar bulgusu %70
s&#305;kl&#305;&#287;&#305;nda g�r�lm�&#351;t�r. <i>PRPN </i>analizinde t�m
olgular&#305;n kodon 129 metionin homozigot olduklar&#305; g�r�lm�&#351;t�r.
Kodon 129�da valin sahibi olmak ink�basyon s�resini uzatt&#305;&#287;&#305;ndan
bu durum hastal&#305;k etmenine ayn&#305; zaman �er�evesinde maruz kalan valin
sahiplerinin hen�z klinik belirti geli&#351;tirmemi&#351; olabilecekleri
endi&#351;esini do&#287;urmu&#351;tur. Di&#287;er insan prion
hastal&#305;klar&#305; ve bu arada sporadik CJH�nin tersine, tonsiller biyopsi
ile hastal&#305;k yapan prion proteinin (PrP<sup>Sc</sup>) g�sterilmesi vCJH
i�in tan&#305; koydurucudur.&nbsp; vCJH, beyin dokusunda da, sporadik CJH�den
farkl&#305; olarak spongiform de&#287;i&#351;ikliklerden �ok prion
plaklar&#305;na neden olur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Avrupa�da vCJH olgular&#305;, ilk deli
dana olgusunun (Bovine Spongiform Encephalopathy � BSE) bildiriminden 10
y&#305;l sonra g�r�lmeye ba&#351;land&#305;.&nbsp; &#304;zleyerek, vCJH�nin BSE
etkeni ile kontamine dana eti yenmesi sonucu geli&#351;ebilece&#287;ini
g�steren �ok say&#305;da delil bulundu.&nbsp; BSE primatlara do&#287;rudan
beyne inok�lasyon yoluyla bula&#351;t&#305;r&#305;labildi ve beyin dokusundaki
patolojik de&#287;i&#351;ikliklerin, vCJH�de g�r�lenin benzerleri oldu&#287;u
izlendi.&nbsp; Sonras&#305;nda, BSE a&#287;&#305;z yoluyla da maymunlara
bula&#351;t&#305;r&#305;labildi.&nbsp; S&#305;&#287;&#305;r PrP�si eksprese
eden transjenik farelerde hem BSE, hem de vCJH beyin ekstreleri ile inok�lasyon
sonucu ortaya �&#305;kan hastal&#305;klar&#305;n ink�basyon zamanlar&#305;,
n�ropatolojik de&#287;i&#351;iklikler ve&nbsp; PrP�nin glikoform profilleri
a�&#305;lar&#305;ndan birbirinin t&#305;pk&#305;s&#305; oldu&#287;u
saptand&#305;.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi prion
hastal&#305;klar&#305;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi
prion hastal&#305;klar&#305; (<b>Tablo 23</b>), otozomal dominant bir tarzda,
20. kromozomda kodlanan PrP geninde (<i>PRPN</i>) olu&#351;an �ok say&#305;da
mutasyon sonucu kal&#305;t&#305;l&#305;r.&nbsp;Bildirilen 50�den fazla
mutasyonun %95�i 4 nokta mutasyonu (kodon 102, 178, 200 ve 210) ve 2 oktapeptid
(5 ve 6) insersiyonu &#351;eklindedir. Biz de <i>PRPN </i>kodon 178 Asp-Asn
mutasyonu ta&#351;&#305;yan aileden 10 y&#305;l i�inde 2 olgu izledik. Ortaya
�&#305;kan hastal&#305;k klinik ve laboratuar bulgular&#305;
a�&#305;lar&#305;ndan sporadik CJH�ye �ok benzer (ailevi CJH - fCJH) veya daha
nadiren klinik fenotip �ok farkl&#305; olabilir (GSS ve FFI).&nbsp; Birbirinin
t&#305;pk&#305;s&#305; mutasyonlar bile ayn&#305; genin farkl&#305; bir b�lgesindeki
(kodon 129) n�kleik asid yap&#305; ta&#351;&#305;n&#305;n biri ya da
di&#287;eri olmas&#305;na g�re farkl&#305; klinik tiplere yola�abilirler (kodon
178 nokta mutasyonunda, kodon 129�da metionin homozigotlu&#287;u FFI�ye, valin
homozigotlu&#287;u CJH�ye neden olur).&nbsp; Farkl&#305; klinik fenotiplerin
�zellikleri i�in Tablo 23�e bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 23. </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi
Prion Hastal&#305;klar&#305;n&#305;n Klinik �zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=132 valign=top style='width:98.9pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>fCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=425 valign=top style='width:318.6pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sporadik
  CJH�ye g�re daha erken ba&#351;lay&#305;p (ge� 40 � erken 50�ler), daha uzun
  s�rebilir (22-24 ay).</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=132 valign=top style='width:98.9pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GSS</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=425 valign=top style='width:318.6pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40�l&#305;
  ya&#351;lar&#305;n ortalar&#305;nda ba&#351;lar ve 5 y&#305;l kadar
  s�rer.&nbsp; Serebellar ataksi ve spastik paraparezi erken d�nemde
  g�r�l�rken, demans ileri evrede kat&#305;l&#305;r.</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;mso-yfti-lastrow:yes'>
  <td width=132 valign=top style='width:98.9pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>FFI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=425 valign=top style='width:318.6pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;lerleyici
  uykusuzluk, disotonomi, dizartri, ataksi, miyoklonus, piramidal bulgular
  erken bulgulard&#305;r.&nbsp; Demans ileri evrede g�r�l�r.&nbsp;</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�ropatoloji</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>TSE�lerin temel n�ropatolojik
�zellikleri n�ron kayb&#305;, gliozis ve status spongiozistir.&nbsp;
Spongiozis, parenkim h�creleri ve n�ronal pro�eslerin vakuolizasyonuna
kar&#351;&#305;l&#305;k gelir.&nbsp; TSE lezyonlar&#305; inflamatuar de&#287;ildir.&nbsp;
Lezyonlar&#305;n da&#287;&#305;l&#305;m&#305; spesifik prion
hastal&#305;&#287;&#305;n&#305;n anatomik yatk&#305;nl&#305;&#287;&#305; ve
klinik fenotipini de yans&#305;t&#305;r.&nbsp; Kuru�da serebellar gri maddeye
s&#305;n&#305;rl&#305;d&#305;r.&nbsp; CJH�de o olgudaki semptomatolojiyi
yans&#305;t&#305;r tarzda beyinde gri ve beyaz maddede de&#287;i&#351;kenlik
g�sterir.&nbsp; Ultrastr�kt�rel olarak, prion �omaklar&#305; da denilen
fibriller mevcuttur.&nbsp; En fazla Kuru, GSS ve vCJH�de, en seyrek olarak da
sporadik CJH�de olmak �zere amiloid boyalar&#305; ile boyanan plaklar
g�r�l�r.&nbsp; Ancak, bu plaklar&#305;n cevherleri AH�de oldu&#287;u gibi A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> de&#287;il
PrP<sup>Sc</sup> ile immun reaksiyon verir.&nbsp; vCJH�de g�r�len eozinofilik
merkez ve soluk kenarl&#305; plaklar s�sl� (�florid�) ad&#305;n&#305;
al&#305;r.&nbsp; Farkl&#305; prion hastal&#305;klar&#305;n&#305;n patolojik
�zellikleri i�in <b>Tablo 24</b>� e bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo
24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nsan
Prion Hastal&#305;klar&#305;n&#305;n N�ropatolojisi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span style='font-size:10.0pt;
font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hastal&#305;k</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�ropatoloji</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuru</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuru
  plaklar&#305;, spongiozis</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�ron
  kayb&#305;, spongiozis, gliozis</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>fCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�ron
  kayb&#305;, spongiozis, gliozis</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>nvCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>S�sl�
  plaklar ve yayg&#305;n spongiozis</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>FFI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Talamik
  gliozis ve n�ron kayb&#305;</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=120 valign=top style='width:90.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GSS</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border:none;border-left:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Plaklar,
  gliozis, +/- spongiozis</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span style='font-size:10.0pt;font-family:Tahoma'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span style='font-size:10.0pt;font-family:Tahoma'><a
href="demans22.JPG"><b><span lang=TR style='mso-ansi-language:TR'>&#350;ekil
22.</span></b><span lang=TR style='mso-ansi-language:TR'> </span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion
n�ropatolojisinde mikroskopi. solda spongiozis izlenirken sa&#287;da PrP (+)
amiloid plaklar izlenmekte. (Kaynak: </span><span style='font-size:10.0pt;
font-family:Tahoma'><a
href="http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass2p2.htm"><span
lang=TR style='mso-ansi-language:TR'>http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass2p2.htm</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion Kavram&#305;</span></b><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Prionlar genetik materyel
ta&#351;&#305;mayan infeksiy�z patojenlerdir.&nbsp; CJH�nin SSPE gibi bir
�yava&#351; vir�s infeksiyonu� oldu&#287;u d�&#351;�n�len bundan 20 y&#305;l
kadar �nce yukardaki c�mleyi s�yledi&#287;inde alaya al&#305;nan Stanley
Prusiner�in, �o&#287;alma i�in genetik kodun &#351;art oldu&#287;unu
d�&#351;�nen genel ge�er biyoloji paradigmas&#305;na bu ger�ekten de taban
tabana z&#305;t gibi g�r�nen iddias&#305;, art&#305;k tart&#305;&#351;ma
g�t�rmez bir kesinlik kazanm&#305;&#351;, hatta kendisi de bu nedenle 1997�de
Nobel T&#305;p �d�l� ile �d�llendirilmi&#351;tir. PrP, daha �nce s�z�
edildi&#287;i gibi 20. kromozom taraf&#305;ndan kodlanan, normal i&#351;levi
ayd&#305;nlat&#305;lamam&#305;&#351; olan bir h�cresel proteindir (PrP<sup>c</sup>).&nbsp;
PrP<sup>c</sup>, infeksiy�z PrP�ye (PrP<sup>Sc</sup>) &#945;-sarmall&#305;
fiziksel konformasyonel yap&#305;s&#305;n&#305; kaybedip &#946;
tabakalar&#305;na katlanarak yeni bir konformasyonel yap&#305; kazanarak
d�n�&#351;�r.&nbsp; Yani, PrP<sup>Sc</sup>, normal proteinle tamamen ayn&#305;
kimyasal yap&#305;ya, amino asid dizisine sahipken, infeksiy�z �zellik bu yeni
fiziksel yap&#305;dan kaynaklanmaktad&#305;r.&nbsp; Su&#351;a spesifik
�zelliklerini genlerde kodlayan n�kleik asid genomlu patojenlerin tersine,
prionlar su&#351;a spesifik �zelliklerini tamamen PrP<sup>Sc</sup>�nin tersiyer
yap&#305;s&#305;nda kodlamaktad&#305;rlar.&nbsp; PrP<sup>Sc</sup> proteaza
diren�li, ��z�nemeyen ve ekstrasel�ler olarak biriken bir �zellik
g�sterir.&nbsp; PrP<sup>Sc</sup> birikimi �evre dokuda n�ron kayb&#305;,
astrositik gliozis ve vakuolizasyona neden olur.&nbsp; Bu vakuoller giderek
birle&#351;erek s�ngersi (spongiform) bir g�r�n�m al&#305;rlar.&nbsp;&nbsp;
Transgenetik �al&#305;&#351;malarla da kan&#305;tland&#305;&#287;&#305; gibi,
PrP<sup>Sc</sup> PrP<sup>C</sup> i�in bir &#351;ablon olu&#351;turmakta ve PrP<sup>C</sup>
molek�l� yeni bir PrP<sup>Sc</sup> olu&#351;turacak &#351;ekilde
katlanmaktad&#305;r.&nbsp; Ba&#351;ka bir deyi&#351;le, tek bir Prp<sup>Sc </sup>molek�l�
dahi PrP geni taraf&#305;ndan normal olarak �retilmekte olan PrP<sup>C</sup>�den
zaman i�inde (ink�basyon s�resi) hastal&#305;k belirtilerini g�stermeye yetecek
miktarda birikmi&#351; PrP<sup>Sc </sup>�retebilmektedir.&nbsp;
Dolay&#305;s&#305;yla da, PrP<sup>Sc</sup> �retimi, ister ailevi olgularda
oldu&#287;u gibi PrP&nbsp; genindeki farkl&#305; mutasyonlarla, ister
infeksiy�z olgularda oldu&#287;u gibi infeksiy�z materyelin ortama
sunulmas&#305;yla tetiklensin, �o&#287;alma mekanizmas&#305;n&#305;n yukarda
tan&#305;mlanan &#351;ekilde oldu&#287;u anla&#351;&#305;lmaktad&#305;r.&nbsp;
Bu durum da bir kal&#305;tsal hastal&#305;&#287;&#305;n nas&#305;l ayn&#305;
zamanda infektif olabilece&#287;ini a�&#305;klamaktad&#305;r.&nbsp; Sporadik
olgulardaki etyoloji hen�z a�&#305;&#287;a
�&#305;kar&#305;lamam&#305;&#351;t&#305;r.&nbsp; Ancak, bunun bir somatik
mutasyon sonucu veya PrP<sup>C</sup>�nin PrP<sup>Sc</sup>�ye kendili&#287;inden
d�n�&#351;�m� sonucu oldu&#287;u ileri s�r�lmektedir.&nbsp; Birbirinden bu
kadar farkl&#305; anatomik yatk&#305;nl&#305;k tarzlar&#305; ve klinik
fenotipik �zellikler g�steren prion hastal&#305;klar&#305;n&#305;n alt&#305;nda
farkl&#305; konformasyonel yap&#305;lara sahip, farkl&#305; PrP<sup>Sc</sup>
su&#351;lar&#305;n&#305;n yatt&#305;&#287;&#305; d�&#351;�n�lmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Prion hastal&#305;klar&#305;n&#305;n
hen�z bir tedavisi yoktur.&nbsp; Ancak, PrP<sup>C</sup>�nin PrP<sup>Sc</sup>�ye
d�n�&#351;�m�n� engellemek gelecekteki tedavi stratejilerinin temel hedefi gibi
durmaktad&#305;r.&nbsp;&nbsp; PrP<sup>C</sup>�ye ba&#287;lanarak
stabilizasyonunu sa&#287;lamak bir yol olabilir.&nbsp; Di&#287;er bir yol da
PrP<sup>Sc</sup>�yi destabilize edecek ajanlar&#305;n geli&#351;tirilmesi ile
olabilir.&nbsp; PrP geni ta&#351;&#305;mayan (PrP<sup>0/0</sup>) nakavt transjenik
farelerin do&#287;al hayvanlara g�re ay&#305;rdedilebilir bir
farkl&#305;l&#305;k g�stermemeleri insanda da PrP genini hedefleyecek
tedavileri �ekici
k&#305;lmaktad&#305;r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;
margin-left:96.0pt;text-align:justify;text-indent:48.0pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>HAREKET BOZUKLU&#286;U VE
DEMANS</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Huntington hastal&#305;&#287;&#305;,
PSP, multi sistem atrofi (MSA) gibi bir grup hastal&#305;kta
&nbsp;hiperkinetik, akinetik-rijid, serebellar ya da bunlar&#305;n i�i�e
ge�mesinden olu&#351;an motor bulgular, klinik tabloda zamansal ve
a&#287;&#305;rl&#305;k olarak �subkortikal� tarzda bir zihinsel bozuklu&#287;un
�n�nde olurlar.&nbsp; Bu antiteler ve tedavileri �<i>Hareket Bozukluklar&#305;</i>�
b�l�m�nde daha ayr&#305;nt&#305;l&#305; bi�imde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Huntington hastal&#305;&#287;&#305;
(HH), otozomal dominant bir n�rodejenerasyondur.&nbsp; Koreye zaman i�inde
demans e&#351;lik etmeye ba&#351;lar.&nbsp; PSP ile birlikte �subkortikal�
demanslar&#305;n prototipi say&#305;lan bu tabloda bradifreni, zihinsel
esneklikte kay&#305;p, soyutlama, planlama bozukluklar&#305; &#351;eklinde bir
frontal y�r�t�c� bozuklu&#287;a, tan&#305;man&#305;n korundu&#287;u sekonder
yak&#305;n bellek bozuklu&#287;u e&#351;lik eder; di&#287;er kognitif
i&#351;levler g�reli korunmu&#351;tur.&nbsp; Patolojik olarak Huntingtin
genindeki artan trin�kleotid (C-A-G) tekrarlar&#305; sonucu olu&#351;an
eksitotoksik hasar&#305;n, tipik klinik sendroma yol a�an anatomik
yatk&#305;nl&#305;&#287;&#305;na ba&#287;l&#305;d&#305;r.&nbsp; Mikroskopisinde
ba&#351;l&#305;ca neostriatumda n�kleer huntingtin birikimleri g�r�l�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Progresif supran�kleer paralizi
(PSP)�de&nbsp; aksiyel bask&#305;n bir akinetik-rijid bozukluk ve �zellikle
a&#351;a&#287;&#305;ya bak&#305;&#351; felci &#351;eklinde bir vertikal
bak&#305;&#351; paralizisi mevcuttur.&nbsp; Di&#287;er ok�ler hareket
bozukluklar&#305; da bulunur.&nbsp; �zellikle elektro-ok�logram (EOG) ile de
saptanabilen sakkadik hareketlerde yava&#351;lama hemen b�t�n olgularda mevcut
olan tipik �zelliktir.&nbsp; Provoke olmayan s&#305;k d�&#351;meler �yk�n�n
ba&#351;l&#305;ca �zelliklerindendir.&nbsp; Demans HH�dekine benzer.&nbsp;G�z
bulgular&#305; yan&#305; s&#305;ra otonom tutulumun beklenmemesi MSA, LCD ve
idyopatik Parkinson hastal&#305;&#287;&#305; gibi &#945;-sin�kleopatili
di&#287;er parkinsonizm sendromlar&#305;ndan ay&#305;rmaya yard&#305;m
eder.&nbsp; MRG�de al&#305;&#351;&#305;k bir g�z �zellikle sagital T1
kesitlerde mezensefalon atrofisini ay&#305;rt edebilir. Vol�metrik olarak
saptanan globus pallidus atrofisinin normal kontrollerin yan&#305; s&#305;ra
PH�l&#305;lar ve LCD�lilerden de ay&#305;rabildi&#287;ine ili&#351;kin bir
bildirim bulunmaktad&#305;r.&nbsp; SPECT ve PET gibi fonksiyonel g�r�nt�leme
ara�lar&#305; ile genellikle simetrik frontal hipoperf�zyon/metabolizma saptan&#305;r.&nbsp;
Patolojik olarak bir taupati olarak s&#305;n&#305;flanabilecek bir
n�rodejenerasyondur.&nbsp; Taupati kendini intran�ronal globoz NFY�ler, n�ropil
i&#287;cikler &#351;eklinde ortaya koyar.&nbsp; N�ron kayb&#305; ve gliozis
e&#351;lik eder.&nbsp; Bu patoloji, beyinsap&#305;nda superior colliculi dahil
peri-akuaduktal gri madde, pre-tektal alan yan&#305; s&#305;ra, substantia
nigra pars reticulata, subtalamik �ekirdek ve globus pallidusta
saptan&#305;r.&nbsp; Kortikal tutulum daha seyrek ve hafiftir.&nbsp;
Ba&#351;l&#305;ca &#964; birikimleri ve daha da seyrek olarak n�ron kayb&#305;,
gliozis ve mikrovakuolizasyon g�r�l�r. KBD ve PSP�nin tipik klinik
sunumlar&#305; dahil birbirlerini taklit edebildikleri yap&#305;lan otopsi
do&#287;rulamal&#305; �al&#305;&#351;malardan bilinmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>KBD�ye yukarda �Progresi Apraksi� ve
�Fronto-temporal Demans� b�l�mleri i�inde de&#287;inilmi&#351;ti.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Multi-sistem Atrofi (MSA)
tablolar&#305;, i�i�e ge�mi&#351;, ancak birinin �n planda oldu&#287;u
�Striato-nigral Dejenerasyon� (SND), �Olivo-ponto-serebellar Atrofi� (OPCA) ve
�Shy-Drager Sendromu� (SDS) tablolar&#305;ndan olu&#351;ur.&nbsp; SND�de
simetrik ve tremorsuz bir akinetik-rijid sendrom, OPCA�da ataksi, SDS�de otonom
disfonksiyon temel �zelliktir.&nbsp; Yeni nomenklat�rde SDS�nin
ba&#287;&#305;ms&#305;z bir antite olarak varl&#305;&#287;&#305;na son
verilmi&#351; ve OPCA &#351;ekli i�in MSA-C (serebellar MSA), SND &#351;ekli
i�in MSA-P (parkinsonyen MSA) kullan&#305;lmaktad&#305;r.&nbsp; Disotonomi her
iki bozuklu&#287;a da olgudan olguya de&#287;i&#351;en zamanlama ve
&#351;iddetlerle kat&#305;lmaktad&#305;r.&nbsp; Hafif d�zeyde ve demans
&#351;iddetine genellikle ula&#351;mayan bir y�r�t�c� bozukluk &#351;eklinde
kognitif disfonksiyon e&#351;lik eder.&nbsp;&nbsp; Patolojik olarak bir &#945;-sin�kleopatidir.&nbsp;Dolay&#305;s&#305;yla,
di&#287;er &#945;-sin�kleopatilerde oldu&#287;u gibi MSA�larda da REM-uykusu
davran&#305;&#351; bozuklu&#287;u s&#305;kt&#305;r. Glial fibriler
&#945;-sin�klein inkl�zyonlar&#305; MSA�lar&#305;n ay&#305;r&#305;c&#305;
patolojik �zelli&#287;idir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Wilson hastal&#305;&#287;&#305;,
Hallervorden-Spatz hastal&#305;&#287;&#305;, Kufs hastal&#305;&#287;&#305;
metabolik bozukluklara ba&#287;l&#305; yirmili ya&#351;lar&#305;n demans
hastal&#305;klar&#305; aras&#305;ndad&#305;r.&nbsp;Gen�
ba&#351;lang&#305;�l&#305; demanslar&#305;n ay&#305;r&#305;c&#305;
tan&#305;s&#305;na girerler. &#304;lk iki hastal&#305;k tipik olarak hareket
bozukluklar&#305; �n planda olan sendromlara sahiptir.&nbsp; Gen� eri&#351;kin
demanslar&#305; aras&#305;nda oldu&#287;u i�in burada an&#305;lan Kufs�a
demans&#305;n yan&#305;s&#305;ra epilepsi e&#351;lik eder.&nbsp; Whipple
hastal&#305;&#287;&#305; da, bazen PSP�yi taklit eden di&#287;er nadir hareket
bozuklu&#287;u � demans sendromlar&#305; aras&#305;ndad&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>SEKONDER DEMANSLAR</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;Vask�ler Demans</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bundan 30 y&#305;l �nce �serebroskleroz�
ad&#305;yla en s&#305;k, 20 y&#305;l �nce �Multi-infarkt demans� (MID)
ad&#305;yla AH�den sonra 2. s&#305;kl&#305;ktaki demans oldu&#287;u
d�&#351;�n�len VaD, son y&#305;llardaki kliniko-patolojik korelasyon
�al&#305;&#351;malar&#305;yla s&#305;ralamadaki yerini iyiden iyiye kaybetmi&#351;
durumdad&#305;r.&nbsp; Bu �al&#305;&#351;malarda klinik olarak VaD
tan&#305;s&#305; alm&#305;&#351; olgular&#305;n b�y�k b�l�m�n�n nekropsilerinde
ger�ekte AH olduklar&#305; veya hem vask�ler, hem de AH patolojilerini birlikte
g�steren �karma (mixed) demans� (MIX) olduklar&#305; g�r�lm�&#351;t�r.&nbsp;
&#304;nme i�in risk fakt�rlerinin b�y�k b�l�m�n�n AH i�in de risk fakt�rleri oldu&#287;u
g�sterilmi&#351;tir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>VaD i�in �ok say&#305;da
yay&#305;nlanm&#305;&#351; tan&#305; kriterleri mevcuttur.&nbsp; Bunlar
aras&#305;nda duyarl&#305;l&#305;k ve �zg�ll�k a�&#305;lar&#305;ndan tek
ba&#351;&#305;na optimuma yakla&#351;an olmad&#305;&#287;&#305; gibi, i�erme ve
d&#305;&#351;lama kriterleri nedeniyle birbirleri aras&#305;nda da ciddi
uzla&#351;mazl&#305;klar bulunmaktad&#305;r.&nbsp; <b>Tablo 25�</b>de sunulan
NINDS-AIREN kriterleri, <i>�Muhtemel Vask�ler Demans� (VaD</i><b>)</b>
tan&#305;s&#305; i�indir. &#304;�leme ve d&#305;&#351;lama kriterleri
a�&#305;s&#305;ndan olduk�a kat&#305;, bu nedenle
duyarl&#305;l&#305;&#287;&#305; d�&#351;�k, ancak �zg�ll�&#287;� olduk�a y�ksek
bir kriterler dizisidir.&nbsp; �Hachinski &#304;skemik Skoru&#305;� (HIS),
VaD�&#305; DAT�dan ve MIX�den ay&#305;rmak ama�l&#305; olarak BT �ncesi d�nemde
geli&#351;tirilmi&#351;, BT sonras&#305;nda bir dizi&nbsp;
modifikasyonlar&#305; �nerilmi&#351;, klinik uygulamada hala bir �l��de yerini
koruyan bir �l�ektir (<b>Tablo 26</b>).&nbsp;&nbsp; Duyarl&#305;l&#305;k ve
�zg�ll�k �al&#305;&#351;malar&#305;, 18 puanl&#305;k versiyonda VaD i�in 7 ve
�st�, DAT i�in 4 ve alt&#305; puanlar&#305; kabul edilebilir bulmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 25.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Muhtemel Vask�ler Demans Tan&#305;s&#305; &#304;�in NINDS-AIREN Kriterleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;daki d&#305;&#351;lama kriterleri bulunmaks&#305;z&#305;n
demans&#305;n mevcudiyeti:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bilin� bozuklu&#287;u, delirium, psikoz, n�ropsikolojik
muayeneyi engelleyecek nitelikte a&#287;&#305;r afazi veya sensoryal-motor
de&#287;i&#351;iklikler, kognitif de&#287;i&#351;iklikleri a�&#305;klayabilecek
nitelikte sistemik veya beyin (Alzheimer hastal&#305;&#287;&#305; gibi)
hastal&#305;klar&#305;.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Serebrovask�ler Hastal&#305;k.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>1</b> ve <b>2 </b>aras&#305;nda a&#351;a&#287;&#305;daki tarzda bir
ili&#351;ki:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:144.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>a)</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Saptanabilen bir inmeyi izleyen 3 ay i�inde ba&#351;layan demans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:144.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>b)</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Kognitif i&#351;levlerin ani bozulmas&#305; veya kognitif bozukluklar&#305;n
dalgalanan tarzda basamaks&#305; ilerleyi&#351;i.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Muhtemel vask�ler demans tan&#305;s&#305;yla uyumlu
olacak klinik �zellikler &#351;unlard&#305;r:</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erken d�nemde y�r�y�&#351; bozuklu&#287;u.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dengesizlik veya kendili&#287;inden d�&#351;meler �yk�s�.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erken d�nemde, �rolojik nedenlerle a�&#305;klanamayan idrara s&#305;k
�&#305;kma, acele etme veya di&#287;er �riner belirtiler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ps�dobulber paralizi.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ki&#351;ilik veya duygudurum de&#287;i&#351;iklikleri, abuli, depresyon,
emosyonel inkontinans veya psikomotor retardasyon ya da y�r�t�c�
i&#351;levlerde bozukluklar&#305; da i�erecek &#351;ekilde di&#287;er
subkortikal bozukluklar.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Vask�ler demans tan&#305;s&#305; ihtimalini azaltan
�zellikler &#351;unlard&#305;r:</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Beyin g�r�nt�lemesinde kar&#351;&#305;l&#305;k gelecek lezyonlar
olmaks&#305;z&#305;n, bellek bozuklu&#287;u ve kognitif i&#351;levlerde
ilerleyici bozulman&#305;n erken d�nemde mevcudiyeti.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kognitif bozukluk d&#305;&#351;&#305;nda di&#287;er fokal n�rolojik
bulgular&#305;n bulunmamas&#305;.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:84.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:12.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BT veya MRG�de serebrovask�ler lezyonlar&#305;n bulunmamas&#305;.<o:p></o:p></span></p>

<div style='margin-left:9.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 26.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Hachinski &#304;skemik Skoru (Orijinal versiyon ve bir modifikasyonu)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=240 valign=top style='width:180.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klinik �zellik</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hachinski</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(1975)</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Loeb-Gandolfo</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(1983)</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ani
  ba&#351;lang&#305;�</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Basamaks&#305;
  k�t�le&#351;me</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dalgalanan
  seyir</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nokt�rnal
  konf�zyon</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;ili&#287;in
  g�reli korunmas&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Depresyon</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Somatik
  yak&#305;nmalar</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Emosyonal
  inkontinans</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipertansiyon
  �yk�s�</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nme
  �yk�s�</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Jeneralize
  ateroskleroz</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fokal
  n�rolojik belirtiler</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fokal
  n�rolojik bulgular</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bilgisayarl&#305; Tomografi</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipodens
  alan � izole</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipodens
  alan � multipl</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Maksimum skor</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>18</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>10</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�ler
  s&#305;n&#305;r</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7-18</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-10</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:19'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Karma
  s&#305;n&#305;r</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-6</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3-4</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:20;mso-yfti-lastrow:yes'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dejeneratif
  s&#305;n&#305;r</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0-4</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0-2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MID tan&#305;m&#305; kardiyo-embolik veya
atero-trombotik inmelerin ayn&#305; hastada tekrarlamas&#305; sonucu bu t�r bir
inmeye e&#351;lik etmesi beklenen sekelin yan&#305; s&#305;ra, tabloya demans
&#351;iddetinde bir zihinsel bozuklu&#287;un da kat&#305;lmas&#305;n&#305;
�ng�r�r.&nbsp;&nbsp; Oysa ki �e&#351;itli VaD serilerinde bu t�r tablolar b�t�n
VaD�l&#305;lar&#305;n d�&#351;�k bir oran&#305;n&#305;
olu&#351;turmaktad&#305;r.&nbsp; Bu d�&#351;�k temsile kardiyo/serebrovask�ler
hastal&#305;&#287;a ili&#351;kin sorunlar&#305;n
a&#287;&#305;rl&#305;&#287;&#305;n&#305;n (hemipleji, yata&#287;a
ba&#287;&#305;ml&#305;l&#305;k, vb.) bu t�r hastalar&#305; demansla
u&#287;ra&#351;an uzmanlar&#305;n �n�ne daha az getirmesi yan&#305;s&#305;ra,
afazi gibi optimal mental durum de&#287;erlendirmesini engelleyecek sorunlar
nedeniyle bu t�r hastalarda demans tan&#305;s&#305;n&#305;n daha az konuyor
olmas&#305; olabilir.&nbsp; S&#305;kl&#305;kla hipertansiyona ba&#287;l&#305;,
daha seyrek olarak amiloid anjiyopati ve genetik nedenler de dahil di&#287;er
k���k damar hastal&#305;&#287;&#305; seyrinde g�r�len VaD serilerin
yar&#305;dan �o&#287;unu olu&#351;turmaktad&#305;r.&nbsp; Bu VaD tablolar&#305;
akut iskemiye ba&#287;l&#305; olarak derin gri madde yap&#305;lar&#305; ve
frontal loblar&#305;n beyaz maddesinde multipl lak�ner infarktlar (lak�ner
durum) veya stratejik lokalizasyonlu tek bir derin infarkt sonucu
olabilece&#287;i gibi, Binswanger hastal&#305;&#287;&#305;n&#305;n
mekanizmas&#305;nda ileri s�r�ld�&#287;� gibi peri ve paraventrik�ler beyaz
maddenin kronik hipoperf�zyonu sonucu yayg&#305;n beyaz madde gliozisi ile de
ortaya �&#305;kabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tipik bir VaD i�in, inme gibi bir vask�ler olay
�evresinde akut ba&#351;lang&#305;�, yine ay&#305;rdedilebilir bir vask�ler
olaya kadar bir �l��de d�zelmeyle birlikte dura&#287;an bir plato d�nemi ve
yeni olay sonras&#305;nda basamaks&#305; k�t�le&#351;me ile seyreden kognitif
y&#305;k&#305;m �yk�s� esast&#305;r.&nbsp; Klinik tablo VaD alt tiplerine �zg�
de&#287;i&#351;iklikler g�sterir.&nbsp; <i>MID</i>, serebral hemisferleri
besleyen ana arterlerin proksimal ve/veya distal t&#305;kanmalar&#305;na
ba&#287;l&#305; olarak, bu alanlarda olu&#351;an infarkt�slerin devreden
�&#305;kard&#305;&#287;&#305; i&#351;levleri yans&#305;t&#305;r.&nbsp; Bu
durumda beklenen tablo, sol hemisfer inmelerinin afazik bozukluklar&#305;yla,
sa&#287; hemisfer inmelerinin ihmal sendromu ve vizyo-spasyal
bozukluklar&#305;n&#305;n kar&#305;&#351;&#305;m&#305; &#351;eklindedir.&nbsp;
Yak&#305;n bellek de nadiren primer bir bozukluk s�z konusudur.&nbsp; Demansa
hemi- veya tetraparezi, y�zeyel duyu bozukluklar&#305; ve g�rme alan&#305;
kusurlar&#305; s&#305;kl&#305;kla e&#351;lik etmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Lak�ner durum,</span></i><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�subkortikal demans� olarak
tan&#305;mlanan tablonun protipidir.&nbsp; Seyir yukarda tan&#305;mlanan
&#351;ekilde akut ba&#351;lang&#305;� ve basamaks&#305; ilerleme
tarz&#305;ndad&#305;r.&nbsp; Demans profili bellekte tan&#305;man&#305;n
korundu&#287;u sekonder bozukluk, frontal y�r�t�c� bozukluk
&#351;eklindedir.&nbsp; Davran&#305;&#351;sal �zellikler aras&#305;nda
bradifreniden apatiye giden psikomotor yava&#351;lama ve emosyonel labilite �n
plandad&#305;r.&nbsp; Somatik n�rolojik bulgular a&#287;&#305;rl&#305;kla
hemiparezi sekelleri, piramidal bulgular, alt beden yar&#305;s&#305; (veya
vask�ler) parkinsonizm &#351;eklinde y�r�y�&#351; bozukluklar&#305; ps�dobulber
paralizi-dizartri tarz&#305;ndad&#305;r.&nbsp; �riner inkontinans erken d�nemde
tablonun esasl&#305; par�alar&#305;ndan birini olu&#351;turmaktad&#305;r.&nbsp;
Afazi ve hemianopsi gibi �kortikal� kognitif ve alg&#305;sal bulgular&#305;n
g�r�lmesi beklenmez. Beyin g�r�nt�lemesinde tabloyla
ili&#351;kilendirilebilecek derin gri madde yap&#305;lar&#305; ve frontal beyaz
madde i�indeki lak�ner lezyonlar&#305;n varl&#305;&#287;&#305; tan&#305;
koydurucu olacakt&#305;r.&nbsp; Ancak tablo her zaman bu kadar tipik
olamayabilir.&nbsp; <i>Binswanger hastal&#305;&#287;&#305;</i> (BH) seyrinde
peri-ventrik�ler beyaz maddenin kronik hipoperf�zyona ba&#287;l&#305;
ilerleyici gliozisinde doku kayb&#305; s&#305;kl&#305;kla sessiz infarktlar
&#351;eklinde olabilir.&nbsp; Bu nedenle �yk� i�inde akut ba&#351;lang&#305;�
veya basamaks&#305; ilerleme bazen hi� ay&#305;rt edilemeyebilir veya birka�
g�n s�r�p d�zelen hafif bir konu&#351;ma/yutma bozuklu&#287;u, taraf zaaf&#305;
&#351;eklinde bir min�r inmeyle tablonun biraz daha bozuldu&#287;u
kaydedilir.&nbsp; Klinik tablo lak�ner duruma �ok benzer.&nbsp; Subkortikal
beyaz maddede an&#305;lan bozukluk kendisini BT�de beyaz madde
yo&#287;unlu&#287;unda yayg&#305;n azalma (l�koareozis), MRG�de T2 ve proton
a&#287;&#305;rl&#305;kl&#305; incelemede peri ve paraventrik�ler b�lgelerde
birle&#351;me e&#287;ilimi (konfluans) g�steren y�ksek sinyal odaklar&#305;
&#351;eklinde ortaya koyar (<b>&#350;ekil 23</b>).&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Medyal talamus, kaudat �ekirdek ba&#351;&#305;,
kapsula interna genusunun ventral b�l�m�n� i�eren <i>stratejik lokalizasyonlu
infarktlar</i> bazen tek ba&#351;lar&#305;na demans tablosunu ortaya
�&#305;karabilirler.&nbsp; Demans profili tutulan stratejik alana g�re
de&#287;i&#351;ir.&nbsp; �rne&#287;in, medyal talamusta dorsomedyal �ekirdekle
birlikte mamillo-talamik traktusun infarkt&#305; frontal y�r�t�c� ve amnestik
bozukluklar&#305;n bir karmas&#305;n&#305; olu&#351;tururken, kaudat �ekirdek
ba&#351;&#305; infarktlar&#305;nda saf bir frontal y�r�t�c� bozukluk g�r�l�r.
Bu durumda, yeni bir vask�ler olay olmazsa akut demans tablosu zaman i�inde
kendili&#287;inden d�zelebilece&#287;i gibi, n�rolojik defisiter bulgular da
mevcut olmayabilir (<b>Tablo 27</b>).&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Notch proteini genindeki mutasyonlar klinik tablo
ve g�r�nt�leme a�&#305;lar&#305;ndan BH�ya �ok benzeyen �<b>C</b>erebral <b>A</b>utosomal
<b>D</b>ominant <b>A</b>rteriyopati <b>S</b>ubkortikal <b>&#304;</b>nfarktlar <b>L</b>�koensefalopati�
(<b>CADASIL</b>) isimli ailevi hastal&#305;&#287;a neden olur.&nbsp; Bu
ailelerde migren �yk�s� ile birlikte BH benzeri demans, otozomal dominant
kal&#305;t&#305;m tarz&#305;yla birlikte bulunur.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>VaD tan&#305;s&#305; pratik olarak iskemik
vask�ler lezyonlara ba&#287;l&#305; demanslara kar&#351;&#305;l&#305;k olarak
kullan&#305;lsa da, b�y�k bir hemorajik inmeyi izleyerek (intraserebral kanama,
subaraknoid kanama) hasta sa&#287; kal&#305;rsa, sekel tablo demans ile uyumlu
statik bir ensefalopati olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>VaD tedavisi serebrovask�ler hastal&#305;k
tedavisi ilkelerini izler.&nbsp; Ba&#351;ta hipertansiyon ve diabet olmak �zere
vask�ler risk fakt�rlerinin kontrol�, asetil salisilik asit ve benzeri
anti-agregan uygulama, kardiyak veya arterden artere emboli riskinde
anti-koag�lasyon, kritik ekstra-kranyal karotis interna daralmalar&#305;nda
uygun olgularda karotis endarterektomisi VaD�&#305;n �nlenmesi ve denetiminde
de etkili olacakt&#305;r.&nbsp; Bir NMDA resept�r antagonisti memantin ve AH�de
kullan&#305;lan kolinesteraz inhibit�rleri VaD�da da etkin olduklar&#305;na
dair �ok g��l� olmasa da deliller mevcuttur.&nbsp; Depresyon ve di&#287;er duygudurum
bozukluklar&#305;n&#305;n uygun tedavisine
�al&#305;&#351;&#305;lmal&#305;d&#305;r.&nbsp; Vask�ler parkinsonizm ve
y�r�y�&#351; bozukluklar&#305; L-dopaya s&#305;kl&#305;kla
cevaps&#305;zd&#305;r, ancak bu ajanlar uygun dozlara �&#305;k&#305;l&#305;p
belli bir cevap al&#305;nd&#305;&#287;&#305; takdirde
kullan&#305;labilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans23.JPG">&#350;ekil 23.<span
style='font-weight:normal'>&nbsp;</span></a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> BT ve MRG�de
&#304;skemik Beyaz Madde Hasar&#305;n&#305;n G�r�n�&#351;�. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BT�de l�koareozis; lateral ventrik�ller d�zeyinden ge�en
kesitte paraventrik�ler beyaz madde<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>dansitesi azalm&#305;&#351;. <b>B. </b>MRG�de ayn&#305;
olgu; T2 a&#287;&#305;rl&#305;kl&#305; kesitte beyaz maddede y�ksek sinyal.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 27.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Vask�ler demans alt tipleri<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multi-infarkt
  Demans</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lak�ner
  Durum</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Stratejik
  &#304;nfarkt</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Binswanger
  Sendromu</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Etyoloji</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kardiyo-emboli,
  karotis hastal&#305;&#287;&#305;, intra-kranyal in-situ tromboz</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Arteriolo-skleroz,</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>amiloid anjiyopati,
  di&#287;er k���k damar hastal&#305;&#287;&#305;</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Arteriolo-skleroz,</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>amiloid anjiyopati,
  di&#287;er k���k damar hastal&#305;&#287;&#305;, intra-kranyal in-situ
  tromboz</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Arteriolo-skleroz,</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>amiloid anjiyopati,
  di&#287;er k���k damar hastal&#305;&#287;&#305;, CADASIL</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Damar
  alan&#305;</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek
  arter</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek
  arter, k���k arteriyol</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek
  arter</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>S&#305;n&#305;r
  sulama alan&#305;, k���k arteriyoller</span><span lang=FI style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Beyin
  hasar&#305; mekanizmas&#305;</span></b><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut
  iskemi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut
  iskemi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut
  iskemi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik
  hipoperf�zyon</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Patoloji</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Birden
  fazla b�lgesel infarkt</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multipl
  lak�nler</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Stratejik
  lokalizasyonlu tek infarkt</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demyelinizasyon
  ve aksonal kay&#305;p</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�r�nt�leme</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-subkortikal
  infarkt alanlar&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Derin
  gri madde ve frontal beyaz maddede lak�ner infarktlar</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Medyal
  talamus, kaudat �ekirdek, kapsula interna genusunda lak�ner infarkt</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Peri,
  paraventrik�ler beyaz maddede l�koareozis / hiperintensite</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lokalizasyon</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Geni&#351;
  boyutlu n�ro-kognitif &#351;ebekeler</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-striato-talamo-kortikal
  devreler</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-striato-talamo-kortikal
  devreler</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-kortikal
  ba&#287;lant&#305;lar</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klinik</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Afazi,
  vizyo-spasyal bozukluk, hemiparezi, hemianopsi</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�r�t�c�
  bozukluk, ps�dobulber paralizi, vask�ler parkinsonizm, �riner inkontinans</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�r�t�c�
  bozukluk, amnezi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�r�t�c�
  bozukluk, y�r�me bozuklu&#287;u, �riner inkontinans, s&#305;kl&#305;kla
  yava&#351; seyir</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Chui�den modifiye edilmi&#351;tir.<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal Bas&#305;n�l&#305;
Hidrosefali</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Normal bas&#305;n�l&#305; hidrosefali
(NPH), BH�ya benzer bir triada sahiptir.&nbsp; &#304;lk kez Adams ve Hakim
taraf&#305;ndan tan&#305;mlanm&#305;&#351;t&#305;r ve dolay&#305;s&#305;yla
Adams-Hakim sendromu olarak da an&#305;l&#305;r.&nbsp; Demans genellikle hafif
&#351;iddettedir ve zamanlama olarak y�r�y�&#351; bozuklu&#287;undan sonra
ba&#351;lar.&nbsp; Y�r�y�&#351; bozuklu&#287;u genellikle ilk, bazen de tek
ba&#351;vuru yak&#305;nmas&#305;d&#305;r.&nbsp; Triad&#305;n di&#287;er �zellikleri
ancak sorgulamayla (daha s&#305;k idrara �&#305;kma, idrar i�in acele etme, GYA�lar&#305;
etkilemeyen unutkanl&#305;k) ve ayr&#305;nt&#305;l&#305; bir mental durum
muayenesi ile ortaya konur.&nbsp; Y�r�y�&#351; bozuklu&#287;u
ba&#351;lang&#305;�ta hafif bir serebellar ataksiyi and&#305;r&#305;rken
giderek parkinsonyen �zellikler kazan&#305;r.&nbsp; Y�r�y�&#351;�
ba&#351;latmak g��t�r, y�r�y�&#351; k&#305;sa ad&#305;mlarlad&#305;r ve
ad&#305;mlama s&#305;ras&#305;nda ayaklar&#305; yerden kald&#305;rmak g��
gibidir (manyetik y�r�y�&#351;).&nbsp; Post�ral dengesizlik, d�&#351;meler ve
donma fenomeni g�r�lebilir.&nbsp; &#304;leri evrelerde giderek ayakta durma,
hatta oturma g��le&#351;ir.&nbsp; Sfinkter kusuru ba&#351;lang&#305;�ta idrar
i�in acele etme (�urgency�) tarz&#305;ndayken ileri evrelerde tam bir
inkontinans yerle&#351;ir.&nbsp; Kognitif bozukluk asl&#305;nda
s&#305;kl&#305;kla demans &#351;iddetine ula&#351;maz.&nbsp; Bazen depresyonla
kar&#305;&#351;t&#305;r&#305;labilecek bir apati e&#287;ilimi e&#351;lik
eder.&nbsp; N�ropsikolojik muayenede, limbik tarzda olmayan tan&#305;man&#305;n
korundu&#287;u bir bellek bozuklu&#287;u ve y�r�t�c� bozuklukla giden bir
demans profiliyle birlikte, g�r�nt�lemede kortikal atrofi ya da subkortikal
iskemik de&#287;i&#351;iklikler olmaks&#305;z&#305;n ventrik�ler dilatasyon NPH
�zellikleridir.&nbsp; Fizyopatolojisinde BOS
ak&#305;&#351;kanl&#305;&#287;&#305;nda bir bozulman&#305;n
yaratt&#305;&#287;&#305; BOS bas&#305;n� art&#305;&#351;&#305;n&#305;n
ventrik�l sistemini geni&#351;letmesinden sonra konveksite ve ventrik�ler
bas&#305;n�lar aras&#305;ndaki dengesizli&#287;in zaman i�inde kaybolmas&#305;
ileri s�r�lmektedir.&nbsp; BOS dola&#351;&#305;m bozuklu&#287;unu tetikleyen
olay bir subaraknoid kanama gibi �yk�de ay&#305;rt edilebilen bir olay
olabilece&#287;i gibi (sekonder NPH) b�yle bir �yk� mevcut olmayabilir
(idyopatik NPH).&nbsp; BOS bo&#351;alt&#305;c&#305; LP�ler ile klinik d�zelme
(yakla&#351;&#305;k 20-50 cc ile �zellikle y�r�y�&#351;te d�zelme) tan&#305;
koydurucudur.&nbsp; Bu d�zelme s&#305;kl&#305;kla ge�ici ama bazen uzun s�reli
de olabilir.&nbsp; Ancak negatif bir LP testi NPH�y&#305;
d&#305;&#351;lamaz.&nbsp; S�rekli bas&#305;n� monitorizasyonu ve baz&#305;
hidrodinamik testlerin de tan&#305; koydurucu oldu&#287;u ileri s�r�lmektedir.&nbsp;
Tedavi ventrik�lo-peritoneal �shunt� &#351;eklindedir.&nbsp; Cerrahi
sonras&#305; iyi prognoz �ng�r�c�leri olarak y�r�y�&#351; bozuklu&#287;unun
zamanlamada ilk belirti olmas&#305;, kognitif bozuklu&#287;un g�rece k&#305;sa
s�reli olmas&#305;, NPH�n&#305;n sekonder olmas&#305; ve LP testiyle pozitif
sonu�, k�t� prognoz �ng�r�c�leri olarak da zamanlama ve &#351;iddet a�&#305;s&#305;ndan
�n planda kognitif bozukluk, MRG�de a&#351;ikar kortikal atrofi ve yayg&#305;n
beyaz madde bozuklu&#287;unun varl&#305;&#287;&#305; ileri s�r�lm�&#351;t�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er Sekonder Demanslar</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>H&#305;zl&#305; seyirli
demanslar&#305;n ay&#305;r&#305;c&#305; tan&#305;s&#305;na <b><i>�paraneoplastik
limbik ensefalit�</i></b> de kat&#305;l&#305;r.&nbsp; Sistemik kanserler i�inde
en s&#305;kl&#305;kla akci&#287;er kanseri ile ilintilidir.&nbsp; Sistemik
kanserin saptanmas&#305;ndan bir ka� y&#305;l �nce ortaya �&#305;kabilir.&nbsp;
Depresyon ve letarji gibi prodromal belirtilerle ba&#351;lang&#305;� s&#305;kt&#305;r.&nbsp;
Araya giren n�betler tabloyu alevlendirebilir.&nbsp; Tablo
yerle&#351;ti&#287;inde kognitif olarak bir izole amnestik durumdur.&nbsp; Buna
diurnal ritim bozukluklar&#305;, disinhibisyon gibi ki&#351;ilik
de&#287;i&#351;iklikleri e&#351;lik eder.&nbsp; G�r�nt�leme t�m�yle normal
olabilece&#287;i gibi, Herpes simpleks ensefaliti tutulum tarz&#305;na benzer
bir &#351;ekilde ba&#351;l&#305;ca mezyal temporal alanlarda y�ksek sinyal
saptanabilir.&nbsp;&nbsp; BOS�ta s&#305;kl&#305;kla protein
art&#305;&#351;&#305; ve lenforaji g�r�l�r.&nbsp; Yine, BOS�ta anti-Hu antikoru
pozitifli&#287;i tan&#305;ya yard&#305;m eder. Son zamanlarda ba&#351;ta NMDA
ve AMPA resept�rleri ve voltaj kap&#305;l&#305; potasyum kanal&#305; (VGKC)
olmak �zere tedaviye g�reli olarak iyi cevapl&#305; kanalopatilerle limbik
ensefalit olgular&#305; bildirileri artmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiy�z (tuberk�loz,
n�rosifilis, kriptokok, Lyme, HIV) inflamatuar (sarkoidoz, �zellikle Hashimoto
tiroiditi olmak �zere vask�litik ve non-vask�litik otoimmun
meningo-ensefalitler) ve neoplastik subakut-kronik menengo-ensefalitler
h&#305;zl&#305; seyirli demanslar ay&#305;r&#305;c&#305; tan&#305;s&#305;nda
de&#287;erlendirilmesi gereken durumlard&#305;r.&nbsp;&nbsp; �zellikle
inorganik c&#305;va olmak �zere toksinler de h&#305;zl&#305; seyirli demanslar&#305;
taklit edebilir.&nbsp; MRG (kontrast madde ile leptomeningeal boyanma,
gran�lomat�z parenkim lezyonlar&#305;), BOS incelemeleri (spesifik patojenin
�retilmesi, spesifik seroloji, sitoloji, h�cre ve protein
art&#305;&#351;&#305;), serebral anjiyografi ve toksik tarama an&#305;lan
farkl&#305; durumlar&#305;n ay&#305;r&#305;c&#305; tan&#305;s&#305;nda
kullan&#305;lan laboratuar y�ntemleridir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Wernicke-Korsakoff
Hastal&#305;&#287;&#305;,</span></i></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> ger�ekte bir izole amnestik durum
olsa da, e&#351;lik eden psikotik bozukluklar ve ki&#351;ilik
de&#287;i&#351;ikli&#287;iyle hastan&#305;n
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; bozarak s&#305;kl&#305;kla
bir demans gibi davran&#305;r.&nbsp; B1 vitamini (thiamin) eksikli&#287;ine
ba&#287;l&#305; olarak limbik (corpus mamillare, dorsomedyal ve pulvinar
talamik �ekirdekler) ve beyinsap&#305; (peri-akuaduktal gri madde)
yap&#305;lar&#305;n&#305;n hasarlanmas&#305; sonucu geli&#351;ir.&nbsp;
Konf�zyon, oftalmoparezi, ataksi ve nistagmustan olu&#351;an ve haftalar s�ren
bir akut d�nem sonras&#305;, bu bulgular �e&#351;itli derecelerde d�zelirken
kronik tablo yerle&#351;ir.&nbsp; En s&#305;kl&#305;kla, kronik alkolizm
zemininde ortaya �&#305;ksa da, �lkemizde a�l&#305;k grevleri de belli
ba&#351;l&#305; nedenleri aras&#305;ndad&#305;r.&nbsp; Bu durumda, tabloyu
ortaya �&#305;karan etkenin a�l&#305;&#287;&#305;n kendisi de&#287;il de,
genellikle B1 i�ermeyen &#351;ekerli parenteral s&#305;v&#305;larla
sonland&#305;r&#305;lmas&#305;na ba&#287;l&#305; iyatrojenik bir etken
oldu&#287;u g�r�lm�&#351;t�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>N�ro-Beh�et ve multipl skleroz
hastal&#305;klar&#305;n&#305;n kronik evrelerinde kognitif bozukluk
&#351;iddeti demans d�zeyine ula&#351;abilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>KAYNAKLAR ve OKUMA �NERILERI</span></b><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Aarsland D, Andersen K, Larsen JP
     ve ark.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> Arch Neurol. 2003 Mar;60(3):387-92. Parkinson
     hastal&#305;&#287;&#305; demans&#305;n&#305;n prevalans ve �zellikleri: 8
     y&#305;ll&#305;k bir ileriye d�n�k �al&#305;&#351;ma.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=2 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Aarsland D, Bronnick K, Ehrt U,
     ve ark.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> J Neurol Neurosurg Psychiatry. 2007
     Jan;78(1):36-42. Parkinson hastal&#305;&#287;&#305; ve demans
     hastalar&#305;nda n�ropsikiyatrik semptolar: frekans, profil ve
     ili&#351;kli bak&#305;c&#305; stresi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=3 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>American Psychiatric Association. Diagnostic
     and Statistical Manual of Mental Disorders, 3rd Edition.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Washington, DC: American Psychiatric Association, 1980 DSM-III demans
     kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=4 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>American Psychiatric Association. Diagnostic
     and Statistical Manual of Mental Disorders, 4th Edition.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Washington, DC: American Psychiatric Association, 1994.DSM-IV Alzheimer
     tipi demans (DAT) kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=5 type=1>
 <li class=MsoNormal style='margin-bottom:11.0pt;text-align:justify;mso-list:
     l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:none'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Bertram L &amp; Tanzi<u> RE.</u></span></b><u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nature
     Reviews Neuroscience 9, 768-778 (2008). Alzheimer hastal&#305;&#287;&#305;
     geneti&#287;inde 30. y&#305;l. Sistemik metaanalizlerin etkisi. &nbsp;<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Binetti G, Pasquier F, Cappa S.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     In: Handbook Clinical Neuropsychology, vol. 6, Ch. 14 (eds. F. Boller and
     S. Cappa). Elsevier Non-Alzheimer dejeneratif demanslar.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=7 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Brown P, Preece M, Brandel JP ve
     ark</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'>. Neurology. 2000 Oct 24;55(8):1075-81. Iyatrogenic
     Creutzfeldt-Jakob hastal&#305;&#287;&#305;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=8 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Chui HC, Victoroff JI, Margolin D ve
     ark.&nbsp; </span></b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Neurology 1992; 42: 473-480.Muhtemel ve
     m�mk�n iskemik vask�ler demans (IVD) ADDTC kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=9 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Collinge J.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):906-19. Prion
     hastal&#305;klar&#305;n&#305;n molek�ler n�rolojisi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=10 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Dickson DW.&nbsp; &#945;-Synuclein and Lewy
     body disorders.</span></b><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>&nbsp; Current Opinion in
     Neurology 2001, 14: 423-432. &#945;-sin�kleopatiler �zerine g�ncel bir
     derleme.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=11 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Emre M, Wentzel-Larsen T,
     Aarsland D.</span></b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'> Mov Disord. 2006 Aug;21(8):1123-30.
     Parkinson hastal&#305;&#287;&#305;nda motor alttiplerdeki
     de&#287;i&#351;iklik ve demans riski.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=12 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Emre M.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Handb
     Clin Neurol. 2007;83:401-19. Parkinson hastal&#305;&#287;&#305; ile
     ili&#351;kili demans&#305;n klinik �zellileri, patofizyolojisi ve
     tedavisi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=13 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Erkinjuntti T and Gauthier S (eds.) Vascular
     Cognitive Impairment.</span></b><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>&nbsp; London, Martin Dunitz LTD,
     2002. Vask�ler kognitif bozukluk kavram&#305;n&#305;n t�m y�nleriyle
     tart&#305;&#351;&#305;ld&#305;&#287;&#305; g�ncel bir kitap.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=14 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Gambetti P, Kong Q, Zou W ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Br Med Bull. 2003;66:213-39. Sporadik ve ailesel CJD: s&#305;n&#305;flama
     ve �zellikler<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=15 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Gurvit H, Emre M, Tinaz S ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Am J Alzheimers Dis Other Demen. 2008 Feb-Mar;23(1):67-76. Kentli bir T�rk
     toplumunda demans prevalans&#305;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=16 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l1 level1 lfo21;
     tab-stops:list 36.0pt'><b style='mso-bidi-font-weight:normal'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�rvit
     H, Emre M.</span></b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'> Parkinson hastal&#305;&#287;&#305;n&#305;n
     kognitif ve davran&#305;&#351;sal belirtileri. Emre M (edit�r), Parkinson
     Hastal&#305;&#287;&#305;�n&#305;n i�inde (s. 157-182). Ankara: G�ne&#351;
     T&#305;p Kitapevi, 2009.<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Hardy J.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> J
     Neurochem. 2009 Aug;110(4):1129-34. Alzheimer hastal&#305;&#287;&#305;nda
     amiloid hipotezi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=18 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Jack CR, Knopman DS, Jagust WJ
     etal.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> Hypothetical model of the Alzheimer�s pathological
     cascade. Lancet Neurol 2010;9:118-28.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=19 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Kertesz A, Munoz DG.&nbsp; Pick�s Disease:
     Frontotemporal Dementia.</span></b><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'> In: Terry R.D., Katzman R., Bick
     K.L., Sisodia S.S. (eds): Alzheimer Disease, Philadelphia, Lippincott
     Williams &amp; Wilkins, 1999 (2nd edition), pp. 133-146. Pick kompleksi
     kavram&#305;n&#305;n kapsaml&#305; bir tart&#305;&#351;mas&#305; ile
     ilgili antitelere ayr&#305;nt&#305;l&#305; bir bak&#305;&#351;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=20 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Kertesz A, Munoz DG.&nbsp; (eds).</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <b>Pick�s
     Disease and Pick�s Complex. </b>Wiley-Liss, New York 1998. Pick kompleksi
     kavram&#305;n&#305;n isim babas&#305; Kertesz�in edit�rl�&#287;�n�
     yapt&#305;&#287;&#305;, ilgili antiteleri b�t�n �zellikleriyle ele alan
     kitap.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=21 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Kertesz A.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):S5-7. Pick kompleksi-tarihi
     bak&#305;&#351;.</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=22 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Lang AE, Riley DE, Bergeron C.&nbsp;
     Cortical-Basal Ganglionic Degeneration.&nbsp; </span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>In: Calne
     DB (ed): Neurodegenerative Diseases. Philadelphia, W. B. Saunders Company,
     1993, pp. 877-894. KBD i�in yay&#305;nlanm&#305;&#351; bir �ok kriter
     dizisinden biri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=23 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Litvan I, Agid Y, Jankovic J ve ark.&nbsp;
     Accuracy of clinical criteria for the diagnosis of progressive
     supranuclear palsy (Steele-Richardson-Olszewski syndrome).</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Neurology 1996; 46: 922-930. PSP kriterleri.</span><span style='font-size:
     10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt;text-autospace:ideograph-numeric'><span
style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=24 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Litvan I, Goetz CG, Lang AE. (eds):
     Corticobasal Degeneration and Related Disorders.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Advances
     in Neurology, vol. 82, Philadelphia, 2000, Lippincott Williams and
     Wilkins. KBD�nin klinik, patolojik ve biyokimyasal �zellikleri �zerine
     mevcut muhtemelen en kapsaml&#305; kitap.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=25 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Mc Khann G, Drachmann D, Folstein M ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Neurology 1984; 34: 939-944. Muhtemel ve m�mk�n AH (PRAD ve PosAD)
     kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=26 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>McKeith I, Galasko D, Kosaka K ve ark. </span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><span
     style='mso-spacerun:yes'>�</span>Neurology 1996; 47: 1113-1124. Lewy
     Cisimci&#287;i ile ilintili demans (LCD) uzla&#351;&#305;m kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=27 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>McKeith I, Mintzer J, Aarsland D
     ve ark.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> Lancet Neurol. 2004 Jan;3(1):19-28. Lewy cisimcikli
     demans<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span class=jrnl><span style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></span></p>

<ol style='margin-top:0cm' start=28 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;
     font-family:Tahoma'>McKeith IG, Dickson DW, Lowe J ve ark. </span></b><span
     class=src><span style='font-size:10.0pt;font-family:Tahoma'>Diagnosis and
     management of dementia with Lewy bodies: third report of the DLB
     Consortium</span></span><span style='font-size:10.0pt;font-family:Tahoma'>
     <a href="http://www.ncbi.nlm.nih.gov/pubmed/16237129"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>.</span></a><span
     class=jrnl>Neurology</span><span class=src>. 2005 Dec 27;65(12):1863-72.
     Lewy cisimcikli demans&#305;n tan&#305; ve tedavisi</span></span><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=29 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Mesulam M-M.&nbsp; Aging, Alzheimer�s Disease
     and Dementia: Clinical and Neurobiological Perspectives.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     In: M.-Marsel Mesulam (ed): Principles of Behavioral&nbsp; and Cognitive
     Neurology, New York, Oxford University Press, 2000 (2nd edition), pp.
     439-522. Alzheimer hastal&#305;&#287;&#305; �zerine, n�roplastisite y�k�
     hipotezinin de tart&#305;&#351;&#305;ld&#305;&#287;&#305; kapsaml&#305; ve
     y�ksek nitelikli bir kitap b�l�m�.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=30 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Mesulam MM.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Ann N Y Acad Sci. 2000;924:42-52. Alzheimer
     hastal&#305;&#287;&#305;n&#305;n patogenezinde plastisite temelli bir
     teori.</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:DA'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=31 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Mesulam MM.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Neuron. 1999 Nov;24(3):521-9. Alzheimer hastal&#305;&#287;&#305;nda n�roplastisite
     bozuklu&#287;u: plaklar ve yumaklar aras&#305;ndaki u�uruma bir k�pr�.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=32 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Morris RC.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Clinical dementia rating: a reliable and valid diagnostic and staging
     measure for dementia of the Alzheimer type. Int. Psychogeriatr 1997; 9
     Suppl 1:173-76<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=33 type=1>
 <li class=MsoNormal style='margin-bottom:11.0pt;text-align:justify;mso-list:
     l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:none'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>M&#305;h�&#305; E, G�rvit H. </span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lewy
     cisimcikli demans. I&#351;&#305;k AT, Tanr&#305;da&#287; O (edit�rler),
     Geriatri Prati&#287;inde Demans Sendromu�nun i�inde (s. 137-157). </span><span
     lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'>&#304;stanbul:
     SomKitap, 2009.<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:11.0pt;text-align:justify;mso-list:
     l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:none'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Reisberg b, Ferris SH,<span
     style='mso-spacerun:yes'>� </span>de Leon MJ, Crook T.</span></b><span
     style='font-size:10.0pt;font-family:Tahoma'> Global Deteriotation Scale.
     Psychopharmacol Bull 1988;24:661-3.<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Neary D, Snowden JS, Gustafson ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
     mso-bidi-font-weight:bold'>&nbsp; Frontotemporal lobar degeneration: A
     consensus on clinical diagnostic criteria. </span><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Neurology
     1998; 51:1546-1554. FTLD uzla&#351;&#305;m kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=36 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b style='mso-bidi-font-weight:normal'><span
     style='font-size:10.0pt;font-family:Tahoma'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petersen%20RC%22%5BAuthor%5D"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>Petersen
     RC</span></a>, <a
     href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thomas%20RG%22%5BAuthor%5D"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>Thomas
     RG</span></a>, <a
     href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Grundman%20M%22%5BAuthor%5D"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>Grundman
     M</span></a></span></b><span style='font-size:10.0pt;font-family:Tahoma'> ve
     ark, Vitamin E and donepezil for the treatment of mild cognitive
     impairment. <a
     href="javascript:AL_get(this,%20'jour',%20'N%20Engl%20J%20Med.');"
     title="The New England journal of medicine."><span lang=DA
     style='color:windowtext;mso-ansi-language:DA;text-decoration:none;
     text-underline:none'>N Engl J Med.</span></a></span><span lang=DA
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'> 2005 Jun
     9;352(23):2379-88. MCI tedavisinde E vitamini ve donepezil</span><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=37 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Roman GC, Tatemichi TK, Erkinjuntti T ev
     ark.&nbsp; Vascular dementia; Diagnostic criteria for research studies.
     Report of the NINDS-AIREN International Workshop.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Neurology 1993; 43: 250-260. NINDS-AIREN muhtemel ve m�mk�n vask�ler demans
     (VaD) kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=38 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Terry R.D., Katzman R., Bick K.L., Sisodia
     S.S. (eds): Alzheimer Disease.</span></b><span lang=TR style='font-size:
     10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Philadelphia, Lippincott
     Williams &amp; Wilkins, 1999 (2nd edition). Alzheimer
     hastal&#305;&#287;&#305; ve benzeri demans bozukluklar&#305;n&#305;n klinik,
     patolojik, biyokimyasal ve genetik �zellikleri �zerine g�ncel en
     kapsaml&#305; kitaplardan biri.&nbsp; Bu cilt 2001 y&#305;l&#305;nda
     Yelkovan Yay&#305;nc&#305;l&#305;k taraf&#305;ndan &#304;.H. G�rvit
     edit�rl�&#287;�nde bir ekibin �evirisiyle T�rk�e olarak da
     yay&#305;nland&#305;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=39 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>The Lund&nbsp; and Manchester Groups.&nbsp;
     Clinical and neuropathological criteria for frontotemporal dementia.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     J Neurol Neurosurg Psychiatry 1994; 57: 416-418. Manchester-Lund
     Fronto-temporal demans (FTD) kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=40 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Vanneste JAL. Diagnosis and Management of
     Normal Pressure Hydrocephal�s.</span></b><span lang=TR style='font-size:
     10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp; J Neurol 2000; 247:
     5-14. Normal bas&#305;n�l&#305; hidrosefali �zerine g�ncel bir derleme.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=41 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Weintraub S, Mesulam M-M.&nbsp; Four
     neuropsychological profiles in dementia.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     In: Boller F, Grafman J (eds): Handbook of Neuropsychology, vol.8, New
     York, Elsevier, 1993, pp. 253-282. &#304;zole ilerleyici kognitif
     bozukluklar&#305;n karakterizasyonu.</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>
